Results NNS 0 1 2 O
from IN 0 0 12 O
human JJ 0 1 1 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
metabolism NN 0 1 16 O
studies NNS 1 1 1 O
and CC 0 0 12 O
nonclinical JJ 0 0 UNK O
studies NNS 1 1 1 O
show VBP 0 1 12 O
that IN 0 0 12 O
REVLIMID NNP 0 1 UNK B-Brand
( ( 0 0 2 O
lenalidomide NN 0 1 UNK B-Drug
) ) 0 0 2 O
is VBZ 1 0 12 O
neither DT 0 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
nor CC 0 0 12 O
inhibits NNS 0 1 UNK O
or CC 0 0 12 O
induces VBZ 1 1 UNK O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
pathway NN 0 1 UNK O
suggesting VBG 1 1 1 O
that IN 0 0 12 O
lenalidomide NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
or CC 0 0 12 O
be VB 0 0 12 O
subject JJ 0 1 UNK O
to TO 0 0 12 O
P9 NNP 0 1 UNK O
- : 0 0 2 O
based VBN 1 1 1 O
metabolic JJ 0 1 6 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
in IN 0 0 12 O
man NN 0 1 12 O
. . 0 0 12 O

Interacts NNS 0 0 UNK O
with IN 0 0 12 O
valproic NN 0 0 16 B-Drug
acid NN 0 1 14 I-Drug

This DT 0 0 2 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
severe JJ 0 1 6 O
ventricular JJ 0 1 8 O
arrhythmia NN 0 1 6 O
typically RB 0 0 UNK O
torsades VBZ 0 0 13 O
de IN 0 1 2 O
pointe NN 0 0 UNK O
. . 0 0 12 O

However RB 0 0 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
the DT 0 0 12 O
consequences NNS 1 1 UNK O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
irbesartan NN 0 1 16 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
were VBD 1 0 12 O
negligible JJ 0 1 UNK O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
g NN 0 1 16 O
bolus NN 0 1 14 O
followed VBN 1 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
g NNS 0 1 16 O
/ JJ 0 0 2 O
hr NN 0 0 16 O
should MD 0 0 12 O
achieve VB 0 0 1 O
and CC 0 0 12 O
sustain VB 0 1 1 O
plasma JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
mL NN 0 1 14 O
. . 0 0 12 O

Therefore RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
other JJ 0 0 12 O
nondepolarizing JJ 0 0 UNK B-Group
muscle NN 0 1 6 I-Group
relaxants NNS 1 0 13 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
in IN 0 0 12 O
succession NN 0 0 UNK O
. . 0 0 12 O

Chlorthalidone NN 0 1 UNK B-Drug
and CC 0 0 12 O
related JJ 0 1 1 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
responsiveness NN 0 1 UNK O
to TO 0 0 12 O
tubocurarine VB 0 1 UNK B-Drug
. . 0 0 12 O

Interaction NN 0 1 2 O
between IN 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
and CC 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Studies NNS 0 1 2 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
possible JJ 0 1 1 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
REVIA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
drugs NNS 1 1 6 O
other JJ 0 0 12 O
than IN 0 0 12 O
opiates NNS 1 1 6 B-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

especially RB 0 0 12 O
if IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
are VBP 1 0 12 O
extensive JJ 0 1 1 O
metabolizers NNS 0 0 UNK O
. . 0 0 12 O

If IN 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
to TO 0 0 12 O
continue VB 0 1 12 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
initiate NN 0 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
PRINIVIL NNP 0 1 UNK B-Brand
at IN 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily RB 0 1 12 O
and CC 0 0 12 O
provide VB 0 1 1 O
close RB 0 1 12 O
medical JJ 0 1 1 O
supervision NN 0 1 1 O
after IN 0 0 12 O
the DT 0 0 12 O
initial JJ 0 1 1 O
dose NN 0 1 6 O
until IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
has VBZ 1 0 12 O
stabilized VBN 1 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interaction NNP 0 1 2 O
Captopril NNP 0 1 0 B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
a DT 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
urine JJ 0 1 6 O
test NN 0 1 1 O
for IN 0 0 12 O
acetone NN 0 1 14 O
. . 0 0 12 O

Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
Probenecid NN 0 1 UNK B-Drug
slows VBZ 1 1 UNK O
the DT 0 0 12 O
renal JJ 0 1 6 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
lome JJ 0 0 UNK O
- : 0 0 2 O
floxacin NN 0 0 UNK O
. . 0 0 12 O

When WRB 0 0 12 O
the DT 0 0 12 O
STADOL NNP 0 1 UNK B-Brand
NS NNP 0 1 13 I-Brand
was VBD 1 0 12 O
administered VBN 1 1 1 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
sumatriptan NN 0 1 16 B-Drug
nasal NN 0 1 6 O
spray VBZ 0 1 3 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
butorphanol NN 0 1 13 B-Drug
increased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
decreased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
was VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
by IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
BEXTRA NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
BID NNP 0 0 11 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
neuroleptics NNS 1 1 13 B-Group
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
oral JJ 0 1 6 O
morphine NN 0 1 14 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
respiratory JJ 0 1 6 O
depression NN 0 1 6 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
profound JJ 0 1 1 O
sedation NN 0 1 6 O
or CC 0 0 12 O
coma NN 0 1 6 O
. . 0 0 12 O

Although IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hydroxy NN 0 1 14 O
- : 0 0 2 O
corticosteroid NN 0 1 UNK O
measurements NNS 1 1 1 O
( ( 0 0 2 O
Porter NNP 0 1 UNK O
- : 0 0 2 O
Silber NNP 0 0 UNK O
test NN 0 1 1 O
) ) 0 0 2 O
do VBP 0 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
artifactually RB 0 0 UNK O
altered VBN 1 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
suggested VBN 1 1 12 O
that IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
naproxen JJ 0 1 16 B-Drug
be VB 0 0 12 O
temporarily RB 0 0 1 O
discontinued VBN 1 1 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
adrenal JJ 0 0 6 O
function NN 0 1 1 O
tests NNS 1 1 1 O
are VBP 1 0 12 O
performed VBN 1 1 1 O
if IN 0 0 12 O
the DT 0 0 12 O
Porter NNP 0 1 UNK O
- : 0 0 2 O
Silber NNP 0 0 UNK O
test NN 0 1 1 O
is VBZ 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
levetiracetam NN 0 1 16 B-Drug
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
Starlix NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
before IN 0 1 12 O
meals NNS 1 1 12 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
to TO 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
there EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
agent NN 0 1 1 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
hypercholesterolemia NN 0 1 14 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
lovastatin NN 0 1 13 B-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Therefore RB 0 0 1 O
drugs NNS 1 1 6 O
that IN 0 0 12 O
affect VBP 0 1 1 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
Pgp NNP 0 1 UNK O
may MD 0 0 1 O
modify VB 0 1 UNK O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
saquinavir NN 0 1 13 B-Drug
. . 0 0 12 O

Combination NNP 0 1 UNK O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
may MD 0 0 1 O
also RB 0 0 12 O
increase VB 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
thromboembolic JJ 0 1 8 O
disorders NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
potential NN 0 1 1 O
for IN 0 0 12 O
supine JJ 0 1 8 O
hypertension NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
in IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
and CC 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
minimized VBN 1 0 1 O
by IN 0 0 12 O
either DT 0 1 12 O
reducing VBG 1 1 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
fludrocortisone NN 0 1 0 B-Drug
acetate NN 0 1 14 I-Drug
or CC 0 0 12 O
decreasing VBG 1 1 1 O
the DT 0 0 12 O
salt NN 0 1 3 O
intake VB 0 1 3 O
prior JJ 0 1 1 O
to TO 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
. . 0 0 12 O

Calcium NN 0 1 7 B-Drug
Supplements NNS 0 1 UNK O
/ VBP 0 0 2 O
Antacids NNS 0 1 UNK B-Group

Routine JJ 0 1 2 O
monitoring NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
performed VBN 1 1 1 O
when WRB 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
BEXTRA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
either RB 0 1 12 O
initiated JJ 0 1 1 O
or CC 0 0 12 O
discontinued VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
anticonvulsant JJ 0 1 14 O
therapy NN 0 1 6 O
. . 0 0 12 O

A DT 0 0 2 O
specific JJ 0 1 1 O
treatment NN 0 1 6 O
for IN 0 0 12 O
extravasation NN 0 1 8 O
reactions NNS 1 1 1 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
at IN 0 0 12 O
this DT 0 0 12 O
time NN 0 1 12 O
. . 0 0 12 O

As IN 0 0 2 O
with IN 0 0 12 O
all DT 0 0 12 O
drugs NNS 1 1 6 O
care NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
treating VBG 1 1 6 O
patients NNS 1 1 6 O
with IN 0 0 12 O
multiple JJ 0 1 1 O
medications NNS 1 1 6 O
. . 0 0 12 O

Aminoglutethimide RB 0 1 UNK B-Drug
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
depo JJ 0 1 UNK B-Brand
- : 0 0 2 O
subQ NN 0 0 15 I-Brand
provera NN 0 1 13 I-Brand
9 CD 0 0 2 I-Brand
may MD 0 0 1 O
significantly RB 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
MPA NNP 0 0 UNK B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
women NNS 1 1 UNK O
requiring VBG 1 0 1 O
treatment NN 0 1 6 O
with IN 0 0 12 O
one CD 0 1 12 O
or CC 0 0 12 O
more JJR 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
must MD 0 0 12 O
use VB 0 1 1 O
two CD 0 1 12 O
OTHER NNP 0 0 11 O
effective JJ 0 1 1 O
or CC 0 0 12 O
highly RB 0 1 1 O
effective JJ 0 1 1 O
methods NNS 1 1 1 O
of IN 0 0 12 O
contraception NN 0 1 13 O
or CC 0 0 12 O
abstain NN 0 0 1 O
from IN 0 0 12 O
heterosexual JJ 0 1 1 O
sexual JJ 0 1 12 O
contact NN 0 1 12 O
while IN 0 0 12 O
taking VBG 1 0 12 O
thalidomide NN 0 1 13 B-Drug
. . 0 0 12 O

Clinically RB 0 0 7 O
meaningful JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
occurred VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
and CC 0 0 12 O
include VBP 0 1 1 O
but CC 0 0 12 O
are VBP 1 0 12 O
not RB 0 1 12 O
limited VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
Agents NNS 0 1 2 O
Highly VBP 0 1 UNK O
Bound NNP 0 1 UNK O
to TO 0 0 12 O
Plasma NNP 0 1 UNK O
Protein NNP 0 1 2 O
Carbamazepine NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
highly RB 0 1 1 O
bound VBN 1 1 12 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
; : 0 0 2 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
/ NN 0 0 2 O
kg NN 0 1 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
x NNP 0 0 10 O
ED9 NNP 0 0 UNK O
) ) 0 0 2 O
NIMBEX NNP 0 1 UNK B-Brand
at IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
or CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
recovery NN 0 1 1 O
following VBG 1 1 1 O
an DT 0 0 12 O
intubating VBG 1 0 UNK O
dose NN 0 1 6 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
produced VBD 1 0 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
neuromuscular JJ 0 1 6 O
block NN 0 1 3 O
. . 0 0 12 O

Phenothiazines NNS 0 1 UNK B-Group
- : 0 0 2 O
Taking VBG 0 0 UNK O
piperazine NN 0 1 UNK B-Drug
and CC 0 0 12 O
a DT 0 0 12 O
phenothiazine NN 0 1 UNK B-Group
together RB 0 1 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
convulsions NNS 1 1 13 O
( ( 0 0 2 O
seizures NNS 1 1 6 O
) ) 0 0 2 O
. . 0 0 12 O

Prolonged JJ 0 1 7 O
recovery NN 0 1 1 O
time NN 0 1 12 O
may MD 0 0 1 O
occur VB 0 1 1 O
if IN 0 0 12 O
barbiturates NNS 1 1 14 B-Group
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
narcotics NNS 1 1 1 B-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
ketamine NN 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
appropriate JJ 0 1 1 O
dose NN 0 1 6 O
for IN 0 0 12 O
nelfinavir JJ 0 1 16 B-Drug
incombination NN 0 0 UNK O
with IN 0 0 12 O
nevirapine JJ 0 1 13 B-Drug
with IN 0 0 12 O
respectto JJ 0 0 UNK O
safety NN 0 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
and CC 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
in IN 0 0 12 O
dogs NNS 1 1 UNK O
but CC 0 0 12 O
not RB 0 1 12 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
at IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
recommended JJ 0 1 1 O
maximum JJ 0 1 1 O
human JJ 0 1 1 O
therapeutic JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
each DT 0 0 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
/ NNP 0 0 2 O
acetaminophen NN 0 1 16 B-Drug
) ) 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
greater JJR 1 1 1 O
gastrointestinal JJ 0 1 6 O
toxicity NN 0 1 6 O
than IN 0 0 12 O
when WRB 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
alone RB 0 1 12 O
. . 0 0 12 O

If IN 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
to TO 0 0 12 O
continue VB 0 1 12 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
provide NN 0 1 1 O
close RB 0 1 12 O
medical JJ 0 1 1 O
supervision NN 0 1 1 O
after IN 0 0 12 O
the DT 0 0 12 O
initial JJ 0 1 1 O
dose NN 0 1 6 O
for IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
two CD 0 1 12 O
hours NNS 1 1 12 O
and CC 0 0 12 O
until IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
has VBZ 1 0 12 O
stabilized VBN 1 1 1 O
for IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
an DT 0 0 12 O
additional JJ 0 1 1 O
hour.. NN 0 1 UNK O

It PRP 0 0 12 O
is VBZ 1 0 12 O
probable JJ 0 1 1 O
that IN 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
given VBN 1 1 12 O
as IN 1 0 12 O
antiemetic JJ 0 1 14 O
prophylaxis NN 0 1 6 O
contributed VBD 1 1 1 O
to TO 0 0 12 O
hyperglycemia VB 0 1 14 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Johns NNP 0 0 UNK O
Wort NNP 0 0 UNK O
) ) 0 0 2 O
may MD 0 0 1 O
significantly RB 0 0 1 O
reduce VB 0 0 1 O
exposure NN 0 1 1 O
to TO 0 0 12 O
Gleevec NNP 0 1 UNK B-Brand
. . 0 0 12 O

= NN 0 0 2 O
decrease NN 0 1 1 O

Agents NNS 0 1 2 O
that WDT 0 0 12 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
hemorrhage NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
prior JJ 0 1 1 O
to TO 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
Fondaparinux NNP 0 1 UNK B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

- : 0 0 2 O
isoniazid NN 0 1 13 B-Drug
( ( 0 0 2 O
Nydrazid NNP 0 1 UNK B-Brand
) ) 0 0 2 O
; : 0 0 2 O

indinavir JJ 0 1 16 B-Drug
concentration NN 0 1 1 O
rifabutin NN 0 1 13 B-Drug
concentration NN 0 1 1 O

Initial JJ 0 1 2 O
doses NNS 1 1 6 O
of IN 0 0 12 O
adrenergic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
dopamine NN 0 1 14 B-Drug
or CC 0 0 12 O
epinephrine NN 0 1 14 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
and CC 0 0 12 O
titrated VBN 1 1 14 O
to TO 0 0 12 O
achieve VB 0 0 1 O
the DT 0 0 12 O
desired JJ 0 1 1 O
response NN 0 1 1 O
. . 0 0 12 O

Apraclonidine NNP 0 1 UNK B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Gastrointestinal JJ 0 1 7 O
agents NNS 1 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
antacids NNS 1 1 14 B-Group
) ) 0 0 2 O
. . 0 0 12 O

Enoxacin NNP 0 1 UNK B-Drug
interferes VBZ 1 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
dose JJ 0 1 6 O
- : 0 0 2 O
related JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
clearance NN 0 1 16 O
and CC 0 0 12 O
a DT 0 0 12 O
subsequent JJ 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
theophylline NN 0 1 16 O
levels NNS 1 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
whether IN 0 0 12 O
this DT 0 0 12 O
potentiation NN 0 1 UNK O
of IN 0 0 12 O
ampicillin NN 0 1 0 B-Drug
rashes NNS 1 1 6 O
is VBZ 1 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
allopurinol VB 0 1 13 B-Drug
or CC 0 0 12 O
the DT 0 0 12 O
hyperuricemia JJ 0 1 14 O
present NN 0 1 1 O
in IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Vardenafil NNP 0 1 UNK B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
exceed VB 0 0 UNK O
a DT 0 0 12 O
maximum NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
period NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
indinavir JJ 0 1 16 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Nifedipine NN 0 1 0 B-Drug
: : 0 0 2 O
Vardenafil NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
when WRB 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
slow JJ 0 1 12 O
- : 0 0 2 O
release NN 0 1 12 O
nifedipine JJ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
once RB 0 0 12 O
daily RB 0 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
relative JJ 0 1 1 O
bioavailability NN 0 1 UNK O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
maximum JJ 0 1 1 O
concentration NN 0 1 1 O
( ( 0 0 2 O
Cmax NNP 0 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
nifedipine NN 0 1 0 B-Drug
a DT 0 0 12 O
drug NN 0 1 1 O
that WDT 0 0 12 O
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
via IN 0 0 1 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Potential NNP 0 1 UNK O
for IN 0 0 12 O
INVEGA NNP 0 1 UNK B-Brand
to TO 0 0 12 O
Affect VB 0 1 UNK O
Other JJ 0 0 2 O
Drugs NNP 0 1 2 O
Paliperidone NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
isozymes NNS 0 1 UNK O
. . 0 0 12 O

Phenobarbital NN 0 1 0 B-Drug
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
delay VB 0 1 1 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
; : 0 0 2 O

. . 0 0 12 O

The DT 0 0 2 O
size NN 0 1 3 O
of IN 0 0 12 O
wheal NN 0 1 UNK O
and CC 0 0 12 O
flare NN 0 1 3 O
were VBD 1 0 12 O
significantly RB 0 0 1 O
larger JJR 1 1 1 O
when WRB 0 0 12 O
fexofenadine NN 0 1 16 B-Drug
hydrochloride NN 0 1 0 I-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
either DT 0 1 12 O
grapefruit NN 0 1 3 O
or CC 0 0 12 O
orange NN 0 1 16 O
juices NNS 1 1 UNK O
compared VBN 1 1 1 O
to TO 0 0 12 O
water NN 0 1 3 O
. . 0 0 12 O

Fluoxetine NNP 0 1 0 B-Drug
OCs NNP 0 0 UNK B-Group
sertraline NN 0 1 16 B-Drug
diltiazem NN 0 1 0 B-Drug
macrolide NN 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
( ( 0 0 2 O
exercise VB 0 1 1 O
caution NN 0 0 1 O
) ) 0 0 2 O
. . 0 0 12 O

Thus RB 0 0 1 O
agents NNS 1 1 1 O
likely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
with IN 0 0 12 O
Chirocaine NNP 0 1 UNK B-Brand
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
this DT 0 0 12 O
isoenzyme JJ 0 1 13 O
family NN 0 1 12 O
may MD 0 0 1 O
potentially RB 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
Chirocaine NNP 0 1 UNK B-Brand
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
relevance NN 0 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
difference NN 0 1 UNK O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
low JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
aspirin JJ 0 1 14 B-Brand
plus CC 0 1 16 O
ibuprofen NNS 0 1 0 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Fat JJ 0 1 UNK O
redistribution NN 0 1 1 O
: : 0 0 2 O
Redistribution NN 0 1 UNK O
/ NNP 0 0 2 O
accumulation NN 0 1 1 O
of IN 0 0 12 O
body NN 0 1 3 O
fat JJ 0 1 3 O
including VBG 1 1 1 O
central JJ 0 1 1 O
obesity NN 0 1 6 O
dorsocervical JJ 0 0 UNK O
fat JJ 0 1 3 O
enlargement NN 0 1 6 O
( ( 0 0 2 O
buffalo JJ 0 1 UNK O
hump NN 0 0 3 O
) ) 0 0 2 O
peripheral NN 0 1 6 O
wasting VBG 1 1 12 O
facial JJ 0 1 3 O
wasting VBG 1 1 12 O
breast NN 0 1 6 O
enlargement NN 0 1 6 O
and CC 0 0 12 O
cushingoid JJ 0 1 UNK O
appearance NN 0 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
antiretroviral JJ 0 0 UNK B-Group
therapy NN 0 1 6 O
. . 0 0 12 O

Cholestyramine NNP 0 1 UNK B-Drug
and CC 0 0 12 O
Drugs NNP 0 1 2 O
that IN 0 0 12 O
Bind NNP 0 1 UNK O
Bile NNP 0 1 7 O
Acids NNP 0 1 UNK O
: : 0 0 2 O
These DT 0 0 1 O
drugs NNS 1 1 6 O
interrupt VBP 0 1 13 O
enterohepatic JJ 0 0 UNK O
recirculation NN 0 0 UNK O
and CC 0 0 12 O
reduce VB 0 0 1 O
MPA NNP 0 0 UNK B-Drug_n
exposure NN 0 1 1 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
mycophenolate NN 0 1 0 B-Drug
mofetil NN 0 0 16 I-Drug
. . 0 0 12 O

Whether IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
also RB 0 0 12 O
occurs VBZ 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
intravenous JJ 0 1 14 O
topical JJ 0 1 6 O
or CC 0 0 12 O
vaginal JJ 0 1 6 O
preparations NNS 1 1 13 O
of IN 0 0 12 O
miconazole NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

These DT 0 0 1 O
effects NNS 1 1 1 O
are VBP 1 0 12 O
usually RB 0 1 12 O
reversible JJ 0 1 3 O
. . 0 0 12 O

As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
dialysis NN 0 1 6 B-Group
solutions NNS 1 1 UNK I-Group
blood VBD 0 1 6 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
dialyzable JJ 0 0 UNK O
drugs NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
dialysis NN 0 1 6 O
. . 0 0 12 O

Digitalis NNP 0 1 15 B-Group
glycosides NNS 1 1 13 I-Group
: : 0 0 2 O
Patients NNS 0 1 7 O
on IN 0 0 12 O
digitalis NNS 0 1 14 B-Group
glycosides NNS 1 1 13 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
at IN 0 0 12 O
increased JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
arrhythmias NNS 1 1 6 O
due JJ 0 1 1 O
to TO 0 0 12 O
hypokalemia VB 0 1 14 O
. . 0 0 12 O

Therefore RB 0 0 1 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
this DT 0 0 12 O
isoenzyme NN 0 1 13 O
including VBG 1 1 1 O
other JJ 0 0 12 O
antidepressants NNS 1 1 13 B-Group
phenothiazines NNS 1 1 UNK B-Group
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
Type NNP 0 1 2 B-Group
9C CD 0 0 UNK I-Group
antiarrhythmics NNS 1 1 UNK I-Group
( ( 0 0 2 O
eg VB 0 1 UNK O
propafenone NN 0 1 16 B-Drug
flecainide NN 0 1 16 B-Drug
and CC 0 0 12 O
encainide NN 0 1 UNK B-Drug
) ) 0 0 2 O
or CC 0 0 12 O
that DT 0 0 12 O
inhibit NN 0 1 13 O
this DT 0 0 12 O
enzyme NN 0 1 14 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
quinidine NN 0 1 16 B-Drug
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
approached VBN 1 1 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Nevirapine NN 0 1 UNK B-Drug

and CC 0 0 12 O
diuretics NNS 1 1 14 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
furosemide NN 0 1 0 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
another DT 0 0 12 O
report NN 0 1 1 O
nine CD 0 1 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
breast JJ 0 1 6 O
cancer NN 0 1 6 O
were VBD 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
have VB 0 0 12 O
decreased VBN 1 1 1 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
- : 0 0 2 O
related JJ 0 1 1 O
toxicity NN 0 1 6 O
when WRB 0 0 12 O
given VBN 1 1 12 O
supplemental JJ 0 1 1 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
glutamine NN 0 1 13 I-Drug
at IN 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
gram NN 0 1 16 O
/ NN 0 0 2 O
kilogram NN 0 1 14 O
/ NNP 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

- : 0 0 2 O
Disulfiram NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Antabuse NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
buspirone NN 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
and CC 0 0 12 O
haloperidol NN 0 1 16 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
serum NN 0 1 14 O
haloperidol NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
induce VBP 0 1 6 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
lowered VBN 1 1 3 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
. . 0 0 12 O

Increases NNS 0 1 UNK O
in IN 0 0 12 O
sertraline NN 0 1 16 B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
guided VBN 1 1 1 O
by IN 0 0 12 O
clinical JJ 0 1 6 O
response NN 0 1 1 O
. . 0 0 12 O

Free JJ 0 1 2 O
T9 NNP 0 1 13 O
and CC 0 0 12 O
T9 NNP 0 1 13 O
concentrations NNS 1 1 13 O
are VBP 1 0 12 O
unaltered JJ 0 1 UNK O
. . 0 0 12 O

Cyclosporine NN 0 1 UNK B-Drug
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
nicardipine JJ 0 1 16 B-Drug
and CC 0 0 12 O
cyclosporine JJ 0 1 14 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
variety NN 0 1 1 O
of IN 0 0 12 O
antiarrhythmics NNS 1 1 UNK B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
quinidine NN 0 1 16 B-Drug
or CC 0 0 12 O
propranolol NN 0 1 16 B-Drug
were VBD 1 0 12 O
also RB 0 0 12 O
added VBN 1 1 12 O
sometimes RB 0 1 12 O
with IN 0 0 12 O
improved JJ 0 1 1 O
control NN 0 1 1 O
of IN 0 0 12 O
ventricular JJ 0 1 8 O
ectopy NN 0 1 8 O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
Cimetidine NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
fosfomycin NN 0 1 13 B-Drug
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
MONUROL NNP 0 1 UNK B-Brand
. . 0 0 12 O

Aripiprazole NNP 0 1 UNK B-Drug
also RB 0 0 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
undergo VB 0 0 1 O
direct JJ 0 1 1 O
glucuronidation NN 0 1 UNK O
. . 0 0 12 O

Geocillin NNP 0 1 UNK B-Brand
( ( 0 0 2 O
carbenicillin JJ 0 1 UNK B-Drug
indanyl NN 0 0 UNK I-Drug
sodium NN 0 1 14 I-Drug
) ) 0 0 2 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
and CC 0 0 12 O
prolonged VBN 1 1 6 O
by IN 0 0 12 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
. . 0 0 12 O

A DT 0 0 2 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
glucose NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

Results NNS 0 1 2 O
of IN 0 0 12 O
preliminary JJ 0 1 1 O
studies NNS 1 1 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
and CC 0 0 12 O
rats NNS 1 1 UNK O
suggest VBP 0 1 1 O
that IN 0 0 12 O
nonabsorbable JJ 0 0 UNK O
antacids NNS 1 1 14 B-Group
given VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
lactulose NN 0 1 14 B-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
desired VBN 1 1 1 O
lactulose JJ 0 1 14 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
drop NN 0 1 12 O
in IN 0 0 12 O
colonic JJ 0 1 6 O
pH NN 0 1 14 O
. . 0 0 12 O

Metoprolol NNP 0 1 0 B-Drug
- : 0 0 2 O
Administration NN 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
LEXAPRO NNP 0 1 UNK B-Brand
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocker NN 0 0 3 I-Group
metoprolol NN 0 1 0 B-Drug
( ( 0 0 2 O
given VBN 1 1 12 O
in IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
lovastatin NN 0 1 13 B-Drug
and CC 0 0 12 O
erythromycin NN 0 1 0 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
; : 0 0 2 O

These DT 0 0 1 O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
conversion NN 0 1 13 O
of IN 0 0 12 O
losartan NN 0 1 0 B-Drug
to TO 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
is VBZ 1 0 12 O
mediated VBN 1 1 13 O
primarily RB 0 0 1 O
by IN 0 0 12 O
P9 NNP 0 1 UNK O
9C9 CD 0 0 UNK O
and CC 0 0 12 O
not RB 0 1 12 O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Haloperidol NN 0 1 0 B-Drug
: : 0 0 2 O
Haloperidol NN 0 1 0 B-Drug
blocks NNS 1 1 3 O
dopamine NN 0 1 14 O
and CC 0 0 12 O
norepinephrine JJ 0 1 14 O
reuptake NN 0 1 13 O
thus RB 0 0 1 O
inhibiting VBG 1 1 UNK O
the DT 0 0 12 O
central JJ 0 1 1 O
stimulant JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
. . 0 0 12 O

Effect NN 0 1 UNK O
on IN 0 0 12 O
Concentration NNP 0 1 UNK O
of IN 0 0 12 O
Nevirapine NNP 0 1 UNK B-Drug
or CC 0 0 12 O
Concomitant NNP 0 1 UNK O
Drug NNP 0 1 2 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
consideration NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
NSAIDs NNP 0 1 UNK B-Group
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Dosage NNP 0 1 UNK O
adjustment NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
warranted VBN 1 0 1 O
when WRB 0 0 12 O
levobupivacaine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
concurrently RB 0 0 1 O
administered VBN 1 1 1 O
with IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
as IN 1 0 12 O
systemic JJ 0 1 6 O
levobupivacaine NN 0 1 UNK B-Drug
levels NNS 1 1 1 O
may MD 0 0 1 O
rise VB 0 0 1 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
toxicity NN 0 1 6 O
. . 0 0 12 O

PEGANONE NNP 0 1 UNK B-Brand
used VBD 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
adversely RB 0 0 UNK O
affect VB 0 1 1 O
the DT 0 0 12 O
hematopoietic JJ 0 1 14 O
system NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
if IN 0 0 12 O
possible JJ 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
occur VB 0 1 1 O
because IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
competitively RB 0 0 UNK O
displaces VBZ 1 0 UNK O
coumarins NNS 0 1 UNK B-Group
from IN 0 0 12 O
protein NN 0 1 14 O
binding VBG 1 1 1 O
sites NNS 1 1 1 O
. . 0 0 12 O

Sympathomimetics NNS 0 1 UNK B-Group
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
methyldopa JJ 0 1 13 B-Drug
mecamylamine NN 0 1 UNK B-Drug
reserpine NN 0 1 UNK B-Drug
and CC 0 0 12 O
veratrum NN 0 1 UNK B-Group
alkaloids NNS 1 1 13 I-Group
. . 0 0 12 O

In IN 0 0 2 O
one CD 0 1 12 O
survey NN 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
labetalol JJ 0 1 0 B-Drug
HCl NNP 0 0 14 I-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
experienced VBD 1 0 12 O
tremor NN 0 1 6 O
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
reported VBD 1 1 1 O
to TO 0 0 12 O
occur VB 0 1 1 O
with IN 0 0 12 O
labetalol JJ 0 1 0 B-Drug
HCl NNP 0 0 14 I-Drug
alone RB 0 1 12 O
. . 0 0 12 O

Antiepileptic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
: : 0 0 2 O
Potential JJ 0 1 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
Trileptal NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
AEDs NNP 0 1 UNK B-Group
were VBD 1 0 12 O
assessed VBN 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Clinically RB 0 0 7 O
significant JJ 0 1 1 O
QTc NNP 0 0 14 O
prolongation NN 0 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
with IN 0 0 12 O
Mefloquineuine NNP 0 0 UNK O
alone RB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
increased VBN 1 1 1 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
metabolite NN 0 1 UNK O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
prolonged JJ 0 1 6 O
QT NNP 0 1 13 O
intervals NNS 1 1 1 O
. . 0 0 12 O

Rifampin NN 0 1 0 B-Drug
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
VIOXX NNP 0 1 UNK B-Brand
with IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily RB 0 1 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
inducer NN 0 1 UNK O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
produced VBD 1 0 1 O
an DT 0 0 12 O
approximate JJ 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
rofecoxib NN 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

approximately RB 0 1 1 O
one CD 0 1 12 O
- : 0 0 2 O
hundredth NN 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
human NN 0 1 1 O
recommended VBD 1 1 1 O
dose RB 0 1 6 O
based VBN 1 1 1 O
on IN 0 0 12 O
body NN 0 1 3 O
surface JJ 0 1 3 O
area NN 0 1 12 O
[ NNP 0 0 2 O
BSA NNP 0 0 13 O
] NNP 0 0 2 O
) ) 0 0 2 O
fulvestrant NN 0 1 13 B-Drug
caused VBD 1 1 1 O
a DT 0 0 12 O
reversible JJ 0 1 3 O
reduction NN 0 1 1 O
in IN 0 0 12 O
female JJ 0 1 12 O
fertility NN 0 1 6 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
embryo NN 0 1 UNK O
/ NNP 0 0 2 O
fetal NN 0 1 6 O
development NN 0 1 1 O
consistent NN 0 1 1 O
with IN 0 0 12 O
its PRP$ 1 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
estrogenic JJ 0 1 UNK O
activity NN 0 1 1 O
. . 0 0 12 O

Combination NN 0 1 UNK O
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
higher JJR 1 1 1 O
frequency NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
clinical JJ 0 1 6 O
experiences NNS 1 1 12 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
dizziness NN 0 1 6 O
nausea NN 0 1 6 O
paresthesia NN 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
laboratory JJ 0 1 1 O
abnormalities NNS 1 1 6 O
( ( 0 0 2 O
elevated VBN 1 1 1 O
liver RB 0 1 6 O
enzymes RB 0 1 14 O
) ) 0 0 2 O
. . 0 0 12 O

Chirocaine NN 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
other JJ 0 0 12 O
local JJ 0 1 12 O
anesthetics NNS 1 1 13 B-Group
or CC 0 0 12 O
agents NNS 1 1 1 O
structurally RB 0 0 1 O
related VBN 1 1 1 O
to TO 0 0 12 O
amide VB 0 1 UNK O
- : 0 0 2 O
type NN 0 1 1 O
local JJ 0 1 12 O
anesthetics NNS 1 1 13 O
since IN 0 1 12 O
the DT 0 0 12 O
toxic JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
could MD 0 0 12 O
be VB 0 0 12 O
additive JJ 0 1 16 O
. . 0 0 12 O

. . 0 0 12 O

therefore IN 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
possible JJ 0 1 1 O
that IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
individual JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
more JJR 0 1 12 O
apt JJ 0 1 12 O
to TO 0 0 12 O
occur VB 0 1 1 O
. . 0 0 12 O

Dose NNP 0 1 7 O
reduction NN 0 1 1 O
of IN 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand
to TO 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Lorazepam NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
single JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
eszopiclone NN 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
lorazepam $ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
did VBD 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
or CC 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
and CC 0 0 12 O
cyclosporine VB 0 1 14 B-Drug
tacrolimus NN 0 1 16 B-Drug
or CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
has VBZ 1 0 12 O
led VBN 1 1 12 O
to TO 0 0 12 O
increased VBN 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
latter JJ 0 0 UNK O
three CD 0 1 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
following JJ 0 1 1 O
similar JJ 0 1 1 O
changes NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
expected VBN 1 1 12 O
with IN 0 0 12 O
larger JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
estrogen NN 0 1 6 B-Group
: : 0 0 2 O
Increased VBN 0 1 7 O
sulfobromophthalein JJ 0 1 UNK O
retention NN 0 1 1 O
; : 0 0 2 O

Dosage NNP 0 1 UNK O
adjustment NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
if IN 0 0 12 O
cyclosporine JJ 0 1 14 B-Drug
tacrolimus NN 0 1 16 B-Drug
or CC 0 0 12 O
methylprednisolone NN 0 1 16 B-Drug
are VBP 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
NIZORAL NNP 0 1 UNK B-Brand
Tablets NNPS 0 1 0 O
. . 0 0 12 O

these DT 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
after IN 0 0 12 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
leveomepromazine NN 0 0 UNK B-Drug
. . 0 0 12 O

Selegiline NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
( ( 0 0 2 O
N= NNP 0 1 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
selegiline NN 0 1 13 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
pramipexole NN 0 1 16 B-Drug
. . 0 0 12 O

However RB 0 0 1 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
leucovorin NN 0 1 16 B-Drug
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
intrathecally RB 0 0 UNK O
administered VBN 1 1 1 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Estrogen NNP 0 1 7 B-Group
- : 0 0 2 O
containing VBG 1 1 1 O
therapies NNS 1 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
ARIMIDEX NNP 0 1 UNK B-Brand
as IN 1 0 12 O
they PRP 0 0 12 O
may MD 0 0 1 O
diminish VB 0 1 UNK O
its PRP$ 1 0 12 O
pharmacologic JJ 0 1 14 O
action NN 0 1 13 O
. . 0 0 12 O

clinical JJ 0 1 6 O
significance NN 0 1 13 O
unknown NN 0 1 12 O
. . 0 0 12 O

However RB 0 0 1 O
in IN 0 0 12 O
selected VBN 1 1 UNK O
circumstances NNS 1 0 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
such JJ 0 0 1 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
appropriate JJ 0 1 1 O
using VBG 1 1 1 O
adequate JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
antibacterial JJ 0 1 UNK B-Group
agents NNS 1 1 1 O
and CC 0 0 12 O
beginning VBG 1 1 12 O
penicillin NN 0 1 14 O
therapy NN 0 1 6 O
first RB 0 1 12 O
should MD 0 0 12 O
minimize VB 0 0 1 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
interaction NN 0 1 UNK O
. . 0 0 12 O

Seizures NNS 0 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
another DT 0 0 12 O
quinolone NN 0 1 UNK B-Group
class NN 0 1 12 I-Group
antimicrobial NN 0 1 14 I-Group
and CC 0 0 12 O
the DT 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti NN 0 0 3 I-Group
- : 0 0 2 O
inflammatory JJ 0 1 6 I-Group
drug NN 0 1 1 I-Group
fenbufen NN 0 1 UNK B-Drug
concurrently RB 0 0 1 O
. . 0 0 12 O

Antifungal JJ 0 1 UNK B-Group
Agents NNS 0 1 2 I-Group

Antihistamines NNS 0 1 UNK B-Group
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
counteract VB 0 0 UNK O
the DT 0 0 12 O
sedative JJ 0 1 6 O
effect NN 0 1 1 O
of IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
controlled JJ 0 1 1 O
studies NNS 1 1 1 O
of IN 0 0 12 O
Nutropin NNP 0 1 UNK B-Brand
interaction NN 0 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
commonly RB 0 0 UNK O
used VBN 1 1 12 O
in IN 0 0 12 O
chronic JJ 0 1 6 O
renal JJ 0 1 6 O
insufficiency NN 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
uricosuric JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
allopurinol NN 0 1 13 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
excretion NN 0 1 14 O
of IN 0 0 12 O
oxypurines NNS 0 1 UNK O
( ( 0 0 2 O
hypoxanthine NN 0 1 UNK O
and CC 0 0 12 O
xanthine NN 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
urinary JJ 0 1 6 O
uric JJ 0 0 14 O
acid NN 0 1 14 O
excretion NN 0 1 14 O
compared VBN 1 1 1 O
with IN 0 0 12 O
that DT 0 0 12 O
observed VBD 1 1 1 O
with IN 0 0 12 O
allopurinol JJ 0 1 13 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

Enoxacin NN 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
the DT 0 0 12 O
active JJ 0 1 1 O
S NNP 0 1 2 O
- : 0 0 2 O
isomer NN 0 1 UNK O
and CC 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
clotting VBG 1 1 14 O
time NN 0 1 12 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
enoxacin NN 0 1 UNK B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
were VBD 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Oral JJ 0 1 2 O
neomycin CC 0 1 16 B-Drug
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
gastrointestinal JJ 0 1 6 O
absorption NN 0 1 1 O
of IN 0 0 12 O
penicillin NN 0 1 14 B-Drug
V NNP 0 0 2 I-Drug
oral JJ 0 1 6 O
vitamin NN 0 1 6 B-Drug
B NNP 0 0 2 I-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
methotrexate NN 0 1 16 B-Drug
and CC 0 0 12 O
9 CD 0 0 2 B-Drug
- : 0 0 2 O
fluorouracil NN 0 1 13 I-Drug
. . 0 0 12 O

At IN 0 0 2 O
steady JJ 0 1 1 O
state NN 0 1 1 O
VIOXX NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
platelet NN 0 1 14 O
activity NN 0 1 1 O
of IN 0 0 12 O
low JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
aspirin NN 0 1 14 B-Brand
as IN 1 0 12 O
assessed VBN 1 1 1 O
by IN 0 0 12 O
ex NN 0 1 12 O
vivo NNS 0 1 13 O
platelet VBP 0 1 14 O
aggregation NN 0 1 UNK O
and CC 0 0 12 O
serum NN 0 1 14 O
TXB9 NNP 0 0 UNK O
generation NN 0 1 UNK O
in IN 0 0 12 O
clotting VBG 1 1 14 O
blood NN 0 1 6 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
other JJ 0 0 12 O
narcotic JJ 0 1 6 B-Group
analgesics NNS 1 1 14 I-Group
antipsychotics NNS 1 1 14 B-Group
antianxiety NN 0 0 0 B-Group
agents NNS 1 1 1 I-Group
or CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
including VBG 1 1 1 O
alcohol NN 0 1 1 B-Drug
) ) 0 0 2 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
hydrocodone NN 0 1 UNK B-Drug
and CC 0 0 12 O
acetaminophen JJ 0 1 16 B-Drug
tablets NNS 1 1 3 O
may MD 0 0 1 O
exhibit VB 0 1 1 O
an DT 0 0 12 O
additive JJ 0 1 16 O
CNS NNP 0 1 6 O
depression NN 0 1 6 O
. . 0 0 12 O

There EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
tumor NN 0 1 6 O
incidences NNS 1 1 UNK O
in IN 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
treated VBN 1 1 1 O
rats NNS 1 1 UNK O
or CC 0 0 12 O
mice NN 1 1 UNK O
. . 0 0 12 O

A DT 0 0 2 O
clinical JJ 0 1 6 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
was VBD 1 0 12 O
also RB 0 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
alosetron NN 0 1 UNK B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
cisapride NN 0 1 UNK B-Drug
. . 0 0 12 O

9 CD 0 0 2 O
- : 0 0 2 O
OH NNP 0 1 UNK O
metabolite CD 0 1 UNK O
concentration NN 0 1 1 O

Phenytoin NNP 0 1 0 B-Drug
/ NNP 0 0 2 O
Phenobarbital NNP 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
will MD 0 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
but CC 0 0 12 O
may MD 0 0 1 O
reduce VB 0 0 1 O
endogenous JJ 0 1 14 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
calcitriol NN 0 1 14 B-Drug
/ NNP 0 0 2 O
ergocalcitriol NN 0 0 UNK O
by IN 0 0 12 O
accelerating VBG 1 1 UNK O
metabolism NN 0 1 16 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
transdermal JJ 0 1 14 O
fentanyl NN 0 1 14 B-Drug
with IN 0 0 12 O
ritonavir NN 0 1 16 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
potent JJ 0 1 UNK O
9A9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
ketoconazole JJ 0 1 16 B-Drug
itraconazole NN 0 1 0 B-Drug
troleandomycin NN 0 1 UNK B-Drug
clarithromycin NN 0 1 13 B-Drug
nelfinavir NN 0 1 16 B-Drug
and CC 0 0 12 O
nefazadone NN 0 0 UNK O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
fentanyl JJ 0 1 14 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Patients NNS 0 1 7 O
treated VBN 1 1 1 O
with IN 0 0 12 O
extended JJ 0 1 1 O
release NN 0 1 12 O
metoprolol NN 0 1 0 B-Drug
succinate NN 0 1 14 I-Drug
plus CC 0 1 16 O
a DT 0 0 12 O
catecholamine JJ 0 1 14 O
depletor NN 0 0 UNK O
should MD 0 0 12 O
therefore RB 0 0 1 O
be VB 0 0 12 O
closely RB 0 0 1 O
observed VBN 1 1 1 O
for IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
hypotension NN 0 1 6 O
or CC 0 0 12 O
marked VBN 1 1 1 O
bradycardia IN 0 1 8 O
which WDT 0 0 12 O
may MD 0 0 1 O
produce VB 0 0 1 O
vertigo JJ 0 1 6 O
syncope NN 0 1 8 O
or CC 0 0 12 O
postural JJ 0 1 13 O
hypotension NN 0 1 6 O
. . 0 0 12 O

When WRB 0 0 12 O
cholestyramine NN 0 1 13 B-Drug
resin NN 0 1 UNK B-Group
is VBZ 1 0 12 O
given VBN 1 1 12 O
for IN 0 0 12 O
long JJ 0 1 12 O
periods NNS 1 1 1 O
of IN 0 0 12 O
time NN 0 1 12 O
concomitant JJ 0 1 6 O
supplementation NN 0 1 14 O
with IN 0 0 12 O
water NN 0 1 3 O
- : 0 0 2 O
miscible NN 0 0 UNK O
( ( 0 0 2 O
or CC 0 0 12 O
parenteral NN 0 1 14 O
) ) 0 0 2 O
forms NNS 1 1 1 O
of IN 0 0 12 O
fat JJ 0 1 3 B-Group
- : 0 0 2 O
soluble JJ 0 1 16 I-Group
vitamins NNS 1 1 6 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
No DT 0 0 2 O
significant JJ 0 1 1 O
differences NNS 1 1 UNK O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
mean JJ 0 1 12 O
phenytoin NN 0 1 16 B-Drug
AUC NNP 0 1 UNK O
C NNP 0 0 2 O
max NNP 0 0 3 O
C NNP 0 0 2 O
min NN 0 1 16 O
or CC 0 0 12 O
T NNP 0 1 2 O
max NN 0 0 3 O
( ( 0 0 2 O
although IN 0 0 12 O
C NNP 0 0 2 O
max NNS 0 0 3 O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
when WRB 0 0 12 O
extended VBN 1 1 1 O
phenytoin NN 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
capsules NNS 1 1 3 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
tid NN 0 1 13 O
) ) 0 0 2 O
were VBD 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
qd NN 0 1 14 O
) ) 0 0 2 O
for IN 0 0 12 O
five CD 0 1 12 O
days NNS 1 1 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
males NNS 1 1 UNK O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
formally RB 0 0 1 O
studied VBN 1 0 1 O
. . 0 0 12 O

Repeat NNP 0 1 2 O
Treatment NNP 0 1 7 O
Studies NNPS 0 1 2 O
evaluating VBG 1 1 1 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
repeated JJ 0 1 1 O
courses NNS 1 1 1 O
of IN 0 0 12 O
Zmax NNP 0 1 UNK B-Brand
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
replacing VBG 1 1 1 O
clonidine NN 0 1 0 B-Drug
by IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blocker NN 0 0 3 I-Group
therapy VBZ 0 1 6 O
the DT 0 0 12 O
introduction NN 0 1 1 O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
delayed VBN 1 1 1 O
for IN 0 0 12 O
several JJ 0 1 12 O
days NNS 1 1 12 O
after IN 0 0 12 O
clonidine JJ 0 1 0 B-Drug
administration NN 0 1 1 O
has VBZ 1 0 12 O
stopped VBN 1 1 12 O
. . 0 0 12 O

When WRB 0 0 12 O
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
hepatic JJ 0 1 14 O
enzyme NN 0 1 14 O
inducers NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
rifampin NN 0 1 16 B-Drug
and CC 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
taken VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
Mexitil NNP 0 1 UNK B-Brand
lowered VBD 1 1 3 O
Mexitil NNP 0 1 UNK B-Brand
plasma NN 0 1 14 O
levels NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
agents NNS 1 1 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
within IN 0 0 1 O
the DT 0 0 12 O
two CD 0 1 12 O
hour NN 0 1 12 O
period NN 0 1 1 O
before IN 0 1 12 O
or CC 0 0 12 O
within IN 0 0 1 O
the DT 0 0 12 O
two CD 0 1 12 O
- : 0 0 2 O
hour NN 0 1 12 O
period NN 0 1 1 O
after IN 0 0 12 O
nalidixic JJ 0 0 UNK B-Drug
acid JJ 0 1 14 I-Drug
administration NN 0 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
qid NN 0 1 15 O
) ) 0 0 2 O
can MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
ALIMTA NNP 0 1 UNK B-Brand
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
normal JJ 0 1 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
( ( 0 0 2 O
creatinine JJ 0 1 14 O
clearance NN 0 1 16 O
9 CD 0 0 2 O
mL NN 0 1 14 O
/ NNP 0 0 2 O
min NN 0 1 16 O
) ) 0 0 2 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
ibuprofen RB 0 1 0 B-Drug
concurrently RB 0 0 1 O
with IN 0 0 12 O
ALIMTA NNP 0 1 UNK B-Brand
to TO 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
mild JJ 0 1 6 O
to TO 0 0 12 O
moderate VB 0 1 1 O
renal JJ 0 1 6 O
insufficiency NN 0 1 6 O
( ( 0 0 2 O
creatinine JJ 0 1 14 O
clearance NN 0 1 16 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mL NNS 0 1 14 O
/ NNP 0 0 2 O
min NN 0 1 16 O
) ) 0 0 2 O
. . 0 0 12 O

CYP9A9 NNP 0 0 UNK O
Interactions NNS 0 1 UNK O

In IN 0 0 2 O
view NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
long JJ 0 1 12 O
and CC 0 0 12 O
variable JJ 0 1 1 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
amiodarone JJ 0 1 0 B-Drug
potential NN 0 1 1 O
for IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
exists VBZ 1 1 UNK O
not RB 0 1 12 O
only RB 0 1 12 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
medication NN 0 1 6 O
but CC 0 0 12 O
also RB 0 0 12 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
administered VBN 1 1 1 O
after IN 0 0 12 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
. . 0 0 12 O

Inhibitors NNS 0 1 7 O
of IN 0 0 12 O
CYP9D9 NN 0 0 UNK O
: : 0 0 2 O
Because IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
is VBZ 1 0 12 O
involved VBN 1 1 12 O
in IN 0 0 12 O
duloxetine JJ 0 1 0 B-Drug
metabolism NN 0 1 16 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
duloxetine NN 0 1 0 B-Drug
with IN 0 0 12 O
potent JJ 0 1 UNK O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
higher JJR 1 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
duloxetine NN 0 1 0 B-Drug
. . 0 0 12 O

Diuretics NNS 0 1 UNK B-Group
: : 0 0 2 O
Patients NNS 0 1 7 O
on IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
especially RB 0 0 12 O
those DT 0 0 12 O
in IN 0 0 12 O
whom WP 0 0 12 O
diuretic JJ 0 1 14 O
therapy NN 0 1 6 O
was VBD 1 0 12 O
recently RB 0 1 12 O
instituted VBN 1 1 1 O
may MD 0 0 1 O
occasionally RB 0 1 12 O
experience VB 0 1 12 O
an DT 0 0 12 O
excessive JJ 0 1 1 O
reduction NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
after IN 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
Lotensin NNP 0 1 UNK B-Brand
. . 0 0 12 O

( ( 0 0 2 O
Note NN 0 1 2 O
: : 0 0 2 O
All DT 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
theophylline NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
appropriately RB 0 0 1 O
regardless JJ 0 1 UNK O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
drug NN 0 1 1 O
therapy NN 0 1 6 O
. . 0 0 12 O
) ) 0 0 2 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
nelfinavir NN 0 1 16 B-Drug
at IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
x RB 0 0 10 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
tablets NNS 1 1 3 O
) ) 0 0 2 O
results NNS 1 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
azithromycin NN 0 1 0 B-Drug
serum NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
crossover NN 0 1 UNK O
steady JJ 0 1 1 O
state NN 0 1 1 O
study VBD 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
propafenone NN 0 1 16 B-Drug
were VBD 1 0 12 O
unaffected VBN 0 1 UNK O
in IN 0 0 12 O
either DT 0 1 12 O
phenotype NN 0 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
mexiletine NN 0 1 16 B-Drug
. . 0 0 12 O

Oxytocin NNP 0 1 UNK B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
oxytocics NNS 1 1 UNK B-Group
( ( 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
with IN 0 0 12 O
dinoprost NN 0 1 UNK B-Drug
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
uterine JJ 0 1 6 O
hypertonus NN 0 1 UNK O
possibly RB 0 1 12 O
causing VBG 1 1 1 O
uterine JJ 0 1 6 O
rupture NN 0 1 6 O
or CC 0 0 12 O
cervical JJ 0 1 6 O
laceration NN 0 1 8 O
especially RB 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
adequate JJ 0 1 1 O
cervical JJ 0 1 6 O
dilatation NN 0 1 8 O
; : 0 0 2 O

Therefore RB 0 0 1 O
intake NN 0 1 3 O
of IN 0 0 12 O
supplemental JJ 0 1 1 O
folic JJ 0 0 14 B-Drug
acid NN 0 1 14 I-Drug
should MD 0 0 12 O
not RB 0 1 12 O
exceed VB 0 0 UNK O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
( ( 0 0 2 O
g NN 0 1 16 O
sometimes RB 0 1 12 O
mcg RB 0 1 0 O
) ) 0 0 2 O
per IN 0 0 1 O
day NN 0 1 12 O
to TO 0 0 12 O
prevent VB 0 1 1 O
folic JJ 0 0 14 B-Drug
acid NN 0 1 14 I-Drug
from IN 0 0 12 O
masking VBG 1 1 UNK O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
vitamin NN 0 1 6 O
B9 NNP 0 0 UNK O
deficiency NN 0 1 6 O
. . 0 0 12 O

Lithium NNP 0 1 UNK B-Drug
generally RB 0 0 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
because IN 0 0 12 O
they PRP 0 0 12 O
reduce VB 0 0 1 O
lithiums NNS 1 0 UNK B-Drug
renal JJ 0 1 6 O
clearance NN 0 1 16 O
and CC 0 0 12 O
add VB 0 1 12 O
a DT 0 0 12 O
high JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

Oral JJ 0 1 2 O
Contraceptive NNP 0 1 UNK B-Group
: : 0 0 2 O
Based VBN 0 1 2 O
on IN 0 0 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
multiple JJ 0 1 1 O
- : 0 0 2 O
dose JJ 0 1 6 O
pharmacokinetic JJ 0 1 UNK O
profiles NNS 1 1 UNK O
of IN 0 0 12 O
norethindrone NN 0 1 13 B-Drug
and CC 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
following VBG 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
tablets NNS 1 1 3 O
containing VBG 1 1 1 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
norethindrone NN 0 1 13 B-Drug
acetate NN 0 1 14 I-Drug
and CC 0 0 12 O
9 CD 0 0 2 O
mcg NN 0 1 0 O
of IN 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NNS 0 1 13 I-Drug
were VBD 1 0 12 O
similar JJ 0 1 1 O
with IN 0 0 12 O
and CC 0 0 12 O
without IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
gabapentin NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
TID NNP 0 1 15 O
; : 0 0 2 O

Drug NN 0 1 2 O
Name NN 0 1 2 O

Cocaine NNP 0 1 2 B-Drug
sometimes RB 0 1 12 O
proves VBZ 1 0 UNK O
to TO 0 0 12 O
be VB 0 0 12 O
fatal JJ 0 1 13 O
when WRB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
heroin NN 0 1 13 B-Drug_n
. . 0 0 12 O

As IN 0 0 2 O
the DT 0 0 12 O
primary JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
adenosine NN 0 1 14 B-Drug
is VBZ 1 0 12 O
to TO 0 0 12 O
decrease VB 0 1 1 O
conduction NN 0 1 6 O
through IN 0 0 12 O
the DT 0 0 12 O
A NNP 0 0 2 O
- : 0 0 2 O
V NNP 0 0 2 O
node IN 0 1 1 O
higher JJR 1 1 1 O
degrees NNS 1 1 1 O
of IN 0 0 12 O
heart NN 0 1 12 O
block NN 0 1 3 O
may MD 0 0 1 O
be VB 0 0 12 O
produced VBN 1 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
. . 0 0 12 O

Methotrexate NNP 0 1 0 B-Drug
VIOXX NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
each DT 0 0 12 O
dose NN 0 1 6 O
administered VBN 1 1 1 O
once RB 0 0 12 O
daily JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
as IN 1 0 12 O
measured VBN 1 1 1 O
by IN 0 0 12 O
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9hr CD 0 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
single JJ 0 1 12 O
weekly JJ 0 1 12 O
methotrexate NN 0 1 16 B-Drug
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
for IN 0 0 12 O
rheumatoid JJ 0 0 6 O
arthritis NN 0 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
detected VBN 1 1 1 O
except IN 0 0 12 O
for IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
symptomatic JJ 0 1 6 O
hypotension NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
oral JJ 0 1 6 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

- : 0 0 2 O
Other JJ 0 0 2 O
anti JJ 0 0 3 B-Group
- : 0 0 2 O
infectives NNS 0 0 UNK I-Group
by IN 0 0 12 O
mouth NN 0 1 3 O
or CC 0 0 12 O
by IN 0 0 12 O
injection NN 0 1 3 O
( ( 0 0 2 O
medicine NN 0 1 6 O
for IN 0 0 12 O
infection NN 0 1 6 O
) ) 0 0 2 O
or CC 0 0 12 O

No DT 0 0 2 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
for IN 0 0 12 O
Fluvoxamine NNP 0 1 UNK B-Drug
Tablets NNP 0 1 0 O
. . 0 0 12 O

Chronic JJ 0 1 7 O
administration NN 0 1 1 O
of IN 0 0 12 O
phenobarbital JJ 0 1 16 B-Drug
a DT 0 0 12 O
known JJ 0 1 12 O
enzyme JJ 0 1 14 O
inducer NN 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
fenoprofen NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
addition NN 0 1 1 O
of IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
in IN 0 0 12 O
a DT 0 0 12 O
limited JJ 0 1 1 O
number NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
in IN 0 0 12 O
three CD 0 1 12 O
well RB 0 1 12 O
- : 0 0 2 O
controlled VBN 1 1 1 O
studies NNS 1 1 1 O
caused VBD 1 1 1 O
no DT 0 0 12 O
systematic JJ 0 1 UNK O
changes NNS 1 1 1 O
in IN 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
or CC 0 0 12 O
primidone NN 0 1 13 B-Drug
concentrations NNS 1 1 13 O
when WRB 0 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
placebo VB 0 1 13 O
. . 0 0 12 O

Erythromycin NNP 0 1 0 B-Drug
use NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
receiving VBG 1 1 1 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
theophylline NN 0 1 16 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
potential JJ 0 1 1 O
theophylline NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
Multiple JJ 0 1 2 O
oral JJ 0 1 6 O
doses NNS 1 1 6 O
of IN 0 0 12 O
Sonata NNP 0 1 UNK B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
q9h NN 0 1 UNK O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
( ( 0 0 2 O
R+ NNP 0 1 UNK O
) ) 0 0 2 O
- : 0 0 2 O
or CC 0 0 12 O
( ( 0 0 2 O
S NNP 0 1 2 O
- : 0 0 2 O
) ) 0 0 2 O
- : 0 0 2 O
enantiomers NNS 1 1 UNK O
or CC 0 0 12 O
the DT 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
( ( 0 0 2 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
) ) 0 0 2 O
following VBG 1 1 1 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Similarly RB 0 0 1 O
saquinavir NN 0 1 13 B-Drug
might MD 0 0 12 O
also RB 0 0 12 O
modify VB 0 1 UNK O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates VBZ 0 1 UNK O
for IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
or CC 0 0 12 O
Pgp NNP 0 1 UNK O
. . 0 0 12 O

If IN 0 0 12 O
this DT 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
possible JJ 0 1 1 O
the DT 0 0 12 O
starting VBG 1 1 12 O
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

Refer NN 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
package NN 0 1 13 O
insert NN 0 1 13 O
for IN 0 0 12 O
lithium NN 0 1 16 B-Drug
preparations NNS 1 1 13 O
before IN 0 1 12 O
use NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
preparations NNS 1 1 13 O
with IN 0 0 12 O
chlorothiazide NN 0 1 16 B-Drug

Carbamazepine NN 0 1 UNK B-Drug
: : 0 0 2 O
Carbamazepine NNP 0 1 UNK B-Drug
causes VBZ 1 1 6 O
an DT 0 0 12 O
approximate JJ 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
at IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
and CC 0 0 12 O
therefore RB 0 0 1 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
results NNS 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
approximate JJ 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
trough IN 0 1 3 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
given VBN 1 1 12 O
as IN 1 0 12 O
monotherapy NN 0 0 14 O
. . 0 0 12 O

Inhibits NNS 0 1 UNK O
CYP9D9 NNP 0 0 UNK O
( ( 0 0 2 O
weak JJ 0 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

Valdecoxib NNP 0 1 UNK B-Drug
steady JJ 0 1 1 O
state NN 0 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
significantly RB 0 0 1 O
with IN 0 0 12 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
omeprazole NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
QD NNP 0 1 13 O
) ) 0 0 2 O
. . 0 0 12 O

N=9 NNP 0 1 UNK O
) ) 0 0 2 O
were VBD 1 0 12 O
not RB 0 1 12 O
different JJ 0 1 1 O
and CC 0 0 12 O
neither DT 0 0 12 O
were VBD 1 0 12 O
gabapentin JJ 0 1 0 B-Drug
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
affected VBN 1 1 1 O
by IN 0 0 12 O
valproic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O

( ( 0 0 2 O
Thiazide NNP 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
responsiveness NN 0 1 UNK O
to TO 0 0 12 O
tubocurarine VB 0 1 UNK B-Drug
. . 0 0 12 O
) ) 0 0 2 O

However RB 0 0 1 O
decreases VBZ 1 1 UNK O
in IN 0 0 12 O
exposure NN 0 1 1 O
were VBD 1 0 12 O
as RB 0 0 12 O
much JJ 0 0 12 O
as IN 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
in IN 0 0 12 O
individual JJ 0 1 1 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
initiating VBG 1 1 1 O
pressor NN 0 1 14 O
therapy NN 0 1 6 O
in IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
initial JJ 0 1 1 O
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
small JJ 0 1 12 O
and CC 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
due JJ 0 1 1 O
caution NN 0 0 1 O
. . 0 0 12 O

None NN 0 0 2 O
known VBN 1 1 12 O
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
Antacids NNP 0 1 UNK B-Group
on IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
The DT 0 0 2 O
rate NN 0 1 1 O
and CC 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
as IN 1 0 12 O
monotherapy NN 0 0 14 O
given VBN 1 1 12 O
as IN 1 0 12 O
tablets NNS 1 1 3 O
was VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
antacids NNS 1 1 14 B-Group
. . 0 0 12 O

Alcohol NNP 0 1 2 B-Drug
( ( 0 0 2 O
increases NNS 1 1 1 O
bioavailability NN 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
cimetidine NN 0 1 13 B-Drug
and CC 0 0 12 O
valproates NNS 0 0 UNK O
. . 0 0 12 O

If IN 0 0 12 O
TRANXENE NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
acting VBG 1 1 12 O
on IN 0 0 12 O
the DT 0 0 12 O
central JJ 0 1 1 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
careful JJ 0 1 12 O
consideration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
pharmacology NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
agents NNS 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
employed VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
on IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
is VBZ 1 0 12 O
variable JJ 0 1 1 O
. . 0 0 12 O

Certain NNP 0 1 UNK O
other JJ 0 0 12 O
antibiotics NNS 1 1 6 B-Group
( ( 0 0 2 O
aminoglycosides NNS 0 1 13 B-Group
and CC 0 0 12 O
polymyxin NN 0 1 16 B-Group
) ) 0 0 2 O
have VBP 0 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
nerve NN 0 1 6 O
transmission NN 0 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
junction NN 0 1 3 O
. . 0 0 12 O

prolonged JJ 0 1 6 B-Group
narcotics NNS 1 1 1 I-Group
; : 0 0 2 O

The DT 0 0 2 O
hypoglycemic JJ 0 1 14 O
action NN 0 1 13 O
of IN 0 0 12 O
sulfonylureas NNS 1 1 UNK B-Group
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
nonsteroidal JJ 0 0 14 B-Group
anti JJ 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
bound NN 0 1 12 O
salicylates VBZ 0 1 13 B-Group
sulfonamides NNS 1 1 13 B-Group
chloramphenicol JJ 0 1 14 B-Drug
probenecid NN 0 1 13 B-Drug
coumarins NNS 0 1 UNK B-Group
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
beta NN 0 1 16 B-Group
adrenergic NNS 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
its PRP$ 1 0 12 O

Only RB 0 1 2 O
at IN 0 0 12 O
the DT 0 0 12 O
highest JJS 1 1 1 O
concentration NN 0 1 1 O
tested VBD 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
diminish VB 0 1 UNK O
oral JJ 0 1 6 O
anticoagulant JJ 0 1 13 B-Group
response NN 0 1 1 O
ie NN 0 0 1 O
decreased VBD 1 1 1 O
prothrom IN 0 0 UNK O
- : 0 0 2 O
bin NN 0 1 UNK O
time NN 0 1 12 O
response NN 0 1 1 O
in IN 0 0 12 O
man NN 0 1 12 O
significantly RB 0 0 1 O
include VBP 0 1 1 O
: : 0 0 2 O
adrenocortical JJ 0 1 UNK B-Group
steroids NNS 1 1 6 I-Group
; : 0 0 2 O

Adrenergic NNP 0 1 UNK B-Group
blockers NNS 1 0 6 I-Group
Adrenergic NNP 0 1 UNK B-Group
blockers NNS 1 0 6 I-Group
are VBP 1 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
. . 0 0 12 O

- : 0 0 2 O
Carbamazepine NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Tegretol NNP 0 1 0 B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Reduce NNP 0 0 UNK O
both CC 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
levomepromazine NN 0 1 UNK B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
mediated VBN 1 1 13 O
by IN 0 0 12 O
cimetidines NNS 1 0 UNK B-Drug
known VBN 1 1 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
the DT 0 0 12 O
enzyme NN 0 1 14 O
system NN 0 1 1 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
- : 0 0 2 O
pass NN 1 1 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
. . 0 0 12 O

GI NNP 0 1 6 O
motility NN 0 1 6 O
agents NNS 1 1 1 O
: : 0 0 2 O
cisapride NN 0 1 UNK B-Drug

The DT 0 0 2 O
following NN 0 1 1 O
are VBP 1 0 12 O
examples NNS 1 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
other JJ 0 0 12 O
related JJ 0 1 1 O
benzodiazepines NNS 1 1 14 B-Group
presumably RB 0 0 12 O
through IN 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
CYP9A NNP 0 0 UNK O
: : 0 0 2 O
nefazodone NN 0 1 16 B-Drug
fluvoxamine NN 0 1 16 B-Drug
cimetidine NN 0 1 13 B-Drug
diltiazem NN 0 1 0 B-Drug
isoniazide NN 0 0 UNK B-Drug
and CC 0 0 12 O
some DT 0 0 12 O
macrolide JJ 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
. . 0 0 12 O

Adrenal JJ 0 0 7 B-Group
steroids NNS 1 1 6 I-Group
or CC 0 0 12 O
ACTH NNP 0 1 UNK B-Drug
In IN 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
edema JJ 0 1 6 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
with IN 0 0 12 O
adrenal JJ 0 0 6 B-Group
cortical JJ 0 1 8 I-Group
steroids NNS 1 1 6 I-Group
or CC 0 0 12 O
ACTH NNP 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
edema NN 0 1 6 O
. . 0 0 12 O

MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
prolong RB 0 0 13 O
and CC 0 0 12 O
intensify VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
. . 0 0 12 O

Probenecid NNP 0 1 UNK B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
cephalosporins NNS 1 1 14 B-Group
when WRB 0 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
increased VBN 1 1 1 O
and CC 0 0 12 O
more RBR 0 1 12 O
prolonged JJ 0 1 6 O
cephalosporin NN 0 1 13 B-Group
blood NN 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
naltrexone NN 0 1 13 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
major JJ 0 1 1 O
metabolite NN 0 1 UNK O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
beta NN 0 1 16 I-Drug_n
- : 0 0 2 O
naltrexol NN 0 1 UNK I-Drug_n
were VBD 1 0 12 O
unaffected JJ 0 1 UNK O
following VBG 1 1 1 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
with IN 0 0 12 O
Acamprosate NNP 0 1 UNK B-Drug
. . 0 0 12 O

there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
major JJ 0 1 1 O
metabolites NNS 1 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
DFUR NN 0 0 UNK I-Drug_n
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
FU NN 0 1 11 I-Drug_n
and CC 0 0 12 O
FBAL NNP 0 1 UNK B-Drug_n
) ) 0 0 2 O
. . 0 0 12 O

MAO NNP 0 1 14 B-Group
Inhibitors NNP 0 1 7 I-Group
- : 0 0 2 O
The DT 0 0 2 O
pressor NN 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
pressor NN 0 1 14 I-Group
amines NNS 1 1 13 I-Group
is VBZ 1 0 12 O
markedly RB 0 1 1 O
potentiated VBN 1 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
MAOI NNP 0 1 UNK B-Group
) ) 0 0 2 O
. . 0 0 12 O

free JJ 0 1 12 O
T9 NNP 0 1 13 O
concentration NN 0 1 1 O
is VBZ 1 0 12 O
unaltered JJ 0 1 UNK O
: : 0 0 2 O
impaired JJ 0 1 6 O
glucose JJ 0 1 14 O
tolerance NN 0 1 1 O
; : 0 0 2 O

NovoSeven RB 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
mixed JJ 0 1 3 O
with IN 0 0 12 O
infusion JJ 0 1 14 O
solutions NNS 1 1 UNK O
until IN 0 0 12 O
clinical JJ 0 1 6 O
data NNS 0 1 1 O
are VBP 1 0 12 O
available JJ 0 1 1 O
to TO 0 0 12 O
direct VB 0 1 1 O
this DT 0 0 12 O
use NN 0 1 1 O
. . 0 0 12 O

Calcium NN 0 1 7 B-Group
Antagonists NNS 0 1 UNK I-Group
: : 0 0 2 O
After IN 0 0 2 O
repeated VBN 1 1 1 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
Trileptal NNP 0 1 UNK B-Brand
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
was VBD 1 0 12 O
lowered VBN 1 1 3 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
[ JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
. . 0 0 12 O

Morphine NN 0 1 0 B-Drug
: : 0 0 2 O
Combination NNP 0 1 UNK O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
morphine NN 0 1 14 B-Drug
. . 0 0 12 O

Fentanyl NNP 0 1 0 B-Drug
Anesthesia NNP 0 1 7 O
: : 0 0 2 O
Severe JJ 0 1 7 O
hypotension NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
during IN 0 0 12 O
fentanyl JJ 0 1 14 B-Drug
anesthesia NN 0 1 6 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
beta NN 0 1 16 B-Group
blocker NN 0 0 3 I-Group
and CC 0 0 12 O
a DT 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blocker NN 0 0 3 I-Group
. . 0 0 12 O

With IN 0 0 2 O
the DT 0 0 12 O
morning NN 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
ceftibuten NNS 0 1 UNK B-Drug
on IN 0 0 12 O
day NN 0 1 12 O
9 CD 0 0 2 O
each DT 0 0 12 O
volunteer NN 0 1 13 O
received VBD 1 1 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
intravenous JJ 0 1 14 O
infusion NN 0 1 14 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
. . 0 0 12 O

influenza JJ 0 1 6 B-Group
virus NN 0 1 6 I-Group
vaccine NN 0 1 6 I-Group
; : 0 0 2 O

Prospective JJ 0 1 UNK O
long RB 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
studies NNS 1 1 1 O
on IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
VIOXX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
aspirin NNS 0 1 14 B-Brand
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Acyclovir NNP 0 1 0 B-Drug
/ NNP 0 0 2 O
Ganciclovir NNP 0 1 UNK B-Drug
: : 0 0 2 O
may MD 0 0 1 O
be VB 0 0 12 O
taken VBN 1 1 12 O
with IN 0 0 12 O
Myfortic NNP 0 1 UNK B-Brand
; : 0 0 2 O

Pyrimethamine NN 0 1 UNK B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
sulfonamides NNS 1 1 13 B-Group
quinine VBP 0 1 16 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
antimalarials NNS 1 1 13 B-Group
and CC 0 0 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
antibiotics NNS 1 1 6 B-Group
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
No NNP 0 0 2 O
laboratory NN 0 1 1 O
test NN 0 1 1 O
abnormalities NNS 1 1 6 O
related VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
guanfacine NN 0 1 13 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
identified VBN 1 1 1 O
. . 0 0 12 O

Histamine NNP 0 1 7 B-Group
H9 NNP 0 0 UNK I-Group
antagonists NNS 1 1 13 I-Group
: : 0 0 2 O
Cimetidine NNP 0 1 0 B-Drug
inhibits VBZ 1 1 UNK O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
can MD 0 0 12 O
increase VB 0 1 1 O
serum VB 0 1 14 O
amiodarone JJ 0 1 0 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
and CC 0 0 12 O
flumazenil NN 0 1 13 B-Drug
. . 0 0 12 O

Such JJ 0 0 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
unresponsive JJ 0 1 6 O
to TO 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
epinephrine NN 0 1 14 B-Drug
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
allergic JJ 0 1 6 O
reactions NNS 1 1 1 O
. . 0 0 12 O

Mazindol NNP 0 1 UNK B-Drug
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
guanethidine NN 0 1 UNK B-Drug
( ( 0 0 2 O
Ismelin NNP 0 1 UNK B-Brand
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
para NN 0 1 13 O
- : 0 0 2 O
aminobenzoic NN 0 0 UNK O
acid IN 0 1 14 O
metabolite NN 0 1 UNK O
of IN 0 0 12 O
chloroprocaine NN 0 1 13 O
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
sulfonamides NNS 1 1 13 B-Group
. . 0 0 12 O

Patients NNS 0 1 7 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Furthermore RB 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
combining VBG 1 1 UNK O
digoxin NN 0 1 14 B-Drug
with IN 0 0 12 O
any DT 0 0 12 O
drug NN 0 1 1 O
that WDT 0 0 12 O
may MD 0 0 1 O
cause VB 0 1 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
deterioration NN 0 1 1 O
in IN 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
since IN 0 1 12 O
a DT 0 0 12 O
decline NN 0 0 1 O
in IN 0 0 12 O
glomerular JJ 0 1 UNK O
filtration NN 0 1 3 O
or CC 0 0 12 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
may MD 0 0 1 O
impair VB 0 0 13 O
the DT 0 0 12 O
excretion NN 0 1 14 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

Additional JJ 0 1 2 O
interactions NNS 1 1 UNK O

TOLECTIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
in IN 0 0 12 O
an DT 0 0 12 O
animal JJ 0 1 13 O
model NN 0 1 UNK O
possibly RB 0 1 12 O
enhancing VBG 1 1 1 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Chlorpropamide NN 0 1 UNK B-Drug
: : 0 0 2 O
Chlorpropamides NNP 0 1 UNK B-Drug
plasma VBP 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
may MD 0 0 1 O
be VB 0 0 12 O
prolonged VBN 1 1 6 O
by IN 0 0 12 O
allopurinol NN 0 1 13 B-Drug
since IN 0 1 12 O
allopurinol NN 0 1 13 B-Drug
and CC 0 0 12 O
chlorpropamide NN 0 1 13 B-Drug
may MD 0 0 1 O
compete VB 0 0 UNK O
for IN 0 0 12 O
excretion NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
renal JJ 0 1 6 O
tubule NN 0 0 UNK O
. . 0 0 12 O

If IN 0 0 12 O
resumed VBN 1 1 12 O
during IN 0 0 12 O
captopril JJ 0 1 0 B-Drug
therapy NN 0 1 6 O
such JJ 0 0 1 O
agents NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
cautiously RB 0 0 UNK O
and CC 0 0 12 O
perhaps RB 0 0 12 O
at IN 0 0 12 O
lower JJR 1 1 1 O
dosage NN 0 1 0 O
. . 0 0 12 O

Hypotension NN 0 1 7 O
: : 0 0 2 O
Patients NNS 0 1 7 O
on IN 0 0 12 O
Diuretic JJ 0 1 UNK O
Therapy NN 0 1 2 O
: : 0 0 2 O
Patients NNS 0 1 7 O
on IN 0 0 12 O
diuretics NNS 1 1 14 B-Drug
and CC 0 0 12 O
especially RB 0 0 12 O
those DT 0 0 12 O
in IN 0 0 12 O
whom WP 0 0 12 O
diuretic JJ 0 1 14 O
therapy NN 0 1 6 O
was VBD 1 0 12 O
recently RB 0 1 12 O
instituted VBN 1 1 1 O
may MD 0 0 1 O
occasionally RB 0 1 12 O
experience VB 0 1 12 O
an DT 0 0 12 O
excessive JJ 0 1 1 O
reduction NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
after IN 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
enalapril NN 0 1 0 B-Drug
or CC 0 0 12 O
enalaprilat NN 0 1 16 B-Drug
. . 0 0 12 O

Morphine NN 0 1 0 B-Drug
: : 0 0 2 O
TORADOLIV NNP 0 0 UNK O
/ NNP 0 0 2 O
IM NNP 0 1 11 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
morphine NN 0 1 14 B-Drug
in IN 0 0 12 O
several JJ 0 1 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
of IN 0 0 12 O
postoperative JJ 0 1 6 O
pain NN 0 1 6 O
without IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Hydrochlorothiazide NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
and CC 0 0 12 O
hydrochlorothiazide NN 0 1 0 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
significantly RB 0 0 1 O
increased VBN 1 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
hydrochlorothiazide NN 0 1 0 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
such JJ 0 0 1 O
patients NNS 1 1 6 O
the DT 0 0 12 O
mean JJ 0 1 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
felodipine NN 0 1 13 B-Drug
plasma NN 0 1 14 O
concentration NN 0 1 1 O
- : 0 0 2 O
time NN 0 1 12 O
curve NN 0 1 13 O
was VBD 1 0 12 O
also RB 0 0 12 O
reduced VBN 1 1 1 O
to TO 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
that DT 0 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Protease NNP 0 1 UNK B-Group
inhibitor NN 0 1 14 I-Group
: : 0 0 2 O
atazanavir NN 0 1 13 B-Drug

TRACRIUM NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
until IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
has VBZ 1 0 12 O
recovered VBN 1 1 12 O
from IN 0 0 12 O
succinylcholine JJ 0 1 16 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
neuromuscular JJ 0 1 6 O
block NN 0 1 3 O
. . 0 0 12 O

9 CD 0 0 2 O
mM NN 0 0 UNK O
) ) 0 0 2 O
was VBD 1 0 12 O
a DT 0 0 12 O
slight JJ 0 1 3 O
degree NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
of IN 0 0 12 O
isoform NN 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
observed VBD 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
tetracycline NN 0 1 0 B-Drug
and CC 0 0 12 O
Penthrane NNP 0 1 UNK B-Brand
( ( 0 0 2 O
methoxyflurane NN 0 1 UNK B-Drug
) ) 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
fatal JJ 0 1 13 O
renal JJ 0 1 6 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Cytochrome NNP 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
) ) 0 0 2 O
is VBZ 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
the DT 0 0 12 O
major JJ 0 1 1 O
enzyme NN 0 1 14 O
involved VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
an DT 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
study NN 0 1 1 O
cytochrome VBP 0 1 UNK O
P9 NNP 0 1 UNK O
isozymes VBZ 0 1 UNK O
9A9 CD 0 0 UNK O
9A9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9D9 CD 0 0 UNK O
9E9 CD 0 0 UNK O
and CC 0 0 12 O
9A9 CD 0 0 UNK O
were VBD 1 0 12 O
not RB 0 1 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
exposure NN 0 1 1 O
to TO 0 0 12 O
cevimeline VB 0 1 13 B-Drug
. . 0 0 12 O

Inhibitors NNS 0 1 7 O
of IN 0 0 12 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
isoenzyme NN 0 1 13 O
could MD 0 0 12 O
increase VB 0 1 1 O
systemic JJ 0 1 6 O
dofetilide JJ 0 1 13 B-Drug
exposure NN 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
medicine NN 0 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
with IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Like IN 0 0 UNK O
isoflurane JJ 0 1 UNK B-Drug
desflurane NN 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
predispose VB 0 0 UNK O
to TO 0 0 12 O
premature VB 0 1 6 O
ventricular JJ 0 1 8 O
arrhythmias NNS 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
exogenously RB 0 0 UNK O
infused VBN 1 0 3 O
epinephrine NN 0 1 14 B-Drug
in IN 0 0 12 O
swine NN 0 1 UNK O
. . 0 0 12 O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
Animal JJ 0 1 UNK O
studies NNS 1 1 1 O
wshow VBP 0 0 UNK O
that IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
given VBN 1 1 12 O
with IN 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory JJ 0 1 6 I-Group
agents NNS 1 1 1 I-Group
including VBG 1 1 1 O
ibuprofen JJ 0 1 0 B-Drug
yields NNS 1 0 UNK O
a DT 0 0 12 O
net JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
inflammatory NN 0 1 6 O
activity NN 0 1 1 O
with IN 0 0 12 O
lowered VBN 1 1 3 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
aspirin JJ 0 1 14 O
drug NN 0 1 1 O
. . 0 0 12 O

Lithium NNP 0 1 UNK B-Drug
toxicity NN 0 1 6 O
was VBD 1 0 12 O
usually RB 0 1 12 O
reversible JJ 0 1 3 O
upon IN 0 0 12 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitor NN 0 1 14 I-Group
. . 0 0 12 O

Ergotamine NN 0 1 UNK B-Drug

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
astemizole NN 0 1 UNK B-Drug
with IN 0 0 12 O
ketoconazole JJ 0 1 16 B-Drug
tablets NNS 1 1 3 O
is VBZ 1 0 12 O
therefore RB 0 0 1 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

therefore IN 0 0 1 O
it PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
recognized VBN 1 0 13 O
that IN 0 0 12 O
a DT 0 0 12 O
positive JJ 0 1 1 O
Coombs NNP 0 1 19 O
test NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Amiodarone NN 0 1 0 B-Drug
( ( 0 0 2 O
e.g. VB 0 0 UNK O
Cordarone NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

alopecia NN 0 1 6 O

The DT 0 0 2 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blocker NN 0 0 3 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
withdrawn VBN 1 1 1 O
first RB 0 1 12 O
. . 0 0 12 O

Oxcarbazepine NN 0 1 UNK B-Drug
can MD 0 0 12 O
inhibit VB 0 1 13 O
CYP9C9 NNP 0 0 UNK O
and CC 0 0 12 O
induce VB 0 1 6 O
CYP9A9 NNP 0 0 UNK O
/ NNP 0 0 2 O
9 CD 0 0 2 O
with IN 0 0 12 O
potentially RB 0 0 1 O
important JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

After IN 0 0 2 O
extensive JJ 0 1 1 O
intake NN 0 1 3 O
of IN 0 0 12 O
grapefruit NN 0 1 3 O
juice NN 0 1 3 O
( ( 0 0 2 O
which WDT 0 0 12 O
inhibits VBZ 1 1 UNK O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
predominantly RB 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
intestinal JJ 0 1 13 O
mucosa NN 0 1 8 O
) ) 0 0 2 O
the DT 0 0 12 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
for IN 0 0 12 O
oral JJ 0 1 6 O
budesonide NN 0 1 16 B-Drug
increased VBD 1 1 1 O
about RB 0 1 12 O
two CD 0 1 12 O
times NNS 1 1 12 O
. . 0 0 12 O

alcohol NN 0 1 1 B-Drug
barbiturates NNS 1 1 14 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Drug
depressants NNS 1 0 13 I-Drug
; : 0 0 2 O

- : 0 0 2 O
Methotrexate NN 0 1 0 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Mexate NNP 0 1 UNK B-Brand
) ) 0 0 2 O
Use NNP 0 1 2 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
with IN 0 0 12 O
sulfapyridine NN 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
chance NN 0 1 12 O
of IN 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
affecting VBG 1 1 1 O
the DT 0 0 12 O
liver NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
the DT 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug

Fibrates NNS 0 1 UNK B-Group
may MD 0 0 1 O
increase VB 0 1 1 O
cholesterol NN 0 1 6 O
excretion NN 0 1 14 O
into IN 0 0 12 O
the DT 0 0 12 O
bile NN 0 1 6 O
leading VBG 1 1 1 O
to TO 0 0 12 O
cholelithiasis NN 0 1 8 O
. . 0 0 12 O

Because IN 0 0 12 O
pregnancy NN 0 1 6 O
could MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
maintained VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
rabbit NN 0 1 16 O
following VBG 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
fulvestrant NN 0 1 13 B-Drug
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
and CC 0 0 12 O
above IN 0 1 12 O
this DT 0 0 12 O
study NN 0 1 1 O
was VBD 1 0 12 O
inadequate JJ 0 1 1 O
to TO 0 0 12 O
fully RB 0 0 1 O
define VB 0 0 1 O
the DT 0 0 12 O
possible JJ 0 1 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
fetal JJ 0 1 6 O
development NN 0 1 1 O
at IN 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
exposures NNS 1 1 UNK O
. . 0 0 12 O

If IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
are VBP 1 0 12 O
also RB 0 0 12 O
being VBG 1 0 12 O
given VBN 1 1 12 O
compensatory NN 0 1 13 O
increases NNS 1 1 1 O
in IN 0 0 12 O
clotting VBG 1 1 14 O
factor NN 0 1 1 O
synthesis NN 0 1 UNK O
are VBP 1 0 12 O
impaired VBN 1 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
other JJ 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
were VBD 1 0 12 O
changed VBN 1 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
sulfonylureas NNS 1 1 UNK B-Group
or CC 0 0 12 O
biguanides NNS 0 1 UNK B-Group
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
adverse JJ 0 0 1 O
event NN 0 1 12 O
profile NN 0 1 1 O
of IN 0 0 12 O
SYMLIN NNP 0 1 UNK B-Brand
. . 0 0 12 O

Carcinogenesis NNP 0 1 UNK O
Mutagenesis NNP 0 1 UNK O
Impairment NNP 0 1 UNK O
of IN 0 0 12 O
Fertility NNP 0 1 7 O
No NNP 0 0 2 O
long JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
carcinogenicity NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
carried VBN 1 1 12 O
out RP 0 1 12 O
with IN 0 0 12 O
dexrazoxane NN 0 1 13 B-Drug
in IN 0 0 12 O
animals NNS 1 1 12 O
. . 0 0 12 O

These DT 0 0 1 O
findings NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
into IN 0 0 12 O
account NN 0 1 1 O
for IN 0 0 12 O
proper JJ 0 0 1 O
interpretation NN 0 1 1 O
of IN 0 0 12 O
serum NN 0 1 14 O
PSA NNP 0 1 13 O
when WRB 0 0 12 O
evaluating VBG 1 1 1 O
men NNS 0 1 13 O
treated VBN 1 1 1 O
with IN 0 0 12 O
finasteride NN 0 1 16 B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
who WP 0 0 12 O
require VBP 0 0 1 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
HIVID NNP 0 1 UNK B-Drug
should MD 0 0 12 O
have VB 0 0 12 O
frequent JJ 0 1 1 O
clinical JJ 0 1 6 O
and CC 0 0 12 O
laboratory JJ 0 1 1 O
monitoring NN 0 1 1 O
with IN 0 0 12 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
for IN 0 0 12 O
any DT 0 0 12 O
significant JJ 0 1 1 O
change NN 0 1 1 O
in IN 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
controlled JJ 0 1 1 O
clinical JJ 0 1 6 O
trial NN 0 1 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
reduction NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
phenytoin NN 0 1 16 B-Drug
dose NN 0 1 6 O
at IN 0 0 12 O
the DT 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
levels NNS 1 1 1 O
comparable JJ 0 0 1 O
to TO 0 0 12 O
those DT 0 0 12 O
prior JJ 0 1 1 O
to TO 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
administration NN 0 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
phenytoin VBN 0 1 16 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
hepatic JJ 0 1 14 O
enzyme NN 0 1 14 O
inducers NNS 1 1 UNK O
are VBP 1 0 12 O
taken VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
Norpace NNP 0 1 0 B-Brand
or CC 0 0 12 O
Norpace NNP 0 1 0 B-Brand
CR NNP 0 1 13 I-Brand
lower JJR 1 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
disopyramide NN 0 1 16 B-Drug
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

Chlorpromazine NN 0 1 UNK B-Drug
: : 0 0 2 O
Chlorpromazine NN 0 1 UNK B-Drug
blocks NNS 1 1 3 O
dopamine NN 0 1 14 O
and CC 0 0 12 O
norepinephrine JJ 0 1 14 O
receptors NNS 1 1 13 O
thus RB 0 0 1 O
inhibiting VBG 1 1 UNK O
the DT 0 0 12 O
central JJ 0 1 1 O
stimulant JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
and CC 0 0 12 O
can MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
amphetamine JJ 0 1 13 B-Group
poisoning NN 0 1 13 O
. . 0 0 12 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
consideration NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
NSAIDs NNP 0 1 UNK B-Group
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Studies NNS 0 1 2 O
with IN 0 0 12 O
furosemide JJ 0 1 0 B-Drug
agents NNS 1 1 1 O
and CC 0 0 12 O
meloxicam NNS 0 1 13 B-Drug
have VBP 0 0 12 O
not RB 0 1 12 O
demonstrated VBN 1 0 1 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
natriuretic JJ 0 1 UNK O
effect NN 0 1 1 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
for IN 0 0 12 O
Vitamin NNP 0 1 2 B-Drug
B9 NNP 0 0 UNK I-Drug
( ( 0 0 2 O
Riboflavin NNP 0 1 UNK B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Alcohol NNP 0 1 2 B-Drug
- : 0 0 2 O
impairs VBZ 1 0 UNK O
the DT 0 0 12 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
riboflavin NN 0 1 13 B-Drug

) ) 0 0 2 O

Potential NNP 0 1 UNK O
for IN 0 0 12 O
ABILIFY NNP 0 1 UNK B-Brand
to TO 0 0 12 O
Affect VB 0 1 UNK O
Other JJ 0 0 2 O
Drugs NNP 0 1 2 O
Aripiprazole NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Positive NNP 0 1 2 O
direct JJ 0 1 1 O
Coombs NNP 0 1 19 O
tests NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
the DT 0 0 12 O
cephalosporin NN 0 1 13 B-Group
antibiotics NNS 1 1 6 I-Group
. . 0 0 12 O

Because IN 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
glucose JJ 0 1 14 O
concentrations NNS 1 1 13 O
with IN 0 0 12 O
valdecoxib JJ 0 1 13 B-Drug
coadministration NN 0 1 UNK O
were VBD 1 0 12 O
within IN 0 0 1 O
the DT 0 0 12 O
normal JJ 0 1 1 O
variability NN 0 1 UNK O
and CC 0 0 12 O
individual JJ 0 1 1 O
glucose NN 0 1 14 O
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
above IN 0 1 12 O
or CC 0 0 12 O
near IN 0 1 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
dL NN 0 1 14 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
for IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
QD NNP 0 1 13 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
with IN 0 0 12 O
valdecoxib JJ 0 1 13 B-Drug
coadministration NN 0 1 UNK O
( ( 0 0 2 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
QD NNP 0 1 13 O
) ) 0 0 2 O
is VBZ 1 0 12 O
not RB 0 1 12 O
indicated VBN 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
possible JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
FOSCAVIR NNP 0 1 UNK B-Brand
and CC 0 0 12 O
intravenous JJ 0 1 14 O
pentamidine NN 0 1 14 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
described VBN 1 1 1 O
. . 0 0 12 O

diet JJ 0 1 6 O
high JJ 0 1 1 O
in IN 0 0 12 O
vitamin JJ 0 1 6 B-Group
K NNP 0 1 2 I-Group
; : 0 0 2 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
peripheral JJ 0 1 6 O
neuropathy JJ 0 1 6 O
include VBP 0 1 1 O
antiretroviral JJ 0 0 UNK B-Drug
nucleoside RB 0 1 UNK I-Drug
analogues VBZ 0 1 UNK I-Drug
chloramphenicol NN 0 1 14 B-Drug
cisplatin NN 0 1 14 B-Drug
dapsone NN 0 1 13 B-Drug
disulfiram NN 0 1 13 B-Drug
ethionamide IN 0 1 UNK B-Drug
glutethimide JJ 0 1 13 B-Drug
gold NN 0 1 UNK B-Drug
hydralazine NN 0 1 14 B-Drug
iodoquinol NN 0 1 13 B-Drug
isoniazid JJ 0 1 13 B-Drug
metronidazole NN 0 1 0 B-Drug
nitrofurantoin NN 0 1 0 B-Drug
phenytoin NN 0 1 16 B-Drug
ribavirin NN 0 1 13 B-Drug
and CC 0 0 12 O
vincristine NN 0 1 16 B-Drug
. . 0 0 12 O

dosage NN 0 1 0 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
antigout IN 0 0 UNK B-Group
medications NNS 1 1 6 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
to TO 0 0 12 O
control VB 0 1 1 O
hyperuricemia NN 0 1 14 O
and CC 0 0 12 O
gout NN 0 1 6 O
. . 0 0 12 O
) ) 0 0 2 O

Some DT 0 0 2 O
diuretics NNS 1 1 14 B-Group
can MD 0 0 12 O
enhance VB 0 1 UNK O
aminoglycoside JJ 0 1 14 B-Group
toxicity NN 0 1 6 O
by IN 0 0 12 O
altering VBG 1 1 1 O
antibiotic JJ 0 1 6 B-Group
concentrations NNS 1 1 13 O
in IN 0 0 12 O
serum NN 0 1 14 O
and CC 0 0 12 O
tissue NN 0 1 6 O
. . 0 0 12 O

SSRIs NN 0 1 UNK B-Group
: : 0 0 2 O
Weakness NNP 0 1 UNK O
hyperreflexia NN 0 1 8 O
and CC 0 0 12 O
incoordination NN 0 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
rarely RB 0 1 UNK O
when WRB 0 0 12 O
9 CD 0 0 2 B-Group
- : 0 0 2 O
HT9 NN 0 1 UNK I-Group
agonists NNS 1 1 UNK I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
SSRIs NNP 0 1 UNK B-Group
( ( 0 0 2 O
e. JJ 0 0 1 O
g NN 0 1 16 O
. . 0 0 12 O

Vasopressors NNS 0 1 UNK B-Group
particularly RB 0 0 1 O
metaraminol VBP 0 1 UNK B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
serious JJ 0 1 12 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
during IN 0 0 12 O
halothane NN 0 1 13 B-Drug
anesthesia NN 0 1 6 O
and CC 0 0 12 O
therefore NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
only RB 0 1 12 O
with IN 0 0 12 O
great JJ 0 1 12 O
caution NN 0 0 1 O
or CC 0 0 12 O
not RB 0 1 12 O
at IN 0 0 12 O
all DT 0 0 12 O
. . 0 0 12 O

conversely RB 0 0 UNK O
diethylpropion NN 0 1 UNK B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
i.e. FW 0 1 1 O
guanethidine VB 0 1 UNK B-Drug
a DT 0 0 12 B-Drug
- : 0 0 2 O
methyldopa NN 0 1 13 I-Drug
) ) 0 0 2 O
. . 0 0 12 O

Rifampicin NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
a DT 0 0 12 O
six CD 0 1 12 O
- : 0 0 2 O
day NN 0 1 12 O
course NN 0 1 12 O
of IN 0 0 12 O
rifampicin NN 0 1 UNK B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
followed VBN 1 1 12 O
by IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
isradipine NN 0 1 13 B-Drug
resulted VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
isradipine NN 0 1 13 B-Drug
levels NNS 1 1 1 O
to TO 0 0 12 O
below IN 0 0 12 O
detectable JJ 0 1 UNK O
limits NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
NUROMAX NNP 0 1 UNK B-Brand
before IN 0 1 12 O
succinylcholine NN 0 1 16 B-Drug
to TO 0 0 12 O
attenuate VB 0 1 UNK O
some DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
side NN 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
appropriate JJ 0 1 1 O
dose JJ 0 1 6 O
adjustments NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
for IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
average JJ 0 1 1 O
infusion NN 0 1 14 O
rate NN 0 1 1 O
requirement NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
as RB 0 0 12 O
much JJ 0 0 12 O
as IN 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Rare JJ 0 1 2 O
instances NNS 1 1 UNK O
of IN 0 0 12 O
dyspnea NN 0 1 8 O
palpitation NN 0 1 UNK O
chest NN 0 1 3 O
pain NN 0 1 6 O
syncope NN 0 1 8 O
. . 0 0 12 O

Cytotoxic JJ 0 1 UNK B-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
Enhanced NNP 0 1 UNK O
bone NN 0 1 6 O
marrow NN 0 1 6 O
suppression NN 0 1 1 O
by IN 0 0 12 O
cyclophosphamide NN 0 1 14 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
cytotoxic NN 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
among IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
neoplastic JJ 0 1 16 O
disease NN 0 1 6 O
except IN 0 0 12 O
leukemia NN 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
allopurinol NN 0 1 13 B-Drug
. . 0 0 12 O

A DT 0 0 2 O
total NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
clinical JJ 0 1 6 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
to TO 0 0 12 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
MYCAMINE NNP 0 1 UNK B-Brand
and CC 0 0 12 O
mycophenolate VB 0 1 0 B-Drug
mofetil NNS 0 0 16 I-Drug
cyclosporine VB 0 1 14 B-Drug
tacrolimus IN 0 1 16 B-Drug
prednisolone NN 0 1 0 B-Drug
sirolimus NN 0 1 16 B-Drug
nifedipine JJ 0 1 0 B-Drug
fluconazole JJ 0 1 0 B-Drug
ritonavir NN 0 1 16 B-Drug
and CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
. . 0 0 12 O

Drugs NNS 0 1 2 O
Demonstrated VBD 0 0 UNK O
to TO 0 0 12 O
be VB 0 0 12 O
CYP NNP 0 1 UNK O
9A CD 0 1 UNK O
Inhibitors NNS 0 1 7 O
of IN 0 0 12 O
Possible JJ 0 1 2 O
Clinical JJ 0 1 7 O
Significance NN 0 1 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
Basis NNP 0 1 UNK O
of IN 0 0 12 O
Clinical NNP 0 1 7 O
Studies NNPS 0 1 2 O
Involving NNP 0 1 UNK O
Alprazolam NNP 0 1 0 B-Drug
( ( 0 0 2 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
during IN 0 0 12 O
coadministration NN 0 1 UNK O
with IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
with IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
increased VBD 1 1 1 O
the DT 0 0 12 O
maximum JJ 0 1 1 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decreased VBN 1 1 1 O
clearance NN 0 1 16 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increased VBD 1 1 1 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
decreased VBN 1 1 1 O
measured JJ 0 1 1 O
psychomotor NN 0 0 13 O
performance NN 0 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
general JJ 0 1 1 O
most JJS 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
dirithromycin NN 0 1 UNK B-Drug
who WP 0 0 12 O
are VBP 1 0 12 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
theophylline JJ 0 1 16 B-Drug
therapy NN 0 1 6 O
may MD 0 0 1 O
not RB 0 1 12 O
require VB 0 0 1 O
empiric JJ 0 1 14 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
dosage NN 0 1 0 O
or CC 0 0 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
- : 0 0 2 O
related JJ 0 1 1 O
side NN 0 1 3 O
effects NNS 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
with IN 0 0 12 O
norfloxacin JJ 0 1 UNK B-Drug
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
. . 0 0 12 O

Ranitidine NNP 0 1 0 B-Drug
also RB 0 0 12 O
has VBZ 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
eprosartan NN 0 1 UNK B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

anabolic JJ 0 1 13 B-Group
steroids NNS 1 1 6 I-Group
; : 0 0 2 O

Enalapril NNP 0 1 0 B-Drug
IV NNP 0 1 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
digitalis NN 0 1 14 B-Group
without IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
. . 0 0 12 O

Increases NNS 0 1 UNK O
in IN 0 0 12 O
INR NNP 0 1 13 O
and CC 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
abnormal JJ 0 1 6 O
bleeding NN 0 1 6 O
and CC 0 0 12 O
even RB 0 0 12 O
death NN 0 1 12 O
. . 0 0 12 O

These DT 0 0 1 O
agents NNS 1 1 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
. . 0 0 12 O

CNS NNP 0 1 6 B-Group
depressant JJ 0 0 UNK I-Group
medications NNS 1 1 6 O
: : 0 0 2 O
Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
procaine NN 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
and CC 0 0 12 O
CNS NNP 0 1 6 B-Group
depressant JJ 0 0 UNK I-Group
medications NNS 1 1 6 I-Group
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
additive JJ 0 1 16 O
depressant NN 0 0 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

Thus RB 0 0 1 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
Lodine NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
require VB 0 0 1 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
vasodilating VBG 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
nitroglycerin NN 0 1 14 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
additive JJ 0 1 16 O
with IN 0 0 12 O
those DT 0 0 12 O
of IN 0 0 12 O
other JJ 0 0 12 O
vasodilators NNS 1 1 13 B-Group
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
alter VBP 0 1 13 O
the DT 0 0 12 O
gastrointestinal JJ 0 1 6 O
flora NN 0 0 UNK O
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
Myfortic JJ 0 1 UNK B-Brand
by IN 0 0 12 O
disrupting VBG 1 1 UNK O
enterohepatic JJ 0 0 UNK O
recirculation NN 0 0 UNK O
. . 0 0 12 O

g NN 0 1 16 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
; : 0 0 2 O

Controlled VBN 0 1 UNK O
and CC 0 0 12 O
uncontrolled VBN 0 1 6 O
domestic JJ 0 1 1 O
studies NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
hydrochloride NN 0 1 0 I-Drug
and CC 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
is VBZ 1 0 12 O
usually RB 0 1 12 O
well RB 0 1 12 O
tolerated VBN 1 0 1 O
but CC 0 0 12 O
available JJ 0 1 1 O
data NNS 0 1 1 O
are VBP 1 0 12 O
not RB 0 1 12 O
sufficient JJ 0 1 1 O
to TO 0 0 12 O
predict VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
treatment NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
left JJ 0 1 12 O
ventricular JJ 0 1 8 O
dysfunction NN 0 1 6 O
or CC 0 0 12 O
cardiac JJ 0 1 6 O
conduction NN 0 1 6 O
abnormalities NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
basis NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
but CC 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
noted VBN 1 0 1 O
when WRB 0 0 12 O
allopurinol NN 0 1 13 B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
patients NNS 1 1 6 O
already RB 0 0 12 O
on IN 0 0 12 O
dicumarol NN 0 1 UNK B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
incidence NN 0 1 6 O
of IN 0 0 12 O
akathisia NN 0 1 UNK O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
weekly JJ 0 1 12 O
dosage NN 0 1 0 O
schedule NN 0 1 12 O
was VBD 1 0 12 O
greater JJR 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
) ) 0 0 2 O
when WRB 0 0 12 O
prochlorperazine NN 0 1 16 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
day NN 0 1 12 O
as IN 1 0 12 O
CAMPTOSAR NNP 0 1 UNK B-Brand
than IN 0 0 12 O
when WRB 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
were VBD 1 0 12 O
given VBN 1 1 12 O
on IN 0 0 12 O
separate JJ 0 1 1 O
days NNS 1 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
with IN 0 0 12 O
digitalis NN 0 1 14 B-Group
and CC 0 0 12 O
calcium NN 0 1 14 B-Group
antagonists NNS 1 1 13 I-Group
may MD 0 0 1 O
have VB 0 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
on IN 0 0 12 O
prolonging VBG 1 0 UNK O
atrioventricular JJ 0 0 8 O
conduction NN 0 1 6 O
time NN 0 1 12 O
. . 0 0 12 O

Chlorprothixene NNP 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
- : 0 0 2 O
level NN 0 1 1 O
of IN 0 0 12 O
concomitantly RB 0 0 14 O
given VBN 1 1 12 O
lithium NN 0 1 16 B-Drug
. . 0 0 12 O

trimethoprim JJ 0 1 16 B-Drug
/ NNP 0 0 2 O
sulfamethoxazole NN 0 1 13 B-Drug
; : 0 0 2 O

9 CD 0 0 2 O
. . 0 0 12 O

Thyroid NNP 0 1 7 O
hormonal JJ 0 1 6 O
replacement NN 0 1 1 O
increases NNS 1 1 1 O
metabolic VBP 0 1 6 O
rate NN 0 1 1 O
which WDT 0 0 12 O
requires VBZ 1 0 1 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
digitalis JJ 0 1 14 B-Group
dosage NN 0 1 0 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
moderate JJ 0 1 1 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP NNP 0 1 UNK O
9C9 CD 0 0 UNK O
( ( 0 0 2 O
IC9 NNP 0 0 UNK O
= VBZ 0 0 2 O
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
or CC 0 0 12 O
9 CD 0 0 2 O
M NNPS 0 1 2 O
) ) 0 0 2 O
and CC 0 0 12 O
9C9 CD 0 0 UNK O
( ( 0 0 2 O
IC9 NNP 0 0 UNK O
= VBZ 0 0 2 O
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
or CC 0 0 12 O
9 CD 0 0 2 O
M NNPS 0 1 2 O
) ) 0 0 2 O
and CC 0 0 12 O
a DT 0 0 12 O
weak JJ 0 1 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP NNP 0 1 UNK O
9D9 CD 0 0 UNK O
( ( 0 0 2 O
IC9 NNP 0 0 UNK O
= VBZ 0 0 2 O
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
or CC 0 0 12 O
9 CD 0 0 2 O
M NNPS 0 1 2 O
) ) 0 0 2 O
and CC 0 0 12 O
9A9 CD 0 0 UNK O
( ( 0 0 2 O
IC9 NNP 0 0 UNK O
= VBZ 0 0 2 O
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
or CC 0 0 12 O
9 CD 0 0 2 O
M NNP 0 1 2 O
) ) 0 0 2 O
.. NN 0 0 UNK O

Other JJ 0 0 2 O
substances NNS 1 1 1 O
: : 0 0 2 O
Grapefruit NNP 0 1 UNK O
juice NN 0 1 3 O
given VBN 1 1 12 O
to TO 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
increased VBD 1 1 1 O
amiodarone RB 0 1 0 B-Drug
AUC NNP 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
increased VBN 1 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
glipizide VB 0 1 0 B-Drug
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
hypoglycemia NN 0 1 6 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
treatment NN 0 1 6 O
of IN 0 0 12 O
four CD 0 1 12 O
patients NNS 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
United NNP 0 0 2 O
Kingdom NNP 0 1 2 O
with IN 0 0 12 O
FOSCAVIR NNP 0 1 UNK B-Brand
and CC 0 0 12 O
intravenous JJ 0 1 14 O
pentamidine NN 0 1 14 B-Drug
may MD 0 0 1 O
have VB 0 0 12 O
caused VBN 1 1 1 O
hypocalcemia NN 0 1 8 O
; : 0 0 2 O

however RB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
considered VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
unlikely JJ 0 1 12 O
that IN 0 0 12 O
this DT 0 0 12 O
decrease NN 0 1 1 O
of IN 0 0 12 O
phosphorylated JJ 0 0 UNK O
lamivudine JJ 0 1 16 B-Drug
concentration NN 0 1 1 O
is VBZ 1 0 12 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
as IN 1 0 12 O
lamivudine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
more RBR 0 1 12 O
efficient JJ 0 1 13 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
deoxycytidine NN 0 1 UNK O
kinase NN 0 1 14 O
than IN 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
EVISTA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
assessed VBN 1 1 1 O
under IN 0 0 12 O
chronic JJ 0 1 6 O
conditions NNS 1 1 1 O
. . 0 0 12 O

Oral JJ 0 1 2 O
Contraceptives NNS 0 1 UNK B-Group
: : 0 0 2 O
Multiple NNP 0 1 2 O
dose VBP 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
monotherapy NN 0 0 14 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
in IN 0 0 12 O
healthy JJ 0 1 12 O
women NNS 1 1 UNK O
of IN 0 0 12 O
childbearing VBG 0 0 UNK O
age NN 0 1 12 O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
increased VBN 1 1 1 O
anticoagulant JJ 0 1 13 O
effects NNS 1 1 1 O
when WRB 0 0 12 O
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
were VBD 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Nitrofurantoin NNP 0 1 UNK B-Drug
interferes VBZ 1 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
action NN 0 1 13 O
of IN 0 0 12 O
nalidixic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O

A DT 0 0 2 O
causal NN 0 1 UNK O
relationship NN 0 1 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O

Auranofin NNP 0 1 UNK B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
together RB 0 1 12 O
with IN 0 0 12 O
penicillamine NN 0 1 13 B-Drug
( ( 0 0 2 O
Depen NNP 0 1 UNK B-Brand
Cuprimine NNP 0 1 UNK B-Brand
) ) 0 0 2 O
another DT 0 0 12 O
arthritis NN 0 1 6 O
medication NN 0 1 6 O
. . 0 0 12 O

Phenothiazines NNS 0 1 UNK B-Group
are VBP 1 0 12 O
capable JJ 0 1 UNK O
of IN 0 0 12 O
potentiating VBG 1 0 UNK O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
barbiturates NNS 1 1 14 B-Group
anesthetics NNS 1 1 13 B-Group
opiates NNS 1 1 6 B-Group
alcohol VBP 0 1 1 B-Drug
etc FW 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O

Microscopic NNP 0 1 7 O
hematuria NN 0 1 8 O
( ( 0 0 2 O
9 CD 0 0 2 O
/ RB 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
gingival JJ 0 1 13 O
bleeding NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
/ RB 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
were VBD 1 0 12 O
also RB 0 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
Cerubidine NNP 0 1 UNK B-Brand
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
who WP 0 0 12 O
has VBZ 1 0 12 O
previously RB 0 0 1 O
received VBN 1 1 12 O
doxorubicin NN 0 1 13 B-Drug
increases VBZ 1 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
cardiotoxicity NN 0 1 UNK O
. . 0 0 12 O

Some DT 0 0 2 O
reports NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
thiazides NNS 1 1 UNK B-Group
with IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
causes VBZ 1 1 6 O
hypercalcemia NN 0 1 8 O
. . 0 0 12 O

- : 0 0 2 O
Hydroxychloroquine NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Plaquenil NNP 0 1 0 B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Antiarrhythmics NNS 0 1 UNK B-Group
: : 0 0 2 O
Amiodarone NNP 0 1 0 B-Drug
bepridil VBD 0 1 UNK B-Drug
flecainide RB 0 1 16 B-Drug
propafenone JJ 0 1 16 B-Drug
quinidine NN 0 1 16 B-Drug
CONTRAINDICATED NNP 0 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening JJ 0 0 12 O
reactions NNS 1 1 1 O
. . 0 0 12 O

Anticonvulsants NNS 0 1 UNK B-Group
( ( 0 0 2 O
Phenytoin NNP 0 1 0 B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Steady JJ 0 1 UNK O
state NN 0 1 1 O
plasma NN 0 1 14 O
exposure NN 0 1 1 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
was VBD 1 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
when WRB 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
QD NNP 0 1 13 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
( ( 0 0 2 O
a DT 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
inducer NN 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
may MD 0 0 1 O
alter VB 0 1 13 O
imatinib NN 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
Drugs VBP 0 1 2 O
that DT 0 0 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
imatinib NN 0 1 16 B-Drug
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
: : 0 0 2 O
Caution NN 0 0 UNK O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
Gleevec NNP 0 1 UNK B-Brand
with IN 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
family NN 0 1 12 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
ketoconazole NN 0 1 16 B-Drug
itraconazole NN 0 1 0 B-Drug
erythromycin FW 0 1 0 B-Drug
clarithromycin NN 0 1 13 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Influence NN 0 0 UNK O
of IN 0 0 12 O
AED NNP 0 1 UNK B-Group
On IN 0 0 2 O
MHD NNP 0 0 UNK B-Drug_n
Concentration NNP 0 1 UNK O
( ( 0 0 2 O
Mean NNP 0 1 2 O
change VBP 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
Confidence NNP 0 1 UNK O
Interval NNP 0 1 13 O
) ) 0 0 2 O

Therefore IN 0 0 1 O
it PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
recognized VBN 1 0 13 O
that IN 0 0 12 O
a DT 0 0 12 O
positive JJ 0 1 1 O
Coombs NNP 0 1 19 O
test NN 0 1 1 O
could MD 0 0 12 O
be VB 0 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

For IN 0 0 2 O
comprehensive JJ 0 1 13 O
information NN 0 1 1 O
concerning VBG 1 1 1 O
laboratory JJ 0 1 1 O
test NN 0 1 1 O
alterations NNS 1 1 1 O
associated VBN 1 1 1 O
with IN 0 0 12 O
ritonavir NNS 0 1 16 B-Drug
physicians NNS 1 1 6 O
should MD 0 0 12 O
refer VB 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
complete JJ 0 1 1 O
prescribing NN 0 1 UNK O
information NN 0 1 1 O
for IN 0 0 12 O
NORVIR NNP 0 1 UNK B-Brand
( ( 0 0 2 O
ritonavir NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Concurrent NN 0 1 13 O
use NN 0 1 1 O
with IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
significantly RB 0 0 1 O
eliminated VBN 1 1 UNK O
by IN 0 0 12 O
active JJ 0 1 1 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
penciclovir NN 0 1 UNK B-Drug
. . 0 0 12 O

Free JJ 0 1 2 O
hormone NN 0 1 6 O
concentrations NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
consumption NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
WELLBUTRIN NNP 0 1 0 B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
minimized VBN 1 0 1 O
or CC 0 0 12 O
avoided VBN 1 0 1 O
( ( 0 0 2 O
also RB 0 0 12 O
see VBP 0 1 12 O
a DT 0 0 12 O
href= NN 0 0 UNK O
bupropz_od.htm NN 0 1 UNK O
# # 0 0 2 O
CI NNP 0 1 UNK O
CONTRAINDICATIONS NNP 0 1 0 O
) ) 0 0 2 O

Metformin NNS 0 1 0 B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
Starlix NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
three CD 0 1 12 O
times NNS 1 1 12 O
daily JJ 0 1 12 O
before IN 0 1 12 O
meals NNS 1 1 12 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
metformin JJ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
three CD 0 1 12 O
times NNS 1 1 12 O
daily RB 0 1 12 O
to TO 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
Type NNP 0 1 2 O
9 CD 0 0 2 O
diabetes NNS 0 1 6 O
there EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
agent NN 0 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
these DT 0 0 12 O
imidazole JJ 0 1 UNK B-Group
and CC 0 0 12 O
triazole JJ 0 1 UNK B-Group
antifungals NNS 1 1 UNK I-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Limited JJ 0 1 2 O
evidence NN 0 1 1 O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
ascorbic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
may MD 0 0 1 O
influence VB 0 0 UNK O
the DT 0 0 12 O
intensity NN 0 1 1 O
and CC 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
bishydroxycoumarin NN 0 1 UNK B-Drug
. . 0 0 12 O

increased VBN 1 1 1 O
norepinephrine JJ 0 1 14 O
- : 0 0 2 O
induced JJ 0 1 6 O
platel NN 0 0 UNK O
et CC 0 0 13 O
aggregation NN 0 1 UNK O
; : 0 0 2 O

While IN 0 0 12 O
all PDT 0 0 12 O
the DT 0 0 12 O
selective JJ 0 1 13 O
serotonin NN 0 1 13 B-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
e.g. VBP 0 0 UNK O
fluoxetine JJ 0 1 16 B-Drug
sertraline NN 0 1 16 B-Drug
and CC 0 0 12 O
paroxetine JJ 0 1 16 B-Drug
inhibit NN 0 1 13 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
they PRP 0 0 12 O
may MD 0 0 1 O
vary VB 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
. . 0 0 12 O

( ( 0 0 2 O
See VB 0 1 2 O
< IN 0 0 16 O
a DT 0 0 12 O
href= NN 0 0 UNK O
`` `` 0 0 13 O
flucon_cp.htm JJ 0 1 UNK O
# # 0 0 2 O
CP NNP 0 1 13 O
'' '' 0 0 13 O
> NNP 0 0 2 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
: : 0 0 2 O
Drug NNP 0 1 2 O
Interaction NNP 0 1 2 O
Studies NNP 0 1 2 O
. . 0 0 12 O
) ) 0 0 2 O

OTHER NNP 0 0 11 O
CONCOMITANT NNP 0 1 UNK O
THERAPY NNP 0 1 UNK O
: : 0 0 2 O
Although IN 0 0 12 O
specific JJ 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
performed VBN 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
cerivastatin VBP 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
was VBD 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
angiotensin JJ 0 1 UNK B-Group
- : 0 0 2 O
converting VBG 1 0 UNK I-Group
enzyme JJ 0 1 14 I-Group
ACE NNP 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
betablockers NNS 0 0 UNK B-Group
calcium VBP 0 1 14 B-Group
- : 0 0 2 O
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
diuretics NNS 1 1 14 B-Group
and CC 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti NN 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
NSAIDs NNP 0 1 UNK B-Group
) ) 0 0 2 O
without IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Phenobarbital NN 0 1 0 B-Drug
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
delay VB 0 1 1 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
; : 0 0 2 O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
CELEBREX NN 0 1 UNK B-Brand
can MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
low JJ 0 1 1 O
dose JJ 0 1 6 O
aspirin NN 0 1 14 B-Brand
. . 0 0 12 O

Naproxen NNP 0 1 0 B-Drug
naproxen CC 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
in IN 0 0 12 O
an DT 0 0 12 O
animal JJ 0 1 13 O
model NN 0 1 UNK O
possibly RB 0 1 12 O
increasing VBG 1 1 1 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Quinidine NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
aripiprazole NN 0 1 16 B-Drug
with IN 0 0 12 O
quinidine NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
increased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
aripiprazole NN 0 1 16 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
but CC 0 0 12 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
metabolite JJ 0 1 UNK O
dehydroaripiprazole NN 0 1 UNK B-Drug_n
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
atropine NN 0 1 14 B-Drug
and CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
triprolidine NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
administering VBG 1 1 1 O
different JJ 0 1 1 O
botulinum NN 0 1 13 B-Group
neurotoxin NN 0 1 UNK I-Group
serotypes NNS 0 1 UNK O
at IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
time NN 0 1 12 O
or CC 0 0 12 O
within IN 0 0 1 O
several JJ 0 1 12 O
months NNS 1 1 12 O
of IN 0 0 12 O
each DT 0 0 12 O
other JJ 0 0 12 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Antagonism NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
between IN 0 0 12 O
clindamycin NN 0 1 0 B-Drug
and CC 0 0 12 O
erythromycin NN 0 1 0 B-Drug
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

Drugs NNS 0 1 2 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
The DT 0 0 2 O
biochemical JJ 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
metabolizing VBG 1 0 UNK O
isozyme JJ 0 1 UNK O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
( ( 0 0 2 O
debrisoquin JJ 0 1 UNK O
hydroxylase NN 0 1 UNK O
) ) 0 0 2 O
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
subset NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
caucasian JJ 0 1 3 O
population NN 0 1 13 O
( ( 0 0 2 O
about IN 0 1 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
caucasians NNS 1 1 UNK O
are VBP 1 0 12 O
so RB 0 1 12 O
called JJ 0 1 12 O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
) ) 0 0 2 O
; : 0 0 2 O

The DT 0 0 2 O
mechanism NN 0 1 13 O
and CC 0 0 12 O
long JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
consequences NNS 1 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
events NNS 1 1 12 O
are VBP 1 0 12 O
currently RB 0 1 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

These DT 0 0 1 O
individuals NNS 1 1 1 O
may MD 0 0 1 O
develop VB 0 0 1 O
higher JJR 1 1 1 O
than IN 0 0 12 O
expected VBN 1 1 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
clozapine NN 0 1 13 B-Drug
when WRB 0 0 12 O
given VBN 1 1 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
deferasirox JJ 0 1 13 B-Drug
metabolism NN 0 1 16 O
by IN 0 0 12 O
hydroxyurea NN 0 1 14 B-Drug
is VBZ 1 0 12 O
expected VBN 1 1 12 O
based VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
results NNS 1 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
study NN 0 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
Itraconazole NNP 0 1 UNK B-Drug
and CC 0 0 12 O
coumarin SYM 0 1 UNK B-Group
- : 0 0 2 O
like IN 0 0 12 O
drugs NNS 1 1 6 O
simultaneously RB 0 1 13 O
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
antibacterial JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
with IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
may MD 0 0 1 O
render VB 0 0 13 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
less RBR 0 1 12 O
effective JJ 0 1 1 O
. . 0 0 12 O

Laboratory JJ 0 1 2 O
Test NNP 0 1 2 O
Interactions NNS 0 1 UNK O

miconazole NN 0 1 16 B-Drug
; : 0 0 2 O

In IN 0 0 2 O
a DT 0 0 12 O
multiple JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
study NN 0 1 1 O
enoxacin NN 0 1 UNK B-Drug
caused VBD 1 1 1 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
related JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
elimination NN 0 1 UNK O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
thereby NN 0 0 UNK O
decreasing VBG 1 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
by IN 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
leading VBG 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
five CD 0 1 12 O
- : 0 0 2 O
fold NN 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
intravenous JJ 0 1 14 O
morphine NN 0 1 14 B-Drug
and CC 0 0 12 O
BREVIBLOC NNP 0 1 UNK B-Brand
were VBD 1 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
in IN 0 0 12 O
normal JJ 0 1 1 O
subjects NNS 1 1 UNK O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
morphine NN 0 1 14 B-Drug
blood NN 0 1 6 O
levels NNS 1 1 1 O
was VBD 1 0 12 O
seen VBN 1 1 12 O
but CC 0 0 12 O
BREVIBLOC NNP 0 1 UNK B-Brand
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
were VBD 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
morphine NN 0 1 14 B-Drug
. . 0 0 12 O

Cardiac NNP 0 1 7 B-Group
Glycosides NNP 0 1 UNK I-Group
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
of IN 0 0 12 O
young JJ 0 1 12 O
healthy JJ 0 1 12 O
male JJ 0 1 12 O
subjects VBZ 1 1 UNK O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
direct JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
captopril NN 0 1 0 B-Drug
- : 0 0 2 O
digoxin NN 0 1 14 B-Drug
interaction NN 0 1 UNK O
could MD 0 0 12 O
be VB 0 0 12 O
found VBN 1 1 12 O
. . 0 0 12 O

When WRB 0 0 12 O
combined VBN 1 1 1 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
contemplated VBN 1 0 UNK O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
one CD 0 1 12 O
or CC 0 0 12 O
both DT 0 0 12 O
agents NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

Steady JJ 0 1 UNK O
- : 0 0 2 O
state NN 0 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
are VBP 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
fluctuate VB 0 1 13 O
significantly RB 0 0 1 O
when WRB 0 0 12 O
cimetidine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
either DT 0 1 12 O
added JJ 0 1 12 O
or CC 0 0 12 O
deleted VBN 1 1 16 O
from IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
regimen NNS 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
relevance NN 0 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
finding NN 0 1 12 O
to TO 0 0 12 O
humans NNS 1 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
at IN 0 0 12 O
this DT 0 0 12 O
time NN 0 1 12 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
celecoxib NN 0 1 16 B-Drug
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
9C9 CD 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
done VBN 1 0 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

When WRB 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
are VBP 1 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
hypertensive JJ 0 1 6 O
reactions NNS 1 1 1 O
including VBG 1 1 1 O
hypertensive JJ 0 1 6 O
crises NNS 1 1 13 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

. . 0 0 12 O

Terfenadine NNP 0 1 UNK B-Drug
astemizole NN 0 1 UNK B-Drug
and CC 0 0 12 O
cisapride NN 0 1 UNK B-Drug
are VBP 1 0 12 O
all DT 0 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9IIIA9 NNP 0 0 UNK O
isozyme NN 0 1 UNK O
and CC 0 0 12 O
it PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
that IN 0 0 12 O
ketoconazole VBZ 0 1 16 B-Drug
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
IIIA9 NNP 0 0 UNK O
blocks VBZ 1 1 3 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
increased VBN 1 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
parent NN 0 1 13 O
drug NN 0 1 1 O
. . 0 0 12 O

Ethanol NNP 0 1 13 B-Drug
decreases VBZ 1 1 UNK O
the DT 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
abacavir NN 0 1 16 B-Drug
causing VBG 1 1 1 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
overall JJ 0 1 1 O
exposure NN 0 1 1 O
. . 0 0 12 O
The DT 0 0 2 O
addition NN 0 1 1 O
of IN 0 0 12 O
methadone NN 0 1 6 B-Drug
has VBZ 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
properties NNS 1 1 UNK O
of IN 0 0 12 O
abacavir NN 0 1 16 B-Drug
. . 0 0 12 O

Thus RB 0 0 1 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
cautioned VBN 1 0 UNK O
about IN 0 1 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
LEXAPRO NNP 0 1 UNK B-Brand
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
data NNS 0 1 1 O
that WDT 0 0 12 O
conclusively RB 0 0 UNK O
establish VB 0 1 UNK O
whether IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
Mefloquineuine NNP 0 0 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
above NN 0 1 12 O
listed VBD 1 1 1 O
agents NNS 1 1 1 O
has VBZ 1 0 12 O
an DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
cardiac JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
should MD 0 0 12 O
also RB 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
blood NN 0 1 6 O
liver NN 0 1 6 O
or CC 0 0 12 O
kidney NN 0 1 6 O
diseases NNS 1 1 6 O
recent JJ 0 1 12 O
radiation NN 0 1 1 O
treatment NN 0 1 6 O
or CC 0 0 12 O
uncontrolled JJ 0 1 6 O
diabetes NNS 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
two CD 0 1 12 O
controlled VBD 1 1 1 O
crossover RB 0 1 UNK O
clinical JJ 0 1 6 O
pharmacology NN 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
male NN 0 1 12 O
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
in IN 0 0 12 O
each DT 0 0 12 O
study NN 0 1 1 O
) ) 0 0 2 O
a DT 0 0 12 O
nd JJ 0 0 12 O
female NN 0 1 12 O
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
in IN 0 0 12 O
each DT 0 0 12 O
study NN 0 1 1 O
) ) 0 0 2 O
volunteers NNS 1 1 UNK O
desloratadine VBP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
( ( 0 0 2 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
daily JJ 0 1 12 O
dose NN 0 1 6 O
) ) 0 0 2 O
once RB 0 0 12 O
daily JJ 0 1 12 O
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
erythromycin JJ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
or CC 0 0 12 O
ketoconazole VB 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

Nifedipine NNP 0 1 0 B-Drug
( ( 0 0 2 O
extended VBN 1 1 1 O
- : 0 0 2 O
release NN 0 1 12 O
tablets NNS 1 1 3 O
) ) 0 0 2 O
: : 0 0 2 O
In IN 0 0 2 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
- : 0 0 2 O
weight NN 0 1 3 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
XENICAL JJ 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
three CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
XENICAL RB 0 1 UNK B-Brand
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
nifedipine NN 0 1 0 B-Drug
( ( 0 0 2 O
extended VBN 1 1 1 O
- : 0 0 2 O
release NN 0 1 12 O
tablets NNS 1 1 3 O
) ) 0 0 2 O
. . 0 0 12 O

this DT 0 0 12 O
was VBD 1 0 12 O
seen VBN 1 1 12 O
in IN 0 0 12 O
studies NNS 1 1 1 O
with IN 0 0 12 O
estazolam NN 0 1 13 B-Drug
. . 0 0 12 O

Human JJ 0 1 2 O
pharmacokinetics NNS 0 1 UNK O
data NNS 0 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
oral JJ 0 1 6 O
ketoconazole FW 0 1 16 B-Drug
potently RB 0 0 UNK O
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
mean JJ 0 1 12 O
eight CD 0 1 12 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
sodium NN 0 1 14 B-Drug
cephalothin NN 0 1 UNK I-Drug
and CC 0 0 12 O
Coly NNP 0 1 UNK B-Brand
- : 0 0 2 O
Mycin NNP 0 0 UNK I-Brand
M NNP 0 1 2 I-Brand
Parenteral NNP 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

- : 0 0 2 O
Plicamycin NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Mithracin NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Rifabutin NN 0 1 UNK B-Drug

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Levodopa NNP 0 1 0 B-Drug
and CC 0 0 12 O
Amantadine NNP 0 1 UNK B-Drug
: : 0 0 2 O
Limited JJ 0 1 2 O
clinical JJ 0 1 6 O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
a DT 0 0 12 O
higher JJR 1 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
experiences NNS 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
bupropion NN 0 1 16 B-Drug
concurrently RB 0 0 1 O
with IN 0 0 12 O
either DT 0 1 12 O
levodopa NN 0 1 UNK B-Drug
or CC 0 0 12 O
amantadine NN 0 1 16 B-Drug
. . 0 0 12 O

Chlorpromazine NN 0 1 UNK B-Drug
: : 0 0 2 O
Chlorpromazine NN 0 1 UNK B-Drug
blocks NNS 1 1 3 O
dopamine NN 0 1 14 O
and CC 0 0 12 O
norepinephrine JJ 0 1 14 O
reuptake NN 0 1 13 O
thus RB 0 0 1 O
inhibiting VBG 1 1 UNK O
the DT 0 0 12 O
central JJ 0 1 1 O
stimulant JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
and CC 0 0 12 O
can MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
amphetamine JJ 0 1 13 B-Group
poisoning NN 0 1 13 O
. . 0 0 12 O

These DT 0 0 1 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
mazindol NN 0 1 UNK B-Drug
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
buspirone NN 0 1 16 B-Drug
may MD 0 0 1 O
displace VB 0 0 13 O
less JJR 0 1 12 O
firmly RB 0 1 UNK O
bound IN 0 1 12 O
drugs NNS 1 1 6 O
like IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

CHOLESTYRAMINE NN 0 1 UNK B-Drug
: : 0 0 2 O
The DT 0 0 2 O
influence NN 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
bile NN 0 1 6 O
- : 0 0 2 O
acidsequestering NN 0 0 UNK O
agent NN 0 1 1 O
cholestyramine NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetits NNS 0 0 UNK O
of IN 0 0 12 O
cerivastatin NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
was VBD 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
males NNS 1 1 UNK O
in IN 0 0 12 O
9 CD 0 0 2 O
separate JJ 0 1 1 O
randomized VBN 1 1 6 O
crossover NN 0 1 UNK O
studies NNS 1 1 1 O
. . 0 0 12 O

. . 0 0 12 O

When WRB 0 0 12 O
estrogen NN 0 1 6 B-Group
therapy NN 0 1 6 O
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
corticosteroid JJ 0 1 UNK B-Group
dosage NN 0 1 0 O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
and CC 0 0 12 O
increased JJ 0 1 1 O
amounts NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
when WRB 0 0 12 O
estrogen NN 0 1 6 B-Group
is VBZ 1 0 12 O
terminated VBN 1 1 1 O
. . 0 0 12 O

Changes NNS 0 1 2 O
in IN 0 0 12 O
the DT 0 0 12 O
testes NNS 1 1 6 O
and CC 0 0 12 O
epididymides NNS 1 1 UNK O
had VBD 1 0 12 O
not RB 0 1 12 O
recovered VBN 1 1 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
after IN 0 0 12 O
cessation NN 0 1 6 O
of IN 0 0 12 O
dosing NN 0 0 14 O
. . 0 0 12 O

General JJ 0 1 2 O
: : 0 0 2 O
In IN 0 0 2 O
humans NNS 1 1 UNK O
valdecoxib JJ 0 1 13 B-Drug
metabolism NN 0 1 16 O
is VBZ 1 0 12 O
predominantly RB 0 0 1 O
mediated VBN 1 1 13 O
via IN 0 0 1 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
and CC 0 0 12 O
9C9 CD 0 0 UNK O
with IN 0 0 12 O
glucuronidation NN 0 1 UNK O
being VBG 1 0 12 O
a DT 0 0 12 O
further NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
route NN 0 1 12 O
of IN 0 0 12 O
metabolism NN 0 1 16 O
. . 0 0 12 O

Buprenorphine NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
to TO 0 0 12 O
norbuprenorphine VB 0 1 UNK B-Drug_n
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
FACTIVE NNP 0 1 UNK B-Brand
with IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
resulted VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
to TO 0 0 12 O
gemifloxacin VB 0 1 UNK B-Drug
. . 0 0 12 O

Ropivacaine NNP 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
other JJ 0 0 12 O
local JJ 0 1 12 O
anesthetics NNS 1 1 13 B-Group
or CC 0 0 12 O
agents NNS 1 1 1 O
structurally RB 0 0 1 O
related VBN 1 1 1 O
to TO 0 0 12 O
amide VB 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
local JJ 0 1 12 I-Group
anesthetics NNS 1 1 13 I-Group
since IN 0 1 12 O
the DT 0 0 12 O
toxic JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
additive JJ 0 1 16 O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
blockers NNS 1 0 6 I-Group
may MD 0 0 1 O
exacerbate VB 0 1 UNK O
the DT 0 0 12 O
hypertensive JJ 0 1 6 O
response NN 0 1 1 O
seen VBN 1 1 12 O
with IN 0 0 12 O
clonidine JJ 0 1 0 B-Drug
withdrawl NN 0 0 13 O
. . 0 0 12 O

However RB 0 0 1 O
theophylline JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
with IN 0 0 12 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
as IN 1 0 12 O
appropriate JJ 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
whose WP$ 0 0 12 O
pulmonary JJ 0 1 6 O
disease NN 0 1 6 O
requires VBZ 1 0 1 O
maintaining VBG 1 1 1 O
a DT 0 0 12 O
given VBN 1 1 12 O
theophylline NN 0 1 16 B-Drug
plasma NN 0 1 14 O
concentration NN 0 1 1 O
for IN 0 0 12 O
optimal JJ 0 1 1 O
pulmonary JJ 0 1 6 O
function NN 0 1 1 O
or CC 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
at IN 0 0 12 O
the DT 0 0 12 O
higher JJR 1 1 1 O
end NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
range NN 0 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
whether IN 0 0 12 O
alosetron NN 0 1 UNK B-Drug
might MD 0 0 12 O
induce VB 0 1 6 O
other JJ 0 0 12 O
enzymes NNS 1 1 14 O
. . 0 0 12 O

John NNP 0 0 19 O
Wort NNP 0 0 UNK O
and CC 0 0 12 O
certain JJ 0 1 1 O
anticonvulsants NNS 1 1 13 B-Group
( ( 0 0 2 O
phenytoin JJ 0 1 16 B-Drug
phenobarbital JJ 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
induce VB 0 1 6 O
mifepristone NN 0 1 UNK B-Drug
metabolism NN 0 1 16 O
( ( 0 0 2 O
lowering VBG 1 1 UNK O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
mifepristone NN 0 1 UNK B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
warned VBN 1 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
potential JJ 0 1 1 O
hazard NN 0 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
9 CD 0 0 2 O
separate JJ 0 1 1 O
studies NNS 1 1 1 O
fexofenadine VBP 0 1 16 B-Drug
hydrochloride RB 0 1 0 I-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
total JJ 0 1 1 O
daily JJ 0 1 12 O
dose NN 0 1 6 O
) ) 0 0 2 O
was VBD 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
either DT 0 1 12 O
erythromycin JJ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
or CC 0 0 12 O
ketoconazole VB 0 1 16 B-Drug
9 CD 0 0 2 O
mg NNS 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
under IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
conditions NNS 1 1 1 O
to TO 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
( ( 0 0 2 O
n=9 IN 0 1 UNK O
each DT 0 0 12 O
study NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
adequate JJ 0 1 1 O
and CC 0 0 12 O
well RB 0 1 12 O
- : 0 0 2 O
controlled VBN 1 1 1 O
studies NNS 1 1 1 O
of IN 0 0 12 O
PEGASYS NNP 0 1 UNK B-Brand
in IN 0 0 12 O
pregnant JJ 0 1 13 O
women NNS 1 1 UNK O
. . 0 0 12 O

Do VB 0 0 2 O
not RB 0 1 12 O
take VB 0 1 12 O
this DT 0 0 12 O
medicine NN 0 1 6 O
with IN 0 0 12 O
St. NNP 0 1 2 O
Johns NNP 0 0 UNK O
Wort NNP 0 0 UNK O
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
of IN 0 0 12 O
sertonin NN 0 0 UNK O
. . 0 0 12 O

In IN 0 0 2 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressants NNS 1 0 13 I-Group
heroin NN 0 1 13 B-Drug_n
may MD 0 0 1 O
still RB 0 0 12 O
kill VB 0 1 12 O
even RB 0 0 12 O
experienced JJ 0 0 12 O
users NNS 1 1 UNK O
particularly RB 0 0 1 O
if IN 0 0 12 O
their PRP$ 0 0 12 O
tolerance NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
has VBZ 1 0 12 O
reduced VBN 1 1 1 O
or CC 0 0 12 O
the DT 0 0 12 O
strength NN 0 1 1 O
of IN 0 0 12 O
their PRP$ 0 0 12 O
usual JJ 0 1 12 O
dose NN 0 1 6 O
has VBZ 1 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

Antiarrhythmics NNS 0 1 UNK B-Group

Diflunisal NNP 0 1 UNK B-Drug
decreased VBD 1 1 1 O
the DT 0 0 12 O
hyperuricemic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
. . 0 0 12 O

This DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
( ( 0 0 2 O
which WDT 0 0 12 O
also RB 0 0 12 O
lowers VBZ 1 1 UNK O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
other JJ 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
given VBN 1 1 12 O
with IN 0 0 12 O
it PRP 0 0 12 O
) ) 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
rheumatoid JJ 0 0 6 O
arthritis NN 0 1 6 O
( ( 0 0 2 O
n= JJ 0 1 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
( ( 0 0 2 O
n= JJ 0 1 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Naproxen NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
( ( 0 0 2 O
N=9 NNP 0 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
naproxen JJ 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
capsules NNS 1 1 3 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
with IN 0 0 12 O
Neurontin NNP 0 1 0 B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
appears VBZ 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
amount NN 0 1 1 O
of IN 0 0 12 O
gabapentin NN 0 1 0 B-Drug
absorbed VBN 1 0 3 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
efavirenz NN 0 1 13 B-Drug
with IN 0 0 12 O
drugs NNS 1 1 6 O
primarily RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
these DT 0 0 12 O
isozymes NNS 0 1 UNK O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
altered JJ 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
coadministered JJ 0 0 UNK O
drug NN 0 1 1 O
. . 0 0 12 O

unreliable JJ 0 1 1 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
determinations NNS 1 1 UNK O
; : 0 0 2 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNPS 0 1 UNK O
: : 0 0 2 O
There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
no DT 0 0 12 O
chemical NN 0 1 13 O
or CC 0 0 12 O
laboratory JJ 0 1 1 O
test NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
ceftibuten NNS 0 1 UNK B-Drug
noted VBN 1 0 1 O
to TO 0 0 12 O
date NN 0 1 12 O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
blockers NNS 1 0 6 I-Group
may MD 0 0 1 O
exacerbate VB 0 1 UNK O
the DT 0 0 12 O
rebound NN 0 0 3 O
hypertension NN 0 1 6 O
which WDT 0 0 12 O
can MD 0 0 12 O
follow VB 0 1 12 O
the DT 0 0 12 O
withdrawal NN 0 1 1 O
of IN 0 0 12 O
clonidine NN 0 1 0 B-Drug
. . 0 0 12 O

glucagon NN 0 1 14 B-Drug
; : 0 0 2 O

Amiodarone NN 0 1 0 B-Drug
: : 0 0 2 O
Amiodarone NNP 0 1 0 B-Drug
therapy NN 0 1 6 O
alone RB 0 1 12 O
can MD 0 0 12 O
cause VB 0 1 12 O
hypothyroidism NN 0 1 6 O
or CC 0 0 12 O
hyperthyroidism NN 0 1 6 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
elevated JJ 0 1 1 O
digoxin NN 0 1 14 B-Drug
serum NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
to TO 0 0 12 O
bleeding VBG 1 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
heparin NN 0 1 14 B-Drug
and CC 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
antagonists VBZ 0 1 13 I-Group
drugs NNS 1 1 6 O
that IN 0 0 12 O
alter NN 0 1 13 O
platelet NN 0 1 14 O
function NN 0 1 1 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
acetylsalicylic JJ 0 0 UNK B-Drug
acid JJ 0 1 14 I-Drug
dipyridamole NN 0 1 0 B-Drug
and CC 0 0 12 O
Abciximab NNP 0 1 UNK B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding VBG 1 1 6 O
if IN 0 0 12 O
administered VBN 1 1 1 O
prior RB 0 1 1 O
to TO 0 0 12 O
during IN 0 0 12 O
or CC 0 0 12 O
after IN 0 0 12 O
Activase NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
. . 0 0 12 O

Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
does VBZ 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
hypoprothrombinemia NN 0 1 UNK O
produced VBN 1 0 1 O
by IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
. . 0 0 12 O

The DT 0 0 2 O
action NN 0 1 13 O
of IN 0 0 12 O
nondepolarizing VBG 0 0 UNK O
relaxants NNS 1 0 13 O
is VBZ 1 0 12 O
augmented VBN 1 1 1 O
by IN 0 0 12 O
Enflurane NNP 0 1 UNK B-Drug
. . 0 0 12 O

no DT 0 0 12 O
clear JJ 0 1 12 O
- : 0 0 2 O
cut NN 0 1 3 O
cause NN 0 1 12 O
and CC 0 0 12 O
effect NN 0 1 1 O
relationship NN 0 1 12 O
was VBD 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
based VBN 1 1 1 O
on IN 0 0 12 O
these DT 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
data NNS 0 1 1 O
estazolam NN 0 1 13 B-Drug
is VBZ 1 0 12 O
very RB 0 1 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
biotransformation NN 0 1 UNK O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
these DT 0 0 12 O
CYP NNP 0 1 UNK O
isoforms NNS 0 1 UNK O

Most JJS 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
above JJ 0 1 12 O
effects NNS 1 1 1 O
concerning VBG 1 1 1 O
diuretics NNS 1 1 14 B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
at IN 0 0 12 O
least JJS 0 1 12 O
in IN 0 0 12 O
part NN 0 1 12 O
to TO 0 0 12 O
mechanisms VB 0 1 UNK O
involving VBG 1 1 1 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
prostaglandin JJ 0 1 13 O
synthesis NN 0 1 UNK O
by IN 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
. . 0 0 12 O

No DT 0 0 2 O
differences NNS 1 1 UNK O
in IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
or CC 0 0 12 O
QTc NNP 0 0 14 O
interval NN 0 1 1 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
subjects NNS 1 1 UNK O
were VBD 1 0 12 O
administered VBN 1 1 1 O
fexofenadine JJ 0 1 16 B-Drug
hydrochloride NN 0 1 0 I-Drug
alone RB 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
either DT 0 1 12 O
erythromycin NN 0 1 0 B-Drug
or CC 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
. . 0 0 12 O

cardiovascular JJ 0 1 6 O
effects NNS 1 1 1 O
can MD 0 0 12 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
. . 0 0 12 O

Although IN 0 0 12 O
studies NNS 1 1 1 O
designed VBN 1 1 UNK O
to TO 0 0 12 O
examine VB 0 0 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
done VBN 1 0 12 O
it PRP 0 0 12 O
was VBD 1 0 12 O
noted VBN 1 0 1 O
that IN 0 0 12 O
corticosteroid NN 0 1 UNK B-Group
or CC 0 0 12 O
ACTH NNP 0 1 UNK B-Drug
treatment NN 0 1 6 O
of IN 0 0 12 O
relapses NNS 1 1 6 O
for IN 0 0 12 O
periods NNS 1 1 1 O
of IN 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
( ( 0 0 2 O
N=9 NNP 0 1 UNK O
) ) 0 0 2 O
receiving VBG 1 1 1 O
Betaseron NNP 0 1 UNK B-Brand
. . 0 0 12 O

Aminoglutethimide RB 0 1 UNK B-Drug
diminishes VBZ 1 1 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
coumarin NN 0 1 UNK B-Group
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Given VBN 0 1 2 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
extravasation NN 0 1 8 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
advisable JJ 0 0 UNK O
to TO 0 0 12 O
closely RB 0 0 1 O
monitor VB 0 1 1 O
the DT 0 0 12 O
infusion NN 0 1 14 O
site NN 0 1 12 O
for IN 0 0 12 O
possible JJ 0 1 1 O
infiltration NN 0 1 1 O
during IN 0 0 12 O
drug NN 0 1 1 O
administration NN 0 1 1 O
. . 0 0 12 O

Androgens NNS 0 1 UNK B-Group
may MD 0 0 1 O
increase VB 0 1 1 O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
oral JJ 0 1 6 O
anticoagulahts NNS 0 0 UNK O
. . 0 0 12 O

Propranolol NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
or CC 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
interaction NN 0 1 UNK O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
single JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
lovastatin NN 0 1 13 B-Drug
and CC 0 0 12 O
propranolol NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
reported VBN 1 1 1 O
dose NN 0 1 6 O
used VBN 1 1 12 O
for IN 0 0 12 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
glutamine NN 0 1 13 I-Drug
was VBD 1 0 12 O
9 CD 0 0 2 O
grams NNS 1 1 3 O
daily RB 0 1 12 O
taken VBN 1 1 12 O
in IN 0 0 12 O
divided JJ 0 1 1 O
doses NNS 1 1 6 O
three CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
. . 0 0 12 O

Other JJ 0 0 2 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
cefepime NN 0 1 14 B-Drug
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
glucose NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
when WRB 0 0 12 O
using VBG 1 1 1 O
Clinitest NNP 0 1 UNK O
tablets NNS 1 1 3 O
. . 0 0 12 O

Other JJ 0 0 2 O
Drugs NNS 0 1 2 O
: : 0 0 2 O
In IN 0 0 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
amlodipine VBP 0 1 0 B-Drug
phenytoin JJ 0 1 16 B-Drug
glyburide JJ 0 1 16 B-Drug
ranitidine NN 0 1 0 B-Drug
omeprazole IN 0 1 0 B-Drug
hormone NN 0 1 6 O
replacement NN 0 1 1 O
therapy NN 0 1 6 O
( ( 0 0 2 O
a DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
conjugated JJ 0 1 14 O
estrogens NNS 1 1 16 B-Group
and CC 0 0 12 O
medroxyprogesterone NN 0 1 16 B-Drug
) ) 0 0 2 O
antacid NN 0 1 UNK B-Group
( ( 0 0 2 O
aluminum NN 0 1 16 B-Drug
and CC 0 0 12 O
magnesium NN 0 1 14 B-Drug
hydroxides NNS 1 1 UNK I-Drug
) ) 0 0 2 O
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
TIKOSYN NNP 0 1 UNK B-Brand
. . 0 0 12 O

Magnesium NNP 0 1 7 B-Drug
- : 0 0 2 O
and CC 0 0 12 O
aluminum VB 0 1 16 B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
antacids NNS 1 1 14 B-Group
administered VBD 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
lomefloxacin NNS 0 1 UNK B-Drug
significantly RB 0 0 1 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
of IN 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
. . 0 0 12 O

Clonidine NNP 0 1 0 B-Drug
hydrochloride NN 0 1 0 I-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
CNS NNP 0 1 6 O
- : 0 0 2 O
depressive JJ 0 0 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
barbiturates NNS 1 1 14 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
sedatives NNS 1 1 6 B-Group
. . 0 0 12 O

AMEVIVE NNP 0 1 UNK B-Brand
underwent NN 0 0 6 O
trans VBZ 0 1 3 O
- : 0 0 2 O
placental JJ 0 1 13 O
passage NN 0 1 1 O
and CC 0 0 12 O
produced VBN 1 0 1 O
in IN 0 0 12 O
utero JJ 0 1 6 O
exposure NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
developing NN 0 0 1 O
monkeys NNS 1 1 UNK O
. . 0 0 12 O

Corticosteroids NNS 0 1 UNK B-Group
ACTH NNP 0 1 UNK B-Drug
: : 0 0 2 O
intensified JJ 0 0 UNK O
electrolyte JJ 0 1 14 O
depletion NN 0 1 1 O
particularly RB 0 0 1 O
hypokalemia NN 0 1 14 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
None NNP 0 0 2 O
known VBN 1 1 12 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
rifabutin NN 0 1 13 B-Drug
be VB 0 0 12 O
reduced VBN 1 1 1 O
to TO 0 0 12 O
one CD 0 1 12 O
- : 0 0 2 O
half PDT 0 1 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
dose NN 0 1 6 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
. . 0 0 12 O

General NNP 0 1 2 O
No NNP 0 0 2 O
clinical JJ 0 1 6 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Specific JJ 0 1 UNK O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
ENBREL NNP 0 1 UNK B-Brand
. . 0 0 12 O

Although IN 0 0 12 O
the DT 0 0 12 O
occurrence NN 0 1 1 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
Cefizox NNP 0 1 UNK B-Brand
nephrotoxicity NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
following VBG 1 1 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
cephalosporins NNS 1 1 14 B-Group
and CC 0 0 12 O
aminoglycosides NNS 0 1 13 B-Group
. . 0 0 12 O

As IN 0 0 2 O
most JJS 0 0 12 O
entacapone JJ 0 1 13 B-Drug
excretion NN 0 1 14 O
is VBZ 1 0 12 O
via IN 0 0 1 O
the DT 0 0 12 O
bile JJ 0 1 6 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
biliary JJ 0 1 8 O
excretion NN 0 1 14 O
glucuronidation NN 0 1 UNK O
and CC 0 0 12 O
intestinal JJ 0 1 13 O
beta NN 0 1 16 O
- : 0 0 2 O
glucuronidase NN 0 1 UNK O
are VBP 1 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
entacapone NN 0 1 13 B-Drug
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
few JJ 0 1 12 O
clinical JJ 0 1 6 O
situations NNS 1 0 UNK O
in IN 0 0 12 O
which WDT 0 0 12 O
the DT 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
''static JJ 0 1 UNK O
'' '' 0 0 13 O
and CC 0 0 12 O
''cidal VB 0 0 UNK O
'' '' 0 0 13 O
antibiotics NNS 1 1 6 B-Group
are VBP 1 0 12 O
indicated VBN 1 1 1 O
. . 0 0 12 O

Ritalin NNP 0 1 0 B-Brand
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
guanethidine NN 0 1 UNK B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
who WP 0 0 12 O
are VBP 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
ZYVOX NNP 0 1 UNK B-Brand
and CC 0 0 12 O
concomitant JJ 0 1 6 O
serotonergic JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
observed VBN 1 1 1 O
for IN 0 0 12 O
signs NNS 1 1 12 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
serotonin JJ 0 1 13 O
syndrome NN 0 1 6 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
cognitive JJ 0 1 1 O
dysfunction NN 0 1 6 O
hyperpyrexia NN 0 1 UNK O
hyperreflexia JJ 0 1 8 O
incoordination NN 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Anti NNP 0 0 UNK B-Group
- : 0 0 2 O
HIV NNP 0 1 6 I-Group
Protease NNP 0 1 UNK I-Group
Inhibitors NNP 0 1 7 I-Group

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
Cimetidine NN 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
other JJ 0 0 12 O
quinolones NNS 0 1 13 B-Group
. . 0 0 12 O

The DT 0 0 2 O
risks NNS 1 1 1 O
of IN 0 0 12 O
using VBG 1 1 1 O
Clozapine NNP 0 1 0 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
systematically RB 0 0 UNK O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Dosage NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
mentioned VBN 1 0 12 O
above IN 0 1 12 O
and CC 0 0 12 O
other JJ 0 0 12 O
similarly RB 0 0 1 O
metabolized VBN 1 1 UNK O
drugs NNS 1 1 6 O
particularly RB 0 0 1 O
those DT 0 0 12 O
of IN 0 0 12 O
low JJ 0 1 1 O
therapeutic JJ 0 1 6 O
ratio NN 0 1 1 O
or CC 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
renal JJ 0 1 6 O
and CC 0 0 12 O
/ JJ 0 0 2 O
or CC 0 0 12 O
hepatic JJ 0 1 14 O
impairment NN 0 1 16 O
may MD 0 0 1 O
require VB 0 0 1 O
adjustment NN 0 1 1 O
when WRB 0 0 12 O
starting VBG 1 1 12 O
or CC 0 0 12 O
stopping VBG 1 1 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
Tagamet NNP 0 1 0 B-Brand
to TO 0 0 12 O
maintain VB 0 1 1 O
optimum JJ 0 1 1 O
therapeutic JJ 0 1 6 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
cinoxacin JJ 0 1 UNK B-Drug
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
cinoxacin NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
caffeine JJ 0 1 6 B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
products NNS 1 1 1 O
. . 0 0 12 O

Carbamazepine NN 0 1 UNK B-Drug
: : 0 0 2 O
Steady JJ 0 1 UNK O
- : 0 0 2 O
state NN 0 1 1 O
trough IN 0 1 3 O
plasma NN 0 1 14 O
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
carbamazepine VB 0 1 16 B-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
epoxide JJ 0 1 UNK I-Drug_n
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
gabapentin NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
TID NNP 0 1 15 O
; : 0 0 2 O

In IN 0 0 2 O
general JJ 0 1 1 O
any DT 0 0 12 O
added JJ 0 1 12 O
antiarrhythmic JJ 0 1 14 B-Drug
drug NN 0 1 1 I-Drug
should MD 0 0 12 O
be VB 0 0 12 O
initiated VBN 1 1 1 O
at IN 0 0 12 O
a DT 0 0 12 O
lower JJR 1 1 1 O
than IN 0 0 12 O
usual JJ 0 1 12 O
dose NN 0 1 6 O
with IN 0 0 12 O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
increased VBN 1 1 1 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
and CC 0 0 12 O
bleeding NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
concomitant JJ 0 1 6 O
TOLECTIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
warfarin JJ 0 1 14 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Rifampin NN 0 1 0 B-Drug
: : 0 0 2 O
Following VBG 0 1 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
ARAVA NNP 0 1 UNK B-Brand
to TO 0 0 12 O
subjects VB 1 1 UNK O
receiving VBG 1 1 1 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
M9 NNP 0 1 UNK O
peak NN 0 1 1 O
levels NNS 1 1 1 O
were VBD 1 0 12 O
increased VBN 1 1 1 O
( ( 0 0 2 O
~9 CD 0 0 UNK O
% NN 0 0 18 O
) ) 0 0 2 O
over IN 0 1 12 O
those DT 0 0 12 O
seen VBN 1 1 12 O
when WRB 0 0 12 O
ARAVA NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
given VBN 1 1 12 O
alone RB 0 1 12 O
. . 0 0 12 O

Thyroid NNP 0 1 7 B-Group
administration NN 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
digitalized VBN 1 1 UNK O
hypothyroid NN 0 1 6 O
patient NN 0 1 6 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
dose JJ 0 1 6 O
requirement NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
plasma JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
when WRB 0 0 12 O
ketoprofen NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
lithium NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
Cmin NNP 0 1 UNK O
increased VBD 1 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ VBP 0 0 2 O
mL NN 0 1 14 O
when WRB 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
of IN 0 0 12 O
felbamate NN 0 1 13 B-Drug
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Acid NNP 0 1 2 O
- : 0 0 2 O
base NN 0 1 3 O
and CC 0 0 12 O
electrolyte JJ 0 1 14 O
alterations NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
with IN 0 0 12 O
brinzolamide NN 0 1 16 B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
glipizide VB 0 1 0 B-Drug
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
hypoglycemia NN 0 1 6 O
. . 0 0 12 O

- : 0 0 2 O
Drugs NN 0 1 2 O
with IN 0 0 12 O
nephrotoxic JJ 0 1 UNK O
potential NN 0 1 1 O
: : 0 0 2 O
There EX 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
no DT 0 0 12 O
experience NN 0 1 12 O
on IN 0 0 12 O
the DT 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
bumetanide NN 0 1 16 B-Drug
with IN 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
nephrotoxic JJ 0 1 UNK O
potential NN 0 1 1 O
. . 0 0 12 O

One CD 0 1 2 O
death NN 0 1 12 O
has VBZ 1 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
from IN 0 0 12 O
foreign JJ 0 1 1 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
sources NNS 1 1 1 O
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
a DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
may MD 0 0 1 O
further RB 1 1 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

Cevimeline NN 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
individuals NNS 1 1 1 O
known VBN 1 1 12 O
or CC 0 0 12 O
suspected VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
deficient JJ 0 1 1 O
in IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
activity NN 0 1 1 O
based VBN 1 1 1 O
on IN 0 0 12 O
previous JJ 0 1 12 O
experience NN 0 1 12 O
as IN 1 0 12 O
they PRP 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
at IN 0 0 12 O
a DT 0 0 12 O
higher JJR 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
. . 0 0 12 O

acidifying VBG 1 0 13 O
drugs NNS 1 1 6 O
or CC 0 0 12 O
foods NNS 1 1 1 O
will MD 0 0 12 O
decrease VB 0 1 1 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
and CC 0 0 12 O
increase VB 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
clonazepam NN 0 1 0 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
investigated VBN 1 1 1 O
. . 0 0 12 O

COPEGUS NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
in IN 0 0 12 O
women NNS 1 1 UNK O
who WP 0 0 12 O
are VBP 1 0 12 O
pregnant JJ 0 1 13 O
and CC 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
male JJ 0 1 12 O
partners NNS 1 1 1 O
of IN 0 0 12 O
women NNS 1 1 UNK O
who WP 0 0 12 O
are VBP 1 0 12 O
pregnant JJ 0 1 13 O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
Atorvastatin NNP 0 1 0 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
LDL NNP 0 0 14 O
- : 0 0 2 O
C NNP 0 0 2 O
reduction NN 0 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
by IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
role NN 0 1 1 O
of IN 0 0 12 O
AMEVIVE NNP 0 1 UNK B-Brand
in IN 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
lymphoid JJ 0 1 8 O
malignancy NN 0 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
hyperplasia NN 0 1 13 O
observed VBD 1 1 1 O
in IN 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
human JJ 0 1 1 O
primates NNS 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
relevance NN 0 1 UNK O
to TO 0 0 12 O
humans NNS 1 1 UNK O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
an DT 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
study NN 0 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomes NNS 1 1 UNK O
inhibition NN 0 1 13 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
hydroxylation NN 0 1 UNK O
of IN 0 0 12 O
coumarin NN 0 1 UNK B-Group
by IN 0 0 12 O
fondaparinux NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
m NN 0 1 2 O
m NN 0 1 2 O
M NNP 0 1 2 O
i.e. VBZ 0 1 1 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
L NNP 0 1 2 O
) ) 0 0 2 O
was VBD 1 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

The DT 0 0 2 O
extent NN 0 1 1 O
to TO 0 0 12 O
which WDT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
- : 0 0 2 O
TCA NNP 0 1 13 B-Group
interactions NNS 1 1 UNK O
may MD 0 0 1 O
pose VB 0 0 UNK O
clinical JJ 0 1 6 O
problems NNS 1 1 1 O
will MD 0 0 12 O
depend VB 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
and CC 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
involved VBN 1 1 12 O
. . 0 0 12 O

Methenamine NN 0 1 UNK B-Drug

Thioridazine NN 0 1 UNK B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
single JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
Sonata NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
thioridazine VB 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
produced VBN 1 0 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
on IN 0 0 12 O
decreased JJ 0 1 1 O
alertness NN 0 1 UNK O
and CC 0 0 12 O
impaired JJ 0 1 6 O
psychomotor NN 0 0 13 O
performance NN 0 1 13 O
for IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
administration NN 0 1 1 O
. . 0 0 12 O

Paliperidone NN 0 1 UNK B-Drug
may MD 0 0 1 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
levodopa NN 0 1 UNK B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
dopamine NN 0 1 14 B-Group
agonists NNS 1 1 UNK I-Group
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
situation NN 0 0 12 O
special JJ 0 1 12 O
patient NN 0 1 6 O
care NN 0 1 12 O
and CC 0 0 12 O
observation NN 0 1 1 O
are VBP 1 0 12 O
appropriate JJ 0 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
MIDAMOR NNP 0 1 UNK B-Brand
and CC 0 0 12 O
non SYM 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
if IN 0 0 12 O
the DT 0 0 12 O
desired JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
is VBZ 1 0 12 O
obtained VBN 1 1 1 O
. . 0 0 12 O

efavirenz DT 0 1 13 B-Drug
concentration NN 0 1 1 O

For IN 0 0 2 O
this DT 0 0 12 O
reason NN 0 1 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
adrenaline NN 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
restricted VBN 1 1 1 O
and CC 0 0 12 O
an DT 0 0 12 O
antiarrhythmic JJ 0 1 14 B-Group
agent NN 0 1 1 I-Group
administered VBD 1 1 1 O
as IN 1 0 12 O
appropriate NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
following JJ 0 1 1 O
agents NNS 1 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
certain JJ 0 1 1 O
actions NNS 1 1 UNK O
or CC 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
: : 0 0 2 O
amantadine NN 0 1 16 B-Drug
antiarrhythmic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
of IN 0 0 12 I-Group
class NN 0 1 12 I-Group
I PRP 0 1 12 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
quinidine NN 0 1 16 B-Drug
) ) 0 0 2 O
antihistamines VBZ 0 1 UNK B-Group
antipsychotic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
phenothiazines NNS 1 1 UNK B-Group
) ) 0 0 2 O
benzodiazepines NNS 1 1 14 B-Group
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
narcotic JJ 0 1 6 B-Group
analgesics NNS 1 1 14 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
meperidine NN 0 1 16 B-Drug
) ) 0 0 2 O
nitrates NNS 1 1 14 B-Group
and CC 0 0 12 O
nitrites NNS 1 1 UNK B-Group
sympathomimetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
having VBG 1 0 12 O
anticholinergic JJ 0 1 13 O
activity NN 0 1 1 O
. . 0 0 12 O

Sodium NNP 0 1 14 B-Drug
Iodide NNP 0 1 UNK I-Drug
( ( 0 0 2 O
9I CD 0 1 UNK O
and CC 0 0 12 O
9I CD 0 1 UNK O
) ) 0 0 2 O
Sodium NN 0 1 14 B-Drug
Pertechnetate NNP 0 1 UNK I-Drug
Tc9m NNP 0 0 UNK I-Drug
: : 0 0 2 O
Uptake NN 0 1 UNK O
of IN 0 0 12 O
radiolabeled JJ 0 1 UNK O
ions NNS 1 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

a DT 0 0 12 O
reduced JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
needed VBN 1 1 12 O
. . 0 0 12 O

Monitor NNP 0 1 2 O
serum VBD 0 1 14 O
potassium NN 0 1 14 O
levels NNS 1 1 1 O
; : 0 0 2 O

Concomitant JJ 0 1 UNK O
Drug NN 0 1 2 O

Cyclophosphamide NNP 0 1 UNK B-Drug
treatment NN 0 1 6 O
which WDT 0 0 12 O
causes VBZ 1 1 6 O
a DT 0 0 12 O
marked JJ 0 1 1 O
and CC 0 0 12 O
persistent JJ 0 1 1 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
cholinesterase NN 0 1 UNK O
activity NN 0 1 1 O
potentiates VBZ 1 0 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
chloride NN 0 1 14 I-Drug
. . 0 0 12 O

Although IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
regimen NNS 0 1 6 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
alternative JJ 0 1 1 O
or CC 0 0 12 O
back RB 0 1 12 O
- : 0 0 2 O
up IN 0 0 12 O
methods NNS 1 1 1 O
of IN 0 0 12 O
contraception NN 0 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

if IN 0 0 12 O
plasma JJ 0 1 14 O
levels NNS 1 1 1 O
are VBP 1 0 12 O
being VBG 1 0 12 O
monitored VBD 1 1 1 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
reassessed VBN 1 0 15 O
. . 0 0 12 O

reliable JJ 0 1 UNK O
estimates NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
prevalence NN 0 1 UNK O
of IN 0 0 12 O
reduced JJ 0 1 1 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
isozyme NN 0 1 UNK O
activity NN 0 1 1 O
among IN 0 0 12 O
Asian JJ 0 1 2 O
African NNP 0 1 UNK O
and CC 0 0 12 O
other JJ 0 0 12 O
populations NNS 1 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
yet RB 0 0 12 O
available JJ 0 1 1 O
. . 0 0 12 O

Since IN 0 1 2 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
AMEVIVE NNP 0 1 UNK B-Brand
on IN 0 0 12 O
pregnancy NN 0 1 6 O
and CC 0 0 12 O
fetal JJ 0 1 6 O
development NN 0 1 1 O
including VBG 1 1 1 O
immune JJ 0 1 6 O
system NN 0 1 1 O
development NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
health NN 0 1 1 O
care NN 0 1 12 O
providers NNS 1 1 1 O
are VBP 1 0 12 O
encouraged VBN 1 0 12 O
to TO 0 0 12 O
enroll VB 0 0 1 O
patients NNS 1 1 6 O
currently RB 0 1 12 O
taking VBG 1 0 12 O
AMEVIVE NNP 0 1 UNK B-Brand
who WP 0 0 12 O
become VBP 0 0 12 O
pregnant JJ 0 1 13 O
into IN 0 0 12 O
the DT 0 0 12 O
Biogen NNP 0 0 UNK O
Pregnancy NNP 0 1 7 O
Registry NNP 0 1 UNK O
by IN 0 0 12 O
calling VBG 1 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
AMEVIVE NNP 0 1 UNK B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

however RB 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
ranitidine NN 0 1 0 B-Drug
q9h NN 0 1 UNK O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
increased VBD 1 1 1 O
the DT 0 0 12 O
ceftibuten JJ 0 1 UNK B-Drug
C NNP 0 0 2 O
max NN 0 0 3 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
ceftibuten JJ 0 1 UNK B-Drug
AUC NNP 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
if IN 0 0 12 O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
differ VBP 0 0 UNK O
in IN 0 0 12 O
their PRP$ 0 0 12 O
effectiveness NN 0 1 UNK O
when WRB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
. . 0 0 12 O

Caverject NN 0 1 UNK B-Brand
: : 0 0 2 O
The DT 0 0 2 O
potential NN 0 1 1 O
for IN 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
alprostadil NN 0 1 13 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
formally RB 0 0 1 O
studied VBN 1 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
mean JJ 0 1 12 O
C NNP 0 0 2 O
max NN 0 0 3 O
T NNP 0 1 2 O
max NN 0 0 3 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
acid JJ 0 1 14 O
metabolite NN 0 1 UNK O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
changed VBN 1 1 12 O
. . 0 0 12 O

- : 0 0 2 O
Furazolidone NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. VB 0 0 UNK O
Furoxone NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

sertraline NN 0 1 16 B-Drug
concentration NN 0 1 1 O

Itraconazole NNP 0 1 UNK B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
when WRB 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
and CC 0 0 12 O
isoniazid NN 0 1 13 B-Drug
are VBP 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

However RB 0 0 1 O
ketoconazole VB 0 1 16 B-Drug
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
may MD 0 0 1 O
increase VB 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
mometasone NN 0 1 13 B-Drug
furoate NN 0 1 13 I-Drug
during IN 0 0 12 O
concomitant JJ 0 1 6 O
dosing NN 0 0 14 O
. . 0 0 12 O

Nabilone NN 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
other JJ 0 0 12 O
psychoactive JJ 0 0 UNK B-Group
drugs NNS 1 1 6 I-Group
or CC 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
including VBG 1 1 1 O
alcohol NN 0 1 1 B-Drug
barbiturates NNS 1 1 14 B-Group
and CC 0 0 12 O
narcotic JJ 0 1 6 B-Group
analgesics NNS 1 1 14 I-Group
or CC 0 0 12 O
to TO 0 0 12 O
those DT 0 0 12 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
psychiatric JJ 0 1 6 O
disorder NN 0 1 6 O
( ( 0 0 2 O
including VBG 1 1 1 O
manic SYM 0 1 13 O
- : 0 0 2 O
depressive JJ 0 0 13 O
illness NN 0 1 6 O
and CC 0 0 12 O
schizophrenia NN 0 1 13 O
) ) 0 0 2 O
. . 0 0 12 O

Read NNP 0 1 2 O
circulars NNS 1 1 UNK O
for IN 0 0 12 O
lithium NN 0 1 16 B-Drug
preparations NNS 1 1 13 O
before IN 0 1 12 O
use NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
. . 0 0 12 O

Medications NNS 0 1 7 O
that WDT 0 0 12 O
interfere VBP 0 1 UNK O
with IN 0 0 12 O
your PRP$ 0 0 12 O
bodys NN 1 0 UNK O
ability NN 0 1 1 O
to TO 0 0 12 O
use VB 0 1 1 O
folate NN 0 1 14 O
may MD 0 0 1 O
also RB 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
need NN 0 1 12 O
for IN 0 0 12 O
this DT 0 0 12 O
vitamin NN 0 1 6 B-Group
. . 0 0 12 O

Isoflurane NNP 0 1 UNK B-Drug
enflurane NN 0 1 UNK B-Drug
and CC 0 0 12 O
halothane NN 0 1 13 B-Drug
decrease NN 0 1 1 O
the DT 0 0 12 O
ED9 NNP 0 0 UNK O
of IN 0 0 12 O
NUROMAX NNP 0 1 UNK B-Brand
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

The DT 0 0 2 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
metoprolol NN 0 1 0 B-Drug
however RB 0 0 12 O
were VBD 1 0 12 O
increased VBN 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O

Studies NNS 0 1 2 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
isoniazid NN 0 1 13 B-Drug
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
significantly RB 0 0 1 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
food NN 0 1 12 O
. . 0 0 12 O

Ritonavir NN 0 1 0 B-Drug

Serotonin NNP 0 1 UNK O
release NN 0 1 12 O
by IN 0 0 12 O
platelets NNS 1 1 14 O
plays VBP 1 1 UNK O
an DT 0 0 12 O
important JJ 0 1 1 O
role NN 0 1 1 O
in IN 0 0 12 O
hemostasis NN 0 1 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
serum JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
to TO 0 0 12 O
avoid VB 0 0 12 O
drug NN 0 1 1 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Before IN 0 1 2 O
taking VBG 1 0 12 O
this DT 0 0 12 O
medication NN 0 1 6 O
tell VB 0 0 12 O
your PRP$ 0 0 12 O
doctor NN 0 1 12 O
if IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
a DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
amitriptyline NN 0 1 16 B-Drug
( ( 0 0 2 O
Elavil NNP 0 1 0 B-Brand
) ) 0 0 2 O
amoxapine NN 0 1 13 B-Drug
( ( 0 0 2 O
Asendin NNP 0 1 UNK B-Brand
) ) 0 0 2 O
doxepin NN 0 1 16 B-Drug
( ( 0 0 2 O
Sinequan NNP 0 1 0 B-Brand
) ) 0 0 2 O
nortriptyline NN 0 1 16 B-Drug
( ( 0 0 2 O
Pamelor NNP 0 1 UNK B-Brand
) ) 0 0 2 O
imipramine NN 0 1 0 B-Drug
( ( 0 0 2 O
Tofranil NNP 0 1 0 B-Brand
) ) 0 0 2 O
clomipramine NN 0 1 13 B-Drug
( ( 0 0 2 O
Anafranil NNP 0 1 UNK B-Brand
) ) 0 0 2 O
protriptyline NN 0 1 UNK B-Drug
( ( 0 0 2 O
Vivactil NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O
desipramine NN 0 1 16 B-Drug
( ( 0 0 2 O
Norpramin NNP 0 1 UNK B-Brand
) ) 0 0 2 O
. . 0 0 12 O

Indinavir NNP 0 1 UNK B-Drug
concentrations NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
nevirapine NN 0 1 13 B-Drug
. . 0 0 12 O

Oral JJ 0 1 2 O
Anticoagulants NNS 0 1 UNK B-Group
: : 0 0 2 O
In IN 0 0 2 O
some DT 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
and CC 0 0 12 O
warfarin VB 0 1 14 B-Drug
acenocoumarol NN 0 1 UNK B-Drug
or CC 0 0 12 O
phenprocoumon NN 0 1 UNK B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

Bosentan NNP 0 1 UNK B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
relevant JJ 0 1 1 O
inhibitory NN 0 1 UNK O
effect NN 0 1 1 O
on IN 0 0 12 O
any DT 0 0 12 O
CYP NNP 0 1 UNK O
isoenzymes NNS 0 1 14 O
tested VBD 1 1 1 O
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Cmax NNP 0 1 UNK O
and CC 0 0 12 O
t9 VB 0 1 13 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
were VBD 1 0 12 O
increased VBN 1 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
respectively RB 0 0 1 O
. . 0 0 12 O

Anagrelide NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
cyclic JJ 0 1 13 O
AMP NNP 0 0 UNK O
PDE NNP 0 0 UNK O
III NNP 0 1 2 O
. . 0 0 12 O

The DT 0 0 2 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
binding NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
to TO 0 0 12 O
human JJ 0 1 1 O
plasma NN 0 1 14 O
proteins NNS 1 1 14 O
is VBZ 1 0 12 O
unaffected VBN 0 1 UNK O
by IN 0 0 12 O
tolmetin NN 0 1 UNK B-Drug
and CC 0 0 12 O
tolmetin NN 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
of IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Methadonea NN 0 0 UNK O

methylphenidate NN 0 1 16 B-Drug
; : 0 0 2 O

Seizure NN 0 1 7 O
associated VBN 1 1 1 O
with IN 0 0 12 O
increased JJ 0 1 1 O
lidocaine NN 0 1 14 B-Drug
concentrations NNS 1 1 13 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
intravenous JJ 0 1 14 O
amiodarone NN 0 1 0 B-Drug
. . 0 0 12 O

Mean NNP 0 1 2 O
T NNP 0 1 2 O
max NN 0 0 3 O
and CC 0 0 12 O
mean JJ 0 1 12 O
plasma NN 0 1 14 O
elimination NN 0 1 UNK O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
albendazole JJ 0 1 13 B-Drug
sulfoxide NN 0 1 UNK I-Drug
were VBD 1 0 12 O
unchanged JJ 0 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
coad VBN 0 1 UNK O
- : 0 0 2 O
ministered VBN 1 1 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
frequent JJ 0 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Laboratory NNP 0 1 2 O
- : 0 0 2 O
Test NN 0 1 2 O
Interactions NNPS 0 1 UNK O
Interactions NNP 0 1 UNK O
between IN 0 0 12 O
tolterodine NN 0 1 16 B-Drug
and CC 0 0 12 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

reliable JJ 0 1 UNK O
estimates NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
prevalence NN 0 1 UNK O
of IN 0 0 12 O
reduced JJ 0 1 1 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
isozyme NN 0 1 UNK O
activity NN 0 1 1 O
among IN 0 0 12 O
Asian JJ 0 1 2 O
African NNP 0 1 UNK O
and CC 0 0 12 O
other JJ 0 0 12 O
populations NNS 1 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
yet RB 0 0 12 O
available JJ 0 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Tests VBZ 0 1 UNK O
Interactions NNP 0 1 UNK O
Because IN 0 0 12 O
false JJ 0 1 13 O
positive JJ 0 1 1 O
readings NNS 1 1 1 O
were VBD 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
Ames NNP 0 1 UNK O
N NNP 0 1 2 O
- : 0 0 2 O
Multistix NNP 0 1 UNK O
SG NNP 0 1 UNK O
dipstick JJ 0 1 13 O
test NN 0 1 1 O
for IN 0 0 12 O
urinary JJ 0 1 6 O
protein NN 0 1 14 O
when WRB 0 0 12 O
gabapentin NN 0 1 0 B-Drug
was VBD 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
other JJ 0 0 12 O
antiepileptic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
the DT 0 0 12 O
more RBR 0 1 12 O
specific JJ 0 1 1 O
sulfosalicylic JJ 0 0 UNK O
acid NN 0 1 14 O
precipitation NN 0 1 1 O
procedure NN 0 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
urine JJ 0 1 6 O
protein NN 0 1 14 O

Oral JJ 0 1 2 O
Contraceptives NNP 0 1 UNK B-Group
Multiple NNP 0 1 2 O
doses NNS 1 1 6 O
of IN 0 0 12 O
cefditoren NN 0 1 UNK B-Drug
pivoxil NN 0 0 UNK I-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
ethinyl NN 0 0 13 B-Drug
estradiol VBP 0 1 13 I-Drug
the DT 0 0 12 O
estrogenic JJ 0 1 UNK O
component NN 0 1 1 O
in IN 0 0 12 O
most JJS 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
. . 0 0 12 O

As IN 0 0 2 O
with IN 0 0 12 O
most RBS 0 0 12 O
psychoactive JJ 0 0 UNK O
medications NNS 1 1 6 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
advised VBN 1 0 12 O
to TO 0 0 12 O
avoid VB 0 0 12 O
alcohol NN 0 1 1 B-Drug
while IN 0 0 12 O
taking VBG 1 0 12 O
ABILIFY NNP 0 1 UNK B-Brand

This DT 0 0 2 O
drug NN 0 1 1 O
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
CNS NNP 0 1 6 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
either CC 0 1 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
or CC 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
) ) 0 0 2 O
anticholinergics NNS 1 1 13 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
with IN 0 0 12 O
anticholinergic JJ 0 1 13 O
activity NN 0 1 1 O
( ( 0 0 2 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
when WRB 0 0 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
are VBP 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
) ) 0 0 2 O
and CC 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
with IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Drug
may MD 0 0 1 O
prolong VB 0 0 13 O
and CC 0 0 12 O
intensify VB 0 0 UNK O
the DT 0 0 12 O
anticholinergic NN 0 1 13 O
and CC 0 0 12 O
CNS NNP 0 1 6 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Mineral JJ 0 1 UNK B-Drug
oil NN 0 1 3 I-Drug
interferes NNS 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
fat JJ 0 1 3 B-Group
- : 0 0 2 O
soluble JJ 0 1 16 I-Group
vitamins NNS 1 1 6 I-Group
including VBG 1 1 1 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
preparations NNS 1 1 13 I-Group
. . 0 0 12 O

cardiac JJ 0 1 6 B-Group
glycosides NNS 1 1 13 I-Group
; : 0 0 2 O

C NNP 0 0 2 O
max VBD 0 0 3 O
AUC NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hrs NN 1 0 16 O
C NNP 0 0 2 O
max NN 0 0 3 O
AUC NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hrs NN 1 0 16 O

- : 0 0 2 O
Impaired VBD 0 1 UNK O
glucose JJ 0 1 14 O
tolerance NN 0 1 1 O

Fluconazole NNP 0 1 0 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 B-Group
- : 0 0 2 O
HT9 NN 0 1 UNK I-Group
antiemetics NNS 1 1 14 I-Group
ondansetron VBP 0 1 16 B-Drug
( ( 0 0 2 O
Zofran NNP 0 1 0 B-Brand
) ) 0 0 2 O
and CC 0 0 12 O
granisetron NN 0 1 13 B-Drug
( ( 0 0 2 O
Kytril NNP 0 1 UNK B-Brand
) ) 0 0 2 O
have VBP 0 0 12 O
all DT 0 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
BUSULFEX NNP 0 1 UNK B-Brand
. . 0 0 12 O

the DT 0 0 12 O
time NN 0 1 12 O
to TO 0 0 12 O
reach VB 0 1 12 O
maximum JJ 0 1 1 O
concentration NN 0 1 1 O
was VBD 1 0 12 O
delayed VBN 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
. . 0 0 12 O

Antacid NN 0 1 UNK B-Group
: : 0 0 2 O
The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
aluminum NN 0 1 16 B-Drug
hydroxide NN 0 1 14 I-Drug
- : 0 0 2 O
and CC 0 0 12 O
magnesium VB 0 1 14 B-Drug
hydroxide JJ 0 1 14 I-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
antacid NN 0 1 UNK B-Group
( ( 0 0 2 O
Maalox NNP 0 1 0 B-Brand
) ) 0 0 2 O
* NN 0 0 2 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
capecitabine NN 0 1 13 B-Drug
was VBD 1 0 12 O
investigated VBN 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
cancer NN 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

Inhibition NN 0 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
metabolic JJ 0 1 6 O
reactions NNS 1 1 1 O
was VBD 1 0 12 O
not RB 0 1 12 O
detected VBN 1 1 1 O
in IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
experiments NNS 1 1 UNK O
. . 0 0 12 O

iii NN 0 1 16 O
. . 0 0 12 O

Thus RB 0 0 1 O
no DT 0 0 12 O
dosing NN 0 0 14 O
adjustments NNS 1 1 1 O
are VBP 1 0 12 O
necessary JJ 0 0 1 O
during IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
with IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

Antidiabetics NNS 0 1 UNK B-Group
: : 0 0 2 O
Because IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
may MD 0 0 1 O
increase VB 0 1 1 O
blood NN 0 1 6 O
glucose JJ 0 1 14 O
concentrations NNS 1 1 13 O
dosage VBP 0 1 0 O
adjustments NNS 1 1 1 O
of IN 0 0 12 O
antidiabetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
a DT 0 0 12 O
diuretic NN 0 1 14 B-Group
is VBZ 1 0 12 O
also RB 0 0 12 O
used VBN 1 1 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
lithium JJ 0 1 16 O
toxicity NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

. . 0 0 12 O

however RB 0 0 12 O
in IN 0 0 12 O
a DT 0 0 12 O
study NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
subjects NNS 1 1 UNK O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
aspirin NNS 0 1 14 B-Brand
decreased VBN 1 1 1 O
ketoprofen NNS 0 1 UNK B-Drug
protein IN 0 1 14 O
binding VBG 1 1 1 O
and CC 0 0 12 O
increased VBD 1 1 1 O
ketoprofen NNS 0 1 UNK B-Drug
plasma JJ 0 1 14 O
clearance NN 0 1 16 O
from IN 0 0 12 O
9 CD 0 0 2 O
L NNP 0 1 2 O
/ NNP 0 0 2 O
kg NNP 0 1 18 O
/ NNP 0 0 2 O
h NN 0 1 16 O
without IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
to TO 0 0 12 O
9 CD 0 0 2 O
L NNP 0 1 2 O
/ NNP 0 0 2 O
kg NNP 0 1 18 O
/ NNP 0 0 2 O
h NN 0 1 16 O
with IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
. . 0 0 12 O

ISUPREL NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
if IN 0 0 12 O
at IN 0 0 12 O
all DT 0 0 12 O
when WRB 0 0 12 O
potent JJ 0 1 UNK O
inhalational JJ 0 1 14 O
anesthetics NNS 1 1 13 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
halothane NN 0 1 13 B-Drug
are VBP 1 0 12 O
employed VBN 1 1 1 O
because IN 0 0 12 O
of IN 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
sensitize VB 0 0 UNK O
the DT 0 0 12 O
myocardium NN 0 1 8 O
to TO 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
amines NNS 1 1 13 I-Group
. . 0 0 12 O

. . 0 0 12 O

The DT 0 0 2 O
appropriate JJ 0 1 1 O
doses NNS 1 1 6 O
for IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
respect NN 0 1 1 O
to TO 0 0 12 O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
safety NN 0 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
possibility NN 0 1 1 O
of IN 0 0 12 O
increased JJ 0 1 1 O
interaction NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
kept VBN 1 1 12 O
in IN 0 0 12 O
mind NN 0 1 12 O
when WRB 0 0 12 O
Orudis NNP 0 1 UNK B-Brand
doses VBZ 1 1 6 O
greater JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
as IN 1 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
ketoprofen JJ 0 1 UNK B-Drug
per IN 0 0 1 O
day NN 0 1 12 O
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
highly RB 0 1 1 O
bound VBN 1 1 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

- : 0 0 2 O
Drug NN 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Thiazides NNS 0 1 UNK B-Group
should MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
before IN 0 1 12 O
carrying VBG 1 1 12 O
out RP 0 1 12 O
tests NNS 1 1 1 O
for IN 0 0 12 O
parathyroid JJ 0 1 14 O
function NN 0 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
whether IN 0 0 12 O
this DT 0 0 12 O
could MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effects NNS 1 1 1 O
caution NN 0 0 1 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
Cerebyx NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
significantly RB 0 0 1 O
bind VBP 0 1 UNK O
to TO 0 0 12 O
serum VB 0 1 14 O
albumin NN 0 1 14 O
. . 0 0 12 O

This DT 0 0 2 O
antagonistic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
on IN 0 0 12 O
bumetanide JJ 0 1 16 B-Drug
natriuresis NN 0 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
direct JJ 0 1 1 O
action NN 0 1 13 O
on IN 0 0 12 O
sodium NN 0 1 14 O
excretion NN 0 1 14 O
but CC 0 0 12 O
is VBZ 1 0 12 O
probably RB 0 1 12 O
secondary JJ 0 1 1 O
to TO 0 0 12 O
its PRP$ 1 0 12 O
inhibitory JJ 0 1 UNK O
effect NN 0 1 1 O
on IN 0 0 12 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
bumetanide NN 0 1 16 B-Drug
. . 0 0 12 O

Terbinafine NN 0 1 UNK B-Drug
decreases VBZ 1 1 UNK O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

In IN 0 0 2 O
renal JJ 0 1 6 O
and CC 0 0 12 O
cardiac JJ 0 1 6 O
transplant NN 0 1 6 O
recipients VBZ 0 1 UNK O
a DT 0 0 12 O
reduction NN 0 1 1 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
dose NN 0 1 6 O
ranging VBG 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
was VBD 1 0 12 O
necessary JJ 0 0 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
cyclosporine JJ 0 1 14 B-Drug
trough IN 0 1 3 O
concentrations NNS 1 1 13 O
similar JJ 0 1 1 O
to TO 0 0 12 O
those DT 0 0 12 O
seen VBN 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
. . 0 0 12 O

Theophylline NN 0 1 UNK B-Drug
: : 0 0 2 O
The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
( ( 0 0 2 O
aminophylline JJ 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
infused VBD 1 0 3 O
over IN 0 1 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
) ) 0 0 2 O
were VBD 1 0 12 O
unchanged JJ 0 1 1 O
following VBG 1 1 1 O
a DT 0 0 12 O
single JJ 0 1 12 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
albendazole NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

Drugs NNS 0 1 2 O
Highly NNP 0 1 UNK O
Bound NNP 0 1 UNK O
to TO 0 0 12 O
Plasma NNP 0 1 UNK O
Protein NNP 0 1 2 O
Zaleplon NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
highly RB 0 1 1 O
bound VBN 1 1 12 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
( ( 0 0 2 O
fraction NN 0 1 1 O
bound RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
; : 0 0 2 O

Exemestane NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
extensively RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
but CC 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
has VBZ 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
exemestane NN 0 1 13 B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
: : 0 0 2 O
Enteric NNP 0 1 7 O
Coated NNP 0 1 2 O
Aspirin NNP 0 1 0 B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
antacids NNS 1 1 14 B-Group
since IN 0 1 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
pH NN 0 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
stomach NN 0 1 6 O
may MD 0 0 1 O
effect NN 0 1 1 O
the DT 0 0 12 O
enteric JJ 0 1 14 O
coating NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
tablets NNS 1 1 3 O
. . 0 0 12 O

however RB 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
methadone NN 0 1 6 B-Drug
dose NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
small JJ 0 1 12 O
number NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
these DT 0 0 12 O
subjects NNS 1 1 UNK O
celecoxib VBP 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
as IN 1 0 12 O
determined VBN 1 1 1 O
by IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
EDECRIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
non SYM 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
if IN 0 0 12 O
the DT 0 0 12 O
desired JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
is VBZ 1 0 12 O
obtained VBN 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
alteration NN 0 1 1 O
will MD 0 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
methadone NN 0 1 6 B-Drug
dose JJ 0 1 6 O
modification NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
majority NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
; : 0 0 2 O

Rhabdomyolysis NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
administered VBD 1 1 1 O
alone RB 0 1 12 O
( ( 0 0 2 O
at IN 0 0 12 O
recommended VBN 1 1 1 O
dosages NNS 1 1 14 O
) ) 0 0 2 O
or CC 0 0 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
immunosuppressive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
including VBG 1 1 1 O
cyclosporine NN 0 1 14 B-Drug
. . 0 0 12 O

tolbutamide NN 0 1 UNK B-Drug
; : 0 0 2 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
TIKOSYN NNP 0 1 UNK B-Brand
with IN 0 0 12 O
verapamil NN 0 1 0 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
dofetilide JJ 0 1 13 B-Drug
peak NN 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
although IN 0 0 12 O
overall JJ 0 1 1 O
exposure NN 0 1 1 O
to TO 0 0 12 O
dofetilide VB 0 1 13 B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
increased VBN 1 1 1 O
. . 0 0 12 O

( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
Q9h NNP 0 1 UNK O
) ) 0 0 2 O

These DT 0 0 1 O
are VBP 1 0 12 O
described VBN 1 1 1 O
in IN 0 0 12 O
greater JJR 1 1 1 O
detail NN 0 1 1 O
below IN 0 0 12 O
: : 0 0 2 O
Oral JJ 0 1 2 O
hypoglycemics NNS 0 1 14 B-Group
Coumarin NNP 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants NNS 1 1 13 I-Group
Phenytoin NNP 0 1 0 B-Drug
Cyclosporine NNP 0 1 UNK B-Drug
Rifampin NNP 0 1 0 B-Drug
Theophylline NNP 0 1 UNK B-Drug
Terfenadine NNP 0 1 UNK B-Drug
Cisapride NNP 0 1 0 B-Drug
Astemizole NNP 0 1 UNK B-Drug
Rifabutin NNP 0 1 UNK B-Drug
Tacrolimus NNP 0 1 0 B-Drug
Short NNP 0 1 2 B-Group
- : 0 0 2 O
acting VBG 1 1 12 I-Group
benzodiazepines NNS 1 1 14 I-Group
Oral JJ 0 1 2 O
hypoglycemics NNS 0 1 14 B-Group
: : 0 0 2 O
Clinically NNP 0 0 7 O
significant JJ 0 1 1 O
hypoglycemia NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
precipitated VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
DIFLUCAN NNP 0 1 UNK B-Brand
with IN 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
; : 0 0 2 O

Fexofenadine NNP 0 1 UNK B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
erythromycin NN 0 1 0 B-Drug
or CC 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Acetaminophen NNP 0 1 0 B-Drug
may MD 0 0 1 O
produce VB 0 0 1 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
test NN 0 1 1 O
results NNS 1 1 1 O
for IN 0 0 12 O
urinary JJ 0 1 6 O
9 CD 0 0 2 O
- : 0 0 2 O
hydroxyindoleacetic JJ 0 0 UNK O
acid NN 0 1 14 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
NSAIDs NNP 0 1 UNK B-Group
have VBP 0 0 12 O
produced VBN 1 0 1 O
an DT 0 0 12 O
elevation NN 0 1 1 O
of IN 0 0 12 O
plasma JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
renal JJ 0 1 6 O
lithium NN 0 1 16 B-Drug
clearance NN 0 1 16 O
. . 0 0 12 O

However RB 0 0 1 O
on IN 0 0 12 O
a DT 0 0 12 O
body NN 0 1 3 O
surface JJ 0 1 3 O
area NN 0 1 12 O
basis NN 0 1 1 O
this DT 0 0 12 O
dose NN 0 1 6 O
was VBD 1 0 12 O
9 CD 0 0 2 O
times NNS 1 1 12 O
maximum JJ 0 1 1 O
recommended VBD 1 1 1 O
human JJ 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
ribavirin NN 0 1 13 B-Drug
. . 0 0 12 O

. . 0 0 12 O

Other JJ 0 0 2 O
kits NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
the DT 0 0 12 O
Coat NNP 0 1 UNK O
- : 0 0 2 O
A DT 0 0 2 O
- : 0 0 2 O
Count NN 0 1 UNK O
RIA NNP 0 1 UNK O
Kit NNP 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
Sanctura NNP 0 1 UNK B-Brand
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
eliminated VBN 1 1 UNK O
by IN 0 0 12 O
active JJ 0 1 1 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
serum JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
Sanctura NNP 0 1 UNK B-Brand
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
the DT 0 0 12 O
coadministered JJ 0 0 UNK O
drug NN 0 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
competition NN 0 1 12 O
for IN 0 0 12 O
this DT 0 0 12 O
elimination NN 0 1 UNK O
pathway NN 0 1 UNK O
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
between IN 0 0 12 O
Argatroban NNP 0 1 0 B-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
or CC 0 0 12 O
erythromycin NN 0 1 0 B-Drug
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
PRINIVIL NNP 0 1 UNK B-Brand
with IN 0 0 12 O
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing NN 0 0 6 I-Group
diuretics NNS 1 1 14 I-Group
( ( 0 0 2 O
e.g. VB 0 0 UNK O
spironolactone NN 0 1 0 B-Drug
triamterene NN 0 1 13 B-Drug
or CC 0 0 12 O
amiloride NN 0 1 16 B-Drug
) ) 0 0 2 O
potassium NN 0 1 14 B-Drug
supplements NNS 1 1 6 O
or CC 0 0 12 O
potassium NN 0 1 14 O
- : 0 0 2 O
containing NN 0 1 1 O
salt NN 0 1 3 O
substitutes NNS 1 0 13 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
significant JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
. . 0 0 12 O

and CC 0 0 12 O
rarely RB 0 1 UNK O
euphoria JJ 0 1 UNK O
excitement NN 0 1 12 O
depression NN 0 1 6 O
hallucinations NNS 1 1 6 O
paresthesia VBP 0 1 UNK O
muscle NN 0 1 6 O
pain NN 0 1 6 O
tinnitus NN 0 1 13 O
slurred VBD 1 1 6 O
speech JJ 0 1 12 O
coordination NN 0 1 1 O
disorder NN 0 1 6 O
tremor NN 0 1 6 O
rigidity NN 0 1 3 O
dystonia NN 0 1 13 O
ataxia NN 0 1 6 O
blurred VBD 1 1 3 O
vision NN 0 1 1 O
nystagmus NN 0 1 8 O
strabismus JJ 0 1 13 O
miosis NN 0 1 13 O
mydriasis NN 0 1 13 O
diplopia NN 0 1 8 O
dysarthria NN 0 1 8 O
epileptic JJ 0 1 13 O
seizure NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
oral JJ 0 1 6 O
( ( 0 0 2 O
gavage NN 0 1 14 O
) ) 0 0 2 O
embryo VBZ 0 1 UNK O
- : 0 0 2 O
fetal NN 0 1 6 O
development NN 0 1 1 O
studies NNS 1 1 1 O
of IN 0 0 12 O
ezetimibe NN 0 1 16 B-Drug
conducted VBN 1 1 1 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
and CC 0 0 12 O
rabbits NNS 1 1 UNK O
during IN 0 0 12 O
organogenesis NN 0 1 UNK O
there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
embryolethal JJ 0 0 UNK O
effects NNS 1 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
doses NNS 1 1 6 O
tested VBN 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

Cefuroxime NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
assay NN 0 1 14 O
of IN 0 0 12 O
serum NN 0 1 14 O
and CC 0 0 12 O
urine JJ 0 1 6 O
creatinine NN 0 1 14 O
by IN 0 0 12 O
the DT 0 0 12 O
alkaline NN 0 1 14 O
picrate NN 0 1 UNK O
method NN 0 1 13 O
. . 0 0 12 O

Digoxin NNP 0 1 0 B-Drug
Methotrexate NNP 0 1 0 B-Drug
Cyclosporine NNP 0 1 UNK B-Drug
: : 0 0 2 O
Diclofenac NNP 0 1 UNK B-Drug
like IN 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
may MD 0 0 1 O
affect VB 0 1 1 O
renal JJ 0 1 6 O
prostaglandins NNS 1 1 UNK O
and CC 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Thus RB 0 0 1 O
SYMLIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
mixed JJ 0 1 3 O
and CC 0 0 12 O
must MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
separately RB 0 0 1 O
. . 0 0 12 O

Note NN 0 1 2 O
: : 0 0 2 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
entecavir NN 0 1 16 B-Drug
with IN 0 0 12 O
lamivudine JJ 0 1 16 B-Drug
adefovir NN 0 1 16 B-Drug
dipivoxil NN 0 0 16 I-Drug
or CC 0 0 12 O
tenofovir NN 0 1 16 B-Drug
disoproxil JJ 0 0 16 I-Drug
fumarate NN 0 1 16 I-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
Exjade NNP 0 1 UNK B-Brand
and CC 0 0 12 O
aluminum SYM 0 1 16 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
antacid JJ 0 1 UNK B-Group
preparations NNS 1 1 13 I-Group
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
formally RB 0 0 1 O
studied VBN 1 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
concentration NN 0 1 1 O
of IN 0 0 12 O
AMICAR NNP 0 1 UNK B-Brand
necessary JJ 0 0 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
fibrinolysis NN 0 1 13 O
is VBZ 1 0 12 O
9 CD 0 0 2 O
mMol NN 0 1 UNK O
/ NNP 0 0 2 O
L NNP 0 1 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
mL NN 0 1 14 O
. . 0 0 12 O

Carbamazepine NN 0 1 UNK B-Drug

Aminoglutethimide IN 0 1 UNK B-Drug
: : 0 0 2 O
May NNP 0 1 2 O
increase VB 0 1 1 O
CYP NNP 0 1 UNK O
metabolism NN 0 1 16 O
of IN 0 0 12 O
progestins NNS 1 1 UNK B-Group
leading VBG 1 1 1 O
to TO 0 0 12 O
possible JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
contraceptive JJ 0 1 13 O
effectiveness NN 0 1 UNK O
. . 0 0 12 O

Prothrombin JJ 0 1 7 O
time NN 0 1 12 O
or CC 0 0 12 O
other JJ 0 0 12 O
suitable JJ 0 1 1 O
anticoagulation NN 0 1 14 O
test NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
if IN 0 0 12 O
tigecycline NN 0 1 13 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Amiodarone NNP 0 1 0 B-Drug
taken VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
procainamide NN 0 1 16 B-Drug
for IN 0 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
seven CD 0 1 12 O
days NNS 1 1 12 O
increases VBZ 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
procainamide NN 0 1 16 B-Drug
and CC 0 0 12 O
n JJ 0 1 12 O
- : 0 0 2 O
acetyl NN 0 0 UNK O
procainamide NN 0 1 16 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O

LABORATORY NNP 0 1 11 O
TEST NNP 0 1 11 O
FINDINGS NNP 0 1 11 O
Asymptomatic NNP 0 1 UNK O
transitory NN 0 1 13 O
changes NNS 1 1 1 O
in IN 0 0 12 O
serum NN 0 1 14 O
iron NN 0 1 3 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O

Although IN 0 0 12 O
specific JJ 0 1 1 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
coadministration NN 0 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
mainly RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
eg JJ 0 1 UNK O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
dapsone VBP 0 1 13 B-Drug
disopyramide JJ 0 1 16 B-Drug
quinine NN 0 1 16 B-Drug
amiodarone NN 0 1 0 B-Drug
quinidine NN 0 1 16 B-Drug
warfarin NN 0 1 14 B-Drug
tacrolimus NN 0 1 16 B-Drug
cyclosporine NN 0 1 14 B-Drug
ergot VBD 0 1 UNK B-Group
derivatives NNS 1 1 13 I-Group
pimozide JJ 0 1 13 B-Drug
carbamazepine NN 0 1 16 B-Drug
fentanyl NN 0 1 14 B-Drug
alfentanyl NN 0 1 UNK B-Drug
alprazolam NN 0 1 0 B-Drug
and CC 0 0 12 O
triazolam NN 0 1 13 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
have VB 0 0 12 O
elevated VBN 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
saquinavir NN 0 1 13 B-Drug
; : 0 0 2 O

Tiagabine NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
shown VBN 1 1 1 O
no DT 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
potentiation NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
triazo JJ 0 0 UNK O
lam NN 0 0 13 O
or CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

Sucralfate NNP 0 1 0 B-Drug
and CC 0 0 12 O
antacids NNS 1 1 14 B-Group
: : 0 0 2 O
Quinolones NNS 0 1 UNK B-Group
form VBP 0 1 1 O
chelates NNS 1 1 UNK O
with IN 0 0 12 O
metal JJ 0 1 3 O
cations NNS 1 1 UNK O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
possible JJ 0 1 1 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
these DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
. . 0 0 12 O

*CBZ NNS 0 0 UNK O
epoxide VBP 0 1 UNK O

Oral JJ 0 1 2 O
Hypoglycemic NNP 0 1 UNK B-Group
Agents NNS 0 1 2 I-Group
: : 0 0 2 O
In IN 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
of IN 0 0 12 O
MEVACOR NNP 0 1 UNK B-Brand
in IN 0 0 12 O
hypercholesterolemic JJ 0 0 UNK O
noninsulin JJ 0 0 15 O
dependent JJ 0 1 1 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
glipizide NN 0 1 0 B-Drug
or CC 0 0 12 O
with IN 0 0 12 O
chlorpropamide NN 0 1 13 B-Drug

Therefore RB 0 0 1 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
these DT 0 0 12 O
enzymes NNS 1 1 14 O
are VBP 1 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
reduce VB 0 0 1 O
vardenafil JJ 0 1 UNK B-Drug
clearance NN 0 1 16 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
False NNP 0 1 UNK O
elevations NNS 1 1 1 O
of IN 0 0 12 O
urinary JJ 0 1 6 O
catecholamine NN 0 1 14 O
levels NNS 1 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
interference VB 0 1 13 O
with IN 0 0 12 O
the DT 0 0 12 O
fluorescence NN 0 1 13 O
test NN 0 1 1 O
. . 0 0 12 O

use NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
nonhormonal JJ 0 0 UNK B-Group
contraceptive JJ 0 1 13 I-Group
product NN 0 1 1 I-Group
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

chloral JJ 0 1 16 B-Drug
hydrate NN 0 1 16 I-Drug
* NN 0 0 2 O
; : 0 0 2 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
can MD 0 0 12 O
inhibit VB 0 1 13 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
may MD 0 0 1 O
require VB 0 0 1 O
lower JJR 1 1 1 O
doses NNS 1 1 6 O
than IN 0 0 12 O
usually RB 0 1 12 O
prescribed VBN 1 1 1 O
for IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant NN 0 1 6 I-Group
or CC 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Estazolam NN 0 1 UNK B-Drug
: : 0 0 2 O
Interaction NN 0 1 2 O
with IN 0 0 12 O
Other JJ 0 0 2 O
Drugs NNS 0 1 2 O
that WDT 0 0 12 O
are VBP 1 0 12 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
Cytochrome NNP 0 1 UNK O
P9 NNP 0 1 UNK O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
) ) 0 0 2 O
: : 0 0 2 O
At IN 0 0 2 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
concentrations NNS 1 1 13 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
estazolam NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
M NNP 0 1 2 O
) ) 0 0 2 O
was VBD 1 0 12 O
not RB 0 1 12 O
inhibitory JJ 0 1 UNK O
towards IN 0 0 12 O
the DT 0 0 12 O
major JJ 0 1 1 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isoforms VBZ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
CYP9E9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A NNP 0 0 UNK O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
male JJ 0 1 12 O
subjects NNS 1 1 UNK O
( ( 0 0 2 O
ages VBZ 1 1 UNK O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
) ) 0 0 2 O
who WP 0 0 12 O
were VBD 1 0 12 O
extensive JJ 0 1 1 O
metabolizers NNS 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
CYP9D9 NNP 0 0 UNK O
isoenzyme JJ 0 1 13 O
daily JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
given VBN 1 1 12 O
as IN 1 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
followed VBN 1 1 12 O
by IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
desipramine NN 0 1 16 B-Drug
increased VBD 1 1 1 O
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
t9 VB 0 1 13 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
of IN 0 0 12 O
desipramine NN 0 1 16 B-Drug
by IN 0 0 12 O
an DT 0 0 12 O
average NN 0 1 1 O
of IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
respectively RB 0 0 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Blood NNP 0 1 2 O
Glucose NNP 0 1 7 O
Blood NNP 0 1 2 O
glucose JJ 0 1 14 O
measurement NN 0 1 1 O
must MD 0 0 12 O
be VB 0 0 12 O
done VBN 1 0 12 O
with IN 0 0 12 O
a DT 0 0 12 O
glucose JJ 0 1 14 O
- : 0 0 2 O
specific JJ 0 1 1 O
method NN 0 1 13 O
to TO 0 0 12 O
prevent VB 0 1 1 O
maltose JJ 0 1 UNK O
interference NN 0 1 13 O
with IN 0 0 12 O
test NN 0 1 1 O
results NNS 1 1 1 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
or CC 0 0 12 O
H $ 0 1 2 B-Group
9 CD 0 0 2 I-Group
receptor NN 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
: : 0 0 2 O
When WRB 0 0 12 O
dirithromycin NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
immediately RB 0 1 12 O
following VBG 1 1 1 O
antacids NNS 1 1 14 B-Group
or CC 0 0 12 O
H $ 0 1 2 B-Group
9 CD 0 0 2 I-Group
- : 0 0 2 O
receptor NN 0 1 14 I-Group
antagonists VBZ 0 1 13 I-Group
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
dirithromycin NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
slightly RB 0 1 3 O
enhanced VBN 1 1 1 O
. . 0 0 12 O

Monoamine NNP 0 1 UNK O
Oxidase NNP 0 1 UNK O
Inhibition NNP 0 1 UNK O
: : 0 0 2 O
Linezolid NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
reversible JJ 0 1 3 O
nonselective JJ 0 0 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
monoamine JJ 0 1 13 O
oxidase NN 0 1 13 O
. . 0 0 12 O

Until IN 0 0 2 O
further JJ 0 1 1 O
data NNS 0 1 1 O
are VBP 1 0 12 O
available JJ 0 1 1 O
regarding VBG 1 0 1 O
the DT 0 0 12 O
potential JJ 0 1 1 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
dirithromycin NN 0 1 UNK B-Drug
with IN 0 0 12 O
these DT 0 0 12 O
compounds NNS 1 1 13 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
during IN 0 0 12 O
coadministration NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
hypoglycemic JJ 0 1 14 O
action NN 0 1 13 O
of IN 0 0 12 O
sulfonylurea NN 0 1 UNK B-Group
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
nonsteroidal JJ 0 0 14 B-Group
anti JJ 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
bound NN 0 1 12 O
salicylates VBZ 0 1 13 B-Group
sulfonamides NNS 1 1 13 B-Group
chloramphenicol JJ 0 1 14 B-Drug
probenecid NN 0 1 13 B-Drug
coumarins NNS 0 1 UNK B-Group
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
beta NN 0 1 16 B-Group
adrenergic NNS 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

this DT 0 0 12 O
effect NN 0 1 1 O
is VBZ 1 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
balanced VBN 1 1 1 O
by IN 0 0 12 O
decreased JJ 0 1 1 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
. . 0 0 12 O

use NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
nonhormonal JJ 0 0 UNK B-Group
contraceptive JJ 0 1 13 I-Group
product NN 0 1 1 I-Group
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Furthermore RB 0 0 1 O
whenever WRB 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
therapy NN 0 1 6 O
an DT 0 0 12 O
increased VBN 1 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressant JJ 0 1 6 I-Group
agent NN 0 1 1 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Antidiabetic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
: : 0 0 2 O
( ( 0 0 2 O
oral JJ 0 1 6 O
agents NNS 1 1 1 O
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
) ) 0 0 2 O
- : 0 0 2 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
antidiabetic JJ 0 1 13 B-Group
drug NN 0 1 1 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Changes NNS 0 1 2 O
in IN 0 0 12 O
hepatic JJ 0 1 14 O
function NN 0 1 1 O
induced VBN 1 1 6 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
therapies NNS 1 1 6 O
may MD 0 0 1 O
affect VB 0 1 1 O
epirubicin JJ 0 1 13 B-Drug
metabolism NN 0 1 16 O
pharmacokinetics NNS 0 1 UNK O
therapeutic JJ 0 1 6 O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Considerable JJ 0 0 UNK O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
if IN 0 0 12 O
PEGANONE NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
Phenurone NNP 0 1 UNK B-Brand
( ( 0 0 2 O
phenacemide NN 0 1 UNK B-Drug
) ) 0 0 2 O
since IN 0 1 12 O
paranoid NN 0 0 12 O
symptoms NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
during IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

Such JJ 0 0 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
unresponsive JJ 0 1 6 O
to TO 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
epinephrine NN 0 1 14 B-Drug
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
allergic JJ 0 1 6 O
reaction NN 0 1 1 O
. . 0 0 12 O

Literature NN 0 1 UNK O
reports NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
indomethacin NN 0 1 14 B-Drug
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
natriuretic JJ 0 1 UNK O
and CC 0 0 12 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
by IN 0 0 12 O
inhibiting VBG 1 1 UNK O
prostaglandin JJ 0 1 13 O
synthesis NN 0 1 UNK O
. . 0 0 12 O

Pregnancy NNP 0 1 7 O
Pregnancy NNP 0 1 7 O
Category NNP 0 1 UNK O
D NNP 0 1 2 O
: : 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
celecoxib VBP 0 1 16 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
of IN 0 0 12 O
glyburide JJ 0 1 16 B-Drug
ketoconazole JJ 0 1 16 B-Drug
methotrexate NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
tolbutamide NN 0 1 UNK B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
vivo NN 0 1 13 O
and CC 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug

Potential JJ 0 1 UNK O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
Mentax NNP 0 1 UNK B-Brand
( ( 0 0 2 O
butenafine JJ 0 1 UNK B-Drug
HCl NNP 0 0 14 I-Drug
cream NN 0 1 3 O
) ) 0 0 2 O
Cream NNP 0 1 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
systematically RB 0 0 UNK O
evaluated VBN 1 1 1 O
. . 0 0 12 O

these DT 0 0 12 O
drugs NNS 1 1 6 O
were VBD 1 0 12 O
not RB 0 1 12 O
tested VBN 1 1 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
administration NN 0 1 1 O
one CD 0 1 12 O
hour NN 0 1 12 O
before IN 0 1 12 O
colestipol JJ 0 1 13 B-Drug
hydrochloride NN 0 1 0 I-Drug
. . 0 0 12 O

Pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
disulfiram NN 0 1 13 B-Drug
or CC 0 0 12 O
diazepam NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
acamprosate NN 0 1 13 B-Drug
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
clinical JJ 0 1 6 O
pharmacology NN 0 1 UNK O
study NN 0 1 1 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
an DT 0 0 12 O
antacid NN 0 1 UNK B-Group
( ( 0 0 2 O
aluminum JJ 0 1 16 B-Drug
hydroxide NN 0 1 14 I-Drug
magnesium NN 0 1 14 B-Drug
hydroxide NN 0 1 14 I-Drug
and CC 0 0 12 O
simethicone NN 0 1 16 B-Drug
) ) 0 0 2 O
with IN 0 0 12 O
fosinopril NN 0 1 13 B-Drug
reduced VBN 1 1 1 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
fosinoprilat NN 0 1 UNK B-Drug_n
as IN 1 0 12 O
compared VBN 1 1 1 O
with IN 0 0 12 O
fosinopril NN 0 1 13 B-Drug
administered VBN 1 1 1 O
alone RB 0 1 12 O
suggesting VBG 1 1 1 O
that IN 0 0 12 O
antacids NNS 1 1 14 B-Group
may MD 0 0 1 O
impair VB 0 0 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
fosinopril NN 0 1 13 B-Drug
. . 0 0 12 O

salicylates NNS 1 1 13 B-Group
; : 0 0 2 O
sulfinpyrazone NN 0 1 13 B-Drug
; : 0 0 2 O

However RB 0 0 1 O
iloprost NN 0 1 13 B-Drug
has VBZ 1 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
vasodilators NNS 1 1 13 B-Group
and CC 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Anticholinergic NNP 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
may MD 0 0 1 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
alter VBP 0 1 13 O
gastrointestinal JJ 0 1 6 O
motility NN 0 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
metoclopramide NN 0 1 16 B-Drug
. . 0 0 12 O

- : 0 0 2 O
Nitrofurantoin NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Furadantin NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Caffeine NNP 0 1 7 B-Drug
- : 0 0 2 O
related JJ 0 1 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
have VBP 0 0 12 O
occurred VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
consuming VBG 1 0 1 O
caffeine NN 0 1 6 B-Drug
while IN 0 0 12 O
on IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
enoxacin NN 0 1 UNK B-Drug
. . 0 0 12 O

Grapefruit NNP 0 1 UNK O
juice NN 0 1 3 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
with IN 0 0 12 O
grapefruit NN 0 1 3 O
juice NN 0 1 3 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
more JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
but CC 0 0 12 O
no DT 0 0 12 O
prolongation NN 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
felodipine NN 0 1 13 B-Drug
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
salts NNS 1 1 13 O

The DT 0 0 2 O
pressor NN 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
diethylpropion NN 0 1 UNK B-Drug
and CC 0 0 12 O
those DT 0 0 12 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
additive JJ 0 1 16 O
when WRB 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
; : 0 0 2 O

these DT 0 0 12 O
agents NNS 1 1 1 O
may MD 0 0 1 O
diminish VB 0 1 UNK O
the DT 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
Permax NNP 0 1 UNK B-Brand
. . 0 0 12 O

Usually RB 0 1 UNK O
severe JJ 0 1 6 O
abdominal JJ 0 1 6 O
symptoms NNS 1 1 6 O
appear VBP 0 1 12 O
before IN 0 1 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
such PDT 0 0 1 O
a DT 0 0 12 O
fall NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
evaluating VBG 1 1 1 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
interactions NNS 1 1 UNK O
among IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
antiepilepsy NN 0 0 UNK O
drugs NNS 1 1 6 O
( ( 0 0 2 O
AEDs NNP 0 1 UNK B-Group
) ) 0 0 2 O
whether IN 0 0 12 O
or CC 0 0 12 O
not RB 0 1 12 O
an DT 0 0 12 O
AED NNP 0 1 UNK B-Group
induces NNS 0 1 UNK O
or CC 0 0 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
induce VB 0 1 6 O
metabolic JJ 0 1 6 O
enzymes NNS 1 1 14 O
is VBZ 1 0 12 O
an DT 0 0 12 O
important JJ 0 1 1 O
consideration NN 0 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Drugs NNS 0 1 2 O
that WDT 0 0 12 O
may MD 0 0 1 O
decrease VB 0 1 1 O
plasma VB 0 1 14 O
phenytoin JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
include VBP 0 1 1 O
: : 0 0 2 O
carbamazepine NN 0 1 16 B-Drug
chronic JJ 0 1 6 O
alcohol NN 0 1 1 B-Drug
abuse NN 0 1 12 O
reserpine NN 0 1 UNK B-Drug

Patients NNS 0 1 7 O
on IN 0 0 12 O
lithium JJ 0 1 16 B-Drug
treatment NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
when WRB 0 0 12 O
MOBIC NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
introduced VBN 1 1 12 O
or CC 0 0 12 O
withdrawn VBN 1 1 1 O
. . 0 0 12 O

Methadone NN 0 1 0 B-Drug

Lodine NNP 0 1 UNK B-Brand
treatment NN 0 1 6 O
is VBZ 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
small JJ 0 1 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
serum NN 0 1 14 O
uric JJ 0 0 14 O
acid NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
affect JJ 0 1 1 O
BREVIBLOC NNP 0 1 UNK B-Brand
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

Another DT 0 0 2 O
investigator NN 0 1 UNK O
found VBD 1 1 12 O
no DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
coronary JJ 0 1 6 O
artery NN 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

( ( 0 0 2 O
Effects NNS 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
when WRB 0 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
; : 0 0 2 O

Paricalcitol NNP 0 1 UNK B-Drug_n
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
CYP9A9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9B9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
CYP9E9 NNP 0 0 UNK O
or CC 0 0 12 O
CYP9A NNP 0 0 UNK O
nor CC 0 0 12 O
induce VB 0 1 6 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9B9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
or CC 0 0 12 O
CYP9A NNP 0 0 UNK O
. . 0 0 12 O

- : 0 0 2 O
Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Lithium NN 0 1 UNK B-Drug
should MD 0 0 12 O
generally RB 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
bumetanide NN 0 1 16 B-Drug
) ) 0 0 2 O
because IN 0 0 12 O
they PRP 0 0 12 O
reduce VB 0 0 1 O
its PRP$ 1 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
and CC 0 0 12 O
add VB 0 1 12 O
a DT 0 0 12 O
high JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
acute JJ 0 1 6 O
MI NNP 0 1 2 O
aspirin NN 0 1 14 B-Brand
when WRB 0 0 12 O
not RB 0 1 12 O
otherwise RB 0 0 1 O
contraindicated VBN 1 1 14 O
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
Streptokinase NNP 0 1 15 B-Drug
( ( 0 0 2 O
see VB 0 1 12 O
below IN 0 0 12 O
) ) 0 0 2 O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
Cimetidine VB 0 1 0 B-Drug
a DT 0 0 12 O
known JJ 0 1 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
of IN 0 0 12 O
organic JJ 0 1 13 O
bases NNS 1 1 1 O
via IN 0 0 1 O
the DT 0 0 12 O
cationic JJ 0 1 UNK O
transport NN 0 1 1 O
system NN 0 1 1 O
caused VBD 1 1 1 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
pramipexole JJ 0 1 16 B-Drug
AUC NNP 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
half JJ 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
( ( 0 0 2 O
N= NNP 0 1 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
clinical JJ 0 1 6 O
data NNS 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
MIVACRON NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
nondepolarizing VBG 0 0 UNK B-Group
neuromuscular JJ 0 1 6 I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Warfarin JJ 0 1 0 B-Drug
: : 0 0 2 O
Increased VBN 0 1 7 O
INR NNP 0 1 13 O
( ( 0 0 2 O
International NNP 0 1 UNK O
Normalized NNP 0 1 UNK O
Ratio NNP 0 1 2 O
) ) 0 0 2 O
when WRB 0 0 12 O
ARAVA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
warfarin WDT 0 1 14 B-Drug
were VBD 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
rarely RB 0 1 UNK O
reported VBN 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
similar JJ 0 1 1 O
association NN 0 1 1 O
though IN 0 0 12 O
less JJR 0 1 12 O
marked VBN 1 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
suggested VBN 1 1 12 O
with IN 0 0 12 O
barbiturates NNS 1 1 14 B-Group
phenyl VBP 0 1 UNK O
- : 0 0 2 O
butazone NN 0 1 UNK O
phenytoin NN 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
possibly RB 0 1 12 O
with IN 0 0 12 O
griseofulvin NN 0 1 UNK B-Drug
ampicillin NN 0 1 0 B-Drug
and CC 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
vasopressors NNS 1 1 UNK B-Group
vasoconstricting VBG 0 0 UNK O
agents NNS 1 1 1 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
ergonovine NN 0 1 UNK B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
some DT 0 0 12 O
oxytocic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
severe JJ 0 1 6 O
hypertension NN 0 1 6 O
. . 0 0 12 O

Latent NNP 0 1 UNK O
LCV NNP 0 0 UNK O
infection NN 0 1 6 O
is VBZ 1 0 12 O
generally RB 0 0 1 O
asymptomatic JJ 0 1 6 O
but CC 0 0 12 O
can MD 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
B NNP 0 0 2 O
- : 0 0 2 O
cell NN 0 1 1 O
lymphomas NN 1 1 13 O
when WRB 0 0 12 O
animals NNS 1 1 12 O
are VBP 1 0 12 O
immune JJ 0 1 6 O
suppressed VBN 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
medication NN 0 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
with IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
hydantoins NNS 1 1 UNK B-Group
sulfonamides NNS 1 1 13 B-Group
or CC 0 0 12 O
sulfonylureas NNS 1 1 UNK B-Group
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
for IN 0 0 12 O
increased JJ 0 1 1 O
activity NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
therefore RB 0 0 1 O
signs NNS 1 1 12 O
of IN 0 0 12 O
toxicity NN 0 1 6 O
from IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Risk NN 0 1 2 O
of IN 0 0 12 O
anaphylactic JJ 0 1 13 O
reaction NN 0 1 1 O
: : 0 0 2 O
While IN 0 0 12 O
taking VBG 1 0 12 O
beta JJ 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
patients NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
severe JJ 0 1 6 O
anaphylactic JJ 0 1 13 O
reaction NN 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
allergens NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
more RBR 0 1 12 O
reactive JJ 0 1 1 O
to TO 0 0 12 O
repeated VBN 1 1 1 O
challenge NN 0 1 12 O
either CC 0 1 12 O
accidental JJ 0 1 13 O
diagnostic NN 0 1 6 O
or CC 0 0 12 O
therapeutic JJ 0 1 6 O
. . 0 0 12 O

antihistamines NNS 1 1 UNK B-Group
; : 0 0 2 O

Potassium NN 0 1 14 O
sparing VBG 1 0 6 O
agents NNS 1 1 1 O
should MD 0 0 12 O
generally RB 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
heart NN 0 1 12 O
failure NN 0 1 1 O
receiving VBG 1 1 1 O
enalapril NN 0 1 0 B-Drug
. . 0 0 12 O

Nevertheless RB 0 0 1 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
postmarketing VBG 0 0 UNK O
observations NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
Lodine NNP 0 1 UNK B-Brand
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
natriuretic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
and CC 0 0 12 O
thiazides NNS 1 1 UNK B-Group
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Theophylline NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
three CD 0 1 12 O
pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
including VBG 1 1 1 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
theophylline JJ 0 1 16 B-Drug
clearance NN 0 1 16 O
and CC 0 0 12 O
concentration NN 0 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
altered VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
. . 0 0 12 O

Methylprednisolone NN 0 1 0 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
chronic JJ 0 1 6 O
high JJ 0 1 1 O
dose NN 0 1 6 O
aspirin NN 0 1 14 B-Brand
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
adenosine NN 0 1 14 B-Drug
are VBP 1 0 12 O
antagonized VBN 1 0 UNK O
by IN 0 0 12 O
methylxanthines NNS 0 1 UNK B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
caffeine NN 0 1 6 B-Drug
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
. . 0 0 12 O

Need NN 0 1 2 O
for IN 0 0 12 O
more JJR 0 1 12 O
inhalations NNS 1 1 UNK O
than IN 0 0 12 O
usual JJ 0 1 12 O
of IN 0 0 12 O
short JJ 0 1 12 B-Group
- : 0 0 2 O
acting VBG 1 1 12 I-Group
inhaled VBN 1 1 14 I-Group
beta9 SYM 0 0 UNK I-Group
- : 0 0 2 O
agonists NNS 1 1 UNK I-Group
. . 0 0 12 O

Mutual JJ 0 1 UNK O
inhibition NN 0 1 13 O
of IN 0 0 12 O
metabolism NN 0 1 16 O
occurs VBZ 1 1 1 O
with IN 0 0 12 O
concurrent JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
cyclosporin NN 0 1 14 B-Drug
and CC 0 0 12 O
methylprednisolone NN 0 1 16 B-Drug
; : 0 0 2 O

Chloral JJ 0 1 UNK B-Drug
hydrate NN 0 1 16 I-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
prothrombin NN 0 1 14 O
response NN 0 1 1 O
by IN 0 0 12 O
displacing VBG 1 1 UNK O
the DT 0 0 12 O
anticoagulant NN 0 1 13 B-Group
from IN 0 0 12 O
protein NN 0 1 14 O
binding VBG 1 1 1 O
sites NNS 1 1 1 O
or CC 0 0 12 O
a DT 0 0 12 O
diminished JJ 0 1 1 O
prothrombin NN 0 1 14 O
response NN 0 1 1 O
through IN 0 0 12 O
increased JJ 0 1 1 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
the DT 0 0 12 O
unbound JJ 0 0 UNK O
drug NN 0 1 1 O
by IN 0 0 12 O
hepatic JJ 0 1 14 O
enzyme JJ 0 1 14 O
induction NN 0 1 1 O
thus RB 0 0 1 O
leading VBG 1 1 1 O
to TO 0 0 12 O
inter VB 0 1 13 O
- : 0 0 2 O
patient NN 0 1 6 O
variation NN 0 1 1 O
in IN 0 0 12 O
ultimate JJ 0 0 UNK O
prothrombin NN 0 1 14 O
effect NN 0 1 1 O
. . 0 0 12 O

adjust JJ 0 0 1 O
dosage NN 0 1 0 O
of IN 0 0 12 O
antidiabetic JJ 0 1 13 B-Group
drug NN 0 1 1 I-Group
upward RB 0 1 3 O
if IN 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

No DT 0 0 2 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Gemfibrozil NNP 0 1 UNK B-Drug
Other JJ 0 0 2 O
fibrates NNS 0 1 UNK B-Group
Niacin NNP 0 1 0 B-Drug
( ( 0 0 2 O
nicotinic JJ 0 1 13 B-Drug
acid NN 0 1 14 I-Drug
) ) 0 0 2 O
( ( 0 0 2 O
=9 JJ 0 0 UNK O
g NN 0 1 16 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O

Although IN 0 0 12 O
trough JJ 0 1 3 O
citalopram NN 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
were VBD 1 0 12 O
unaffected JJ 0 1 UNK O
given VBN 1 1 12 O
the DT 0 0 12 O
enzyme NN 0 1 14 O
- : 0 0 2 O
inducing NN 0 1 6 O
properties NNS 1 1 UNK O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
the DT 0 0 12 O
possibility NN 0 1 1 O
that WDT 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
might MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
escitalopram NN 0 1 0 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
if IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Adrenergic JJ 0 1 UNK B-Group
blockers NNS 1 0 6 I-Group
: : 0 0 2 O
Adrenergic NNP 0 1 UNK B-Group
blockers NNS 1 0 6 I-Group
are VBP 1 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
nonbenzodiazepine JJ 0 0 UNK O
agonists NNS 1 1 UNK O
at IN 0 0 12 O
benzodiazepine JJ 0 1 14 O
receptors NNS 1 1 13 O
such JJ 0 0 1 O
as IN 1 0 12 O
zopiclone NN 0 1 UNK B-Drug
triazolopyridazines NNS 0 0 UNK O
and CC 0 0 12 O
others NNS 0 1 12 O
are VBP 1 0 12 O
also RB 0 0 12 O
blocked VBN 1 1 13 O
by IN 0 0 12 O
ROMAZICON NNP 0 1 UNK B-Brand
. . 0 0 12 O

Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
b SYM 0 0 16 B-Group
- : 0 0 2 O
lactam NN 0 1 UNK I-Group
antibiotics NNS 1 1 6 I-Group
co VBP 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
with IN 0 0 12 O
cefditoren NNS 0 1 UNK B-Drug
pivoxil RB 0 0 UNK I-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
exposure NN 0 1 1 O
of IN 0 0 12 O
cefditoren NN 0 1 UNK B-Drug
with IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
mean JJ 0 1 12 O
Cmax NNP 0 1 UNK O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
mean JJ 0 1 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
half JJ 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
indinavir NN 0 1 16 B-Drug
erythromycin NN 0 1 0 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
increase VB 0 1 1 O
their PRP$ 0 0 12 O
clearance NN 0 1 16 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
decreased JJ 0 1 1 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ProAmatine NNP 0 1 UNK B-Brand
cardiac JJ 0 1 6 B-Group
glycosides NNS 1 1 13 I-Group
may MD 0 0 1 O
enhance VB 0 1 UNK O
or CC 0 0 12 O
precipitate VB 0 1 13 O
bradycardia JJ 0 1 8 O
A.V NNP 0 0 UNK O
. . 0 0 12 O

If IN 0 0 12 O
rifampicin JJ 0 1 UNK B-Drug
therapy NN 0 1 6 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
isradipine JJ 0 1 13 B-Drug
concentrations NNS 1 1 13 O
and CC 0 0 12 O
therapeutic JJ 0 1 6 O
effects NNS 1 1 1 O
are VBP 1 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
markedly RB 0 1 1 O
reduced VBN 1 1 1 O
or CC 0 0 12 O
abolished VBN 1 0 UNK O
as IN 1 0 12 O
a DT 0 0 12 O
consequence NN 0 1 1 O
of IN 0 0 12 O
increased JJ 0 1 1 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
higher JJR 1 1 1 O
clearance NN 0 1 16 O
of IN 0 0 12 O
isradipine NN 0 1 13 B-Drug
. . 0 0 12 O

Methenamine NN 0 1 UNK B-Drug
: : 0 0 2 O
Efficacy NN 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
urinary JJ 0 1 6 O
alkalizing VBG 1 0 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
metolazone NN 0 1 16 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
rheumatoid JJ 0 0 6 O
arthritis NN 0 1 6 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
besides IN 0 0 12 O
MTX NNP 0 1 UNK B-Drug
were VBD 1 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti JJ 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
folic JJ 0 0 14 B-Drug
acid JJ 0 1 14 I-Drug
corticosteroids NNS 1 1 14 B-Group
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
narcotics NNS 1 1 1 B-Group
. . 0 0 12 O

If IN 0 0 12 O
hypotension NN 0 1 6 O
does VBZ 1 0 12 O
occur RP 0 1 1 O
during IN 0 0 12 O
anesthesia NNS 0 1 6 O
it PRP 0 0 12 O
usually RB 0 1 12 O
can MD 0 0 12 O
be VB 0 0 12 O
controlled VBN 1 1 1 O
by IN 0 0 12 O
vasopressors NNS 1 1 UNK B-Group
. . 0 0 12 O

Heparin NNP 0 1 0 B-Drug
Sodium NNP 0 1 14 I-Drug
Injection NNP 0 1 7 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
mixed JJ 0 1 3 O
with IN 0 0 12 O
doxorubicin JJ 0 1 13 B-Drug
droperidol NN 0 1 0 B-Drug
ciprofloxacin NN 0 1 0 B-Drug
or CC 0 0 12 O
mitoxantrone NN 0 1 13 B-Drug
since IN 0 1 12 O
it PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
that IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
incompatible JJ 0 1 13 O
with IN 0 0 12 O
heparin NN 0 1 14 B-Drug
and CC 0 0 12 O
a DT 0 0 12 O
precipitate NN 0 1 13 O
may MD 0 0 1 O
form VB 0 1 1 O
. . 0 0 12 O

Abciximab NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
ischemic JJ 0 1 6 O
heart NN 0 1 12 O
disease NN 0 1 6 O
treated VBD 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
a DT 0 0 12 O
broad JJ 0 1 1 O
range NN 0 1 1 O
of IN 0 0 12 O
medications NNS 1 1 6 O
used VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
angina JJ 0 1 6 O
myocardial JJ 0 1 6 O
infarction NN 0 1 6 O
and CC 0 0 12 O
hypertension NN 0 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
consideration NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
NSAIDs NNP 0 1 UNK B-Group
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ACE NNP 0 1 13 B-Group
- : 0 0 2 O
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

therefore RB 0 0 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
with IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Small JJ 0 1 2 O
decreases NNS 1 1 UNK O
in IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
TRENTAL NNP 0 1 UNK B-Brand
; : 0 0 2 O

None NN 0 0 2 O
Reported VBD 0 1 2 O

Therefore RB 0 0 1 O
paliperidone NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
clearance NN 0 1 16 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
these DT 0 0 12 O
metabolic JJ 0 1 6 O
pathways NNS 1 1 13 O
in IN 0 0 12 O
a DT 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
manner NN 0 0 1 O
. . 0 0 12 O

SUSTIVAhas NNP 0 0 UNK O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
amprenavir NN 0 1 13 B-Drug
. . 0 0 12 O

St NNP 0 1 2 O
. . 0 0 12 O
John NNP 0 0 19 O
wort NN 0 0 UNK O
( ( 0 0 2 O
Hypericum NNP 0 1 UNK O
perforatum NN 0 0 UNK O
) ) 0 0 2 O

These DT 0 0 1 O
fulvestrant JJ 0 1 13 B-Drug
doses NNS 1 1 6 O
correspond NN 0 0 13 O
to TO 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold VBD 0 1 3 O
the DT 0 0 12 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
[ NNP 0 0 2 O
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
] RB 0 0 2 O
achieved VBN 1 0 1 O
in IN 0 0 12 O
women NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
occurrence NN 0 1 1 O
of IN 0 0 12 O
stupor JJ 0 1 16 O
muscular JJ 0 1 6 O
rigidity NN 0 1 3 O
severe JJ 0 1 6 O
agitation NN 0 1 1 O
and CC 0 0 12 O
elevated JJ 0 1 1 O
temperature NN 0 1 3 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
selegiline NN 0 1 13 B-Drug
and CC 0 0 12 O
meperidine NN 0 1 16 B-Drug
. . 0 0 12 O

ETHANOL NNP 0 1 11 B-Drug
/ NNP 0 0 2 O
NUTRITION NNP 0 1 11 O
/ NNP 0 0 2 O
HERB NNP 0 1 UNK O
INTERACTIONS NNP 0 1 UNK O
: : 0 0 2 O
Food NN 0 1 2 O
: : 0 0 2 O
CNS NNP 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
enhanced VBN 1 1 1 O
if IN 0 0 12 O
combination NN 0 1 1 B-Group
hormonal JJ 0 1 6 I-Group
contraceptives NNS 1 1 13 I-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
. . 0 0 12 O

Even RB 0 0 UNK O
when WRB 0 0 12 O
an DT 0 0 12 O
aminoglycoside NN 0 1 14 B-Group
and CC 0 0 12 O
a DT 0 0 12 O
penicillin NN 0 1 14 B-Group
- : 0 0 2 O
type JJ 0 1 1 O
drug NN 0 1 1 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
separately RB 0 0 1 O
by IN 0 0 12 O
different JJ 0 1 1 O
routes NNS 1 1 1 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
aminoglycoside JJ 0 1 14 B-Group
serum NN 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
or CC 0 0 12 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
impaired JJ 0 1 6 O
renal JJ 0 1 6 O
function NN 0 1 1 O
and CC 0 0 12 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
normal JJ 0 1 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

Also RB 0 0 2 O
flucytosine NN 0 1 13 B-Drug
. . 0 0 12 O

Chlorthalidone NN 0 1 UNK B-Drug
may MD 0 0 1 O
add VB 0 1 12 O
to TO 0 0 12 O
or CC 0 0 12 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
other JJ 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

However RB 0 0 1 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
at IN 0 0 12 O
high JJ 0 1 1 O
concentrations NNS 1 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
mMol NN 0 1 UNK O
/ NNP 0 0 2 O
L NNP 0 1 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
mL NN 0 1 14 O
and CC 0 0 12 O
greater JJR 1 1 1 O
) ) 0 0 2 O
EACA NNP 0 0 UNK B-Drug
inhibits VBZ 1 1 UNK O
ADP NNP 0 1 UNK O
and CC 0 0 12 O
collagen NN 0 1 13 O
- : 0 0 2 O
induced JJ 0 1 6 O
platelet NN 0 1 14 O
aggregation NN 0 1 UNK O
the DT 0 0 12 O
release NN 0 1 12 O
of IN 0 0 12 O
ATP NNP 0 1 UNK O
and CC 0 0 12 O
serotonin NN 0 1 13 O
and CC 0 0 12 O
the DT 0 0 12 O
binding NN 0 1 1 O
of IN 0 0 12 O
fibrinogen NN 0 1 14 O
to TO 0 0 12 O
the DT 0 0 12 O
platelets NNS 1 1 14 O
in IN 0 0 12 O
a DT 0 0 12 O
concentration NN 0 1 1 O
- : 0 0 2 O
response NN 0 1 1 O
manner NN 0 0 1 O
. . 0 0 12 O

Convulsions NNS 0 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
this DT 0 0 12 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
presence NN 0 1 1 O
of IN 0 0 12 O
sulfamethoxazole NN 0 1 13 B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
Jaff NNP 0 0 UNK O
alkaline NN 0 1 14 O
picrate NN 0 1 UNK O
reaction NN 0 1 1 O
assay NN 0 1 14 O
for IN 0 0 12 O
creatinine NN 0 1 14 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
overestimations NNS 1 0 UNK O
of IN 0 0 12 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
the DT 0 0 12 O
range NN 0 1 1 O
of IN 0 0 12 O
normal JJ 0 1 1 O
values NNS 1 1 1 O
. . 0 0 12 O

Recent JJ 0 1 2 O
better RB 1 1 12 O
designed VBN 1 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
reported VBN 1 1 1 O
these DT 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

laryngeal NN 0 1 8 O
edema NN 0 1 6 O

Women NNS 0 1 2 O
should MD 0 0 12 O
practice NN 0 1 UNK O
additional JJ 0 1 1 O
methods NNS 1 1 1 O
of IN 0 0 12 O
contraception NN 0 1 13 O
and CC 0 0 12 O
not RB 0 1 12 O
rely VB 0 0 UNK O
on IN 0 0 12 O
hormonal JJ 0 1 6 O
contraception NN 0 1 13 O
alone RB 0 1 12 O
when WRB 0 0 12 O
taking VBG 1 0 12 O
TRACLEER NNP 0 1 UNK B-Brand
. . 0 0 12 O

No DT 0 0 2 O
specific JJ 0 1 1 O
information NN 0 1 1 O
available JJ 0 1 1 O

Anakinra NN 0 1 UNK B-Drug
: : 0 0 2 O
Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
anakinra NN 0 1 13 B-Drug
( ( 0 0 2 O
an DT 0 0 12 O
interleukin NN 0 1 13 B-Group
- : 0 0 2 O
9 CD 0 0 2 I-Group
antagonist NN 0 1 13 I-Group
) ) 0 0 2 O
and CC 0 0 12 O
another DT 0 0 12 O
TNF NNP 0 1 UNK B-Group
- : 0 0 2 O
blocking NN 0 1 UNK I-Group
agent NN 0 1 1 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
serious JJ 0 1 12 O
infections NNS 1 1 6 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
neutropenia NN 0 1 14 O
and CC 0 0 12 O
no DT 0 0 12 O
additional JJ 0 1 1 O
benefit NN 0 1 1 O
compared VBN 1 1 1 O
to TO 0 0 12 O
these DT 0 0 12 O
medicinal JJ 0 0 16 O
products NNS 1 1 1 O
alone RB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
appropriate JJ 0 1 1 O
doses NNS 1 1 6 O
for IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
respect NN 0 1 1 O
to TO 0 0 12 O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
safety NN 0 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
treatment NN 0 1 6 O
with IN 0 0 12 O
coumarin JJ 0 1 UNK B-Group
derivatives NNS 1 1 13 I-Group
( ( 0 0 2 O
vitamin JJ 0 1 6 B-Group
K NNP 0 1 2 I-Group
antagonists NNS 1 1 13 I-Group
) ) 0 0 2 O
and CC 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
affect VBP 0 1 1 O
platelet NN 0 1 14 O
function NN 0 1 1 O
may MD 0 0 1 O
also RB 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
mean JJ 0 1 12 O
minimum JJ 0 1 1 O
lithium NN 0 1 16 B-Drug
concentration NN 0 1 1 O
increased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
the DT 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
was VBD 1 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Warfarin NNP 0 1 0 B-Drug
- : 0 0 2 O
Administration NN 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
racemic JJ 0 1 14 O
citalopram NN 0 1 16 B-Drug
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
case NN 0 1 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
developed VBD 1 0 1 O
increased VBN 1 1 1 O
BUN NNP 0 0 14 O
serum JJ 0 1 14 O
creatinine NN 0 1 14 O
and CC 0 0 12 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
weight NN 0 1 3 O
gain NN 0 1 1 O
when WRB 0 0 12 O
furosemide NN 0 1 0 B-Drug
was VBD 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
. . 0 0 12 O

Patients NNS 0 1 7 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
were VBD 1 0 12 O
prohibited VBN 1 1 UNK O
from IN 0 0 12 O
receiving VBG 1 1 1 O
growth NN 0 1 1 O
factor NN 0 1 1 O
treatment NN 0 1 6 O
for IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
ZEVALIN NNP 0 1 UNK B-Brand
therapeutic JJ 0 1 6 O
regimen NNS 0 1 6 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
following VBG 1 1 1 O
completion NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
regimen NNS 0 1 6 O
. . 0 0 12 O

Because IN 0 0 12 O
prostaglandina NN 0 0 UNK O
play VBP 0 1 13 O
an DT 0 0 12 O
important JJ 0 1 1 O
role NN 0 1 1 O
in IN 0 0 12 O
hemostasis NN 0 1 UNK O
and CC 0 0 12 O
ketoprofen NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
an DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
platelet NN 0 1 14 O
function NN 0 1 1 O
as IN 1 0 12 O
well RB 0 1 12 O
concurent JJ 0 0 UNK O
therapy NN 0 1 6 O
with IN 0 0 12 O
ketoprofen NN 0 1 UNK B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
requires VBZ 1 0 1 O
close JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Phenytoin NNP 0 1 0 B-Drug
/ NNP 0 0 2 O
Phenobarbital NNP 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
will MD 0 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
but CC 0 0 12 O
may MD 0 0 1 O
reduce VB 0 0 1 O
endogenous JJ 0 1 14 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
calcitriol NN 0 1 14 B-Drug
/ NNP 0 0 2 O
ergocalcitriol NN 0 0 UNK O
by IN 0 0 12 O
accelerating VBG 1 1 UNK O
metabolism NN 0 1 16 O
. . 0 0 12 O

The DT 0 0 2 O
possibility NN 0 1 1 O
of IN 0 0 12 O
reduced JJ 0 1 1 O
statin JJ 0 1 14 B-Group
efficacy NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Hydrocodone NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
Neurontin NNP 0 1 0 B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
; : 0 0 2 O

T9 NNP 0 1 13 O
resin NN 0 1 UNK O
uptake NN 0 1 14 O
is VBZ 1 0 12 O
decreased VBN 1 1 1 O
reflecting VBG 1 1 1 O
the DT 0 0 12 O
elevated JJ 0 1 1 O
TBG NNP 0 1 UNK O
. . 0 0 12 O

Serum NNP 0 1 7 O
transaminase NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
obtained VBN 1 1 1 O
before IN 0 1 12 O
starting VBG 1 1 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
Plenaxis NNP 0 1 UNK B-Brand
and CC 0 0 12 O
periodically RB 0 1 1 O
during IN 0 0 12 O
treatment NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
oxybutynin NN 0 1 13 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
or CC 0 0 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
which WDT 0 0 12 O
produce VBP 0 0 1 O
dry JJ 0 1 3 O
mouth NN 0 1 3 O
constipation NN 0 1 6 O
somnolence NN 0 1 8 O
( ( 0 0 2 O
drowsiness NN 0 1 13 O
) ) 0 0 2 O
and CC 0 0 12 O
/ $ 0 0 2 O
or CC 0 0 12 O
other JJ 0 0 12 O
anticholinergic JJ 0 1 13 O
- : 0 0 2 O
like IN 0 0 12 O
effects NNS 1 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
frequency NN 0 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
severity NN 0 1 6 O
of IN 0 0 12 O
such JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
aluminum NN 0 1 16 B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
antacid NN 0 1 UNK B-Group
had VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
9MNA CD 0 0 UNK B-Drug_n
. . 0 0 12 O

Although IN 0 0 12 O
it PRP 0 0 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
definitively RB 0 0 1 O
demonstrated VBN 1 0 1 O
that IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
IIIA9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
the DT 0 0 12 O
substantial JJ 0 0 1 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
with IN 0 0 12 O
alprazolam NN 0 1 0 B-Drug
. . 0 0 12 O

Human NNP 0 1 2 O
pharmacokinetic JJ 0 1 UNK O
data NNS 0 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
oral JJ 0 1 6 O
ketoconazole NNS 0 1 16 B-Drug
markedly RB 0 1 1 O
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
mean JJ 0 1 12 O
eight CD 0 1 12 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
using VBG 1 1 1 O
these DT 0 0 12 O
blocking VBG 1 1 UNK O
agents NNS 1 1 1 O
to TO 0 0 12 O
treat VB 0 1 12 O
hypertension NN 0 1 6 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
carefully RB 0 0 12 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
confirm VB 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
desired JJ 0 1 1 O
therapeutic JJ 0 1 6 O
effect NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
obtained VBN 1 1 1 O
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinefics NNS 0 0 UNK O
of IN 0 0 12 O
aprepitant NN 0 1 13 B-Drug

N=9 NNP 0 1 UNK O
) ) 0 0 2 O
administration NN 0 1 1 O
. . 0 0 12 O

Diazoxide NNP 0 1 UNK B-Drug
Hypotension NNP 0 1 7 O

Since IN 0 1 2 O
higher JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
daily RB 0 1 12 O
) ) 0 0 2 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
higher JJR 1 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
exceeded VBN 1 0 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
period NN 0 1 1 O
when WRB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
ketoconazole JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily RB 0 1 12 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
with IN 0 0 12 O
ketoconazole JJ 0 1 16 B-Drug
tablets NNS 1 1 3 O
reduces VBZ 1 0 UNK O
the DT 0 0 12 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
latter NN 0 0 UNK O
. . 0 0 12 O

Oral JJ 0 1 2 O
anticoagulant JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
: : 0 0 2 O
Pharmacokinetic JJ 0 1 UNK O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
Argatroban NNP 0 1 0 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
single JJ 0 1 12 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
) ) 0 0 2 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
drugs NNS 1 1 6 O
primarily RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
which WDT 0 0 12 O
could MD 0 0 12 O
increase VB 0 1 1 O
or CC 0 0 12 O
prolong VB 0 0 13 O
its PRP$ 1 0 12 O
therapeutic JJ 0 1 6 O
and CC 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Lincomycin NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
have VB 0 0 12 O
neuromuscular JJ 0 1 6 O
blocking VBG 1 1 UNK O
properties NNS 1 1 UNK O
that WDT 0 0 12 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
other JJ 0 0 12 O
neuromuscular JJ 0 1 6 B-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

antacids NNS 1 1 14 B-Group
; : 0 0 2 O

Adrenocorticoids NNS 0 0 UNK O
: : 0 0 2 O
Metabolic JJ 0 1 7 O
clearance NN 0 1 16 O
of IN 0 0 12 O
adrenocorticoids NNS 0 0 UNK O
is VBZ 1 0 12 O
decreased VBN 1 1 1 O
in IN 0 0 12 O
hypothyroid JJ 0 1 6 O
patients NNS 1 1 6 O
and CC 0 0 12 O
increased VBN 1 1 1 O
in IN 0 0 12 O
hyperthyroid NN 0 1 UNK O
patients NNS 1 1 6 O
and CC 0 0 12 O
may MD 0 0 1 O
therefore VB 0 0 1 O
change NN 0 1 1 O
with IN 0 0 12 O
changing VBG 1 1 1 O
thyroid JJ 0 1 6 O
status NN 0 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
response NN 0 1 1 O
to TO 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
his PRP$ 0 0 12 O
/ NN 0 0 2 O
her PRP$ 0 0 12 O
thyroid NN 0 1 6 O
and CC 0 0 12 O
metabolic JJ 0 1 6 O
status NN 0 1 1 O
. . 0 0 12 O

Caffeine NN 0 1 7 B-Drug
: : 0 0 2 O
Two CD 0 1 2 O
hundred VBD 0 0 UNK O
mg NNS 0 1 0 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
( ( 0 0 2 O
equivalent JJ 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
cups NNS 1 1 UNK O
of IN 0 0 12 O
American NNP 0 1 2 O
coffee NN 0 1 12 O
) ) 0 0 2 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
who WP 0 0 12 O
had VBD 1 0 12 O
achieved VBN 1 0 1 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
blood NN 0 1 6 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
after IN 0 0 12 O
being VBG 1 0 12 O
dosed VBN 1 1 14 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
qd NN 0 1 14 O
. . 0 0 12 O

Labor NN 0 1 2 O
and CC 0 0 12 O
Delivery NNP 0 1 2 O
The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
ZETIA NNP 0 1 UNK B-Brand
on IN 0 0 12 O
labor NN 0 1 1 O
and CC 0 0 12 O
delivery NN 0 1 1 O
in IN 0 0 12 O
pregnant JJ 0 1 13 O
women NNS 1 1 UNK O
are VBP 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Although IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
cefditoren NN 0 1 UNK B-Drug
pivoxil NN 0 0 UNK I-Drug
be VB 0 0 12 O
taken VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
antacids NNS 1 1 14 B-Group
. . 0 0 12 O

increased VBN 1 1 1 O
norepinephrine JJ 0 1 14 O
- : 0 0 2 O
induced JJ 0 1 6 O
platelet NN 0 1 14 O
aggregability NN 0 0 UNK O

A DT 0 0 2 O
chemically RB 0 1 UNK O
similar JJ 0 1 1 O
drug NN 0 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
class NN 0 1 12 O
produced VBD 1 0 1 O
optic JJ 0 1 3 O
nerve NN 0 1 6 O
degeneration NN 0 1 6 O
( ( 0 0 2 O
Wallerian JJ 0 0 UNK O
degeneration NN 0 1 6 O
of IN 0 0 12 O
retinogeniculate NN 0 0 UNK O
fibers NNS 1 1 3 O
) ) 0 0 2 O
in IN 0 0 12 O
clinically RB 0 0 6 O
normal JJ 0 1 1 O
dogs NNS 1 1 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
fashion NN 0 0 12 O
at IN 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
that WDT 0 0 12 O
produced VBD 1 0 1 O
plasma JJ 0 1 14 O
drug NN 0 1 1 O
levels NNS 1 1 1 O
about IN 0 1 12 O
9 CD 0 0 2 O
times NNS 1 1 12 O
higher JJR 1 1 1 O
than IN 0 0 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
drug NN 0 1 1 O
level NN 0 1 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
taking VBG 1 0 12 O
the DT 0 0 12 O
highest JJS 1 1 1 O
recommended VBD 1 1 1 O
dose NN 0 1 6 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
if IN 0 0 12 O
an DT 0 0 12 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitor NN 0 1 14 I-Group
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
levels NNS 1 1 1 O
or CC 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
endogenous JJ 0 1 14 O
steroid JJ 0 1 6 O
hormones NNS 1 1 13 O
such JJ 0 0 1 O
as IN 1 0 12 O
ketoconazole JJ 0 1 16 B-Drug
spironolactone NN 0 1 0 B-Drug
and CC 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

Some DT 0 0 2 O
quinolones NNS 0 1 13 B-Group
have VBP 0 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
including VBG 1 1 1 O
oral JJ 0 1 6 O
injectable JJ 0 1 UNK O
transdermal NN 0 1 14 O
and CC 0 0 12 O
implantable JJ 0 1 13 O
forms NNS 1 1 1 O
may MD 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
reliable JJ 0 1 UNK O
when WRB 0 0 12 O
TRACLEER NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
teratogenic JJ 0 1 UNK O
effects NNS 1 1 1 O
were VBD 1 0 12 O
seen VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
offspring NN 0 1 UNK O
delivered VBN 1 1 12 O
at IN 0 0 12 O
term NN 0 1 1 O
. . 0 0 12 O

Combined VBN 0 1 UNK O
effects NNS 1 1 1 O
may MD 0 0 1 O
induce VB 0 1 6 O
serious JJ 0 1 12 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
is VBZ 1 0 12 O
especially RB 0 0 12 O
important JJ 0 1 1 O
for IN 0 0 12 O
drugs NNS 1 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
serious JJ 0 1 12 O
toxicity NN 0 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
other JJ 0 0 12 O
antiarrhythmics NNS 1 1 UNK B-Group
. . 0 0 12 O

A DT 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
ganciclovir NN 0 1 14 B-Drug
was VBD 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
VIDEX NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
administered VBN 1 1 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
ganciclovir VB 0 1 14 B-Drug
but CC 0 0 12 O
not RB 0 1 12 O
when WRB 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
were VBD 1 0 12 O
administered VBN 1 1 1 O
simultaneously RB 0 1 13 O
( ( 0 0 2 O
n JJ 0 1 12 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Diuretic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
reduce VB 0 0 1 O
the DT 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
and CC 0 0 12 O
add VB 0 1 12 O
a DT 0 0 12 O
high JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
one CD 0 1 12 O
reported JJ 0 1 1 O
case NN 0 1 12 O
of IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
with IN 0 0 12 O
acute JJ 0 1 6 O
delirium NN 0 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
simultaneous JJ 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
fluphenazine NN 0 1 13 B-Drug
and CC 0 0 12 O
oral JJ 0 1 6 O
clonidine NN 0 1 0 B-Drug
. . 0 0 12 O

Studies NNS 0 1 2 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
potential JJ 0 1 1 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
with IN 0 0 12 O
azithromycin NNS 0 1 0 B-Drug
are VBP 1 0 12 O
in IN 0 0 12 O
progress NN 0 1 1 O
. . 0 0 12 O

Testicular JJ 0 1 UNK O
atrophy NN 0 1 6 O
was VBD 1 0 12 O
seen VBN 1 1 12 O
with IN 0 0 12 O
dexrazoxane JJ 0 1 13 B-Drug
administration NN 0 1 1 O
at IN 0 0 12 O
doses NNS 1 1 6 O
as RB 0 0 12 O
low JJ 0 1 1 O
as IN 1 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg VBZ 0 1 18 O
weekly JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
/ RB 0 0 2 O
9 CD 0 0 2 O
the DT 0 0 12 O
human JJ 0 1 1 O
dose NN 0 1 6 O
on IN 0 0 12 O
a DT 0 0 12 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
m VBZ 0 1 2 O
9 CD 0 0 2 O
basis NN 0 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
as RB 0 0 12 O
low JJ 0 1 1 O
as IN 1 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg VBZ 0 1 18 O
weekly JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
in IN 0 0 12 O
dogs NNS 1 1 UNK O
( ( 0 0 2 O
approximately RB 0 1 1 O
equal JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
dose NN 0 1 6 O
on IN 0 0 12 O
a DT 0 0 12 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
m VBZ 0 1 2 O
9 CD 0 0 2 O
basis NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
: : 0 0 2 O
The DT 0 0 2 O
biochemical JJ 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
metabolizing VBG 1 0 UNK O
isozyme JJ 0 1 UNK O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
( ( 0 0 2 O
debrisoquin JJ 0 1 UNK O
hydroxylase NN 0 1 UNK O
) ) 0 0 2 O
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
subset NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
Caucasian JJ 0 1 13 O
population NN 0 1 13 O
( ( 0 0 2 O
about IN 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
Caucasians NNPS 0 1 UNK O
are VBP 1 0 12 O
so RB 0 1 12 O
- : 0 0 2 O
called VBN 1 1 12 O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
) ) 0 0 2 O
; : 0 0 2 O

Drugs NNS 0 1 2 O
which WDT 0 0 12 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blocking VBG 1 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
TRACRIUM NNP 0 1 UNK B-Brand
include VBP 0 1 1 O
: : 0 0 2 O
enflurane NN 0 1 UNK B-Drug
; : 0 0 2 O
isoflurane NN 0 1 UNK B-Drug
; : 0 0 2 O
halothane NN 0 1 13 B-Drug
; : 0 0 2 O
certain JJ 0 1 1 O
antibiotics NNS 1 1 6 B-Group
especially RB 0 0 12 O
the DT 0 0 12 O
aminoglycosides NNS 0 1 13 B-Group
and CC 0 0 12 O
polymyxins NNS 1 1 UNK B-Group
; : 0 0 2 O
lithium NN 0 1 16 B-Drug
; : 0 0 2 O
magnesium NN 0 1 14 B-Drug
salts NNS 1 1 13 O
; : 0 0 2 O
procainamide NN 0 1 16 B-Drug
; : 0 0 2 O
and CC 0 0 12 O
quinidine VB 0 1 16 B-Drug
. . 0 0 12 O

( ( 0 0 2 O
SGOT NNP 0 0 14 O
) ) 0 0 2 O
ALT NNP 0 1 13 O
( ( 0 0 2 O
SGPT NNP 0 0 14 O
) ) 0 0 2 O

Examples NNS 0 1 UNK O
of IN 0 0 12 O
Drugs NNP 0 1 2 O
in IN 0 0 12 O
Which NNP 0 0 UNK O
Plasma NNP 0 1 UNK O
Concentrations NNP 0 1 UNK O
May NNP 0 1 2 O
Be NNP 0 0 UNK O
Decreased VBN 0 1 7 O
By IN 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
With IN 0 0 2 O
Nevirapine NNP 0 1 UNK B-Drug

Dosages NNS 0 1 UNK O
of IN 0 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
opioids NNS 0 1 14 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
half NN 0 1 12 O
because IN 0 0 12 O
levomepromazine JJ 0 1 UNK B-Drug
amplifies NNS 0 0 UNK O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
actions NNS 1 1 UNK O
and CC 0 0 12 O
side JJ 0 1 3 O
- : 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
opioids NNS 0 1 14 B-Group
. . 0 0 12 O

Certain NNP 0 1 UNK O
antibiotic JJ 0 1 6 B-Group
cisplatin NN 0 1 14 B-Drug
cyclosporine NN 0 1 14 B-Drug
diuretic JJ 0 1 14 B-Group
foscarnet NN 0 1 16 B-Drug
and CC 0 0 12 O
vaccines NNS 1 1 6 B-Group
. . 0 0 12 O

Unfortunately RB 0 0 12 O
folic JJ 0 0 14 B-Drug
acid NN 0 1 14 I-Drug
will MD 0 0 12 O
not RB 0 1 12 O
correct VB 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
that WDT 0 0 12 O
result NN 0 1 1 O
from IN 0 0 12 O
vitamin NN 0 1 6 O
B9 NNP 0 0 UNK O
deficiency NN 0 1 6 O
. . 0 0 12 O

the DT 0 0 12 O
disulfiram NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
if IN 0 0 12 O
such JJ 0 0 1 O
signs NNS 1 1 12 O
appear VBP 0 1 12 O
. . 0 0 12 O

Exert NNP 0 1 UNK O
particular JJ 0 0 1 O
caution NN 0 0 1 O
in IN 0 0 12 O
combining VBG 1 1 UNK O
chlorprothixene NN 0 1 UNK B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
and CC 0 0 12 O
antiparkinsonian JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
) ) 0 0 2 O
: : 0 0 2 O
Particularly RB 0 0 UNK O
the DT 0 0 12 O
elderly JJ 0 1 12 O
may MD 0 0 1 O
develop VB 0 0 1 O
delirium NN 0 1 6 O
high JJ 0 1 1 O
fever NN 0 1 6 O
severe JJ 0 1 6 O
obstipation NN 0 1 UNK O
even RB 0 0 12 O
ileus JJ 0 1 8 O
and CC 0 0 12 O
glaucoma NN 0 1 6 O
. . 0 0 12 O

Read NNP 0 1 2 O
circulars NNS 1 1 UNK O
for IN 0 0 12 O
lithium NN 0 1 16 B-Drug
preparations NNS 1 1 13 O
before IN 0 1 12 O
use NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
. . 0 0 12 O

antacids NNS 1 1 14 B-Group
after IN 0 0 12 O
meals NNS 1 1 12 O
. . 0 0 12 O

Because IN 0 0 12 O
Nalfon NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
produce VB 0 0 1 O
any DT 0 0 12 O
additional JJ 0 1 1 O
effect NN 0 1 1 O
beyond IN 0 0 12 O
that DT 0 0 12 O
obtained VBD 1 1 1 O
with IN 0 0 12 O
aspirin JJ 0 1 14 B-Brand
alone RB 0 1 12 O
and CC 0 0 12 O
because IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
increases VBZ 1 1 1 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
excretion NN 0 1 14 O
of IN 0 0 12 O
Nalfon NNP 0 1 UNK B-Brand
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
Nalfon NNP 0 1 UNK B-Brand
and CC 0 0 12 O
salicylates NNS 1 1 13 B-Group
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
Norpace NNP 0 1 0 B-Brand
and CC 0 0 12 O
quinidine NN 0 1 16 B-Drug
resulted VBN 1 1 1 O
in IN 0 0 12 O
slight JJ 0 1 3 O
increases NNS 1 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
disopyramide NN 0 1 16 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
slight JJ 0 1 3 O
decreases NNS 1 1 UNK O
in IN 0 0 12 O
plasma JJ 0 1 14 O
quinidine NN 0 1 16 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Increased VBD 0 1 7 O
serum JJ 0 1 14 O
triglyceride NN 0 1 14 O
and CC 0 0 12 O
phospholipid JJ 0 1 UNK O
concentration NN 0 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Nine NNP 0 1 UNK O
additional JJ 0 1 1 O
patients NNS 1 1 6 O
who WP 0 0 12 O
had VBD 1 0 12 O
initial JJ 0 1 1 O
positive JJ 0 1 1 O
tests NNS 1 1 1 O
were VBD 1 0 12 O
negative JJ 0 1 1 O
on IN 0 0 12 O
repeat NN 0 1 12 O
testing NN 0 1 1 O
. . 0 0 12 O

Restoration NN 0 1 UNK O
of IN 0 0 12 O
female JJ 0 1 12 O
fertility NN 0 1 6 O
to TO 0 0 12 O
values NNS 1 1 1 O
similar JJ 0 1 1 O
to TO 0 0 12 O
controls NNS 1 1 UNK O
was VBD 1 0 12 O
evident JJ 0 1 1 O
following VBG 1 1 1 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
withdrawal NN 0 1 1 O
period NN 0 1 1 O
after IN 0 0 12 O
dosing VBG 1 0 14 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
twice RB 0 1 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
dose NN 0 1 6 O
based VBN 1 1 1 O
on IN 0 0 12 O
BSA NNP 0 0 13 O
) ) 0 0 2 O
. . 0 0 12 O

however RB 0 0 12 O
as IN 1 0 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
Lodine NNP 0 1 UNK B-Brand
and CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
generally RB 0 0 1 O
recommended VBN 1 1 1 O
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
of IN 0 0 12 O
increased JJ 0 1 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

one CD 0 1 12 O
- : 0 0 2 O
half PDT 0 1 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
dose NN 0 1 6 O
on IN 0 0 12 O
BSA NNP 0 0 13 O
) ) 0 0 2 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
during IN 0 0 12 O
the DT 0 0 12 O
period NN 0 1 1 O
of IN 0 0 12 O
organogenesis NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
ten JJ 0 1 12 O
- : 0 0 2 O
subject NN 0 1 UNK O
study NN 0 1 1 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
bid NN 0 0 12 O
) ) 0 0 2 O
with IN 0 0 12 O
lovastatin NN 0 1 13 B-Drug
resulted VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
times NNS 1 1 12 O
increase VB 0 1 1 O
in IN 0 0 12 O
mean JJ 0 1 12 O
lovastatin NN 0 1 13 B-Drug
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
vs. FW 0 1 2 O
lovastatin NN 0 1 13 B-Drug
alone RB 0 1 12 O
; : 0 0 2 O

Both DT 0 0 2 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
COREG NNP 0 1 UNK B-Brand
slow VB 0 1 12 O
AV NNP 0 0 13 O
conduction NN 0 1 6 O
. . 0 0 12 O

this DT 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
its PRP$ 1 0 12 O
effect NN 0 1 1 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
ELLENCE NNP 0 1 UNK B-Brand
after IN 0 0 12 O
previous JJ 0 1 12 O
radiation NN 0 1 1 O
therapy NN 0 1 6 O
may MD 0 0 1 O
induce VB 0 1 6 O
an DT 0 0 12 O
inflammatory NN 0 1 6 O
recall NN 0 1 12 O
reaction NN 0 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
site NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
irradiation NN 0 1 14 O
. . 0 0 12 O

Itraconazole NN 0 1 UNK B-Drug
: : 0 0 2 O
Torsades NNP 0 0 UNK O
de IN 0 1 2 O
pointes NNS 0 0 UNK O
and CC 0 0 12 O
elevated JJ 0 1 1 O
parent NN 0 1 13 O
terfenadine NN 0 1 UNK B-Drug
levels NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
during IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
and CC 0 0 12 O
itraconazole NN 0 1 0 B-Drug
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
of IN 0 0 12 O
itraconazole NN 0 1 0 B-Drug
and CC 0 0 12 O
from IN 0 0 12 O
foreign JJ 0 1 1 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
sources NNS 1 1 1 O
. . 0 0 12 O

Fenofibrate NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
study NN 0 1 1 O
concomitant JJ 0 1 6 O
fenofibrate JJ 0 1 16 B-Drug
administration NN 0 1 1 O
increased VBD 1 1 1 O
total JJ 0 1 1 O
ezetimibe JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
. . 0 0 12 O

Fluoxetine NN 0 1 0 B-Drug

The DT 0 0 2 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
progestin NN 0 1 UNK B-Group
- : 0 0 2 O
only RB 0 1 12 O
pills VBZ 0 1 6 O
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
hepatic JJ 0 1 14 O
enzyme NN 0 1 14 O
- : 0 0 2 O
inducing VBG 1 1 6 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
the DT 0 0 12 O
anticonvulsants NNS 1 1 13 B-Group
phenytoin VBP 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
barbiturates NNS 1 1 14 B-Group
and CC 0 0 12 O
the DT 0 0 12 O
antituberculosis JJ 0 1 UNK B-Group
drug NN 0 1 1 I-Group
rifampin NN 0 1 16 B-Drug
. . 0 0 12 O

Laboratory NN 0 1 2 O
Tests VBZ 0 1 UNK O
The DT 0 0 2 O
pathologist NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
advised VBN 1 0 12 O
of IN 0 0 12 O
progestin NN 0 1 UNK O
therapy NN 0 1 6 O
when WRB 0 0 12 O
relevant NN 0 1 1 O
specimens NNS 1 1 1 O
are VBP 1 0 12 O
submitted VBN 1 1 UNK O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
Myfortic NNP 0 1 UNK B-Drug
and CC 0 0 12 O
antacids NNS 1 1 14 B-Group
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
simultaneously RB 0 1 13 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Induce NNP 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
Rifampin NNP 0 1 0 B-Drug
: : 0 0 2 O
CYP9A9 NNP 0 0 UNK O
is VBZ 1 0 12 O
ordinarily RB 0 0 UNK O
a DT 0 0 12 O
minor JJ 0 1 1 O
metabolizing NN 0 0 UNK O
enzyme NN 0 1 14 O
of IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
. . 0 0 12 O

- : 0 0 2 O
Androgens NNS 0 1 UNK B-Group
( ( 0 0 2 O
male JJ 0 1 12 O
hormones NNS 1 1 13 O
) ) 0 0 2 O
or CC 0 0 12 O

Warfarin NNP 0 1 0 B-Drug
Digoxin NNP 0 1 0 B-Drug
Salicylate NNP 0 1 UNK B-Group
and CC 0 0 12 O
Heparin NNP 0 1 0 B-Drug
The DT 0 0 2 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
binding NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
is VBZ 1 0 12 O
only RB 0 1 12 O
slightly RB 0 1 3 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
ketorolac NN 0 1 16 B-Drug
tromethamine NN 0 1 13 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
control NN 0 1 1 O
vs VBZ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
when WRB 0 0 12 O
ketorolac NN 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
reach VBP 0 1 12 O
9 CD 0 0 2 O
to9 JJ 0 0 UNK O
m NN 0 1 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
. . 0 0 12 O

Clinically RB 0 0 7 O
significant JJ 0 1 1 O
effects NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
tricyclic JJ 0 0 14 B-Drug
antidepressants NNS 1 1 13 I-Drug
when WRB 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

Rifampin NN 0 1 0 B-Drug
: : 0 0 2 O
Rifampin NNP 0 1 0 B-Drug
enhances VBZ 1 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
concurrently RB 0 0 1 O
administered VBN 1 1 1 O
DIFLUCAN NNP 0 1 UNK B-Brand
. . 0 0 12 O

Phenobarbital NN 0 1 0 B-Drug
: : 0 0 2 O
It PRP 0 0 12 O
appears VBZ 1 1 12 O
that IN 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
may MD 0 0 1 O
reduce VB 0 0 1 O
plasma NN 0 1 14 O
felbamate NN 0 1 13 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

DEA NNP 0 1 UNK O
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
finding NN 0 1 12 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

If IN 0 0 12 O
the DT 0 0 12 O
TARCEVA NNP 0 1 UNK B-Brand
dose NN 0 1 6 O
is VBZ 1 0 12 O
adjusted VBN 1 1 1 O
upward RB 0 1 3 O
the DT 0 0 12 O
dose NN 0 1 6 O
will MD 0 0 12 O
need VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
upon IN 0 0 12 O
discontinuation NN 0 1 6 O
of IN 0 0 12 O
rifampicin NN 0 1 UNK B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
inducers NNS 1 1 UNK O
. . 0 0 12 O

Carcinogenesis NNP 0 1 UNK O
Mutagenesis NNP 0 1 UNK O
Impairment NNP 0 1 UNK O
of IN 0 0 12 O
Fertility NNP 0 1 7 O
A NNP 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
week NN 0 1 12 O
dietary JJ 0 1 6 O
carcinogenicity NN 0 1 UNK O
study NN 0 1 1 O
with IN 0 0 12 O
ezetimibe NN 0 1 16 B-Drug
was VBD 1 0 12 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
at IN 0 0 12 O
doses NNS 1 1 6 O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ JJ 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
males NNS 1 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
females NNS 1 1 UNK O
) ) 0 0 2 O
( ( 0 0 2 O
~9 JJ 0 0 UNK O
times NNS 1 1 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
exposure NN 0 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
daily RB 0 1 12 O
based VBN 1 1 1 O
on IN 0 0 12 O
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9hr CD 0 0 UNK O
for IN 0 0 12 O
total JJ 0 1 1 O
ezetimibe NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
serum JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
frequently RB 0 1 1 O
if IN 0 0 12 O
PRINIVIL NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
lithium NN 0 1 16 B-Drug
. . 0 0 12 O

RESPIRATORY NNP 0 1 11 O
DEPRESSION NNP 0 1 11 O
HYPOTENSION NNP 0 1 UNK O
AND NNP 0 0 11 O
PROFOUND NNP 0 1 UNK O
SEDATION NNP 0 1 UNK O
OR NNP 0 0 11 O
COMA NNP 0 1 15 O
MAY NNP 0 0 11 O
RESULT NNP 0 1 UNK O
. . 0 0 12 O

prolonged VBN 1 1 6 O
hot JJ 0 1 3 O
weather NN 0 1 13 O
; : 0 0 2 O

The DT 0 0 2 O
appropriate JJ 0 1 1 O
interval NN 0 1 1 O
between IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
and CC 0 0 12 O
dexfenfluramine NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Also RB 0 0 2 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
hepatic JJ 0 1 14 O
injury NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
Rebif NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
products NNS 1 1 1 O
associated VBN 1 1 1 O
with IN 0 0 12 O
hepatic JJ 0 1 14 O
injury NN 0 1 6 O
or CC 0 0 12 O
when WRB 0 0 12 O
new JJ 0 1 12 O
agents NNS 1 1 1 O
are VBP 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
regimen NNS 0 1 6 O
of IN 0 0 12 O
patients NNS 1 1 6 O
already RB 0 0 12 O
on IN 0 0 12 O
Rebif NNP 0 1 UNK B-Brand
. . 0 0 12 O

FORADIL NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
substitute NN 0 0 16 O
for IN 0 0 12 O
oral JJ 0 1 6 O
or CC 0 0 12 O
inhaled JJ 0 1 14 O
corticosteroids NNS 1 1 14 B-Group
. . 0 0 12 O

. . 0 0 12 O

metronidazole NN 0 1 0 B-Drug
; : 0 0 2 O

Preliminary NNP 0 1 2 O
animal NN 0 1 13 O
and CC 0 0 12 O
human JJ 0 1 1 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
small JJ 0 1 12 O
quantities NNS 1 1 UNK O
of IN 0 0 12 O
systemically RB 0 0 UNK O
administered VBN 1 1 1 O
leucovorin NN 0 1 16 B-Drug
enter NN 0 1 12 O
the DT 0 0 12 O
CSF NNP 0 1 14 O
primarily RB 0 0 1 O
as IN 1 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
methyltetrahydro NN 0 0 UNK O
- : 0 0 2 O
folate NN 0 1 14 O
and CC 0 0 12 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
remain VBP 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
orders NNS 1 1 1 O
of IN 0 0 12 O
magnitude NN 0 1 UNK O
lower JJR 1 1 1 O
than IN 0 0 12 O
the DT 0 0 12 O
usual JJ 0 1 12 O
methotrexate NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
following VBG 1 1 1 O
intrathecal JJ 0 1 16 O
administration NN 0 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
individuals NNS 1 1 1 O
may MD 0 0 1 O
have VB 0 0 12 O
higher JJR 1 1 1 O
than IN 0 0 12 O
expected VBN 1 1 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
when WRB 0 0 12 O
given VBN 1 1 12 O
usual JJ 0 1 12 O
doses NNS 1 1 6 O
. . 0 0 12 O

reliable JJ 0 1 UNK O
estimates NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
prevalence NN 0 1 UNK O
of IN 0 0 12 O
reduced JJ 0 1 1 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
isozyme NN 0 1 UNK O
activity NN 0 1 1 O
among IN 0 0 12 O
Asian JJ 0 1 2 O
African NNP 0 1 UNK O
and CC 0 0 12 O
other JJ 0 0 12 O
populations NNS 1 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
yet RB 0 0 12 O
available JJ 0 1 1 O
. . 0 0 12 O

Absorption NN 0 1 UNK O
of IN 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
is VBZ 1 0 12 O
impaired VBN 1 1 6 O
by IN 0 0 12 O
antacids NNS 1 1 14 B-Group
containing VBG 1 1 1 O
aluminum NN 0 1 16 B-Drug
calcium NN 0 1 14 B-Drug
or CC 0 0 12 O
magnesium NN 0 1 14 B-Drug
and CC 0 0 12 O
iron NN 0 1 3 B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
preparations NNS 1 1 13 O
. . 0 0 12 O

Aprepitant NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates VBZ 0 1 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
transporter NN 0 1 UNK O
as IN 1 0 12 O
demonstrated VBN 1 0 1 O
by IN 0 0 12 O
the DT 0 0 12 O
lack NN 0 1 1 O
of IN 0 0 12 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
with IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
in IN 0 0 12 O
a DT 0 0 12 O
clinical JJ 0 1 6 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
TORADOL NNP 0 1 UNK B-Brand
with IN 0 0 12 O
muscle NN 0 1 6 B-Group
relaxants NNS 1 0 13 I-Group
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
formally RB 0 0 1 O
studied VBN 1 0 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
short JJ 0 1 12 B-Group
- : 0 0 2 O
acting VBG 1 1 12 I-Group
beta NN 0 1 16 I-Group
adrenergic JJ 0 1 UNK I-Group
aerosol JJ 0 1 3 I-Group
bronchodilators NNS 1 1 14 I-Group
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
MAXAIR NNP 0 1 UNK B-Brand
AUTOHALER NNP 0 0 UNK I-Brand
because IN 0 0 12 O
they PRP 0 0 12 O
may MD 0 0 1 O
have VB 0 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
itraconazole JJ 0 1 0 B-Drug
and CC 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

These DT 0 0 1 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

NOTE NN 0 1 11 O
: : 0 0 2 O
Do NNP 0 0 2 O
not RB 0 1 12 O
use VB 0 1 1 O
the DT 0 0 12 O
injection NN 0 1 3 O
if IN 0 0 12 O
it PRP 0 0 12 O
contains VBZ 1 1 1 O
precipitate NN 0 1 13 O
. . 0 0 12 O

Theophylline NNP 0 1 UNK B-Drug
- : 0 0 2 O
Combined JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
racemic JJ 0 1 14 O
citalopram NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
theophylline NN 0 1 16 B-Drug
( ( 0 0 2 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
. . 0 0 12 O

Although IN 0 0 12 O
erythromycin NN 0 1 0 O
measurably RB 0 0 UNK O
decreases VBZ 1 1 UNK O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
the DT 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
acid VBZ 0 1 14 O
metabolite CC 0 1 UNK O
its PRP$ 1 0 12 O
influence NN 0 0 UNK O
on IN 0 0 12 O
terfenadine NN 0 1 UNK O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
is VBZ 1 0 12 O
still RB 0 0 12 O
under IN 0 0 12 O
investigation NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
if IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
observations NNS 1 1 1 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
: : 0 0 2 O
The DT 0 0 2 O
biochemical JJ 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
metabolizing VBG 1 0 UNK O
isozyme JJ 0 1 UNK O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
( ( 0 0 2 O
debrisoquin JJ 0 1 UNK O
hydroxylase NN 0 1 UNK O
) ) 0 0 2 O
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
subset NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
caucasian JJ 0 1 3 O
population NN 0 1 13 O
( ( 0 0 2 O
about IN 0 1 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
caucasians NNS 1 1 UNK O
are VBP 1 0 12 O
so RB 0 1 12 O
called JJ 0 1 12 O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
) ) 0 0 2 O
; : 0 0 2 O

Ibuprofen NNP 0 1 0 B-Drug
- : 0 0 2 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
arginine NN 0 1 13 I-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
if IN 0 0 12 O
taken VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Other JJ 0 0 2 O
binding VBG 1 1 1 O
proteins NNS 1 1 14 O
may MD 0 0 1 O
be VB 0 0 12 O
elevated VBN 1 1 1 O
in IN 0 0 12 O
serum NN 0 1 14 O
( ( 0 0 2 O
i.e. JJ 0 1 1 O
corticosteroid NN 0 1 UNK O
binding VBG 1 1 1 O
globulin NN 0 1 14 O
( ( 0 0 2 O
CBG NNP 0 0 UNK O
) ) 0 0 2 O
sex NN 0 1 13 O
hormone NN 0 1 6 O
binding VBG 1 1 1 O
globulin NN 0 1 14 O
( ( 0 0 2 O
SHBG NNP 0 0 UNK O
) ) 0 0 2 O
) ) 0 0 2 O
leading VBG 1 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
total JJ 0 1 1 O
circulating NN 0 1 13 O
corticosteroids NNS 1 1 14 B-Group
and CC 0 0 12 O
sex NN 0 1 13 B-Group
steroids NNS 1 1 6 I-Group
respectively RB 0 0 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
raise VBP 0 0 12 O
the DT 0 0 12 O
gastrointestinal JJ 0 1 6 O
pH NN 0 1 14 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
an DT 0 0 12 O
earlier JJR 1 1 12 O
release NN 0 1 12 O
of IN 0 0 12 O
duloxetine NN 0 1 0 B-Drug
. . 0 0 12 O

Mixing VBG 0 1 UNK O
of IN 0 0 12 O
Insulins NNS 0 1 UNK B-Group

FLUOTHANE NNP 0 1 UNK B-Brand
may MD 0 0 1 O
augment VB 0 1 13 O
the DT 0 0 12 O
hypotension NN 0 1 6 O
caused VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
ganglionic JJ 0 1 UNK O
- : 0 0 2 O
blocking VBG 1 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
tubocurarine NN 0 1 UNK B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
precaution NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
when WRB 0 0 12 O
coadministration NN 0 1 UNK O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Cimetidine NNP 0 1 0 B-Drug
- : 0 0 2 O
In IN 0 0 2 O
subjects NNS 1 1 UNK O
who WP 0 0 12 O
had VBD 1 0 12 O
received VBN 1 1 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
racemic JJ 0 1 14 O
citalopram NN 0 1 16 B-Drug
combined VBN 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
cimetidine NN 0 1 13 B-Drug
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
citalopram JJ 0 1 16 B-Drug
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O

Each DT 0 0 2 O
month NN 0 1 12 O
of IN 0 0 12 O
therapy NN 0 1 6 O
the DT 0 0 12 O
patient NN 0 1 6 O
must MD 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
negative JJ 0 1 1 O
result NN 0 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
urine NN 0 1 6 O
or CC 0 0 12 O
serum JJ 0 1 14 O
pregnancy NN 0 1 6 O
test NN 0 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
serious JJ 0 1 12 O
reactions NNS 1 1 1 O
( ( 0 0 2 O
including VBG 1 1 1 O
severe JJ 0 1 6 O
agitation NN 0 1 1 O
hallucinations NNS 1 1 6 O
and CC 0 0 12 O
death NN 0 1 12 O
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
this DT 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
adversely RB 0 0 UNK O
affect VB 0 1 1 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
control NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
methyldopa NN 0 1 13 B-Drug
. . 0 0 12 O

Dasatinib NNP 0 1 UNK B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
are VBP 1 0 12 O
minimally RB 0 0 6 O
excreted VBN 1 1 UNK O
via IN 0 0 1 O
the DT 0 0 12 O
kidney NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
finding NN 0 1 12 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
; : 0 0 2 O

No DT 0 0 2 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
isoforms NNS 0 1 UNK O
tested VBN 1 1 1 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
at IN 0 0 12 O
gabapentin NN 0 1 0 B-Drug
concentrations NNS 1 1 13 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
mL NN 0 1 14 O
( ( 0 0 2 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

ACE NNP 0 1 13 B-Group
- : 0 0 2 O
inhibitors NNS 1 1 14 I-Group
: : 0 0 2 O
Reports NNS 0 1 2 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
may MD 0 0 1 O
diminish VB 0 1 UNK O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
ACE NNP 0 1 13 B-Group
- : 0 0 2 O
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
undergoing VBG 1 0 6 O
PTCA NNP 0 1 8 O
/ NNP 0 0 2 O
PCI NNP 0 1 UNK O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
Angiomax NNP 0 1 UNK B-Brand
with IN 0 0 12 O
heparin JJ 0 1 14 B-Drug
warfarin NN 0 1 14 B-Drug
thrombolytics NNS 1 1 14 B-Group
or CC 0 0 12 O
glycoprotein NN 0 1 UNK O
IIb NNP 0 0 UNK O
/ NNP 0 0 2 O
IIIa NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
increased JJ 0 1 1 O
risks NNS 1 1 1 O
of IN 0 0 12 O
major JJ 0 1 1 O
bleeding VBG 1 1 6 O
events NNS 1 1 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
not RB 0 1 12 O
receiving VBG 1 1 1 O
these DT 0 0 12 O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
genotoxicity NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
mouse NN 0 1 UNK O
micronucleus JJ 0 1 UNK O
test NN 0 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
cyclophosphamide NN 0 1 14 B-Drug
within IN 0 0 1 O
9 CD 0 0 2 O
days NNS 1 1 12 O
of IN 0 0 12 O
general JJ 0 1 1 O
anesthesia IN 0 1 6 O
the DT 0 0 12 O
anesthesiologist NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
alerted VBN 1 1 12 O
. . 0 0 12 O

However RB 0 0 1 O
it PRP 0 0 12 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
ENBREL NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
unaltered VBN 0 1 UNK O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
methotrexate NN 0 1 16 B-Drug
in IN 0 0 12 O
rheumatoid JJ 0 0 6 O
arthritis NN 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
to TO 0 0 12 O
established VBN 1 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
there EX 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
potential JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
nevirapine NN 0 1 13 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
classes NNS 1 1 UNK O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
short JJ 0 1 12 B-Group
- : 0 0 2 O
acting VBG 1 1 12 I-Group
benzodiazepines NNS 1 1 14 I-Group
which WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
are VBP 1 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
with IN 0 0 12 O
fluconazole JJ 0 1 0 B-Drug
consideration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
decreasing VBG 1 1 1 O
the DT 0 0 12 O
benzodiazepine NN 0 1 14 B-Group
dosage NN 0 1 0 O
and CC 0 0 12 O
the DT 0 0 12 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
appropriately RB 0 0 1 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Ritonavir NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
b.i.d NN 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O
co SYM 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
vardenafil JJ 0 1 UNK B-Drug
AUC NNP 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
vardenafil JJ 0 1 UNK B-Drug
Cmax NNP 0 1 UNK O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
adrenergic NN 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
: : 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
may MD 0 0 1 O
blunt VB 0 1 3 O
the DT 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
arbutamine VB 0 1 UNK B-Drug
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
Targretin NNP 0 1 UNK B-Brand
capsules NNS 1 1 3 O
and CC 0 0 12 O
gemfibrozil NN 0 1 16 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
substantial JJ 0 0 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
bexarotene NN 0 1 UNK B-Drug
probably RB 0 1 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
partially RB 0 0 1 O
related VBN 1 1 1 O
to TO 0 0 12 O
cytochrome VB 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
inhibition NN 0 1 13 O
by IN 0 0 12 O
gemfibrozil NN 0 1 16 B-Drug
. . 0 0 12 O

Histamine NNP 0 1 7 B-Group
H9 NNP 0 0 UNK I-Group
- : 0 0 2 O
receptor NN 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
: : 0 0 2 O
Histamine NNP 0 1 7 B-Group
H9 NNP 0 0 UNK I-Group
- : 0 0 2 O
receptor NN 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
appear VBP 0 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
given VBN 1 1 12 O
Lodine NNP 0 1 UNK B-Brand
or CC 0 0 12 O
any DT 0 0 12 O
other JJ 0 0 12 O
NSAID NNP 0 1 14 B-Group
and CC 0 0 12 O
particularly RB 0 0 1 O
those DT 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
altered JJ 0 1 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
specific JJ 0 1 1 O
toxicities NNS 1 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
principal JJ 0 1 1 O
drugs NNS 1 1 6 O
given VBN 1 1 12 O
( ( 0 0 2 O
number NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
in IN 0 0 12 O
parentheses NNS 1 0 UNK O
) ) 0 0 2 O
were VBD 1 0 12 O
: : 0 0 2 O
cardiac JJ 0 1 6 B-Group
glycosides NNS 1 1 13 I-Group
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
sedatives NNS 1 1 6 B-Group
and CC 0 0 12 O
hypnotics NNS 1 1 13 B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
coronary NN 0 1 6 B-Group
vasodilators NNS 1 1 13 I-Group
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
oral JJ 0 1 6 O
hypoglycemics NNS 0 1 14 B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
cough NN 0 1 6 O
and CC 0 0 12 O
cold JJ 0 1 3 O
preparations NNS 1 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
NSAIDs NNP 0 1 UNK B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
antihyperlipidemics NNS 0 1 UNK B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
antigout NN 0 0 UNK B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
bronchodilators NNS 1 1 14 B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
insulin NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
beta NN 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Finasteride NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
- : 0 0 2 O
linked VBN 1 1 UNK O
drug NN 0 1 1 O
- : 0 0 2 O
metabolizing NN 0 0 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
and CC 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
CYP9A NNP 0 0 UNK O
may MD 0 0 1 O
increase VB 0 1 1 O
nelfinavir JJ 0 1 16 B-Drug
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Influence NN 0 0 UNK O
of IN 0 0 12 O
Trileptal NNP 0 1 UNK B-Brand
on IN 0 0 12 O
AED NNP 0 1 UNK B-Group
Concentration NNP 0 1 UNK O
( ( 0 0 2 O
Mean NNP 0 1 2 O
change VBP 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
Confidence NNP 0 1 UNK O
Interval NNP 0 1 13 O
) ) 0 0 2 O

Other JJ 0 0 2 O
binding VBG 1 1 1 O
proteins NNS 1 1 14 O
may MD 0 0 1 O
be VB 0 0 12 O
elevated VBN 1 1 1 O
in IN 0 0 12 O
serum NN 0 1 14 O
i.e. NN 0 1 1 O
corticosteroid NN 0 1 UNK O
binding VBG 1 1 1 O
globulin NN 0 1 14 O
( ( 0 0 2 O
CBG NNP 0 0 UNK O
) ) 0 0 2 O
sex NN 0 1 13 O
hormone NN 0 1 6 O
- : 0 0 2 O
binding NN 0 1 1 O
globulin NN 0 1 14 O
( ( 0 0 2 O
SHBG NNP 0 0 UNK O
) ) 0 0 2 O
leading VBG 1 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
total JJ 0 1 1 O
circulating NN 0 1 13 O
corticosteroids NNS 1 1 14 B-Group
and CC 0 0 12 O
sex NN 0 1 13 B-Group
steroids NNS 1 1 6 I-Group
respectively RB 0 0 1 O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily RB 0 1 12 O
) ) 0 0 2 O

Patients NNS 0 1 7 O
on IN 0 0 12 O
warfarin JJ 0 1 14 B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulant JJ 0 1 13 I-Group
therapy NN 0 1 6 O
may MD 0 0 1 O
require VB 0 0 1 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
anticoagulant NN 0 1 13 O
during IN 0 0 12 O
and CC 0 0 12 O
after IN 0 0 12 O
griseofulvin JJ 0 1 UNK B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

cardiovascular JJ 0 1 6 O
effects NNS 1 1 1 O
can MD 0 0 12 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
. . 0 0 12 O

Ketoconazole NNS 0 1 UNK B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
on IN 0 0 12 O
Day9 NNP 0 0 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
regimen NNS 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
a DT 0 0 12 O
strong JJ 0 1 12 O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
aprepitant NN 0 1 13 B-Drug
increased VBD 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
and CC 0 0 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
terminal JJ 0 1 1 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
aprepitant NN 0 1 13 B-Drug
increased VBD 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
on IN 0 0 12 O
GI NNP 0 1 6 O
bleeding VBG 1 1 6 O
are VBP 1 0 12 O
synergistic JJ 0 1 UNK O
such JJ 0 0 1 O
that IN 0 0 12 O
users NNS 1 1 UNK O
of IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
together RB 0 1 12 O
have VBP 0 0 12 O
a DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
serious JJ 0 1 12 O
GI NNP 0 1 6 O
bleeding NN 0 1 6 O
higher JJR 1 1 1 O
than IN 0 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
users NNS 1 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
alone RB 0 1 12 O
. . 0 0 12 O

Furosemide NN 0 1 0 B-Drug
: : 0 0 2 O
Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
observations NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
natriuretic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
and CC 0 0 12 O
thiazides NNS 1 1 UNK B-Group
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Similarly RB 0 0 1 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
the DT 0 0 12 O
drug NN 0 1 1 O
and CC 0 0 12 O
a DT 0 0 12 O
hydantoin JJ 0 1 13 B-Group
sulfonamide NN 0 1 UNK B-Group
or CC 0 0 12 O
sulfonylurea NN 0 1 UNK B-Group
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
toxicity NN 0 1 6 O
to TO 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Interactions NNP 0 1 UNK O
No NNP 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
with IN 0 0 12 O
Campath NNP 0 1 0 B-Brand
. . 0 0 12 O

Monitor NNP 0 1 2 O
cardiovascular JJ 0 1 6 O
status NN 0 1 1 O
. . 0 0 12 O

Pimozide NNP 0 1 UNK B-Drug
and CC 0 0 12 O
Celexa NNP 0 1 0 B-Brand
- : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
controlled VBN 1 1 1 O
study NN 0 1 1 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
pimozide JJ 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
racemic JJ 0 1 14 O
citalopram NN 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
given VBN 1 1 12 O
once RB 0 0 12 O
daily JJ 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
mean JJ 0 1 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
QTc NNP 0 0 14 O
values NNS 1 1 1 O
of IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
msec NNS 0 1 14 O
compared VBN 1 1 1 O
to TO 0 0 12 O
pimozide VB 0 1 13 B-Drug
given VBN 1 1 12 O
alone RB 0 1 12 O
. . 0 0 12 O

Epidural JJ 0 1 7 O
clonidine NN 0 1 0 B-Drug
may MD 0 0 1 O
prolong VB 0 0 13 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
pharmacologic JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
epidural JJ 0 1 6 O
local JJ 0 1 12 O
anesthetics NNS 1 1 13 B-Group
including VBG 1 1 1 O
both DT 0 0 12 O
sensory JJ 0 1 6 O
and CC 0 0 12 O
motor NN 0 1 3 O
blockade NN 0 1 1 O
. . 0 0 12 O

Short NNP 0 1 2 B-Group
- : 0 0 2 O
acting VBG 1 1 12 I-Group
Benzodiazepines NNS 0 1 UNK I-Group
: : 0 0 2 O
Following VBG 0 1 2 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
midazolam JJ 0 1 16 B-Drug
fluconazole NN 0 1 0 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
substantial JJ 0 0 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
midazolam JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
and CC 0 0 12 O
psychomotor NN 0 0 13 O
effects NNS 1 1 1 O
. . 0 0 12 O

increased JJ 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
fibrinogen NN 0 1 14 B-Drug
and CC 0 0 12 O
fibrinogen NN 0 1 14 B-Drug
activity NN 0 1 1 O
; : 0 0 2 O

The DT 0 0 2 O
following NN 0 1 1 O
are VBP 1 0 12 O
examples NNS 1 1 UNK O
of IN 0 0 12 O
substances NNS 1 1 1 O
that WDT 0 0 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
blood NN 0 1 6 O
- : 0 0 2 O
glucose JJ 0 1 14 O
- : 0 0 2 O
lowering VBG 1 1 UNK O
effect NN 0 1 1 O
and CC 0 0 12 O
susceptibility NN 0 1 6 O
to TO 0 0 12 O
hypoglycemia NN 0 1 6 O
: : 0 0 2 O
oral JJ 0 1 6 O
antidiabetes NNS 0 0 UNK O
products NNS 1 1 1 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
disopyramide VBP 0 1 16 B-Drug
fibrates NNS 0 1 UNK B-Group
fluoxetine VBP 0 1 16 B-Drug
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
propoxyphene VBP 0 1 16 B-Drug
salicylates NNS 1 1 13 B-Group
somatostatin VBP 0 1 14 B-Group
analog NN 0 1 UNK I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
octreotide NN 0 1 14 B-Drug
) ) 0 0 2 O
sulfonamide NN 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
. . 0 0 12 O

Extended JJ 0 1 2 O
Release NNP 0 1 2 O
Tablets NNP 0 1 0 O
: : 0 0 2 O
Administration NN 0 1 UNK O
of IN 0 0 12 O
nifedipine JJ 0 1 0 B-Drug
with IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
increased VBN 1 1 1 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

When WRB 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
therapy NN 0 1 6 O
aripiprazole NN 0 1 16 B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
then RB 0 1 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

Nephrotoxic JJ 0 1 UNK O
agents NNS 1 1 1 O
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
VISTIDE NNP 0 1 UNK B-Brand
and CC 0 0 12 O
agents NNS 1 1 1 O
with IN 0 0 12 O
nephrotoxic JJ 0 1 UNK O
potential JJ 0 1 1 O
[ NN 0 0 2 O
e.g. VBP 0 0 UNK O
intravenous JJ 0 1 14 O
aminoglycosides NNS 0 1 13 B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
tobramycin NN 0 1 16 B-Drug
gentamicin NN 0 1 14 B-Drug
and CC 0 0 12 O
amikacin NN 0 1 0 B-Drug
) ) 0 0 2 O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
foscarnet NN 0 1 16 B-Drug
intravenous JJ 0 1 14 O
pentamidine NN 0 1 14 B-Drug
vancomycin NN 0 1 14 B-Drug
and CC 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
] VBP 0 0 2 O
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

propranolol NN 0 1 16 B-Drug
to TO 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
under IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
conditions NNS 1 1 1 O
had VBD 1 0 12 O
no DT 0 0 12 O
relevant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
either CC 0 1 12 O
drug NN 0 1 1 O
bioavailability NN 0 1 UNK O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
differences NNS 1 1 UNK O
were VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
between IN 0 0 12 O
isradipine NN 0 1 13 B-Drug
given VBN 1 1 12 O
singly RB 0 0 3 O
and CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
and CC 0 0 12 O
between IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
given VBN 1 1 12 O
singly RB 0 0 3 O
and CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
isradipine NN 0 1 13 B-Drug
. . 0 0 12 O

Cross NNP 0 1 UNK O
- : 0 0 2 O
reactions NNS 1 1 1 O
with IN 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
Aspergillus CC 0 1 UNK O
polysaccharides NNS 1 1 16 O
and CC 0 0 12 O
polyfuranoses NNS 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
Bio NNP 0 1 UNK O
- : 0 0 2 O
Rad NNP 0 1 13 O
Laboratories NNPS 0 1 2 O
Platelia NNP 0 0 UNK O
Aspergillus NNP 0 1 UNK O
EIA NNP 0 1 13 O
test NN 0 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
since IN 0 1 12 O
aspirin NN 0 1 14 B-Brand
NSAIDs NNP 0 1 UNK B-Group
and CC 0 0 12 O
bisphosphonates NNS 0 1 13 B-Group
are VBP 1 0 12 O
all DT 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
irritation NN 0 1 6 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
or CC 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
with IN 0 0 12 O
Ibandronate NNP 0 1 UNK B-Drug
. . 0 0 12 O

**No JJ 0 0 UNK O
significant JJ 0 1 1 O
effect NN 0 1 1 O
. . 0 0 12 O

Monitoring NN 0 1 UNK O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
possible JJ 0 1 1 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
cyclosporine JJ 0 1 14 B-Drug
dosage NN 0 1 0 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
. . 0 0 12 O

Dexamethasone NNP 0 1 0 O
suppression NN 0 1 1 O
test NN 0 1 1 O
( ( 0 0 2 O
DST NNP 0 1 UNK O
) ) 0 0 2 O
: : 0 0 2 O
False JJ 0 1 UNK O
- : 0 0 2 O
negative JJ 0 1 1 O
results NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
dexamethasone NN 0 1 16 O
suppression NN 0 1 1 O
test NN 0 1 1 O
( ( 0 0 2 O
DST NNP 0 1 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
patients NNS 1 1 6 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
indomethacin NNS 0 1 14 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Exert NNP 0 1 UNK O
particular JJ 0 0 1 O
caution NN 0 0 1 O
in IN 0 0 12 O
combining VBG 1 1 UNK O
levomepromazine NN 0 1 UNK B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
and CC 0 0 12 O
antiparkinsonian JJ 0 1 UNK B-Group
- : 0 0 2 O
agents NNS 1 1 1 I-Group
) ) 0 0 2 O
: : 0 0 2 O
Particularly RB 0 0 UNK O
the DT 0 0 12 O
elderly JJ 0 1 12 O
may MD 0 0 1 O
develop VB 0 0 1 O
delirium NN 0 1 6 O
high JJ 0 1 1 O
fever NN 0 1 6 O
severe JJ 0 1 6 O
obstipation NN 0 1 UNK O
even RB 0 0 12 O
ileus JJ 0 1 8 O
and CC 0 0 12 O
glaucoma NN 0 1 6 O
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
combined VBN 1 1 1 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
contemplated VBN 1 0 UNK O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
one CD 0 1 12 O
or CC 0 0 12 O
both DT 0 0 12 O
agents NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

TAMBOCOR NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
a DT 0 0 12 O
large JJ 0 1 3 O
number NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
diuretics NNS 1 1 14 B-Group
without IN 0 0 12 O
apparent JJ 0 1 1 O
interaction NN 0 1 UNK O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
: : 0 0 2 O
Nonclinical NNP 0 0 UNK O
data NNS 0 1 1 O
demonstrate NN 0 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
solubility NN 0 1 UNK O
of IN 0 0 12 O
dasatinib NN 0 1 13 B-Drug
is VBZ 1 0 12 O
pH JJ 0 1 14 O
dependent NN 0 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
reduced JJ 0 1 1 O
Clozapine NNP 0 1 0 B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
the DT 0 0 12 O
frequent JJ 0 1 1 O
occurrence NN 0 1 1 O
of IN 0 0 12 O
severe JJ 0 1 6 O
and CC 0 0 12 O
prolonged JJ 0 1 6 O
thrombocytopenia NN 0 1 14 O
the DT 0 0 12 O
potential JJ 0 1 1 O
benefits NNS 1 1 1 O
of IN 0 0 12 O
medications NNS 1 1 6 O
which WDT 0 0 12 O
interfere VBP 0 1 UNK O
with IN 0 0 12 O
platelet NN 0 1 14 O
function NN 0 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
anticoagulation NN 0 1 14 O
should MD 0 0 12 O
be VB 0 0 12 O
weighed VBN 1 0 12 O
against IN 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
increased JJ 0 1 1 O
risks NNS 1 1 1 O
of IN 0 0 12 O
bleeding NN 0 1 6 O
and CC 0 0 12 O
hemorrhage NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
absorption NN 0 1 1 O
of IN 0 0 12 O
tetracycline JJ 0 1 0 B-Drug
furosemide JJ 0 1 0 B-Drug
penicillin NN 0 1 14 B-Drug
G NNP 0 1 2 I-Drug
hydrochlorothiazide NN 0 1 0 B-Drug
and CC 0 0 12 O
gemfibrozil NN 0 1 16 B-Drug
was VBD 1 0 12 O
significantly RB 0 0 1 O
decreased VBN 1 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
simultaneously RB 0 1 13 O
with IN 0 0 12 O
colestipol JJ 0 1 13 B-Drug
hydrochloride NN 0 1 0 I-Drug
; : 0 0 2 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
ETOPOPHOS NNP 0 1 UNK B-Brand
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
phosphatase JJ 0 1 14 O
activities NNS 1 1 1 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
levamisole NN 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
) ) 0 0 2 O
. . 0 0 12 O

A DT 0 0 2 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
glucose NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
may MD 0 0 1 O
occur VB 0 1 1 O
with IN 0 0 12 O
copper NN 0 1 3 O
reduction NN 0 1 1 O
tests NNS 1 1 1 O
( ( 0 0 2 O
Benedicts NNPS 0 0 UNK O
or CC 0 0 12 O
Fehlings NNPS 0 0 UNK O
solution NN 0 1 1 O
or CC 0 0 12 O
with IN 0 0 12 O
CLINITEST NNP 0 1 UNK O
tablets NNS 1 1 3 O
) ) 0 0 2 O
but CC 0 0 12 O
not RB 0 1 12 O
with IN 0 0 12 O
enzyme SYM 0 1 14 O
- : 0 0 2 O
based VBN 1 1 1 O
tests NNS 1 1 1 O
for IN 0 0 12 O
glycosuria NN 0 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
CLINISTIX NNP 0 0 UNK O
TES NNP 0 1 UNK O
- : 0 0 2 O
TAPE NN 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

An DT 0 0 2 O
initial JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
concomitantly RB 0 0 14 O
being VBG 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

Caution NN 0 0 UNK O
however RB 0 0 12 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
which WDT 0 0 12 O
can MD 0 0 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
uptake NN 0 1 14 O
of IN 0 0 12 O
circulating VBG 1 1 13 O
amines NNS 1 1 13 O
. . 0 0 12 O

Pretreatment NN 0 1 UNK O
and CC 0 0 12 O
follow VB 0 1 12 O
- : 0 0 2 O
up IN 0 0 12 O
measurements NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
obtained VBN 1 1 1 O
under IN 0 0 12 O
fasting VBG 1 1 6 O
conditions NNS 1 1 1 O
. . 0 0 12 O

Phenobarbital NN 0 1 0 B-Drug
: : 0 0 2 O
Estimates NNS 0 1 UNK O
of IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
for IN 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
or CC 0 0 12 O
gabapentin NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
TID NNP 0 1 15 O
; : 0 0 2 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
with IN 0 0 12 O
doses NNS 1 1 6 O
higher JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
valdecoxib NN 0 1 13 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
9 CD 0 0 2 O
mg JJ 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
DIABINESE NNP 0 1 UNK B-Brand
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
observed VBN 1 1 1 O
for IN 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
control NN 0 1 1 O
. . 0 0 12 O

Potassium NNP 0 1 14 B-Group
- : 0 0 2 O
sparing VBG 1 0 6 I-Group
diuretics NNS 1 1 14 I-Group
( ( 0 0 2 O
spironolactone NN 0 1 0 B-Drug
amiloride RB 0 1 16 B-Drug
triamterene NN 0 1 13 B-Drug
and CC 0 0 12 O
others NNS 0 1 12 O
) ) 0 0 2 O
or CC 0 0 12 O
potassium JJ 0 1 14 B-Drug
supplements NNS 1 1 6 O
can MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
hyperkalemia NN 0 1 14 O
. . 0 0 12 O

clarithromycin NN 0 1 13 B-Drug
concentration NN 0 1 1 O
indinavir NN 0 1 16 B-Drug
concentration NN 0 1 1 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
thioridazine NN 0 1 13 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
worsen VB 0 1 6 O
the DT 0 0 12 O
tremor NN 0 1 6 O
in IN 0 0 12 O
elderly JJ 0 1 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
Parkinsons NNP 0 1 7 O
disease NN 0 1 6 O
; : 0 0 2 O

Labetalol NNP 0 1 0 B-Drug
HCl NNP 0 0 14 I-Drug
has VBZ 1 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
produce VB 0 0 1 O
a DT 0 0 12 O
false JJ 0 1 13 O
positive JJ 0 1 1 O
test NN 0 1 1 O
for IN 0 0 12 O
amphetamine NN 0 1 13 B-Drug
when WRB 0 0 12 O
screening VBG 1 1 1 O
urine NN 0 1 6 O
for IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
using VBG 1 1 1 O
the DT 0 0 12 O
commercially RB 0 0 UNK O
available JJ 0 1 1 O
assay VBP 0 1 14 O
methods NNS 1 1 1 O
Toxi NNP 0 1 UNK O
- : 0 0 2 O
Lab VBZ 0 1 2 O
A NNP 0 0 2 O
( ( 0 0 2 O
thin JJ 0 1 3 O
- : 0 0 2 O
layer NN 0 1 3 O
chromatographic JJ 0 1 UNK O
assay NN 0 1 14 O
) ) 0 0 2 O
and CC 0 0 12 O
Emit NNP 0 1 UNK O
- : 0 0 2 O
d.a.u NN 0 1 UNK O
. . 0 0 12 O
( ( 0 0 2 O
radioenzymatic JJ 0 0 UNK O
assay NN 0 1 14 O
) ) 0 0 2 O
. . 0 0 12 O

Verapamil NNP 0 1 0 B-Drug
produced VBD 1 0 1 O
a DT 0 0 12 O
decrease NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
[ JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
MHD NNP 0 0 UNK B-Drug_n
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
if IN 0 0 12 O
REGRANEX NNP 0 1 UNK B-Brand
Gel NNP 0 1 2 O
interacts NNS 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
topical JJ 0 1 6 O
medications NNS 1 1 6 O
applied VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
ulcer JJ 0 1 6 O
site NN 0 1 12 O
. . 0 0 12 O

Because IN 0 0 12 O
the DT 0 0 12 O
small JJ 0 1 12 O
magnitude NN 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
direction NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
clearance NN 0 1 16 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
clinical JJ 0 1 6 O
concern NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
following JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
undergoing JJ 0 0 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
oral JJ 0 1 6 O
allopurinol NN 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
intravenously RB 0 0 14 O
or CC 0 0 12 O
orally RB 0 1 14 O
administered VBN 1 1 1 O
methylxanthines NNS 0 1 UNK B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
aminophylline VBP 0 1 13 B-Drug
theophylline NN 0 1 16 B-Drug
) ) 0 0 2 O
by IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
BROVANA NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
completely RB 0 1 12 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Plasma NNP 0 1 UNK O
valproate NN 0 1 16 B-Drug
concentration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
when WRB 0 0 12 O
isoniazid NN 0 1 13 B-Drug
and CC 0 0 12 O
valproate NN 0 1 16 B-Drug
are VBP 1 0 12 O
co VBN 0 1 12 O
administered JJ 0 1 1 O
and CC 0 0 12 O
appropriate JJ 0 1 1 O
dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
of IN 0 0 12 O
valproate NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
made VBN 1 1 12 O
. . 0 0 12 O

Aprepitant NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
a DT 0 0 12 O
moderate JJ 0 1 1 O
inhibitor NN 0 1 14 O
and CC 0 0 12 O
an DT 0 0 12 O
inducer NN 0 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Steroids NNS 0 1 7 B-Group
enhance VBP 0 1 UNK O
the DT 0 0 12 O
renal JJ 0 1 6 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
edetate JJ 0 1 UNK B-Drug
calcium NN 0 1 14 I-Drug
disodium NN 0 0 13 I-Drug
in IN 0 0 12 O
animals NNS 1 1 12 O
. . 0 0 12 O
9 CD 0 0 2 O
Edetate NNP 0 1 UNK B-Drug
calcium NN 0 1 14 I-Drug
disodium NN 0 0 13 I-Drug
interferes VBZ 1 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
zinc NN 0 1 14 B-Drug
insulin NN 0 1 14 I-Drug
preparations NNS 1 1 13 O
by IN 0 0 12 O
chelating VBG 1 1 13 O
the DT 0 0 12 O
zinc NN 0 1 14 B-Drug
. . 0 0 12 O
9 CD 0 0 2 O

When WRB 0 0 12 O
methyldopa NN 0 1 13 B-Drug
is VBZ 1 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
potentiation NN 0 1 UNK O
of IN 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
on IN 0 0 12 O
Exjade NNP 0 1 UNK B-Brand
pharmacokinetics NNS 0 1 UNK O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Avoid NNP 0 0 2 O
saw VBD 0 1 12 O
palmetto JJ 0 0 UNK O
red JJ 0 1 3 O
clover NN 0 1 UNK O
ginseng NN 0 1 14 O
. . 0 0 12 O

Thalidomide NN 0 1 UNK B-Drug
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
with IN 0 0 12 O
thalidomide NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
employed VBN 1 1 1 O
cautiously RB 0 0 UNK O
as IN 1 0 12 O
toxic JJ 0 1 1 O
epidermal JJ 0 1 13 O
necrolysis NN 0 0 13 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
. . 0 0 12 O

one CD 0 1 12 O
patient NN 0 1 6 O
died VBD 1 1 12 O
with IN 0 0 12 O
severe JJ 0 1 6 O
hypocalcemia NN 0 1 8 O
. . 0 0 12 O

Prothrombin NNP 0 1 7 O
time NN 0 1 12 O
was VBD 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
which WDT 0 0 12 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Interaction NN 0 1 2 O
with IN 0 0 12 O
Other JJ 0 0 2 O
Central NNP 0 1 2 B-Group
Nervous NNP 0 1 UNK I-Group
System NNP 0 1 2 I-Group
Depressants VBZ 0 0 UNK I-Group
: : 0 0 2 O
MEPERIDINE NNP 0 1 UNK B-Drug
SHOULD NNP 0 0 UNK O
BE NNP 0 0 11 O
USED NNP 0 1 11 O
WITH NNP 0 0 11 O
GREAT NNP 0 1 UNK O
CAUTION NNP 0 0 UNK O
AND NNP 0 0 11 O
IN NNP 0 0 11 O
REDUCED NNP 0 1 UNK O
DOSAGE NNP 0 1 UNK O
IN NNP 0 0 11 O
PATIENTS NNP 0 1 UNK O
WHO WP 0 0 11 O
ARE VBP 0 0 UNK O
CONCURRENTLY NNP 0 0 UNK O
RECEIVING NNP 0 1 UNK O
OTHER NNP 0 0 11 O
NARCOTIC NNP 0 1 UNK B-Group
ANALGESICS NNP 0 1 UNK I-Group
GENERAL NNP 0 1 11 O
ANESTHETICS NNP 0 1 UNK B-Group
PHENOTHIAZINES NNP 0 1 UNK B-Group
OTHER NNP 0 0 11 O
TRANQUILIZERS NNP 0 1 UNK B-Group
SEDATIVE NNP 0 1 UNK B-Group
- : 0 0 2 O
HYPNOTICS NNP 0 1 UNK I-Group
( ( 0 0 2 O
INCLUDING NNP 0 1 11 O
BARBITURATES NNP 0 1 UNK B-Group
) ) 0 0 2 O
TRICYCLIC NNP 0 0 UNK B-Group
ANTIDEPRESSANTS NNP 0 1 UNK I-Group
AND NNP 0 0 11 O
OTHER NNP 0 0 11 O
CNS NNP 0 1 6 B-Group
DEPRESSANTS NNP 0 0 UNK I-Group
( ( 0 0 2 O
INCLUDING NNP 0 1 11 O
ALCOHOL NNP 0 1 11 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Reduced VBN 0 1 UNK O
response NN 0 1 1 O
to TO 0 0 12 O
metyrapone VB 0 1 13 O
test NN 0 1 1 O
. . 0 0 12 O

Methscopolamine NNP 0 1 UNK B-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
antidepressants NNS 1 1 13 B-Group
( ( 0 0 2 O
tricyclic JJ 0 0 14 B-Group
type NN 0 1 1 O
) ) 0 0 2 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
phenelzine NN 0 1 16 B-Drug
linezolid JJ 0 1 0 B-Drug
tranylcypromine NN 0 1 13 B-Drug
isocarboxazid NN 0 1 UNK B-Drug
selegiline VB 0 1 13 B-Drug
furazolidone NN 0 1 UNK B-Drug
) ) 0 0 2 O
quinidine NN 0 1 16 B-Drug
amantadine NN 0 1 16 B-Drug
antihistamines NNS 1 1 UNK B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
diphenhydramine NN 0 1 16 B-Drug
) ) 0 0 2 O
other JJ 0 0 12 O
anticholinergics NNS 1 1 13 B-Group
potassium JJ 0 1 14 B-Drug
chloride JJ 0 1 14 I-Drug
supplements NNS 1 1 6 O
antacids NNS 1 1 14 B-Group
absorbent JJ 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
diarrhea NN 0 1 6 I-Group
medicines NNS 1 1 6 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
kaolin SYM 0 1 13 B-Drug
- : 0 0 2 O
pectin NN 0 1 13 B-Drug
) ) 0 0 2 O
phenothiazines NNS 1 1 UNK B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
chlorpromazine NN 0 1 16 B-Drug
promethazine NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
elevation NN 0 1 1 O
of IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
induced VBN 1 1 6 O
by IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
Exelon NNP 0 1 UNK B-Brand
. . 0 0 12 O

. . 0 0 12 O

An DT 0 0 2 O
interval NN 0 1 1 O
of IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
two CD 0 1 12 O
hours NNS 1 1 12 O
between IN 0 0 12 O
intake NN 0 1 3 O
of IN 0 0 12 O
this DT 0 0 12 O
agent NN 0 1 1 O
and CC 0 0 12 O
chloroquine NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
gabapentin NN 0 1 0 B-Drug
on IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

*Increased VBN 0 1 UNK O
and CC 0 0 12 O
decreased VBN 1 1 1 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
responses NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Marked VBN 0 1 2 O
symptomatic JJ 0 1 6 O
orthostatic JJ 0 1 8 O
hypotension NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
when WRB 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
and CC 0 0 12 O
organic JJ 0 1 13 B-Group
nitrates NNS 1 1 14 I-Group
were VBD 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

Tissue NN 0 1 7 O
culture NN 0 1 1 O
and CC 0 0 12 O
animal NN 0 1 13 O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
ELSPAR NNP 0 1 UNK B-Brand
can MD 0 0 12 O
diminish VB 0 1 UNK O
or CC 0 0 12 O
abolish VB 0 0 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
on IN 0 0 12 O
malignant JJ 0 1 6 O
cells.9 NN 0 1 UNK O
This DT 0 0 2 O
effect NN 0 1 1 O
on IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
activity NN 0 1 1 O
persists VBZ 1 0 1 O
as RB 0 0 12 O
long RB 0 1 12 O
as IN 1 0 12 O
plasma JJ 0 1 14 O
asparagine NN 0 1 UNK O
levels NNS 1 1 1 O
are VBP 1 0 12 O
suppressed VBN 1 1 1 O
. . 0 0 12 O

Such JJ 0 0 1 O
interactions NNS 1 1 UNK O
might MD 0 0 12 O
be VB 0 0 12 O
manifested VBN 1 1 UNK O
by IN 0 0 12 O
increased JJ 0 1 1 O
susceptibility NN 0 1 6 O
to TO 0 0 12 O
bruising VBG 1 1 6 O
nosebleeds NNS 1 1 UNK O
hemoptysis NN 0 1 8 O
hematemesis NN 0 1 8 O
hematuria NN 0 1 8 O
and CC 0 0 12 O
blood NN 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
stool NN 0 1 3 O
. . 0 0 12 O

in IN 0 0 12 O
9 CD 0 0 2 O
out IN 0 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
methadone JJ 0 1 6 B-Drug
AUC NNP 0 1 UNK O
doubled VBD 1 1 12 O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
with IN 0 0 12 O
carbamazepine JJ 0 1 16 B-Drug
cyclosporine NN 0 1 14 B-Drug
tacrolimus NN 0 1 16 B-Drug
hexobarbital JJ 0 1 UNK B-Drug
phenytoin NN 0 1 16 B-Drug
alfentanil NN 0 1 UNK B-Drug
cisapride NN 0 1 UNK B-Drug
disopyramide IN 0 1 16 B-Drug
lovastatin JJ 0 1 13 B-Drug
bromocriptine NN 0 1 16 B-Drug
valproate NN 0 1 16 B-Drug
terfenadine NN 0 1 UNK B-Drug
and CC 0 0 12 O
astemizole NN 0 1 UNK B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
if IN 0 0 12 O
the DT 0 0 12 O
desired VBN 1 1 1 O
diuretic JJ 0 1 14 O
and CC 0 0 12 O
/ JJ 0 0 2 O
or CC 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
is VBZ 1 0 12 O
achieved VBN 1 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
ethanol NNS 0 1 1 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
multiple JJ 0 1 1 O
- : 0 0 2 O
dose JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
also RB 0 0 12 O
be VB 0 0 12 O
applied VBN 1 1 1 O
for IN 0 0 12 O
other JJ 0 0 12 O
sympathomimetics NNS 0 1 13 B-Group
and CC 0 0 12 O
for IN 0 0 12 O
aminophylline NN 0 1 13 B-Drug
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
and CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
which WDT 0 0 12 O
may MD 0 0 1 O
also RB 0 0 12 O
precipitate VB 0 1 13 O
arrhythmias NNS 1 1 6 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
increase VB 0 1 1 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
pseudoephedrine NN 0 1 16 B-Drug
while IN 0 0 12 O
kaolin NN 0 1 13 B-Drug
decreases VBZ 1 1 UNK O
it PRP 0 0 12 O
. . 0 0 12 O

If IN 0 0 12 O
possible JJ 0 1 1 O
anticholinesterase NN 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
withdrawn VBN 1 1 1 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
initiating VBG 1 1 1 O
corticosteroid JJ 0 1 UNK B-Group
therapy NN 0 1 6 O
. . 0 0 12 O

Fluconazole NNP 0 1 0 B-Drug
and CC 0 0 12 O
Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Ketoconazole NNP 0 1 UNK B-Drug
and CC 0 0 12 O
fluconazole NN 0 1 0 B-Drug
are VBP 1 0 12 O
predominantly RB 0 0 1 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
and CC 0 0 12 O
9C9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
respectively RB 0 0 1 O
. . 0 0 12 O

Potentiation NN 0 1 UNK O
occurs VBZ 1 1 1 O
with IN 0 0 12 O
ganglionic JJ 0 1 UNK B-Group
peripheral JJ 0 1 6 I-Group
adrenergic NN 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

( ( 0 0 2 O
Concurrent NNP 0 1 13 O
use NN 0 1 1 O
with IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
as IN 1 0 12 O
they PRP 0 0 12 O
may MD 0 0 1 O
provoke VB 0 0 UNK O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
because IN 0 0 12 O
of IN 0 0 12 O
reduced JJ 0 1 1 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
. . 0 0 12 O
) ) 0 0 2 O

Care NN 0 1 2 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
if IN 0 0 12 O
labetalol NN 0 1 0 B-Drug
is VBZ 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
calcium NN 0 1 14 B-Group
antagonists NNS 1 1 13 I-Group
of IN 0 0 12 O
the DT 0 0 12 O
verapamil NN 0 1 0 B-Drug
type NN 0 1 1 O
. . 0 0 12 O

thyroid JJ 0 1 6 O
function NN 0 1 1 O
and CC 0 0 12 O
basal NN 0 1 6 O
metabolism NN 0 1 16 O
are VBP 1 0 12 O
unaffected VBN 0 1 UNK O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
and CC 0 0 12 O
verapamil NN 0 1 0 B-Drug
use NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
rarely RB 0 1 UNK O
associated VBN 1 1 1 O
with IN 0 0 12 O
ventricular JJ 0 1 8 O
fibrillation NN 0 1 6 O
when WRB 0 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
Adenocard NNP 0 1 UNK B-Brand
. . 0 0 12 O

Additive JJ 0 1 UNK O
depressant NN 0 0 UNK O
effect NN 0 1 1 O
when WRB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
sedatives NNS 1 1 6 B-Group
antianxiety VBP 0 0 0 B-Group
drugs NNS 1 1 6 I-Group
hypnotics NNS 1 1 13 B-Group
alcohol NN 0 1 1 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
opiate NN 0 1 6 B-Group
analgesics NNS 1 1 14 I-Group
. . 0 0 12 O

In IN 0 0 2 O
adjuvant JJ 0 1 14 O
trials NNS 1 1 1 O
of IN 0 0 12 O
epirubicin JJ 0 1 13 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
CEF NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
or CC 0 0 12 O
FEC NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
chemotherapies NNS 1 1 UNK O
breast IN 0 1 6 O
irradiation NN 0 1 14 O
was VBD 1 0 12 O
delayed VBN 1 1 1 O
until IN 0 0 12 O
after IN 0 0 12 O
chemotherapy NN 0 1 6 O
was VBD 1 0 12 O
completed VBN 1 1 12 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Although IN 0 0 12 O
not RB 0 1 12 O
studied VBN 1 0 1 O
with IN 0 0 12 O
alosetron JJ 0 1 UNK B-Drug
inhibition NN 0 1 13 O
of IN 0 0 12 O
N NNP 0 1 2 O
- : 0 0 2 O
acetyltransferase NN 0 1 UNK O
may MD 0 0 1 O
have VB 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
consequences NNS 1 1 UNK O
for IN 0 0 12 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
isoniazid JJ 0 1 13 B-Drug
procainamide NN 0 1 16 B-Drug
and CC 0 0 12 O
hydralazine NN 0 1 14 B-Drug
. . 0 0 12 O

CANCIDAS NNP 0 1 UNK B-Brand
reduced VBD 1 1 1 O
the DT 0 0 12 O
blood NN 0 1 6 O
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
of IN 0 0 12 O
tacrolimus NN 0 1 16 B-Drug
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
peak JJ 0 1 1 O
blood NN 0 1 6 O
concentration NN 0 1 1 O
( ( 0 0 2 O
Cmax NNP 0 1 UNK O
) ) 0 0 2 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
blood NN 0 1 6 O
concentration NN 0 1 1 O
( ( 0 0 2 O
C9hr NNP 0 0 UNK O
) ) 0 0 2 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
when WRB 0 0 12 O
tacrolimus NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg VBD 0 1 18 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
apart RB 0 0 12 O
) ) 0 0 2 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
9th CD 0 0 13 O
day NN 0 1 12 O
of IN 0 0 12 O
CANCIDAS NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily RB 0 1 12 O
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
results NNS 1 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
control NN 0 1 1 O
period NN 0 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
tacrolimus NN 0 1 16 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
alone RB 0 1 12 O
. . 0 0 12 O

Geriatric NNP 0 1 7 O
Use NNP 0 1 2 O
Of IN 0 0 2 O
the DT 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
received VBD 1 1 12 O
ZETIA NNP 0 1 UNK B-Brand
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
9 CD 0 0 2 O
were VBD 1 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
older JJR 1 1 12 O
( ( 0 0 2 O
this DT 0 0 12 O
included VBD 1 1 1 O
9 CD 0 0 2 O
who WP 0 0 12 O
were VBD 1 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
older JJR 1 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Measurement NN 0 1 UNK O
of IN 0 0 12 O
serum JJ 0 1 14 O
creatinine NN 0 1 14 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
determined VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
Jaffe NNP 0 0 UNK O
reaction NN 0 1 1 O
since IN 0 1 12 O
Ancobon NNP 0 1 UNK B-Brand
does VBZ 1 0 12 O
not RB 0 1 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
determination NN 0 1 13 O
of IN 0 0 12 O
creatinine NN 0 1 14 O
values NNS 1 1 1 O
by IN 0 0 12 O
this DT 0 0 12 O
method NN 0 1 13 O
. . 0 0 12 O

Gentamicin NNP 0 1 0 B-Drug
- : 0 0 2 O
Methionine NN 0 1 UNK B-Drug
may MD 0 0 1 O
protect VB 0 0 1 O
against IN 0 0 12 O
the DT 0 0 12 O
ototoxic JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
gentamicin NN 0 1 14 B-Drug
. . 0 0 12 O

Due NNP 0 1 2 O
to TO 0 0 12 O
high VB 0 1 1 O
inter NN 0 1 13 O
- : 0 0 2 O
patient NN 0 1 6 O
variability NN 0 1 UNK O
and CC 0 0 12 O
limited VBD 1 1 1 O
sampling VBG 1 1 13 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
SN9 NNP 0 0 UNK B-Drug_n
levels NNS 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concurrent JJ 0 1 1 O
irinotecan JJ 0 1 13 B-Drug
and CC 0 0 12 O
AVASTIN NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
uncertain JJ 0 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
diuretics NNS 1 1 14 B-Group
are VBP 1 0 12 O
at IN 0 0 12 O
a DT 0 0 12 O
greater JJR 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
developing VBG 1 0 1 O
renal JJ 0 1 6 O
failure NN 0 1 1 O
secondary JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
renal JJ 0 1 6 O
blood NN 0 1 6 O
flow NN 0 1 1 O
caused VBN 1 1 1 O
by IN 0 0 12 O
prostaglandin JJ 0 1 13 O
inhibition NN 0 1 13 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
to TO 0 0 12 O
assess VB 0 1 1 O
if IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
an DT 0 0 12 O
interactive JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
bone NN 0 1 6 O
loss NN 0 1 1 O
between IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
. . 0 0 12 O

The DT 0 0 2 O
therapeutic JJ 0 1 6 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
compromised VBN 1 0 1 O
in IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
when WRB 0 0 12 O
cimetidine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
discontinued VBN 1 1 1 O
. . 0 0 12 O

Rifabutin NN 0 1 UNK B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
rifabutin NN 0 1 13 B-Drug
and CC 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
nelfinavir JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
rifabutin JJ 0 1 13 B-Drug
plasma NN 0 1 14 O
A.C NNP 0 0 UNK O
. . 0 0 12 O

Intravenous JJ 0 1 7 O
infusion NN 0 1 14 O
of IN 0 0 12 O
iloprost NN 0 1 13 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
of IN 0 0 12 O
schizophrenic JJ 0 0 13 O
patients NNS 1 1 6 O
who WP 0 0 12 O
received VBD 1 1 12 O
clozapine NN 0 1 13 B-Drug
under IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
conditions NNS 1 1 1 O
fluvoxamine VBP 0 1 16 B-Drug
or CC 0 0 12 O
paroxetine NN 0 1 16 B-Drug
was VBD 1 0 12 O
added VBN 1 1 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
respectively RB 0 0 1 O
. . 0 0 12 O

phophatase NN 0 0 UNK O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
Keppra NNP 0 1 0 B-Brand
on IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

This DT 0 0 2 O
allows VBZ 1 1 UNK O
bitolterol NN 0 1 UNK B-Drug
to TO 0 0 12 O
open VB 0 1 12 O
air NN 0 1 3 O
passages NNS 1 1 13 O
increasing VBG 1 1 1 O
the DT 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
steroid NN 0 1 6 B-Group
. . 0 0 12 O

Interations NNS 0 0 UNK O

* NN 0 0 2 O
No NNP 0 0 2 O
longer RB 0 1 12 O
marketed VBD 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
US NNP 0 0 2 O
. . 0 0 12 O

If IN 0 0 12 O
you PRP 0 0 12 O
think VBP 0 1 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
an DT 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitor NN 0 1 14 I-Group
talk NN 0 1 12 O
to TO 0 0 12 O
your PRP$ 0 0 12 O
doctor NN 0 1 12 O
or CC 0 0 12 O
pharmacist NN 0 1 13 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

pentoxifylline NN 0 1 16 B-Drug
; : 0 0 2 O

Expected VBN 0 1 2 O
to TO 0 0 12 O
substantially RB 0 0 1 O
decrease VB 0 1 1 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
efavirenz NN 0 1 13 B-Drug
; : 0 0 2 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
single JJ 0 1 12 O
- : 0 0 2 O
dose NN 0 1 6 O
crossover NN 0 1 UNK O
study NN 0 1 1 O
examining VBG 1 1 UNK O
lansoprazole JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
omeprazole JJ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NNS 0 1 0 O
each DT 0 0 12 O
administered VBN 1 1 1 O
alone RB 0 1 12 O
and CC 0 0 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
sucralfate JJ 0 1 0 B-Drug
9 CD 0 0 2 O
gram JJ 0 1 16 O
absorption NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
proton NN 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
was VBD 1 0 12 O
delayed VBN 1 1 1 O
and CC 0 0 12 O
their PRP$ 0 0 12 O
bioavailability NN 0 1 UNK O
was VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
sucralfate NN 0 1 0 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
Cmin NNP 0 1 UNK O
increased VBD 1 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ VBP 0 0 2 O
mL NN 0 1 14 O
when WRB 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
of IN 0 0 12 O
felbamate NN 0 1 13 B-Drug
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
by IN 0 0 12 O
using VBG 1 1 1 O
the DT 0 0 12 O
lowest JJS 1 1 13 O
dose NN 0 1 6 O
possible JJ 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
substances NNS 1 1 1 O
in IN 0 0 12 O
question NN 0 1 12 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interaction NNP 0 1 2 O
Fosinopril NNP 0 1 UNK B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
a DT 0 0 12 O
false JJ 0 1 13 O
low JJ 0 1 1 O
measurement NN 0 1 1 O
of IN 0 0 12 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
Digi NNP 0 0 UNK O
- : 0 0 2 O
Tab NN 0 1 2 O
RIA NNP 0 1 UNK O
Kit NNP 0 1 UNK O
for IN 0 0 12 O
Digoxin NNP 0 1 0 B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
on IN 0 0 12 O
thyroid JJ 0 1 6 O
replacement NN 0 1 1 O
therapy NN 0 1 6 O
may MD 0 0 1 O
require VB 0 0 1 O
higher JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
thyroid JJ 0 1 6 B-Group
hormone NN 0 1 6 I-Group
. . 0 0 12 O

Dolasetron NNP 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
safely RB 0 0 UNK O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
used VBN 1 1 12 O
in IN 0 0 12 O
chemotherapy NN 0 1 6 O
and CC 0 0 12 O
surgery NN 0 1 6 O
. . 0 0 12 O

Use NNP 0 1 2 O
cautiously RB 0 0 UNK O
with IN 0 0 12 O
pressor NN 0 1 14 O
agents NNS 1 1 1 O
. . 0 0 12 O

Antimyasthenics NNS 0 0 UNK O
Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
procaine NN 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
and CC 0 0 12 O
antimyasthenics NNS 0 0 UNK O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
control NN 0 1 1 O
of IN 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
myasthenia NN 0 1 6 O
gravis NNS 0 1 6 O
due JJ 0 1 1 O
to TO 0 0 12 O
antagonism NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antimyasthenics NNS 0 0 UNK O
on IN 0 0 12 O
skeletal JJ 0 1 13 O
muscle NN 0 1 6 O
. . 0 0 12 O

Naproxen NNP 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
that IN 0 0 12 O
EPA NNP 0 0 UNK B-Drug
supplements NNS 1 1 6 O
have VBP 0 0 12 O
detrimental JJ 0 0 UNK O
effects NNS 1 1 1 O
on IN 0 0 12 O
glucose JJ 0 1 14 O
tolerance NN 0 1 1 O
insulin NN 0 1 14 O
secretion NN 0 1 14 O
or CC 0 0 12 O
insulin NN 0 1 14 O
resistance NN 0 1 1 O
in IN 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
diabetic JJ 0 1 6 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

Laboratory NN 0 1 2 O
Tests NNS 0 1 UNK O
Because IN 0 0 12 O
serious JJ 0 1 12 O
GI NNP 0 1 6 O
tract NN 0 1 6 O
ulceration NN 0 1 8 O
and CC 0 0 12 O
bleeding NN 0 1 6 O
can MD 0 0 12 O
occur VB 0 1 1 O
without IN 0 0 12 O
warning VBG 1 1 12 O
symptoms NNS 1 1 6 O
physicians NNS 1 1 6 O
should MD 0 0 12 O
follow VB 0 1 12 O
chronically RB 0 0 6 O
treated JJ 0 1 1 O
patients NNS 1 1 6 O
for IN 0 0 12 O
the DT 0 0 12 O
signs NNS 1 1 12 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
ulceration NN 0 1 8 O
and CC 0 0 12 O
bleeding NN 0 1 6 O
and CC 0 0 12 O
should MD 0 0 12 O
inform VB 0 1 UNK O
them PRP 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
importance NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
follow NN 0 1 12 O
- : 0 0 2 O
up RB 0 0 12 O
. . 0 0 12 O

Therefore RB 0 0 1 O
a DT 0 0 12 O
starting JJ 0 1 12 O
daily JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
VIOXX NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
osteoarthritis NN 0 1 6 O
when WRB 0 0 12 O
VIOXX NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
potent JJ 0 1 UNK O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
. . 0 0 12 O

These DT 0 0 1 O
drugs NNS 1 1 6 O
include VBP 0 1 1 O
the DT 0 0 12 O
thiazides NNS 1 1 UNK B-Group
and CC 0 0 12 O
other JJ 0 0 12 O
diuretics NNS 1 1 14 B-Group
corticosteroids NNS 1 1 14 B-Group
phe VBP 0 1 UNK O
- : 0 0 2 O
nothiazines NNS 0 0 UNK O
thyroid JJ 0 1 6 B-Group
products NNS 1 1 1 I-Group
estrogens VBZ 0 1 16 B-Group
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
phenytoin VBP 0 1 16 B-Drug
nicotinic JJ 0 1 13 B-Drug
acid NN 0 1 14 I-Drug
sympathomimet VBD 0 0 UNK O
- : 0 0 2 O
ics NNS 1 1 13 O
calcium JJ 0 1 14 B-Group
channel NNS 0 1 1 I-Group
blocking VBG 1 1 UNK I-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
isoniazid NN 0 1 13 B-Drug
. . 0 0 12 O

TABLE NN 0 1 UNK O
9 CD 0 0 2 O
Effects NNS 0 1 UNK O
on IN 0 0 12 O
Plasma NNP 0 1 UNK O
Concentrations NNP 0 1 UNK O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hrs NN 1 0 16 O
) ) 0 0 2 O
of IN 0 0 12 O
Loratadine NNP 0 1 UNK B-Drug
and CC 0 0 12 O
Descarboethoxyloratadine NNP 0 1 UNK B-Drug
After IN 0 0 2 O
9 CD 0 0 2 O
Days NNS 0 1 2 O
of IN 0 0 12 O
Coadministration NNP 0 1 UNK O
( ( 0 0 2 O
Loratadine NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
in IN 0 0 12 O
Normal NNP 0 1 2 O
Volunteers NNS 0 1 UNK O

When WRB 0 0 12 O
daily JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
sulfasalazine NN 0 1 0 B-Drug
9 CD 0 0 2 O
g NN 0 1 16 O
and CC 0 0 12 O
weekly JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
were VBD 1 0 12 O
coadministered VBN 0 0 UNK O
to TO 0 0 12 O
9 CD 0 0 2 O
rheumatoid NNS 0 0 6 O
arthritis NN 0 1 6 O
patients NNS 1 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study VBD 0 1 1 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
disposition NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
was VBD 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
. . 0 0 12 O

Phenytoin NNP 0 1 0 B-Drug
decreases VBZ 1 1 UNK O
serum VBP 0 1 14 O
amiodarone NN 0 1 0 O
levels NNS 1 1 1 O
. . 0 0 12 O

Ethosuximide NN 0 1 UNK B-Drug
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
delay VB 0 1 1 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
ethosuximide NN 0 1 13 B-Drug
. . 0 0 12 O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
with IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
GI NNP 0 1 6 O
ulceration NN 0 1 8 O
and CC 0 0 12 O
complications NNS 1 1 6 O
compared VBN 1 1 1 O
to TO 0 0 12 O
valdecoxib VB 0 1 13 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

. . 0 0 12 O

Paroxetine NN 0 1 0 B-Drug
produced VBN 1 0 1 O
only RB 0 1 12 O
minor JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
levels NNS 1 1 1 O
of IN 0 0 12 O
clozapine NN 0 1 13 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
SULAR NNP 0 1 UNK B-Brand
tablets NNS 1 1 3 O
in IN 0 0 12 O
epileptic JJ 0 1 13 O
patients NNS 1 1 6 O
lowered VBD 1 1 3 O
the DT 0 0 12 O
nisoldipine JJ 0 1 13 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
to TO 0 0 12 O
undetectable JJ 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

While IN 0 0 12 O
only RB 0 1 12 O
a DT 0 0 12 O
limited JJ 0 1 1 O
number NN 0 1 1 O
of IN 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
chiefly NN 0 0 13 O
with IN 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
formulation NN 0 1 13 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
other JJ 0 0 12 O
interactions NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
anticipated VBN 1 1 1 O
. . 0 0 12 O

Methyldopa NNP 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
measurement NN 0 1 1 O
of IN 0 0 12 O
VMA NNP 0 1 13 B-Drug_n
( ( 0 0 2 O
vanillylmandelic JJ 0 0 UNK B-Drug_n
acid NN 0 1 14 I-Drug_n
) ) 0 0 2 O
a DT 0 0 12 O
test NN 0 1 1 O
for IN 0 0 12 O
pheochromocytoma NN 0 1 UNK O
by IN 0 0 12 O
those DT 0 0 12 O
methods NNS 1 1 1 O
which WDT 0 0 12 O
convert VBP 0 0 1 O
VMA NNP 0 1 13 B-Drug_n
to TO 0 0 12 O
vanillin VB 0 1 UNK B-Drug_n
. . 0 0 12 O

Anastrozole NNP 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
or CC 0 0 12 O
the DT 0 0 12 O
polymorphic JJ 0 1 13 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
in IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomes NNS 1 1 UNK O
. . 0 0 12 O

. . 0 0 12 O

Antidiabetic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
oral JJ 0 1 6 O
agents NNS 1 1 1 O
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
) ) 0 0 2 O
diminished VBD 1 1 1 O
antidiabetic JJ 0 1 13 O
effect NN 0 1 1 O
. . 0 0 12 O

Gastrointestinal JJ 0 1 7 O
: : 0 0 2 O
Nausea NN 0 1 7 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
constipation NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
; : 0 0 2 O

when WRB 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
were VBD 1 0 12 O
administered VBN 1 1 1 O
together RB 0 1 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
were VBD 1 0 12 O
additive JJ 0 1 16 O
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
the DT 0 0 12 O
chemical NN 0 1 13 O
similarity NN 0 1 UNK O
of IN 0 0 12 O
other JJ 0 0 12 O
azole JJ 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
antifungal JJ 0 1 14 I-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
including VBG 1 1 1 O
fluconazole JJ 0 1 0 B-Drug
metronidazole NN 0 1 0 B-Drug
and CC 0 0 12 O
miconazole NN 0 1 16 B-Drug
) ) 0 0 2 O
to TO 0 0 12 O
ketoconazole VB 0 1 16 B-Drug
and CC 0 0 12 O
itraconazole VB 0 1 0 B-Drug
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
products NNS 1 1 1 O
with IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended JJ 0 1 1 O
pending VBG 0 0 1 O
full JJ 0 1 12 O
examination NN 0 0 1 O
of IN 0 0 12 O
potential JJ 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
. . 0 0 12 O

This DT 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
CLINITEST NNP 0 1 UNK O
reagent NN 0 1 14 O
tablets NNS 1 1 3 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
single JJ 0 1 12 O
oral JJ 0 1 6 O
doses NNS 1 1 6 O
of IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
with IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
respectively RB 0 0 1 O
) ) 0 0 2 O
a DT 0 0 12 O
strong JJ 0 1 12 O
selective JJ 0 1 13 O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
produced VBD 1 0 1 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
zaleplons NNS 0 0 UNK B-Drug
maximal JJ 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
- : 0 0 2 O
time NN 0 1 12 O
curve NN 0 1 13 O
. . 0 0 12 O

Exposure NN 0 1 2 O
from IN 0 0 12 O
the DT 0 0 12 O
proposed VBN 1 1 UNK O
topical NN 0 1 6 O
dose NN 0 1 6 O
is VBZ 1 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
that DT 0 0 12 O
from IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
even RB 0 0 12 O
when WRB 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
TMP NNP 0 0 UNK B-Drug
/ NNP 0 0 2 O
SMX NNP 0 1 UNK B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
such JJ 0 0 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
dorzolamide NN 0 1 16 B-Drug
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
bosentan NNS 0 1 13 B-Drug
decreased VBD 1 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

In IN 0 0 2 O
vivo JJ 0 1 13 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
that IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
do VBP 0 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
PK NNP 0 0 UNK O
properties NNS 1 1 UNK O
of IN 0 0 12 O
anagrelide JJ 0 1 13 B-Drug
nor CC 0 0 12 O
does VBZ 1 0 12 O
anagrelide VB 0 1 13 B-Drug
affect VB 0 1 1 O
the DT 0 0 12 O
PK NNP 0 0 UNK O
properties NNS 1 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
or CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Inducers NNS 0 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O

Blood NNP 0 1 2 O
glucose JJ 0 1 14 O
concentrations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
when WRB 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
and CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
are VBP 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Quinidine NN 0 1 0 B-Drug
and CC 0 0 12 O
procainamide NN 0 1 16 O
doses NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
one CD 0 1 12 O
- : 0 0 2 O
third NN 0 1 12 O
when WRB 0 0 12 O
either DT 0 1 12 O
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
amount NN 0 1 1 O
of IN 0 0 12 O
metformin NN 0 1 0 B-Drug
absorbed VBN 1 0 3 O
while IN 0 0 12 O
taking VBG 1 0 12 O
Acarbose NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
bioequivalent NN 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
amount NN 0 1 1 O
absorbed VBD 1 0 3 O
when WRB 0 0 12 O
taking VBG 1 0 12 O
placebo NN 0 1 13 O
as IN 1 0 12 O
indicated VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
AUC NNP 0 1 UNK O
values NNS 1 1 1 O
. . 0 0 12 O

SYMLIN NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
delay VB 0 1 1 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
oral JJ 0 1 6 O
medications NNS 1 1 6 O
. . 0 0 12 O

Permanent NNP 0 1 2 O
nerve NN 0 1 6 O
damage NN 0 1 1 O
could MD 0 0 12 O
theoretically RB 0 0 UNK O
occur VB 0 1 1 O
if IN 0 0 12 O
vitamin JJ 0 1 6 O
B9 NNP 0 0 UNK O
deficiency NN 0 1 6 O
is VBZ 1 0 12 O
not RB 0 1 12 O
treated VBN 1 1 1 O
. . 0 0 12 O

Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
b SYM 0 0 16 B-Group
- : 0 0 2 O
lactam NN 0 1 UNK I-Group
antibiotics NNS 1 1 6 I-Group
renal JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
loracarbef NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
and CC 0 0 12 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
approximate JJ 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
for IN 0 0 12 O
loracarbef NN 0 1 UNK B-Drug
. . 0 0 12 O

May NNP 0 1 2 O
interact NN 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
these DT 0 0 12 O
medicines NNS 1 1 6 O
may MD 0 0 1 O
make VB 0 1 12 O
your PRP$ 0 0 12 O
condition NN 0 1 1 O
worse NN 0 1 12 O
and CC 0 0 12 O
prevent VB 0 1 1 O
the DT 0 0 12 O
adrenergic JJ 0 1 UNK B-Group
bronchodilators NNS 1 1 14 I-Group
from IN 0 0 12 O
working VBG 1 1 12 O
properly RB 0 0 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
disopyramide JJ 0 1 16 B-Drug
quinidine NN 0 1 16 B-Drug
phenothiazines NNS 1 1 UNK B-Group
and CC 0 0 12 O
procainamide NN 0 1 16 B-Drug
( ( 0 0 2 O
these DT 0 0 12 O
medicines NNS 1 1 6 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
heart NN 0 1 12 O
problems NNS 1 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

sulfonamides NNS 1 1 13 B-Group
long JJ 0 1 12 O
acting NN 0 1 12 O
; : 0 0 2 O

Antacid NNP 0 1 UNK B-Group
( ( 0 0 2 O
Maalox NNP 0 1 0 B-Brand
) ) 0 0 2 O
: : 0 0 2 O
Maalox NN 0 1 0 B-Brand
reduced VBD 1 1 1 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
gabapentin NN 0 1 0 B-Drug
( ( 0 0 2 O
N=9 NNP 0 1 UNK O
) ) 0 0 2 O
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
this DT 0 0 12 O
isoenzyme JJ 0 1 13 O
including VBG 1 1 1 O
many JJ 0 0 12 O
antidepressants NNS 1 1 13 B-Group
( ( 0 0 2 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
selective JJ 0 1 13 B-Group
serotonin NNS 0 1 13 I-Group
reuptake VBP 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
others NNS 0 1 12 O
) ) 0 0 2 O
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
isoenzyme NN 0 1 13 O
and CC 0 0 12 O
thus RB 0 0 1 O
may MD 0 0 1 O
make VB 0 1 12 O
normal JJ 0 1 1 O
metab SYM 0 0 13 O
- : 0 0 2 O
olizers NNS 0 0 UNK O
resemble JJ 0 0 UNK O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
with IN 0 0 12 O
regard NN 0 0 1 O
to TO 0 0 12 O
concomitant VB 0 1 6 O
therapy NN 0 1 6 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
this DT 0 0 12 O
enzyme NN 0 1 14 O
system NN 0 1 1 O
leading VBG 1 1 1 O
to TO 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
oxidation NN 0 1 13 O
which WDT 0 0 12 O
is VBZ 1 0 12 O
catalyzed VBN 1 0 UNK O
by IN 0 0 12 O
xanthine JJ 0 1 UNK O
oxidase NN 0 1 13 O
inactivates VBZ 1 0 UNK O
mercaptopurine NN 0 1 13 B-Drug
. . 0 0 12 O

Clonidine NN 0 1 0 B-Drug
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
clonidine NN 0 1 0 B-Drug
with IN 0 0 12 O
agents NNS 1 1 1 B-Group
with IN 0 0 12 I-Group
b SYM 0 0 16 I-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
properties NNS 1 1 UNK I-Group
may MD 0 0 1 O
potentiate VB 0 0 UNK O
blood NN 0 1 6 O
- : 0 0 2 O
pressure NN 0 1 1 O
- : 0 0 2 O
and CC 0 0 12 O
heart NN 0 1 12 O
- : 0 0 2 O
rate NN 0 1 1 O
- : 0 0 2 O
lowering NN 0 1 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

CANCIDAS NNP 0 1 UNK B-Brand
did VBD 1 0 12 O
not RB 0 1 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
. . 0 0 12 O

antibiotics NNS 1 1 6 B-Group
; : 0 0 2 O

CIMETlDINE NN 0 0 UNK B-Drug
: : 0 0 2 O
Cerivastatin NNP 0 1 UNK B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

Other JJ 0 0 2 O
depressasnts NNS 0 0 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
alcohol NN 0 1 1 B-Drug
barbiturates NNS 1 1 14 B-Group
and CC 0 0 12 O
MAOIs NNP 0 1 UNK B-Group
may MD 0 0 1 O
enhance VB 0 1 UNK O
CNS NNP 0 1 6 O
depression NN 0 1 6 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
ethchlorvynol NN 0 1 UNK B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
can MD 0 0 12 O
cause VB 0 1 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
elevation NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
corticosteroid NN 0 1 UNK B-Group
levels NNS 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
evaluation NN 0 1 1 O
of IN 0 0 12 O
EXTRANEALs NNP 0 0 UNK B-Brand
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
was VBD 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
elimination NN 0 1 UNK O
half JJ 0 1 12 O
life NN 0 1 12 O
of IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
and CC 0 0 12 O
triazolam NN 0 1 13 B-Drug
also RB 0 0 12 O
increased VBD 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
fold NN 0 1 3 O
) ) 0 0 2 O
during IN 0 0 12 O
coadministration NN 0 1 UNK O
with IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
q9h NN 0 1 UNK O
) ) 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
9% CD 0 0 UNK O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
with IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
lowered VBD 1 1 3 O
the DT 0 0 12 O
diltiazem NN 0 1 0 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
to TO 0 0 12 O
undetectable JJ 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Mephenytoin NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Mesantoin NNP 0 1 UNK B-Brand
) ) 0 0 2 O
Use NNP 0 1 2 O
of IN 0 0 12 O
sulfapyridine NN 0 1 UNK B-Drug
with IN 0 0 12 O
these DT 0 0 12 O
medicines NNS 1 1 6 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
chance NN 0 1 12 O
of IN 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
medicines NNS 1 1 6 O

If IN 0 0 12 O
additional JJ 0 1 1 O
adrenergic NN 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
are VBP 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
by IN 0 0 12 O
any DT 0 0 12 O
route NN 0 1 12 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
because IN 0 0 12 O
the DT 0 0 12 O
pharmacologically RB 0 0 UNK O
predictable JJ 0 1 UNK O
sympathetic JJ 0 0 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
BROVANA NNP 0 1 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
. . 0 0 12 O

Drugs NNS 0 1 2 O
Prolonging VBG 0 0 UNK O
the DT 0 0 12 O
QT NNP 0 1 13 O
/ NNP 0 0 2 O
QTc NNP 0 0 14 O
Interval NNP 0 1 13 O
Caution NNP 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
prescribing VBG 1 1 UNK O
apomorphine NN 0 1 UNK B-Drug
concomitantly RB 0 0 14 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
prolong VBP 0 0 13 O
the DT 0 0 12 O
QT NNP 0 1 13 O
/ NNP 0 0 2 O
QTc NNP 0 0 14 O
interval NN 0 1 1 O
. . 0 0 12 O

Each DT 0 0 2 O
volunteer NN 0 1 13 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
one CD 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
ceftibuten JJ 0 1 UNK B-Drug
capsule NN 0 1 3 O
. . 0 0 12 O

The DT 0 0 2 O
findings NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
studies NNS 1 1 1 O
are VBP 1 0 12 O
summarized VBN 1 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
table NN 0 1 3 O
: : 0 0 2 O
Effects NNS 0 1 UNK O
on IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
fexofenadine NN 0 1 16 B-Drug
pharmacokinetics NNS 0 1 UNK O
after IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
of IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
with IN 0 0 12 O
fexofenadine JJ 0 1 16 B-Drug
hydrochloride NN 0 1 0 I-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
( ( 0 0 2 O
two CD 0 1 12 O
times NNS 1 1 12 O
the DT 0 0 12 O
recommended JJ 0 1 1 O
twice JJ 0 1 12 O
daily RB 0 1 12 O
dose VBP 0 1 6 O
) ) 0 0 2 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O

Probenecid NNP 0 1 UNK B-Drug
- : 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
decreases VBZ 1 1 UNK O
gastrointestinal JJ 0 1 6 O
absorption NN 0 1 1 O
of IN 0 0 12 O
riboflavin NN 0 1 13 B-Drug
; : 0 0 2 O

Interconversion NN 0 0 UNK O
between IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
preterm NN 0 1 6 O
neonates NNS 1 1 16 O
. . 0 0 12 O

Anticholinergic NNP 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
increased JJ 0 1 1 O
intraocular JJ 0 1 13 O
pressure NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
hazardous JJ 0 1 13 O
when WRB 0 0 12 O
taken VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
agents NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
corticosteroids NNS 1 1 14 B-Group
. . 0 0 12 O

Alcohol NN 0 1 2 B-Drug
: : 0 0 2 O
There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
difference NN 0 1 UNK O
between IN 0 0 12 O
aripiprazole JJ 0 1 16 B-Drug
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
and CC 0 0 12 O
placebo NN 0 1 13 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
on IN 0 0 12 O
performance NN 0 1 13 O
of IN 0 0 12 O
gross JJ 0 1 1 O
motor NN 0 1 3 O
skills NNS 1 1 UNK O
or CC 0 0 12 O
stimulus JJ 0 1 1 O
response NN 0 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

Careful JJ 0 1 UNK O
monitoring NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
theophylline JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
DIFLUCAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Increased VBN 0 1 7 O
anticoagulation NN 0 1 14 O
effects NNS 1 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
with IN 0 0 12 O
various JJ 0 1 1 O
oral JJ 0 1 6 O
anticoagulents NNS 0 0 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
more JJR 0 1 12 O
pronounced JJ 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
elderly JJ 0 1 12 O
. . 0 0 12 O

Diltiazem NNP 0 1 0 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affected VBN 1 1 1 O
by IN 0 0 12 O
lovastatin NN 0 1 13 B-Drug
or CC 0 0 12 O
pravastatin NN 0 1 16 B-Drug
. . 0 0 12 O

Diuretic JJ 0 1 UNK B-Group
: : 0 0 2 O
Hydrochlorothiazide NNP 0 1 0 B-Drug
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ketoprofen NN 0 1 UNK B-Drug
produces VBZ 1 0 1 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
urinary JJ 0 1 6 O
potassium NN 0 1 14 O
and CC 0 0 12 O
chloride JJ 0 1 14 O
excretion NN 0 1 14 O
compared VBN 1 1 1 O
to TO 0 0 12 O
hydrochlorothiazide VB 0 1 0 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

Tell VB 0 0 UNK O
your PRP$ 0 0 12 O
doctor NN 0 1 12 O
if IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
drugs NNS 1 1 6 O
: : 0 0 2 O
blood NN 0 1 6 B-Group
thinners NNS 1 1 14 I-Group
( ( 0 0 2 O
Coumadin NNP 0 1 0 B-Brand
) ) 0 0 2 O
other JJ 0 0 12 O
antidepressants NNS 1 1 13 B-Group
metoprolol JJ 0 1 0 B-Drug
antihistamines NNS 1 1 UNK B-Group
carbamazepine NN 0 1 16 B-Drug
( ( 0 0 2 O
Tegretol NNP 0 1 0 B-Brand
) ) 0 0 2 O
cimetidine NN 0 1 13 B-Drug
( ( 0 0 2 O
Tagamet NNP 0 1 0 B-Brand
) ) 0 0 2 O
estrogens VBZ 0 1 16 B-Group
fluoxetine JJ 0 1 16 B-Drug
( ( 0 0 2 O
Prozac NNP 0 1 0 B-Brand
) ) 0 0 2 O
intraconazole NN 0 0 UNK O
( ( 0 0 2 O
Sporanox NNP 0 1 UNK B-Brand
) ) 0 0 2 O
ketoconazole NN 0 1 16 B-Drug
( ( 0 0 2 O
Nizoral NNP 0 1 UNK B-Brand
) ) 0 0 2 O
levodopa VBP 0 1 UNK B-Drug
lithium JJ 0 1 16 B-Drug
muscle NN 0 1 6 B-Group
relaxants NNS 1 0 13 I-Group
birth IN 0 1 12 O
control NN 0 1 1 O
pills NNS 1 1 6 O
sleeping VBG 1 1 12 O
pills NNS 1 1 6 O
thyroid JJ 0 1 6 O
medications NNS 1 1 6 O

in IN 0 0 12 O
vitro JJ 0 1 UNK O
Gleevec NNP 0 1 UNK B-Brand
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isoenzyme NN 0 1 13 O
CYP9D9 NNP 0 0 UNK O
activity NN 0 1 1 O
at IN 0 0 12 O
similar JJ 0 1 1 O
concentrations NNS 1 1 13 O
that WDT 0 0 12 O
affect VBP 0 1 1 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
several JJ 0 1 12 O
well RB 0 1 12 O
- : 0 0 2 O
controlled VBN 1 1 1 O
studies NNS 1 1 1 O
guanfacine NN 0 1 13 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
together RB 0 1 12 O
with IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
with IN 0 0 12 O
no DT 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
reported VBD 1 1 1 O
. . 0 0 12 O

. . 0 0 12 O

Vecuronium NN 0 1 0 B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
perioperative JJ 0 1 6 O
period NN 0 1 1 O
piperacillin NN 0 1 16 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
implicated VBN 1 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blockade NN 0 1 1 O
of IN 0 0 12 O
vecuronium NN 0 1 16 B-Drug
. . 0 0 12 O

These DT 0 0 1 O
doses VBZ 1 1 6 O
correspond NN 0 0 13 O
to TO 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
( ( 0 0 2 O
in IN 0 0 12 O
females NNS 1 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
( ( 0 0 2 O
in IN 0 0 12 O
males NNS 1 1 UNK O
) ) 0 0 2 O
the DT 0 0 12 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
[ NNP 0 0 2 O
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
] RB 0 0 2 O
] VBP 0 0 2 O
achieved VBN 1 0 1 O
in IN 0 0 12 O
women NNS 1 1 UNK O
receiving VBG 1 1 1 O
the DT 0 0 12 O
recommended VBN 1 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
month NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
utilization NN 0 1 UNK O
of IN 0 0 12 O
digitoxin NN 0 1 UNK B-Drug
for IN 0 0 12 O
such JJ 0 0 1 O
patients NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
considered VBN 1 1 1 O
as IN 1 0 12 O
an DT 0 0 12 O
alternative NN 0 1 1 O
. . 0 0 12 O

Potential NNP 0 1 UNK O
for IN 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
anticonvulsant NN 0 1 14 B-Group
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
efavirenz VB 0 1 13 B-Drug
plasma JJ 0 1 14 O
levels NNS 1 1 1 O
; : 0 0 2 O

Since IN 0 1 2 O
bacteriostatic JJ 0 0 UNK O
drugs NNS 1 1 6 O
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
bactericidal JJ 0 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
penicillin NN 0 1 14 B-Drug
it PRP 0 0 12 O
is VBZ 1 0 12 O
advisable JJ 0 0 UNK O
to TO 0 0 12 O
avoid VB 0 0 12 O
giving VBG 1 1 12 O
tetracyclines NNS 1 1 13 B-Group
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
penicillin NN 0 1 14 B-Group
. . 0 0 12 O

Carbamazepine NNP 0 1 UNK B-Drug
- : 0 0 2 O
Combined JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
racemic JJ 0 1 14 O
citalopram NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
( ( 0 0 2 O
titrated VBN 1 1 14 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affect VBP 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
. . 0 0 12 O

On IN 0 0 2 O
the DT 0 0 12 O
average NN 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
group NN 0 1 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
was VBD 1 0 12 O
reduced VBN 1 1 1 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Other JJ 0 0 2 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
antimycotic JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
itraconazole NN 0 1 0 B-Drug
and CC 0 0 12 O
miconazole NN 0 1 16 B-Drug
) ) 0 0 2 O
or CC 0 0 12 O
macrolide JJ 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
clarithromycin NN 0 1 13 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
alter VB 0 1 13 O
oxybutynin JJ 0 1 13 B-Drug
mean JJ 0 1 12 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
( ( 0 0 2 O
i.e. JJ 0 1 1 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
dobutamine NN 0 1 14 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
digitalis NN 0 1 14 B-Group
preparations NNS 1 1 13 I-Group
furosemide VBP 0 1 0 B-Drug
spironolactone CD 0 1 0 B-Drug
lidocaine JJ 0 1 14 B-Drug
glyceryl NN 0 0 UNK B-Drug
trinitrate NN 0 0 UNK I-Drug
isosorbide NN 0 1 16 B-Drug
dinitrate NN 0 0 0 I-Drug
morphine NN 0 1 14 B-Drug
atropine NN 0 1 14 B-Drug
heparin NN 0 1 14 B-Drug
protamine NN 0 1 16 B-Drug
potassium NN 0 1 14 B-Drug
chloride NN 0 1 14 I-Drug
folic JJ 0 0 14 B-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
Erythromycin NNP 0 1 0 B-Drug
on IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
The DT 0 0 2 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
of IN 0 0 12 O
Cmax NNP 0 1 UNK O
Cmin NNP 0 1 UNK O
AUC NNP 0 1 UNK O
CI NNP 0 1 UNK O
/ NNP 0 0 2 O
kg VBD 0 1 18 O
or CC 0 0 12 O
tmax NN 0 1 UNK O
at IN 0 0 12 O
felbamate JJ 0 1 13 B-Drug
daily JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
day NN 0 1 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
otherwise RB 0 0 1 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
with IN 0 0 12 O
epilepsy NN 0 1 13 O
. . 0 0 12 O

May NNP 0 1 2 O
interact NN 0 0 UNK O
with IN 0 0 12 O
addictive JJ 0 1 UNK O
medications NNS 1 1 6 O
especially RB 0 0 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
CNS NNP 0 1 6 I-Group
depressants NNS 1 0 13 I-Group
with IN 0 0 12 O
habituating VBG 1 0 UNK O
potential JJ 0 1 1 O
( ( 0 0 2 O
prolonged JJ 0 1 6 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
habituation NN 0 1 UNK O
) ) 0 0 2 O
alcohol NN 0 1 1 B-Drug
or CC 0 0 12 O
CNS NNP 0 1 6 O
depression NN 0 1 6 O
producing VBG 1 0 1 O
medications NNS 1 1 6 O
( ( 0 0 2 O
concurrent JJ 0 1 1 O
use NN 0 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
CNS NNP 0 1 6 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
either CC 0 1 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
or CC 0 0 12 O
ethinamate NN 0 1 UNK B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Sildenafil NNP 0 1 UNK B-Drug
citrate NN 0 1 14 I-Drug
- : 0 0 2 O
Theoretically RB 0 0 UNK O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
arginine NN 0 1 13 I-Drug
supplements NNS 1 1 6 O
taken VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
sildenafil JJ 0 1 16 B-Drug
citrate NN 0 1 14 I-Drug
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
study NN 0 1 1 O
of IN 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
BREVIBLOC NNP 0 1 UNK B-Brand
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
showed VBD 1 1 12 O
that IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
BREVIBLOC NNP 0 1 UNK B-Brand
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
warfarin JJ 0 1 14 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

Among IN 0 0 UNK O
9 CD 0 0 2 O
subjects NNS 1 1 UNK O
who WP 0 0 12 O
received VBD 1 1 12 O
Angiomax NNP 0 1 UNK B-Brand
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
and CC 0 0 12 O
were VBD 1 0 12 O
tested VBN 1 1 1 O
for IN 0 0 12 O
antibodies NNS 1 1 14 O
9 CD 0 0 2 O
subjects NNS 1 1 UNK O
had VBD 1 0 12 O
treatment NN 0 1 6 O
- : 0 0 2 O
emergent NN 0 1 1 O
positive JJ 0 1 1 O
bivalirudin NN 0 1 13 B-Drug
antibody NN 0 1 14 O
tests NNS 1 1 1 O
. . 0 0 12 O

Steady JJ 0 1 UNK O
- : 0 0 2 O
state NN 0 1 1 O
bosentan NN 0 1 13 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
higher JJR 1 1 1 O
than IN 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
A NNP 0 0 2 I-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
in IN 0 0 12 O
a DT 0 0 12 O
clinical JJ 0 1 6 O
study NN 0 1 1 O
who WP 0 0 12 O
were VBD 1 0 12 O
on IN 0 0 12 O
established VBN 1 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
sulfasalazine NN 0 1 0 B-Drug
to TO 0 0 12 O
which WDT 0 0 12 O
ENBREL NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
added VBN 1 1 12 O
were VBD 1 0 12 O
noted VBN 1 0 1 O
to TO 0 0 12 O
develop VB 0 0 1 O
a DT 0 0 12 O
mild JJ 0 1 6 O
decrease NN 0 1 1 O
in IN 0 0 12 O
mean JJ 0 1 12 O
neutrophil JJ 0 1 14 O
counts NNS 1 1 1 O
in IN 0 0 12 O
comparison NN 0 1 1 O
to TO 0 0 12 O
groups NNS 1 1 1 O
treated VBN 1 1 1 O
with IN 0 0 12 O
either DT 0 1 12 O
ENBREL NNP 0 1 UNK B-Brand
CI NNP 0 1 UNK O
or CC 0 0 12 O
sulfasalazine VB 0 1 0 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

Alternatives NNS 0 1 UNK O
to TO 0 0 12 O
clarithromycin VB 0 1 13 B-Drug
such JJ 0 0 1 O
as IN 1 0 12 O
azithromycin NN 0 1 0 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
inducing VBG 1 1 6 O
orthostatic JJ 0 1 8 O
hypotension NN 0 1 6 O
an DT 0 0 12 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
INVEGA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
therapeutic JJ 0 1 6 O
agents NNS 1 1 1 O
that WDT 0 0 12 O
have VBP 0 0 12 O
this DT 0 0 12 O
potential NN 0 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
bosentan NN 0 1 13 B-Drug
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
but CC 0 0 12 O
increased JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
bosentan NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Both DT 0 0 2 O
itraconazole JJ 0 1 0 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
major JJ 0 1 1 O
metabolite JJ 0 1 UNK O
hydroxyitraconazole NN 0 1 UNK B-Drug_n
are VBP 1 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
. . 0 0 12 O

Further RB 0 1 2 O
in IN 0 0 12 O
rabbits NNS 1 1 UNK O
dosed VBN 1 1 14 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
about IN 0 1 12 O
one CD 0 1 12 O
- : 0 0 2 O
half PDT 0 1 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
dose NN 0 1 6 O
on IN 0 0 12 O
BSA NNP 0 0 13 O
) ) 0 0 2 O
increases VBZ 1 1 1 O
in IN 0 0 12 O
placental JJ 0 1 13 O
weight NN 0 1 3 O
and CC 0 0 12 O
post NN 0 1 12 O
- : 0 0 2 O
implantation NN 0 1 6 O
loss NN 0 1 1 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
but CC 0 0 12 O
there EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
observed JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
fetal JJ 0 1 6 O
development NN 0 1 1 O
. . 0 0 12 O

Drug NN 0 1 2 O
and CC 0 0 12 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
9 CD 0 0 2 O
. . 0 0 12 O

fenoprofen NN 0 1 UNK B-Drug
; : 0 0 2 O

Data NNS 0 1 2 O
from IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
of IN 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
other JJ 0 0 12 O
than IN 0 0 12 O
alprazolam JJ 0 1 0 B-Drug
suggest VBP 0 1 1 O
a DT 0 0 12 O
possible JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
ergotamine JJ 0 1 UNK B-Drug
cyclosporine NN 0 1 14 B-Drug
amiodarone NN 0 1 0 B-Drug
nicardipine NN 0 1 16 B-Drug
and CC 0 0 12 O
nifedipine NN 0 1 0 B-Drug
. . 0 0 12 O

Nicotine NNP 0 1 7 B-Drug
Transdermal NNP 0 1 7 O
System NNP 0 1 2 O
: : 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
safety NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
with IN 0 0 12 O
Activase NNP 0 1 UNK B-Brand
for IN 0 0 12 O
the DT 0 0 12 O
management NN 0 1 1 O
of IN 0 0 12 O
acute JJ 0 1 6 O
ischemic JJ 0 1 6 O
stroke NN 0 1 6 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
similar JJ 0 1 1 O
study NN 0 1 1 O
with IN 0 0 12 O
tamsulosin NN 0 1 16 B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
9 CD 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
subjects NNS 1 1 UNK O
dosed VBN 1 1 14 O
with IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
tamsulosin NN 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
separated VBN 1 1 3 O
by IN 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
experienced VBD 1 0 12 O
a DT 0 0 12 O
standing VBG 1 1 12 O
systolic JJ 0 1 8 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
below IN 0 0 12 O
9 CD 0 0 2 O
mm NN 0 0 18 O
Hg NNP 0 1 14 O
. . 0 0 12 O

Other JJ 0 0 2 O
strong JJ 0 1 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
itraconazole NN 0 1 0 B-Drug
) ) 0 0 2 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
similar JJ 0 1 1 O
effects NNS 1 1 1 O
and CC 0 0 12 O
need VBP 0 1 12 O
similar JJ 0 1 1 O
dose JJ 0 1 6 O
reductions NNS 1 1 1 O
; : 0 0 2 O

Carbamazepine NNP 0 1 UNK B-Drug
( ( 0 0 2 O
CBZ NNP 0 0 UNK B-Drug
) ) 0 0 2 O

Since IN 0 1 2 O
colestipol NN 0 1 13 B-Drug
hydrochloride NN 0 1 0 I-Drug
is VBZ 1 0 12 O
an DT 0 0 12 O
anion NN 0 1 14 B-Group
exchange NN 0 1 1 I-Group
resin NN 0 1 UNK I-Group
it PRP 0 0 12 O
may MD 0 0 1 O
have VB 0 0 12 O
a DT 0 0 12 O
strong JJ 0 1 12 O
affinity NN 0 1 UNK O
for IN 0 0 12 O
anions NNS 1 1 UNK O
other JJ 0 0 12 O
than IN 0 0 12 O
the DT 0 0 12 O
bile JJ 0 1 6 O
acids NNS 1 1 14 O
. . 0 0 12 O

Delavirdine NN 0 1 UNK B-Drug

See VB 0 1 2 O

Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Potential JJ 0 1 UNK O
interaction NN 0 1 UNK O
of IN 0 0 12 O
Ketoconazole NNP 0 1 UNK B-Drug
and CC 0 0 12 O
Isoniazid NNP 0 1 UNK B-Drug
may MD 0 0 1 O
exist VB 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
epinephrine NN 0 1 14 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
drug NN 0 1 1 O
induced VBN 1 1 6 O
hypotension NN 0 1 6 O
because IN 0 0 12 O
of IN 0 0 12 O
a DT 0 0 12 O
possible JJ 0 1 1 O
reverse NN 0 1 1 O
epinephrine NN 0 1 14 B-Drug
effect NN 0 1 1 O
. . 0 0 12 O

. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
with IN 0 0 12 O
Cetrotide NNP 0 1 UNK B-Brand
. . 0 0 12 O

Drugs NNS 0 1 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
troleandomycin NN 0 1 UNK B-Drug
and CC 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
and CC 0 0 12 O
thus RB 0 0 1 O
decrease VB 0 1 1 O
their PRP$ 0 0 12 O
clearance NN 0 1 16 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
perfusion NN 0 1 8 O
of IN 0 0 12 O
isolated JJ 0 1 1 O
rat NN 0 1 13 O
liver NN 0 1 6 O
has VBZ 1 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
caused VBD 1 1 1 O
a DT 0 0 12 O
significant JJ 0 1 1 O
reduction NN 0 1 1 O
in IN 0 0 12 O
trimetrexate JJ 0 1 UNK B-Drug
metabolism NN 0 1 16 O
and CC 0 0 12 O
that IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
altered VBD 1 1 1 O
the DT 0 0 12 O
relative JJ 0 1 1 O
concentration NN 0 1 1 O
of IN 0 0 12 O
trimetrexate NN 0 1 UNK O
metabolites NNS 1 1 UNK O
possibly RB 0 1 12 O
by IN 0 0 12 O
competing VBG 1 0 UNK O
for IN 0 0 12 O
sulfate NN 0 1 14 O
metabolites NNS 1 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
no DT 0 0 12 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
performed VBN 1 1 1 O
with IN 0 0 12 O
HERCEPTIN NNP 0 1 UNK B-Brand
in IN 0 0 12 O
humans NNS 1 1 UNK O
. . 0 0 12 O

Azathioprine NNP 0 1 UNK B-Drug
/ NNP 0 0 2 O
Mycophenolate NNP 0 1 0 B-Drug
Mofetil NNP 0 0 0 I-Drug
: : 0 0 2 O
Given VBN 0 1 2 O
that IN 0 0 12 O
azathioprine NN 0 1 13 B-Drug
and CC 0 0 12 O
mycophenolate NN 0 1 0 B-Drug
mofetil NNS 0 0 16 I-Drug
inhibit VBP 0 1 13 O
purine JJ 0 1 13 O
metabolism NN 0 1 16 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
Myfortic NNP 0 1 UNK B-Brand
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
azathioprine NN 0 1 13 B-Drug
or CC 0 0 12 O
mycophenolate NN 0 1 0 B-Drug
mofetil NNS 0 0 16 I-Drug
. . 0 0 12 O

Pediatric NNP 0 1 7 O
Use NNP 0 1 2 O

In IN 0 0 2 O
vivo PDT 0 1 13 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
clearance NN 0 1 16 O
of IN 0 0 12 O
ropivacaine NN 0 1 16 B-Drug
was VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
during IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
bid NN 0 0 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
a DT 0 0 12 O
selective JJ 0 1 13 O
and CC 0 0 12 O
potent JJ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
. . 0 0 12 O

The DT 0 0 2 O
atorvastatin NN 0 1 0 B-Drug
Cmax NNP 0 1 UNK O
values NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affected VBN 1 1 1 O
by IN 0 0 12 O
fenofibrate NN 0 1 16 B-Drug
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 B-Drug
supplements NNS 1 1 6 O
and CC 0 0 12 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
lysine NN 0 1 13 I-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
calcium NN 0 1 14 B-Drug
absorption NN 0 1 1 O

Indomethacin NNP 0 1 0 B-Drug
may MD 0 0 1 O
also RB 0 0 12 O
affect VB 0 1 1 O
plasma NN 0 1 14 O
renin NN 0 1 UNK O
levels NNS 1 1 1 O
aldosterone VBP 0 1 UNK O
excretion NN 0 1 14 O
and CC 0 0 12 O
renin NN 0 1 UNK O
profile NN 0 1 1 O
evaluation NN 0 1 1 O
. . 0 0 12 O

Clinically RB 0 0 7 O
significant JJ 0 1 1 O
effects NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
warfarin NN 0 1 14 B-Group
anticoagulants NNS 1 1 13 I-Group
; : 0 0 2 O

In IN 0 0 2 O
order NN 0 1 1 O
to TO 0 0 12 O
avoid VB 0 0 12 O
the DT 0 0 12 O
occurrence NN 0 1 1 O
of IN 0 0 12 O
severe JJ 0 1 6 O
hypersensitivity NN 0 1 6 O
reactions NNS 1 1 1 O
all DT 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
premedicated VBN 0 0 UNK O
with IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
dexamethasone NN 0 1 16 B-Drug
) ) 0 0 2 O
diphen VBZ 0 1 UNK O
- : 0 0 2 O
hydramine NN 0 1 UNK O
and CC 0 0 12 O
H9 NNP 0 0 UNK B-Group
antagonists NNS 1 1 13 I-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
cimetidine NN 0 1 13 B-Drug
or CC 0 0 12 O
ranitidine NN 0 1 0 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
vitro NNP 0 1 UNK O
data NNS 0 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
phosphorylation NN 0 1 UNK O
of IN 0 0 12 O
stavudine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
also RB 0 0 12 O
inhibited VBN 1 1 13 O
at IN 0 0 12 O
relevant JJ 0 1 1 O
concentrations NNS 1 1 13 O
by IN 0 0 12 O
doxorubicin NN 0 1 13 B-Drug
and CC 0 0 12 O
ribavirin NN 0 1 13 B-Drug
. . 0 0 12 O

Some DT 0 0 2 O
quinolone NN 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
similar JJ 0 1 1 O
effects NNS 1 1 1 O
and CC 0 0 12 O
these DT 0 0 12 O
combinations NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

. . 0 0 12 O

A DT 0 0 2 O
further JJ 0 1 1 O
phenomenon NN 0 1 1 O
of IN 0 0 12 O
toxicity NN 0 1 6 O
common JJ 0 1 1 O
to TO 0 0 12 O
many JJ 0 0 12 O
hydrazine JJ 0 1 UNK B-Group
derivatives NNS 1 1 13 I-Group
is VBZ 1 0 12 O
hemolysis NN 0 1 13 O
and CC 0 0 12 O
the DT 0 0 12 O
appearance NN 0 1 12 O
of IN 0 0 12 O
Heinz NNP 0 1 UNK O
- : 0 0 2 O
Ehrlich JJ 0 0 UNK O
inclusion NN 0 1 13 O
bodies NNS 1 1 1 O
in IN 0 0 12 O
erythrocytes NNS 1 1 UNK O
. . 0 0 12 O

Depending VBG 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
fraction NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
the DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
small JJ 0 1 12 O
or CC 0 0 12 O
quite JJ 0 0 12 O
large JJ 0 1 3 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
TCA NNP 0 1 13 B-Group
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
possibility NN 0 1 1 O
of IN 0 0 12 O
worsened JJ 0 1 6 O
glucose JJ 0 1 14 O
control NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
using VBG 1 1 1 O
these DT 0 0 12 O
agents NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug

MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
prolong RB 0 0 13 O
and CC 0 0 12 O
intensify VB 0 0 UNK O
the DT 0 0 12 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
when WRB 0 0 12 O
TRISENOX NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
that WDT 0 0 12 O
can MD 0 0 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
( ( 0 0 2 O
e.g FW 0 0 UNK O
. . 0 0 12 O
certain JJ 0 1 1 O
antiarrhythmics NNS 1 1 UNK B-Group
or CC 0 0 12 O
thioridazine NN 0 1 13 B-Drug
) ) 0 0 2 O
or CC 0 0 12 O
lead JJ 0 1 12 O
to TO 0 0 12 O
electrolyte VB 0 1 14 O
abnormalities NNS 1 1 6 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
diuretics NNS 1 1 14 B-Group
or CC 0 0 12 O
amphotericin VB 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
) ) 0 0 2 O
. . 0 0 12 O

H NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
Antagonists NNS 0 1 UNK O
: : 0 0 2 O
In IN 0 0 2 O
studies NNS 1 1 1 O
with IN 0 0 12 O
human JJ 0 1 1 O
volunteers NNS 1 1 UNK O
co VBP 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
or CC 0 0 12 O
ranitidine NN 0 1 0 B-Drug
with IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
substantive JJ 0 0 UNK O
effect NN 0 1 1 O
on IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
serum NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

therefore RB 0 0 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
EQUETROTM NNP 0 0 UNK B-Brand
to TO 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
taking VBG 1 0 12 O
another DT 0 0 12 O
drug NN 0 1 1 O
that WDT 0 0 12 O
is VBZ 1 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
bound NN 0 1 12 O
should MD 0 0 12 O
not RB 0 1 12 O
cause VB 0 1 12 O
increased VBD 1 1 1 O
free JJ 0 1 12 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Videx NNP 0 1 UNK B-Brand
( ( 0 0 2 O
Didanosine NNP 0 1 0 B-Drug
) ) 0 0 2 O
chewable JJ 0 0 16 O
/ NN 0 0 2 O
buffered VBD 1 1 16 O
tablets NNS 1 1 3 O
or CC 0 0 12 O
the DT 0 0 12 O
pediatric JJ 0 1 6 O
powder NN 0 1 3 O
for IN 0 0 12 O
oral JJ 0 1 6 O
solution NN 0 1 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
or CC 0 0 12 O
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
norfloxacin JJ 0 1 UNK B-Drug
because IN 0 0 12 O
these DT 0 0 12 O
products NNS 1 1 1 O
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
absorption NN 0 1 1 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
lower JJR 1 1 1 O
serum NN 0 1 14 O
and CC 0 0 12 O
urine JJ 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
norfloxacin NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
magnitude NN 0 1 UNK O
and CC 0 0 12 O
relative JJ 0 1 1 O
importance NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
noted VBN 1 0 1 O
below IN 0 0 12 O
are VBP 1 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
patient JJ 0 1 6 O
specific JJ 0 1 1 O
and CC 0 0 12 O
may MD 0 0 1 O
vary VB 0 0 1 O
by IN 0 0 12 O
such JJ 0 0 1 O
factors NNS 1 1 1 O
as IN 1 0 12 O
age NN 0 1 12 O
gender NN 0 1 1 O
race NN 0 1 16 O
intercurrent NN 0 0 UNK O
illnesses NNS 1 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
either DT 0 1 12 O
agent JJ 0 1 1 O
additional JJ 0 1 1 O
concomitant NN 0 1 6 O
medications NNS 1 1 6 O
and CC 0 0 12 O
timing NN 0 1 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
administration NN 0 1 1 O
. . 0 0 12 O

Among IN 0 0 UNK O
aspirin JJ 0 1 14 B-Brand
or CC 0 0 12 O
NSAID JJ 0 1 14 B-Group
users NNS 1 1 UNK O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
upper JJ 0 1 3 O
gastrointestinal JJ 0 1 6 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
ibandronate JJ 0 1 13 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily JJ 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
was VBD 1 0 12 O
similar JJ 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
in IN 0 0 12 O
placebo NN 0 1 13 O
- : 0 0 2 O
treated JJ 0 1 1 O
patients NNS 1 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

Netilmicin NNP 0 1 UNK B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
potent JJ 0 1 UNK O
loop JJ 0 1 3 B-Group
diuretics NNS 1 1 14 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
furosemide NN 0 1 0 B-Drug
and CC 0 0 12 O
ethacrynic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
as IN 1 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
ototoxicity NN 0 1 UNK O
is VBZ 1 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
. . 0 0 12 O

Elevated VBN 0 1 7 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
some DT 0 0 12 O
quinolones NNS 0 1 13 B-Group
and CC 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
. . 0 0 12 O

monitor NN 0 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
excessive JJ 0 1 1 O
bradycardia NN 0 1 8 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
vertigo NN 0 1 6 O
syncope NN 0 1 8 O
postural JJ 0 1 13 O
hypotension NN 0 1 6 O
) ) 0 0 2 O
. . 0 0 12 O

Alternate NNP 0 1 UNK O
or CC 0 0 12 O
additional JJ 0 1 1 O
contraceptive NN 0 1 13 O
measures NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
during IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand

Compounds NNS 0 1 UNK O
that WDT 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
tested VBN 1 1 1 O
in IN 0 0 12 O
man NN 0 1 12 O
include VBP 0 1 1 O
antipyrine JJ 0 1 UNK B-Drug
digoxin NN 0 1 14 B-Drug
propranolol NN 0 1 16 B-Drug
theophylline NN 0 1 16 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
meaningful JJ 0 1 1 O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
found VBN 1 1 12 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
small JJ 0 1 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
with IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
to TO 0 0 12 O
extend VB 0 1 1 O
the DT 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
ertapenem NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

certain JJ 0 1 1 O
antipsychotic JJ 0 1 UNK B-Group
medications NNS 1 1 6 I-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
sertindole NN 0 1 UNK B-Drug
) ) 0 0 2 O
; : 0 0 2 O

Observations NNS 0 1 UNK O
from IN 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
FORTOVASE NNP 0 1 UNK B-Brand
may MD 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
predictive JJ 0 1 UNK O
for IN 0 0 12 O
INVIRASE NNP 0 1 UNK B-Brand
. . 0 0 12 O

Pregnancy NNP 0 1 7 O
Pregnancy NNP 0 1 7 O
Category NNP 0 1 UNK O
: : 0 0 2 O
C NNP 0 0 2 O
There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
adequate JJ 0 1 1 O
and CC 0 0 12 O
well RB 0 1 12 O
- : 0 0 2 O
controlled VBN 1 1 1 O
studies NNS 1 1 1 O
of IN 0 0 12 O
ezetimibe NN 0 1 16 B-Drug
in IN 0 0 12 O
pregnant JJ 0 1 13 O
women NNS 1 1 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
corticosteroid NN 0 1 UNK B-Group
should MD 0 0 12 O
be VB 0 0 12 O
titrated VBN 1 1 14 O
to TO 0 0 12 O
avoid VB 0 0 12 O
steroid JJ 0 1 6 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Dexbrompheniramine NN 0 1 UNK B-Drug
can MD 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
CNS NNP 0 1 6 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
either CC 0 1 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
or CC 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
) ) 0 0 2 O
anticholinergics NNS 1 1 13 B-Group
or CC 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
with IN 0 0 12 O
anticholinergic JJ 0 1 13 O
activity NN 0 1 1 O
( ( 0 0 2 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
when WRB 0 0 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
are VBP 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
) ) 0 0 2 O
and CC 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
with IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
may MD 0 0 1 O
prolong VB 0 0 13 O
and CC 0 0 12 O
intensify VB 0 0 UNK O
the DT 0 0 12 O
anticholinergic NN 0 1 13 O
and CC 0 0 12 O
CNS NNP 0 1 6 O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
) ) 0 0 2 O
. . 0 0 12 O

No DT 0 0 2 O
effects NNS 1 1 1 O
on IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
or CC 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
were VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
Acarbose NNP 0 1 UNK B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
sulfonylureas NNS 1 1 UNK B-Group
or CC 0 0 12 O
insulin NN 0 1 14 B-Drug
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
any DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
hypoglycemia NN 0 1 6 O
. . 0 0 12 O

Pregnancy NNP 0 1 7 O
( ( 0 0 2 O
Category NNP 0 1 UNK O
B NNP 0 0 2 O
) ) 0 0 2 O

fluoxetine JJ 0 1 16 B-Drug
fluvoxamine NN 0 1 16 B-Drug
paroxetine NN 0 1 16 B-Drug
sertraline NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Drug NN 0 1 2 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
are VBP 1 0 12 O
summarized VBN 1 0 1 O
in IN 0 0 12 O
Table JJ 0 1 UNK O
9 CD 0 0 2 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
SUTENT NNP 0 1 0 B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
take VB 0 1 12 O
St NNP 0 1 2 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
because IN 0 0 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
affinity NN 0 1 UNK O
for IN 0 0 12 O
protein $ 0 1 14 O
9MNA CD 0 0 UNK B-Drug_n
may MD 0 0 1 O
displace VB 0 0 13 O
other JJ 0 0 12 O
protein NN 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
drugs NNS 1 1 6 O
from IN 0 0 12 O
their PRP$ 0 0 12 O
binding NN 0 1 1 O
site NN 0 1 12 O
. . 0 0 12 O

Medications NNS 0 1 7 O
can MD 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
folate JJ 0 1 14 O
utilization NN 0 1 UNK O
including VBG 1 1 1 O
: : 0 0 2 O
anticonvulsant JJ 0 1 14 B-Group
medications NNS 1 1 6 I-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
primidone NN 0 1 13 B-Drug
) ) 0 0 2 O
metformin NN 0 1 0 B-Drug
( ( 0 0 2 O
sometimes RB 0 1 12 O
prescribed VBN 1 1 1 O
to TO 0 0 12 O
control VB 0 1 1 O
blood NN 0 1 6 O
sugar NN 0 1 3 O
in IN 0 0 12 O
type NN 0 1 1 O
9 CD 0 0 2 O
diabetes NNS 0 1 6 O
) ) 0 0 2 O
sulfasalazine NN 0 1 0 B-Drug
( ( 0 0 2 O
used VBN 1 1 12 O
to TO 0 0 12 O
control VB 0 1 1 O
inflammation NN 0 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
Crohns NNP 0 1 UNK O
disease NN 0 1 6 O
and CC 0 0 12 O
ulcerative JJ 0 1 6 O
colitis NN 0 1 6 O
) ) 0 0 2 O
triamterene NN 0 1 13 B-Drug
( ( 0 0 2 O
a DT 0 0 12 O
diuretic NN 0 1 14 B-Group
) ) 0 0 2 O
Methotrexate NNP 0 1 0 B-Drug
There EX 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
concern NN 0 1 1 O
about IN 0 1 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
vitamin NN 0 1 6 B-Drug
B9 NNP 0 0 UNK I-Drug
and CC 0 0 12 O
folic JJ 0 0 14 B-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O

While IN 0 0 12 O
all PDT 0 0 12 O
the DT 0 0 12 O
selective JJ 0 1 13 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
e. VBP 0 0 1 O
g. JJ 0 1 13 O
fluoxetine JJ 0 1 16 B-Drug
sertraline NN 0 1 16 B-Drug
and CC 0 0 12 O
paroxetine JJ 0 1 16 B-Drug
inhibit NN 0 1 13 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
they PRP 0 0 12 O
may MD 0 0 1 O
vary VB 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
. . 0 0 12 O

Reproductive JJ 0 1 UNK O
toxicology NN 0 1 6 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
in IN 0 0 12 O
cynomolgus JJ 0 1 UNK O
monkeys NNS 1 1 UNK O
at IN 0 0 12 O
doses NNS 1 1 6 O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg NNS 0 1 18 O
/ VBP 0 0 2 O
week NN 0 1 12 O
( ( 0 0 2 O
about IN 0 1 12 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
dose NN 0 1 6 O
based VBN 1 1 1 O
on IN 0 0 12 O
body NN 0 1 3 O
weight NN 0 1 3 O
) ) 0 0 2 O
and CC 0 0 12 O
have VBP 0 0 12 O
revealed VBN 1 1 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
impaired JJ 0 1 6 O
fertility NN 0 1 6 O
or CC 0 0 12 O
harm NN 0 0 1 O
to TO 0 0 12 O
the DT 0 0 12 O
fetus NN 0 1 13 O
due JJ 0 1 1 O
to TO 0 0 12 O
AMEVIVE NNP 0 1 UNK B-Brand
. . 0 0 12 O

e.g. RB 0 0 UNK O
other JJ 0 0 12 O
belladonna NN 0 1 16 B-Group
alkaloids NNS 1 1 13 I-Group
antihistamines NNS 1 1 UNK B-Group
( ( 0 0 2 O
including VBG 1 1 1 O
meclizine NN 0 1 16 B-Drug
) ) 0 0 2 O
tricyclic NN 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
and CC 0 0 12 O
muscle NN 0 1 6 B-Group
relaxants NNS 1 0 13 I-Group
. . 0 0 12 O

Because IN 0 0 12 O
antacids NNS 1 1 14 B-Group
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
simultaneous JJ 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

CNS NNP 0 1 6 O
- : 0 0 2 O
Active JJ 0 1 2 O
Drugs NNP 0 1 2 O
Ethanol NNP 0 1 13 B-Drug
An DT 0 0 2 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
on IN 0 0 12 O
psychomotor NN 0 0 13 O
performance NN 0 1 13 O
was VBD 1 0 12 O
seen VBN 1 1 12 O
with IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
eszopiclone NN 0 1 13 B-Drug
and CC 0 0 12 O
ethanol $ 0 1 1 B-Drug
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
for IN 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
ethanol DT 0 1 1 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

Because IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
patients NNS 1 1 6 O
who WP 0 0 12 O
require VBP 0 0 1 O
anticoagulation NN 0 1 14 O
should MD 0 0 12 O
receive VB 0 1 1 O
low JJ 0 1 1 O
- : 0 0 2 O
molecular JJ 0 1 1 O
weight NN 0 1 3 O
or CC 0 0 12 O
standard JJ 0 1 1 O
heparin NN 0 1 14 B-Drug
. . 0 0 12 O

Laboratory NN 0 1 2 O
Tests NNS 0 1 UNK O
Response NNP 0 1 UNK O
to TO 0 0 12 O
Plenaxis NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
by IN 0 0 12 O
measuring VBG 1 1 1 O
serum JJ 0 1 14 O
total JJ 0 1 1 O
testosterone NN 0 1 6 B-Drug
concentrations NNS 1 1 13 O
just RB 0 0 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
administration NN 0 1 1 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
every DT 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
thereafter RB 0 0 1 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
dopamine NN 0 1 14 B-Drug
HCl NNP 0 0 14 I-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
bradycardia NN 0 1 8 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
That WDT 0 0 2 O
Inhibit NNP 0 1 UNK O
Alprazolam NNP 0 1 0 B-Drug
Metabolism NNP 0 1 UNK O
Via NNP 0 0 2 O
Cytochrome NNP 0 1 UNK O
P9 NNP 0 1 UNK O
9A CD 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
initial JJ 0 1 1 O
step NN 0 1 12 O
in IN 0 0 12 O
alprazolam JJ 0 1 0 B-Drug
metabolism NN 0 1 16 O
is VBZ 1 0 12 O
hydroxylation JJ 0 1 UNK O
catalyzed VBN 1 0 UNK O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A CD 0 1 UNK O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
9A CD 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

indinavir NN 0 1 16 B-Drug
concentration NN 0 1 1 O

The DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
data NNS 0 1 1 O
described VBN 1 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
section NN 0 1 1 O
were VBD 1 0 12 O
obtained VBN 1 1 1 O
from IN 0 0 12 O
studies NNS 1 1 1 O
involving VBG 1 1 1 O
healthy JJ 0 1 12 O
adults NNS 1 1 13 O
and CC 0 0 12 O
adult NN 0 1 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
epilepsy NN 0 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacodynamic JJ 0 1 UNK O
effects NNS 1 1 1 O
can MD 0 0 12 O
be VB 0 0 12 O
explained VBN 1 0 12 O
by IN 0 0 12 O
a DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
dofetilide JJ 0 1 13 B-Drug
exposure NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
reductions NNS 1 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
. . 0 0 12 O

During IN 0 0 2 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
systemic JJ 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
TMP NNP 0 0 UNK B-Drug
and CC 0 0 12 O
SMX NNP 0 1 UNK B-Drug
were VBD 1 0 12 O
essentially RB 0 0 1 O
unchanged JJ 0 1 1 O
. . 0 0 12 O

They PRP 0 0 12 O
are VBP 1 0 12 O
weak JJ 0 1 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
mild VB 0 1 6 O
- : 0 0 2 O
to TO 0 0 12 O
- : 0 0 2 O
moderate JJ 0 1 1 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
at IN 0 0 12 O
therapeutic JJ 0 1 6 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Clinical JJ 0 1 7 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
indicated VBD 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
Femara NNP 0 1 UNK B-Brand
with IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
does VBZ 1 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
clinically RB 0 0 6 O
- : 0 0 2 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
of IN 0 0 12 O
Aranesp NNP 0 1 0 B-Brand
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Also RB 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
quinolones NNS 0 1 13 B-Group
with IN 0 0 12 O
products NNS 1 1 1 O
containing VBG 1 1 1 O
iron NN 0 1 3 B-Drug
multivitamins NNS 1 1 14 B-Group
containing VBG 1 1 1 O
zinc NN 0 1 14 B-Drug
or CC 0 0 12 O
Videx NNP 0 1 UNK B-Brand
( ( 0 0 2 O
didanosine NN 0 1 16 B-Drug
) ) 0 0 2 O
chewable JJ 0 0 16 O
/ NN 0 0 2 O
buffered VBD 1 1 16 O
tablets NNS 1 1 3 O
or CC 0 0 12 O
the DT 0 0 12 O
pediatric JJ 0 1 6 O
powder NN 0 1 3 O
for IN 0 0 12 O
oral JJ 0 1 6 O
solution NN 0 1 1 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
low JJ 0 1 1 O
urine NN 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

( ( 0 0 2 O
Indomethacin NNP 0 1 0 B-Drug
) ) 0 0 2 O
diuretics NNS 1 1 14 B-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
if IN 0 0 12 O
the DT 0 0 12 O
desired JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
is VBZ 1 0 12 O
obtained VBN 1 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
information NN 0 1 1 O
available JJ 0 1 1 O
from IN 0 0 12 O
adequate JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
classes NNS 1 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
: : 0 0 2 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
hormone VBP 0 1 6 O
replacement NN 0 1 1 O
therapies NNS 1 1 6 O
hypoglycemics VBP 0 1 14 B-Group
theophyllines NNS 1 1 UNK B-Drug
phenytoins NNS 1 0 UNK B-Drug
thiazide IN 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
beta JJ 0 1 16 B-Group
blockers NNS 1 0 6 I-Group
and CC 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
rare JJ 0 1 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
reddish JJ 0 0 3 O
stools NNS 1 1 3 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
have VBP 0 0 12 O
received VBN 1 1 12 O
cefdinir NNS 0 1 UNK B-Drug
in IN 0 0 12 O
Japan NNP 0 1 UNK O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
: : 0 0 2 O
Administration NN 0 1 UNK O
of IN 0 0 12 O
flurbiprofen NN 0 1 16 B-Drug
to TO 0 0 12 O
volunteers NNS 1 1 UNK O
under IN 0 0 12 O
fasting VBG 1 1 6 O
conditions NNS 1 1 1 O
or CC 0 0 12 O
with IN 0 0 12 O
antacid JJ 0 1 UNK B-Group
suspension NN 0 1 3 O
yielded VBD 1 0 1 O
similar JJ 0 1 1 O
serum NN 0 1 14 O
flurbiprofen NN 0 1 16 B-Drug
time NN 0 1 12 O
profiles NNS 1 1 UNK O
in IN 0 0 12 O
young JJ 0 1 12 O
subjects NNS 1 1 UNK O
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Although IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
based VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
involvement NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
9A CD 0 1 UNK O
family NN 0 1 12 O
in IN 0 0 12 O
clonazepam JJ 0 1 0 B-Drug
metabolism NN 0 1 16 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
this DT 0 0 12 O
enzyme NN 0 1 14 O
system NN 0 1 1 O
notably RB 0 0 1 O
oral JJ 0 1 6 O
antifungal JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
clonazepam NN 0 1 0 B-Drug
. . 0 0 12 O

Indinavir NNP 0 1 UNK B-Drug
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
Cmax NNP 0 1 UNK O
A.C. NNP 0 0 UNK O
and CC 0 0 12 O
Cmin NNP 0 1 UNK O
were VBD 1 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
amprenavir NN 0 1 13 B-Drug
. . 0 0 12 O

angioedema NN 0 1 16 O

Other JJ 0 0 2 O
Antihypertensives NNS 0 1 UNK B-Group
: : 0 0 2 O
When WRB 0 0 12 O
MYKROX NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
are VBP 1 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
care NN 0 1 12 O
must MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
especially RB 0 0 12 O
during IN 0 0 12 O
initial JJ 0 1 1 O
therapy NN 0 1 6 O
. . 0 0 12 O

Grapefruit NN 0 1 UNK O
may MD 0 0 1 O
also RB 0 0 12 O
increase VB 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
SUTENT NNP 0 1 0 B-Brand
. . 0 0 12 O

Although IN 0 0 12 O
not RB 0 1 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
could MD 0 0 12 O
potentially RB 0 0 1 O
arise VB 0 0 1 O
from IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
cephalexin NN 0 1 16 B-Drug
and CC 0 0 12 O
metformin NN 0 1 0 B-Drug
by IN 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
via IN 0 0 1 O
organic JJ 0 1 13 O
cationic JJ 0 1 UNK O
transporter NN 0 1 UNK O
systems NNS 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
concurrent JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
and CC 0 0 12 O
ketoprofen NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

increased VBN 1 1 1 O
alkaline NN 0 1 14 O

Carbamazepine NN 0 1 UNK B-Drug
: : 0 0 2 O
Felbatol NNP 0 1 UNK B-Brand
causes VBZ 1 1 6 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
carbamazepine NN 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
carbamazepine NN 0 1 16 B-Drug_n
epoxide NN 0 1 UNK I-Drug_n
plasma NN 0 1 14 O
concentration NN 0 1 1 O
. . 0 0 12 O

Since IN 0 1 2 O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
high JJ 0 1 1 O
degree NN 0 1 1 O
of IN 0 0 12 O
variability NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
verapamil NN 0 1 0 B-Drug
the DT 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
finding NN 0 1 12 O
is VBZ 1 0 12 O
unclear JJ 0 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
cases NNS 1 1 UNK O
reported VBN 1 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
and CC 0 0 12 O
hydrocortisone NN 0 1 14 B-Drug
was VBD 1 0 12 O
followed VBN 1 1 12 O
by IN 0 0 12 O
cardiac JJ 0 1 6 O
enlargement NN 0 1 6 O
and CC 0 0 12 O
congestive JJ 0 1 6 O
heart NN 0 1 12 O
failure NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
coumarin JJ 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants VBZ 0 1 13 I-Group
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
Nalfon NNP 0 1 UNK B-Brand
to TO 0 0 12 O
therapy VB 0 1 6 O
could MD 0 0 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

With IN 0 0 2 O
oral JJ 0 1 6 O
dapsone NN 0 1 13 B-Drug
treatment NN 0 1 6 O
folic JJ 0 0 14 B-Group
acid JJ 0 1 14 I-Group
antagonists NNS 1 1 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
pyrimethamine NN 0 1 16 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
noted VBN 1 0 1 O
to TO 0 0 12 O
possibly RB 0 1 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
likelihood NN 0 1 1 O
of IN 0 0 12 O
hematologic JJ 0 1 14 O
reactions NNS 1 1 1 O

Cardiac JJ 0 1 7 O
effects NNS 1 1 1 O
of IN 0 0 12 O
dopamine NN 0 1 14 B-Drug
are VBP 1 0 12 O
antagonized VBN 1 0 UNK O
by IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
propranolol NN 0 1 16 B-Drug
and CC 0 0 12 O
metoprolol NN 0 1 0 B-Drug
. . 0 0 12 O

Renal JJ 0 1 7 O
Impairment NNP 0 1 UNK O
There EX 0 0 12 O
are VBP 1 0 12 O
currently RB 0 1 12 O
no DT 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
with IN 0 0 12 O
SPRYCEL NNP 0 1 UNK B-Brand
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
impaired JJ 0 1 6 O
renal JJ 0 1 6 O
function NN 0 1 1 O
( ( 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
excluded VBN 1 1 1 O
patients NNS 1 1 6 O
with IN 0 0 12 O
serum JJ 0 1 14 O
creatinine NN 0 1 14 O
concentration NN 0 1 1 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
upper JJ 0 1 3 O
limit NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
normal JJ 0 1 1 O
range NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
methylprednisolone NN 0 1 16 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
titrated VBN 1 1 14 O
to TO 0 0 12 O
avoid VB 0 0 12 O
steroid JJ 0 1 6 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
substances NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Thiabendazole NN 0 1 UNK B-Drug
may MD 0 0 1 O
compete VB 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
theophylline NN 0 1 16 B-Drug
for IN 0 0 12 O
sites NNS 1 1 1 O
of IN 0 0 12 O
metabolism NN 0 1 16 O
in IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
thus RB 0 0 1 O
elevating VBG 1 1 UNK O
the DT 0 0 12 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
compounds NNS 1 1 13 O
to TO 0 0 12 O
potentially RB 0 0 1 O
toxic JJ 0 1 1 O
levels NNS 1 1 1 O
. . 0 0 12 O

Methadone NN 0 1 0 B-Drug
levels NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
decreased VBN 1 1 1 O
; : 0 0 2 O
increased VBN 1 1 1 O
dosages NNS 1 1 14 O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
to TO 0 0 12 O
prevent VB 0 1 1 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
opiate NN 0 1 6 B-Group
withdrawal NN 0 1 1 O
. . 0 0 12 O
Methadone NNP 0 1 0 B-Drug
maintained VBD 1 1 1 O
patients NNS 1 1 6 O
beginning VBG 1 1 12 O
nevirapine JJ 0 1 13 B-Drug
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
forevidence NN 0 0 UNK O
of IN 0 0 12 O
withdrawal NN 0 1 1 O
and CC 0 0 12 O
methadone NN 0 1 6 B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
adjusted VBN 1 1 1 O
accordingly RB 0 0 1 O
. . 0 0 12 O

Acetazolamide NNP 0 1 0 B-Drug
and CC 0 0 12 O
sodium NN 0 1 14 B-Drug
bicarbonate NN 0 1 14 I-Drug
used VBN 1 1 12 O
concurrently RB 0 0 1 O
increases VBZ 1 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
renal JJ 0 1 6 O
calculus NN 0 1 1 O
formation NN 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
this DT 0 0 12 O
sample NN 0 1 1 O
size NN 0 1 3 O
is VBZ 1 0 12 O
too RB 0 0 12 O
small JJ 0 1 12 O
to TO 0 0 12 O
allow VB 0 1 1 O
for IN 0 0 12 O
any DT 0 0 12 O
conclusions NNS 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
drawn VBN 1 0 12 O
regarding VBG 1 0 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
rashes NNS 1 1 6 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
AUGMENTIN NNP 0 1 UNK B-Brand
XR NNP 0 1 0 I-Brand
and CC 0 0 12 O
allopurinol NN 0 1 13 B-Drug
use NN 0 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
combination NN 0 1 1 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
needed VBN 1 1 12 O
careful JJ 0 1 12 O
consideration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
pharmacology NN 0 1 UNK O
of IN 0 0 12 O
all DT 0 0 12 O
agents NNS 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

Compounds NNS 0 1 UNK O
tested VBN 1 1 1 O
in IN 0 0 12 O
man NN 0 1 12 O
include VBP 0 1 1 O
warfarin JJ 0 1 14 B-Drug
theophylline JJ 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
diazepam NN 0 1 0 B-Drug
aminopyrine NN 0 1 UNK B-Drug
and CC 0 0 12 O
antipyrine NN 0 1 UNK B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
glipizide VB 0 1 0 B-Drug
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
control NN 0 1 1 O
. . 0 0 12 O

Approximately RB 0 1 2 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
patients NNS 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
Phase NNP 0 1 UNK O
9 CD 0 0 2 O
study NN 0 1 1 O
received VBD 1 1 12 O
either RB 0 1 12 O
prophylactic JJ 0 1 6 O
low JJ 0 1 1 O
dose NN 0 1 6 O
heparin NN 0 1 14 B-Drug
( ( 0 0 2 O
unfractionated JJ 0 0 UNK B-Drug
heparin NN 0 1 14 I-Drug
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
units NNS 1 1 1 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
or CC 0 0 12 O
prophylactic JJ 0 1 6 O
doses NNS 1 1 6 O
of IN 0 0 12 O
low JJ 0 1 1 B-Group
molecular JJ 0 1 1 I-Group
weight NN 0 1 3 I-Group
heparins NNS 1 1 UNK I-Group
as IN 1 0 12 O
indicated VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
prescribing NN 0 1 UNK O
information NN 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
specific JJ 0 1 1 O
products NNS 1 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
little JJ 0 1 12 O
risk NN 0 1 1 O
for IN 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
contraceptive JJ 0 1 13 O
efficacy NN 0 1 UNK O
the DT 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
increased VBN 1 1 1 O
exposures NNS 1 1 UNK O
in IN 0 0 12 O
terms NNS 1 1 1 O
of IN 0 0 12 O
safety NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
SPRYCEL NNP 0 1 UNK B-Brand
and CC 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
CYP9A9 NNP 0 0 UNK O
( ( 0 0 2 O
eg JJ 0 1 UNK O
ketoconazole NN 0 1 16 B-Drug
itraconazole NN 0 1 0 B-Drug
erythromycin NN 0 1 0 B-Drug
clarithromycin NN 0 1 13 B-Drug
ritonavir NN 0 1 16 B-Drug
atazanavir NN 0 1 13 B-Drug
indinavir NN 0 1 16 B-Drug
nefazodone NN 0 1 16 B-Drug
nelfinavir JJ 0 1 16 B-Drug
saquinavir NN 0 1 13 B-Drug
telithromycin NN 0 1 UNK B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
increase VB 0 1 1 O
exposure NN 0 1 1 O
to TO 0 0 12 O
dasatinib VB 0 1 13 B-Drug
and CC 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
nitrofurantoin NN 0 1 0 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
since IN 0 1 12 O
nitrofurantoin NN 0 1 0 B-Drug
may MD 0 0 1 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
antibacterial JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
Norfloxacin NNP 0 1 UNK B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
urinary JJ 0 1 6 O
tract NN 0 1 6 O
. . 0 0 12 O

Products NNS 0 1 2 O
containing VBG 1 1 1 O
calcium NN 0 1 14 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
multivalent NN 0 0 UNK B-Drug
cations NNS 1 1 UNK I-Drug
likely RB 0 1 12 O
will MD 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
alendronate NN 0 1 16 B-Drug
. . 0 0 12 O

Studies NNS 0 1 2 O
showed VBD 1 1 12 O
that IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
increased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
and CC 0 0 12 O
triazolam NN 0 1 13 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
fold NN 0 1 3 O
and CC 0 0 12 O
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
compared VBN 1 1 1 O
to TO 0 0 12 O
placebo VB 0 1 13 O
. . 0 0 12 O

No DT 0 0 2 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
these DT 0 0 12 O
CYP NNP 0 1 UNK O
enzymes NNS 1 1 14 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
listed VBN 1 1 1 O
below IN 0 0 12 O
are VBP 1 0 12 O
potentially RB 0 0 1 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
controlled JJ 0 1 1 O
studies NNS 1 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
bepridil VBP 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
either CC 0 1 12 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
( ( 0 0 2 O
one CD 0 1 12 O
study NN 0 1 1 O
) ) 0 0 2 O
or CC 0 0 12 O
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
modest JJ 0 1 1 O
increases NNS 1 1 1 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
two CD 0 1 12 O
studies NNS 1 1 1 O
) ) 0 0 2 O
in IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
treatment NN 0 1 6 O
with IN 0 0 12 O
NEXAVAR NNP 0 1 UNK B-Brand
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
doxorubicin NN 0 1 13 B-Drug
. . 0 0 12 O

Although IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
nelfinavir JJ 0 1 16 B-Drug
close JJ 0 1 12 O
monitoring NN 0 1 1 O
for IN 0 0 12 O
known JJ 0 1 12 O
side NN 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
such JJ 0 0 1 O
as IN 1 0 12 O
liver NN 0 1 6 O
enzyme NN 0 1 14 O
abnormalities NNS 1 1 6 O
and CC 0 0 12 O
hearing VBG 1 1 12 O
impairment NN 0 1 16 O
is VBZ 1 0 12 O
warranted VBN 1 0 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
treatment NN 0 1 6 O
with IN 0 0 12 O
thrombolytics NNS 1 1 14 B-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
rt NN 0 1 13 O
- : 0 0 2 O
PA NNP 0 1 2 O
or CC 0 0 12 O
streptokinase NN 0 1 13 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
: : 0 0 2 O
- : 0 0 2 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding VBG 1 1 6 O
complications NNS 1 1 6 O
- : 0 0 2 O
considerably RB 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
REFLUDAN NNP 0 1 UNK B-Brand
on IN 0 0 12 O
aPTT NN 0 1 UNK O
prolongation NN 0 1 6 O

In IN 0 0 2 O
these DT 0 0 12 O
studies NNS 1 1 1 O
no DT 0 0 12 O
interaction NN 0 1 UNK O
that WDT 0 0 12 O
altered VBD 1 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
micafungin NN 0 1 16 B-Drug
was VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
No DT 0 0 2 O
significant JJ 0 1 1 O
differences NNS 1 1 UNK O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
R NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin NN 0 1 14 I-Drug
or CC 0 0 12 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin NN 0 1 14 I-Drug
with IN 0 0 12 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
given VBN 1 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
Isocarboxazid NNP 0 1 UNK B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
psychotropic NN 0 1 13 B-Group
agents NNS 1 1 1 I-Group
is VBZ 1 0 12 O
generally RB 0 0 1 O
not RB 0 1 12 O
recommended JJ 0 1 1 O
because IN 0 0 12 O
of IN 0 0 12 O
possible JJ 0 1 1 O
potentiating NN 0 0 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
in IN 0 0 12 O
view NN 0 1 12 O
however RB 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
well RB 0 1 12 O
documented VBN 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
rimantadine NN 0 1 13 B-Drug
HCl NNP 0 0 14 I-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
one CD 0 1 12 O
hour NN 0 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
Cimetidine NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
four CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
) ) 0 0 2 O
the DT 0 0 12 O
apparent JJ 0 1 1 O
total JJ 0 1 1 O
rimantadine JJ 0 1 13 B-Drug
clearance NN 0 1 16 O
of IN 0 0 12 O
this DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
in IN 0 0 12 O
normal JJ 0 1 1 O
healthy JJ 0 1 12 O
adults NNS 1 1 13 O
was VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
compared VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
apparent JJ 0 1 1 O
total JJ 0 1 1 O
rimantadine NN 0 1 13 B-Drug
clearance NN 0 1 16 O
in IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
subjects NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
situations NNS 1 0 UNK O
when WRB 0 0 12 O
concurrent NN 0 1 1 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
careful JJ 0 1 12 O
patient NN 0 1 6 O
monitoring NN 0 1 1 O
is VBZ 1 0 12 O
essential JJ 0 1 13 O
. . 0 0 12 O

These DT 0 0 1 O
agents NNS 1 1 1 O
may MD 0 0 1 O
also RB 0 0 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
clinically RB 0 0 6 O
effective JJ 0 1 1 O
duration NN 0 1 1 O
of IN 0 0 12 O
action NN 0 1 13 O
by IN 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

H9 NNP 0 0 UNK B-Group
- : 0 0 2 O
Receptor NN 0 1 UNK I-Group
Antagonists NNS 0 1 UNK I-Group
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
intravenously RB 0 0 14 O
administered VBN 1 1 1 O
famotidine NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
reduced VBD 1 1 1 O
the DT 0 0 12 O
oral JJ 0 1 6 O
absorption NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
cefditoren NNS 0 1 UNK B-Drug
pivoxil VBP 0 0 UNK I-Drug
administered VBN 1 1 1 O
following VBG 1 1 1 O
a DT 0 0 12 O
meal NN 0 1 12 O
as IN 1 0 12 O
evidenced VBN 1 1 1 O
by IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
mean JJ 0 1 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
mean JJ 0 1 12 O
AUC NNP 0 1 UNK O
. . 0 0 12 O

A DT 0 0 2 O
possible JJ 0 1 1 O
interaction NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
suggested VBN 1 1 12 O
with IN 0 0 12 O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
and CC 0 0 12 O
the DT 0 0 12 O
herbal JJ 0 1 6 O
supplement NN 0 1 1 O
St. NNP 0 1 2 O
Johns NNP 0 0 UNK O
Wort NNP 0 0 UNK O
based VBN 1 1 1 O
on IN 0 0 12 O
some DT 0 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
users NNS 1 1 UNK O
experiencing VBG 1 1 12 O
breakthrough IN 0 1 1 O
bleeding VBG 1 1 6 O
shortly RB 0 0 12 O
after IN 0 0 12 O
starting VBG 1 1 12 O
St. NNP 0 1 2 O
Johns NNP 0 0 UNK O
Wort NNP 0 0 UNK O
. . 0 0 12 O

Do NNP 0 0 2 O
not RB 0 1 12 O
start VB 0 1 12 O
or CC 0 0 12 O
stop VB 0 1 12 O
any DT 0 0 12 O
medicine NN 0 1 6 O
without IN 0 0 12 O
doctor NN 0 1 12 O
or CC 0 0 12 O
pharmacist NN 0 1 13 O
approval NN 0 1 1 O
. . 0 0 12 O

While IN 0 0 12 O
mean JJ 0 1 12 O
INR NNP 0 1 13 O
values NNS 1 1 1 O
were VBD 1 0 12 O
only RB 0 1 12 O
slightly RB 0 1 3 O
increased VBN 1 1 1 O
with IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
the DT 0 0 12 O
day NN 0 1 12 O
- : 0 0 2 O
to TO 0 0 12 O
- : 0 0 2 O
day NN 0 1 12 O
variability NN 0 1 UNK O
in IN 0 0 12 O
individual JJ 0 1 1 O
INR NNP 0 1 13 O
values NNS 1 1 1 O
was VBD 1 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
OMNICEF NNP 0 1 UNK B-Brand
for IN 0 0 12 O
Oral NNP 0 1 2 O
Suspension NNP 0 1 2 O
can MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
iron NN 0 1 3 B-Drug_n
- : 0 0 2 O
fortified VBN 1 0 3 O
infant JJ 0 1 6 O
formula NN 0 1 1 O
. . 0 0 12 O

block NN 0 1 3 O
or CC 0 0 12 O
arrhythmia NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
on IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
is VBZ 1 0 12 O
variable JJ 0 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Anticoagulants NNS 0 1 UNK B-Group
: : 0 0 2 O
Interaction NN 0 1 2 O
studies NNS 1 1 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
have VBP 0 0 12 O
shown VBN 1 1 1 O
bumetanide NN 0 1 16 B-Drug
to TO 0 0 12 O
have VB 0 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
warfarin JJ 0 1 14 B-Drug
metabolism NN 0 1 16 O
or CC 0 0 12 O
on IN 0 0 12 O
plasma JJ 0 1 14 O
prothrombin NN 0 1 14 O
activity NN 0 1 1 O
. . 0 0 12 O

. . 0 0 12 O

Nevertheless RB 0 0 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
Mefloquine NNP 0 1 UNK B-Drug
on IN 0 0 12 O
travelers NNS 1 1 UNK O
receiving VBG 1 1 1 O
comedication NN 0 0 UNK O
particularly RB 0 0 1 O
diabetics NNS 1 1 UNK O
or CC 0 0 12 O
patients NNS 1 1 6 O
using VBG 1 1 1 O
anticoagulants NNS 1 1 13 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
checked VBN 1 1 12 O
before IN 0 1 12 O
departure NN 0 1 12 O
. . 0 0 12 O

Since IN 0 1 2 O
entecavir NN 0 1 16 B-Drug
is VBZ 1 0 12 O
primarily RB 0 0 1 O
eliminated VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
kidneys NNS 1 1 6 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
BARACLUDE NNP 0 1 UNK B-Brand
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
reduce VB 0 0 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
or CC 0 0 12 O
compete NN 0 0 UNK O
for IN 0 0 12 O
active JJ 0 1 1 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
may MD 0 0 1 O
increase VB 0 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
either DT 0 1 12 O
entecavir NN 0 1 16 B-Drug
or CC 0 0 12 O
the DT 0 0 12 O
coadministered JJ 0 0 UNK O
drug NN 0 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
concomitant JJ 0 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
naratriptan NN 0 1 13 B-Drug
and CC 0 0 12 O
an DT 0 0 12 O
SSRI NNP 0 1 UNK B-Group
is VBZ 1 0 12 O
clinically RB 0 0 6 O
warranted JJ 0 0 1 O
appropriate JJ 0 1 1 O
observation NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
. . 0 0 12 O

Antihistamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
partially RB 0 0 1 O
counteract VB 0 0 UNK O
the DT 0 0 12 O
anticoagulation NN 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
heparin NN 0 1 14 B-Drug
or CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Limited VBN 0 1 2 O
published VBN 1 1 UNK O
data NNS 0 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
GH NNP 0 1 13 B-Drug
treatment NN 0 1 6 O
increases VBZ 1 1 1 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
( ( 0 0 2 O
CP9 NNP 0 0 UNK O
) ) 0 0 2 O
mediated VBD 1 1 13 O
antipyrine JJ 0 1 UNK B-Drug
clearance NN 0 1 16 O
in IN 0 0 12 O
man NN 0 1 12 O
. . 0 0 12 O

therefore RB 0 0 1 O
the DT 0 0 12 O
disposition NN 0 1 1 O
of IN 0 0 12 O
eszopiclone NN 0 1 13 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
sensitive JJ 0 1 1 O
to TO 0 0 12 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
troleandomycin NN 0 1 UNK B-Drug
and CC 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
methylprednisolone NN 0 1 16 B-Drug
and CC 0 0 12 O
thus RB 0 0 1 O
decrease VB 0 1 1 O
its PRP$ 1 0 12 O
clearance NN 0 1 16 O
. . 0 0 12 O

Of IN 0 0 2 O
particular JJ 0 0 1 O
importance NN 0 1 1 O
sufficient JJ 0 1 1 O
time NN 0 1 12 O
must MD 0 0 12 O
elapse VB 0 1 UNK O
before IN 0 1 12 O
initiating VBG 1 1 1 O
TCA NNP 0 1 13 O
treatment NN 0 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
being VBG 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
given VBN 1 1 12 O
the DT 0 0 12 O
long JJ 0 1 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
parent NN 0 1 13 O
and CC 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
( ( 0 0 2 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
) ) 0 0 2 O
. . 0 0 12 O

Patients NNS 0 1 7 O
medicated VBN 1 1 UNK O
with IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
trimetrexate NN 0 1 UNK B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

aBased VBN 0 0 UNK O
on IN 0 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
narcotic JJ 0 1 6 O
withdrawal NN 0 1 1 O
syndrome NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
nevirapine NN 0 1 13 B-Drug
and CC 0 0 12 O
methadone NN 0 1 6 B-Drug
concurrently RB 0 0 1 O
and CC 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
decreased JJ 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
methadone NN 0 1 6 B-Drug
. . 0 0 12 O

Other JJ 0 0 2 O
interactions NNS 1 1 UNK O
: : 0 0 2 O
Vardenafil NNP 0 1 UNK B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
of IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
( ( 0 0 2 O
glucose JJ 0 1 14 O
and CC 0 0 12 O
insulin JJ 0 1 14 O
concentrations NNS 1 1 13 O
) ) 0 0 2 O
and CC 0 0 12 O
warfarin $ 0 1 14 B-Drug
( ( 0 0 2 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
other JJ 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
parameters NNS 1 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Special JJ 0 1 2 O
consideration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
ETHYOL NNP 0 1 UNK B-Brand
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
antihypertensive JJ 0 1 14 B-Group
medications NNS 1 1 6 I-Group
or CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
could MD 0 0 12 O
cause VB 0 1 12 O
or CC 0 0 12 O
potentiate VB 0 0 UNK O
hypotension NN 0 1 6 O
. . 0 0 12 O

Once RB 0 0 12 O
a DT 0 0 12 O
stable JJ 0 1 1 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
documented VBN 1 1 1 O
prothrombin JJ 0 1 14 O
times NNS 1 1 12 O
can MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
intervals NNS 1 1 1 O
usually RB 0 1 12 O
recommended VBD 1 1 1 O
for IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
coumarin JJ 0 1 UNK B-Group
anticoagulants NNS 1 1 13 I-Group
. . 0 0 12 O

A DT 0 0 2 O
greater JJR 1 1 1 O
potentiation NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blocking NN 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
MIVACRON NNP 0 1 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
expected VBN 1 1 12 O
with IN 0 0 12 O
higher JJR 1 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
enflurane NN 0 1 UNK B-Drug
or CC 0 0 12 O
isoflurane NN 0 1 UNK B-Drug
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
an DT 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
rat NN 0 1 13 O
liver NN 0 1 6 O
model NN 0 1 UNK O
nitrogen NN 0 1 1 O
substituted VBN 1 0 UNK O
imidazole JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
clotrimazole JJ 0 1 0 B-Drug
ketoconazole NN 0 1 16 B-Drug
miconazole NN 0 1 16 B-Drug
) ) 0 0 2 O
were VBD 1 0 12 O
potent JJ 0 1 UNK O
non JJ 0 1 1 O
- : 0 0 2 O
competitive JJ 0 1 UNK O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
trimetrexate JJ 0 1 UNK B-Drug
metabolism NN 0 1 16 O
. . 0 0 12 O

. . 0 0 12 O

Multivalent NNP 0 0 UNK O
Cation NNP 0 1 UNK O
- : 0 0 2 O
Containing NN 0 1 2 O
Products NNS 0 1 2 O
: : 0 0 2 O
Concurrent NNP 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
quinolone NN 0 1 UNK B-Group
including VBG 1 1 1 O
ciprofloxacin NN 0 1 0 B-Drug
with IN 0 0 12 O
multivalent JJ 0 0 UNK O
cation NN 0 1 UNK O
- : 0 0 2 O
containing VBG 1 1 1 O
products NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
magnesium NN 0 1 14 B-Drug
or CC 0 0 12 O
aluminum NN 0 1 16 B-Drug
antacids NNS 1 1 14 B-Group
sucralfate VBP 0 1 0 B-Drug
VIDEX NNP 0 1 UNK B-Brand
chewable JJ 0 0 16 O
/ NN 0 0 2 O
buffered VBD 1 1 16 O
tablets NNS 1 1 3 O
or CC 0 0 12 O
pediatric JJ 0 1 6 O
powder NN 0 1 3 O
or CC 0 0 12 O
products NNS 1 1 1 O
containing VBG 1 1 1 O
calcium NN 0 1 14 B-Drug
iron NN 0 1 3 B-Drug
or CC 0 0 12 O
zinc NN 0 1 14 B-Drug
may MD 0 0 1 O
substantially RB 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
serum NN 0 1 14 O
and CC 0 0 12 O
urine JJ 0 1 6 O
levels NNS 1 1 1 O
considerably RB 0 0 1 O
lower JJR 1 1 1 O
than IN 0 0 12 O
desired VBN 1 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
is VBZ 1 0 12 O
continued VBN 1 1 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
particularly RB 0 0 1 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
especially RB 0 0 12 O
conduction JJ 0 1 6 O
disturbances NNS 1 1 6 O
and CC 0 0 12 O
exacerbation NN 0 0 6 O
of IN 0 0 12 O
tachyarrhythmias NN 0 1 UNK O
as IN 1 0 12 O
amiodarone NN 0 1 0 B-Drug
is VBZ 1 0 12 O
continued VBN 1 1 12 O
. . 0 0 12 O

. . 0 0 12 O

Neither DT 0 0 12 O
subject NN 0 1 UNK O
demonstrated VBD 1 0 1 O
clinical JJ 0 1 6 O
evidence NN 0 1 1 O
of IN 0 0 12 O
allergic NN 0 1 6 O
or CC 0 0 12 O
anaphylactic JJ 0 1 13 O
reactions NNS 1 1 1 O
and CC 0 0 12 O
repeat NN 0 1 12 O
testing NN 0 1 1 O
was VBD 1 0 12 O
not RB 0 1 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Oral JJ 0 1 2 O
neomycin JJ 0 1 16 B-Drug
sulfate NN 0 1 14 I-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
coumarin NN 0 1 UNK B-Group
in IN 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
by IN 0 0 12 O
decreasing VBG 1 1 1 O
vitamin NN 0 1 6 O
K NNP 0 1 2 O
availability NN 0 1 UNK O
. . 0 0 12 O

Thus RB 0 0 1 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
observed VBD 1 1 1 O
between IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
for IN 0 0 12 O
dirithromycin NN 0 1 UNK B-Drug
. . 0 0 12 O

For IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
ketoconazole NN 0 1 16 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
potent JJ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
other JJ 0 0 12 O
azole JJ 0 1 UNK B-Group
antifungals NNS 1 1 UNK I-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
itraconazole JJ 0 1 0 B-Drug
miconazole NN 0 1 16 B-Drug
) ) 0 0 2 O
or CC 0 0 12 O
macrolide JJ 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
( ( 0 0 2 O
eg JJ 0 1 UNK O
erythromycin NN 0 1 0 B-Drug
clarithromycin NN 0 1 13 B-Drug
) ) 0 0 2 O
or CC 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
or CC 0 0 12 O
vinblastine VB 0 1 13 B-Drug
the DT 0 0 12 O
recommended JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
DETROL NNP 0 1 UNK B-Brand
LA NNP 0 1 2 I-Brand
is VBZ 1 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily RB 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
one CD 0 1 12 O
controlled VBD 1 1 1 O
clinical JJ 0 1 6 O
study NN 0 1 1 O
the DT 0 0 12 O
ureidopenicillins NNS 0 0 UNK O
including VBG 1 1 1 O
piperacillin NN 0 1 16 B-Drug
were VBD 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
vecuronium NN 0 1 16 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
five CD 0 1 12 O
men NNS 0 1 13 O
terfenadine NN 0 1 UNK B-Drug
levels NNS 1 1 1 O
were VBD 1 0 12 O
undetectable JJ 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
ng RB 0 1 13 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
) ) 0 0 2 O
throughout IN 0 0 12 O
the DT 0 0 12 O
study NN 0 1 1 O
; : 0 0 2 O

Avoid IN 0 0 2 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
preparations NNS 1 1 13 O
such JJ 0 0 1 O
as IN 1 0 12 O
decongestants NNS 1 1 UNK B-Group
and CC 0 0 12 O
local JJ 0 1 12 O
anesthetics NNS 1 1 13 B-Group
which WDT 0 0 12 O
contain VBP 0 1 UNK O
any DT 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
amine NN 0 1 UNK I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
epinephrine VBP 0 1 14 B-Drug
norepinephrine NN 0 1 14 B-Drug
) ) 0 0 2 O
since IN 0 1 12 O
it PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
that IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
can MD 0 0 12 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
catecholamines NNS 1 1 14 O
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
phenothiazines NNS 1 1 UNK B-Group
may MD 0 0 1 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
anorectic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
diethylpropion NN 0 1 UNK B-Drug
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
definitive JJ 0 1 1 O
information NN 0 1 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
coadministering VBG 0 0 UNK O
fluconazole NN 0 1 0 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
precaution NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
when WRB 0 0 12 O
coadministration NN 0 1 UNK O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Leucovorin NN 0 1 UNK B-Drug
: : 0 0 2 O
The DT 0 0 2 O
concentration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug
- : 0 0 2 O
fluorouracil NN 0 1 13 I-Drug
is VBZ 1 0 12 O
increased VBN 1 1 1 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
toxicity NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
leucovorin NN 0 1 16 B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
aripiprazole VB 0 1 16 B-Drug
therapy NN 0 1 6 O
aripiprazole NN 0 1 16 B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
doubled VBN 1 1 12 O
. . 0 0 12 O

administration NN 0 1 1 O
9 CD 0 0 2 O
hour NN 0 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
colestipol NN 0 1 13 B-Drug
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O
) ) 0 0 2 O

= JJ 0 0 2 O
increase NN 0 1 1 O
; : 0 0 2 O

Since IN 0 1 2 O
animal NN 0 1 13 O
studies NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
barbiturates NNS 1 1 14 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
prolonged VBN 1 1 6 O
by IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
chlorpropamide JJ 0 1 13 B-Drug
barbiturates NNS 1 1 14 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
employed VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
potential JJ 0 1 1 O
for IN 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
affected VBN 1 1 1 O
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes NNS 1 1 14 O
may MD 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
ruled VBN 1 1 12 O
out RP 0 1 12 O
. . 0 0 12 O

therefore RB 0 0 1 O
the DT 0 0 12 O
disposition NN 0 1 1 O
of IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
sensitive JJ 0 1 1 O
to TO 0 0 12 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
based VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
population NN 0 1 13 O
pharmacokinetics NNS 0 1 UNK O
analysis NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
combined VBN 1 1 1 O
data NNS 0 1 1 O
from IN 0 0 12 O
grapefruit NN 0 1 3 O
and CC 0 0 12 O
orange NN 0 1 16 O
juices NNS 1 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
data NNS 0 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
bioequivalence NN 0 1 UNK O
study NN 0 1 1 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
fexofenadine NN 0 1 16 B-Drug
was VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Elevated VBN 0 1 7 O
cyclosporine JJ 0 1 14 B-Drug
serum NN 0 1 14 O
levels NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
quinolones NNS 0 1 13 B-Group
and CC 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
. . 0 0 12 O

However RB 0 0 1 O
there EX 0 0 12 O
were VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increases NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
respectively RB 0 0 1 O
of IN 0 0 12 O
the DT 0 0 12 O
combined JJ 0 1 1 O
moieties NNS 1 0 UNK O
of IN 0 0 12 O
threohydrobupropion NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
erythrohydrobupropion NN 0 1 UNK B-Drug_n
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
clofarabine NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
p9 NN 0 1 UNK O
substrates NNS 1 1 UNK O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Hypotension NN 0 1 7 O
Patients NNS 0 1 7 O
on IN 0 0 12 O
Diuretic JJ 0 1 UNK B-Group
Therapy NN 0 1 2 O
: : 0 0 2 O
Patients NNS 0 1 7 O
on IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
and CC 0 0 12 O
especially RB 0 0 12 O
those DT 0 0 12 O
in IN 0 0 12 O
whom WP 0 0 12 O
diuretic JJ 0 1 14 B-Group
therapy NN 0 1 6 O
was VBD 1 0 12 O
recently RB 0 1 12 O
instituted VBN 1 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
those DT 0 0 12 O
on IN 0 0 12 O
severe JJ 0 1 6 O
dietary JJ 0 1 6 O
salt NN 0 1 3 O
restriction NN 0 1 1 O
or CC 0 0 12 O
dialysis NN 0 1 6 O
may MD 0 0 1 O
occasionally RB 0 1 12 O
experience VB 0 1 12 O
a DT 0 0 12 O
precipitous JJ 0 0 13 O
reduction NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
usually RB 0 1 12 O
within IN 0 0 1 O
the DT 0 0 12 O
first JJ 0 1 12 O
hour NN 0 1 12 O
after IN 0 0 12 O
receiving VBG 1 1 1 O
the DT 0 0 12 O
initial JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
captopril NN 0 1 0 B-Drug
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
potential JJ 0 1 1 O
exists NNS 0 1 UNK O
for IN 0 0 12 O
a DT 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
WELLBUTRIN NNP 0 1 0 B-Brand
and CC 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
affect VBP 0 1 1 O
the DT 0 0 12 O
CYP9B9 NNP 0 0 UNK O
isoenzyme NN 0 1 13 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
orphenadrine NN 0 1 13 B-Drug
and CC 0 0 12 O
cyclophosphamide NN 0 1 14 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
SN9 NNP 0 0 UNK B-Drug_n
the DT 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
of IN 0 0 12 O
irinotecan JJ 0 1 13 B-Drug
were VBD 1 0 12 O
on IN 0 0 12 O
average JJ 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
higher JJR 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
bolus JJ 0 1 14 O
- : 0 0 2 O
IFL NN 0 1 UNK O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
AVASTIN NNP 0 1 UNK B-Brand
when WRB 0 0 12 O
compared VBN 1 1 1 O
with IN 0 0 12 O
bolus JJ 0 1 14 O
- : 0 0 2 O
IFL NNP 0 1 UNK O
alone RB 0 1 12 O
. . 0 0 12 O

Although IN 0 0 12 O
such PDT 0 0 1 O
a DT 0 0 12 O
reaction NN 0 1 1 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
with IN 0 0 12 O
roxithromycin NN 0 1 UNK B-Drug
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
roxithromycin NN 0 1 UNK B-Drug
with IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
or CC 0 0 12 O
astemizole NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
% NN 0 0 18 O

Rare JJ 0 1 2 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
disulfiram JJ 0 1 13 O
- : 0 0 2 O
like IN 0 0 12 O
reaction NN 0 1 1 O
to TO 0 0 12 O
alcohol NNS 0 1 1 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
several JJ 0 1 12 O
closely RB 0 0 1 O
related JJ 0 1 1 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
methylphenidate NN 0 1 16 B-Drug
or CC 0 0 12 O
hepatic JJ 0 1 14 O
enzyme NN 0 1 14 O
inhibitors NNS 1 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
cimetidine NN 0 1 13 B-Drug
fluoxetine NN 0 1 16 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
enzyme NN 0 1 14 O
inducers NNS 1 1 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
barbiturates NNS 1 1 14 B-Group
phenytoin VBP 0 1 16 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
such JJ 0 0 1 O
an DT 0 0 12 O
effect NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
anticipated VBN 1 1 1 O
with IN 0 0 12 O
CMI NNP 0 0 13 B-Drug
as RB 0 0 12 O
well RB 0 1 12 O
. . 0 0 12 O

Terfenadine NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
prospective JJ 0 1 UNK O
study NN 0 1 1 O
involving VBG 1 1 1 O
six CD 0 1 12 O
- : 0 0 2 O
healthy JJ 0 1 12 O
- : 0 0 2 O
male NN 0 1 12 O
volunteers NNS 1 1 UNK O
dirithromycin VBP 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
was VBD 1 0 12 O
decreased VBN 1 1 1 O
an DT 0 0 12 O
average NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
given VBN 1 1 12 O
ciprofloxacin NNS 0 1 0 B-Drug
and CC 0 0 12 O
didanosine VB 0 1 16 B-Drug
- : 0 0 2 O
placebo NN 0 1 13 O
tablets NNS 1 1 3 O
concurrently RB 0 0 1 O
. . 0 0 12 O

Antiarrhythmics NNS 0 1 UNK B-Group
: : 0 0 2 O
amiodarone NN 0 1 0 B-Drug

Prednisone NNP 0 1 0 B-Drug
/ NNP 0 0 2 O
prednisolone NN 0 1 0 B-Drug
: : 0 0 2 O
Rofecoxib NN 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
any DT 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
prednisolone NN 0 1 0 B-Drug
or CC 0 0 12 O
prednisone NN 0 1 0 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
PBI NNP 0 1 UNK O
and CC 0 0 12 O
radioactive JJ 0 1 1 O
iodine NN 0 1 14 O
uptake NN 0 1 14 O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

Hypersensitivity NNP 0 1 7 O
reactions NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
combination NN 0 1 1 O
regimens NNS 1 1 UNK O
containing VBG 1 1 1 O
sequential JJ 0 1 1 O
high JJ 0 1 1 O
dose NN 0 1 6 O
PROLEUKIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
antineoplastic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
specifically RB 0 0 1 O
dacarbazine VBP 0 1 13 B-Drug
cis SYM 1 1 13 B-Drug
- : 0 0 2 O
platinum NN 0 1 UNK I-Drug
tamoxifen NN 0 1 0 B-Drug
and CC 0 0 12 O
interferon NN 0 1 14 B-Drug
- : 0 0 2 O
alfa NN 0 1 16 I-Drug
. . 0 0 12 O

Anastrozole NNP 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
antipyrine NN 0 1 UNK B-Drug
. . 0 0 12 O

Fluvoxamine NNP 0 1 UNK B-Drug
increased VBD 1 1 1 O
mean JJ 0 1 12 O
alosetron NN 0 1 UNK B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
and CC 0 0 12 O
prolonged VBD 1 1 6 O
the DT 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
. . 0 0 12 O

Therefore RB 0 0 1 O
concurrent JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
Trileptal NNP 0 1 UNK B-Brand
with IN 0 0 12 O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
may MD 0 0 1 O
render VB 0 0 13 O
these DT 0 0 12 O
contraceptives NNS 1 1 13 B-Group
less RBR 0 1 12 O
effective JJ 0 1 1 O
. . 0 0 12 O

Quinolone NN 0 1 UNK B-Group
Antibiotics NNS 0 1 7 I-Group
: : 0 0 2 O
VIDEX NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
dosing VBG 1 0 14 O
with IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
because IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
are VBP 1 0 12 O
decreased VBN 1 1 1 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
antacids NNS 1 1 14 B-Group
containing VBG 1 1 1 O
magnesium NN 0 1 14 B-Drug
calcium NN 0 1 14 B-Drug
or CC 0 0 12 O
aluminum NN 0 1 16 B-Drug
. . 0 0 12 O

These DT 0 0 1 O
are VBP 1 0 12 O
described VBN 1 1 1 O
in IN 0 0 12 O
greater JJR 1 1 1 O
detail NN 0 1 1 O
below IN 0 0 12 O
: : 0 0 2 O
DIFLUCAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
agents NNS 1 1 1 O
/ VBP 0 0 2 O
classes NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Ritonavir NNP 0 1 0 B-Drug
- : 0 0 2 O
Combined JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
ritonavir NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
both CC 0 0 12 O
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
and CC 0 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
escitalopram NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
ritonavir NN 0 1 16 B-Drug
or CC 0 0 12 O
escitalopram NN 0 1 0 B-Drug
. . 0 0 12 O

Amprenavir NN 0 1 UNK B-Drug

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
MICRONASE NNP 0 1 UNK B-Brand
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
observed VBN 1 1 1 O
for IN 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
control NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
second JJ 0 1 12 O
pregnancy NN 0 1 6 O
test NN 0 1 1 O
( ( 0 0 2 O
a DT 0 0 12 O
confirmation NN 0 1 1 O
test NN 0 1 1 O
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
done VBN 1 0 12 O
during IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
menstrual JJ 0 1 6 O
period NN 0 1 1 O
immediately RB 0 1 12 O
preceding VBG 1 1 1 O
the DT 0 0 12 O
beginning NN 0 1 12 O
of IN 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
. . 0 0 12 O

Because IN 0 0 12 O
severe JJ 0 1 6 O
hypoglycemia NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
concomitantly RB 0 0 14 O
receiving VBG 1 1 1 O
oral JJ 0 1 6 O
miconazole NN 0 1 16 B-Drug
( ( 0 0 2 O
an DT 0 0 12 O
imidazole NN 0 1 UNK B-Group
) ) 0 0 2 O
and CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
such JJ 0 0 1 O
a DT 0 0 12 O
potential JJ 0 1 1 O
interaction NN 0 1 UNK O
involving VBG 1 1 1 O
the DT 0 0 12 O
latter JJ 0 0 UNK O
agents NNS 1 1 1 O
when WRB 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
ketoconazole JJ 0 1 16 B-Drug
tablets NNS 1 1 3 O
( ( 0 0 2 O
an DT 0 0 12 O
imidazole NN 0 1 UNK B-Group
) ) 0 0 2 O
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
ruled VBN 1 1 12 O
out RP 0 1 12 O
. . 0 0 12 O

Itraconazole NN 0 1 UNK B-Drug

Concomitant NNP 0 1 UNK O
Crohn NNP 0 1 6 O
disease NN 0 1 6 O
medications NNS 1 1 6 O
were VBD 1 0 12 O
antibiotics NNS 1 1 6 B-Group
antivirals NNS 1 1 UNK B-Group
corticosteroids NNS 1 1 14 B-Group
9 CD 0 0 2 B-Drug
- : 0 0 2 O
MP NNP 0 1 13 I-Drug
/ NNP 0 0 2 O
AZA NNP 0 1 UNK B-Drug
and CC 0 0 12 O
aminosalicylates NNS 0 1 UNK O
. . 0 0 12 O

Fluvoxamine NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
an DT 0 0 12 O
isoform NN 0 1 UNK O
also RB 0 0 12 O
involved VBN 1 1 12 O
in IN 0 0 12 O
TCA NNP 0 1 13 B-Group
metabolism NN 0 1 16 O
. . 0 0 12 O

Acute NNP 0 1 7 O
symptoms NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
short JJ 0 1 12 O
- : 0 0 2 O
acting VBG 1 1 12 O
inhaled VBN 1 1 14 O
beta9 SYM 0 0 UNK B-Group
- : 0 0 2 O
agonist NN 0 1 14 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
salbutamol NN 0 1 UNK B-Drug
( ( 0 0 2 O
the DT 0 0 12 O
physician NN 0 1 6 O
should MD 0 0 12 O
provide VB 0 1 1 O
the DT 0 0 12 O
patient NN 0 1 6 O
with IN 0 0 12 O
such JJ 0 0 1 O
medication NN 0 1 6 O
and CC 0 0 12 O
instruct VB 0 0 13 O
the DT 0 0 12 O
patient NN 0 1 6 O
in IN 0 0 12 O
how WRB 0 0 12 O
it PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

. . 0 0 12 O

The DT 0 0 2 O
mean JJ 0 1 12 O
minimum JJ 0 1 1 O
lithium NN 0 1 16 B-Drug
concentration NN 0 1 1 O
increased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
the DT 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
was VBD 1 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
during IN 0 0 12 O
this DT 0 0 12 O
period NN 0 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
drug NN 0 1 1 O
administration NN 0 1 1 O
. . 0 0 12 O

Erythromycin NNP 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
triazolam NN 0 1 13 B-Drug
and CC 0 0 12 O
midazolam NN 0 1 16 B-Drug
and CC 0 0 12 O
thus RB 0 0 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
pharmacologic JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
. . 0 0 12 O

Usually RB 0 1 UNK O
this DT 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
diabetes NNS 0 1 6 O
mellitus VBP 0 0 6 O
or CC 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
glucose JJ 0 1 14 O
intolerance NN 0 1 6 O
prior RB 0 1 1 O
to TO 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
CAMPTOSAR NNP 0 1 UNK B-Brand
. . 0 0 12 O

Acetaminophen NNP 0 1 0 B-Drug
and CC 0 0 12 O
methotrexate VB 0 1 16 B-Drug
- : 0 0 2 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
methionine NN 0 1 UNK I-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
hepatic JJ 0 1 14 O
toxicity NN 0 1 6 O
in IN 0 0 12 O
those DT 0 0 12 O
with IN 0 0 12 O
acetaminophen JJ 0 1 16 B-Drug
overdosage NN 0 0 UNK O
or CC 0 0 12 O
in IN 0 0 12 O
those DT 0 0 12 O
taking VBG 1 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
succimer NN 0 1 UNK B-Drug
to TO 0 0 12 O
cause VB 0 1 12 O
false JJ 0 1 13 O
positive JJ 0 1 1 O
results NNS 1 1 1 O
for IN 0 0 12 O
ketones NNS 1 1 14 O
in IN 0 0 12 O
urine JJ 0 1 6 O
using VBG 1 1 1 O
nitroprusside JJ 0 1 14 O
reagents NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
Ketostix NNP 0 1 UNK O
and CC 0 0 12 O
falsely RB 0 0 1 O
decreased JJ 0 1 1 O
measurements NNS 1 1 1 O
of IN 0 0 12 O
serum NN 0 1 14 O
uric JJ 0 0 14 O
acid NN 0 1 14 O
and CC 0 0 12 O
CPK NNP 0 0 15 O
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
if IN 0 0 12 O
patients NNS 1 1 6 O
receive VBP 0 1 1 O
large JJ 0 1 3 O
doses NNS 1 1 6 O
of IN 0 0 12 O
ethchlorvynol NN 0 1 UNK B-Drug
concurrently RB 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
imipramine NN 0 1 0 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
hepatic JJ 0 1 14 O
enzyme NN 0 1 14 O
inhibitors NNS 1 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
cimetidine NN 0 1 13 B-Drug
fluoxetine NN 0 1 16 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
decrease NN 0 1 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
enzyme NN 0 1 14 O
inducers NNS 1 1 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
barbiturates NNS 1 1 14 B-Group
phenytoin VBP 0 1 16 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
imipramine NN 0 1 0 B-Drug
may MD 0 0 1 O
therefore RB 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
findings NNS 1 1 1 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
some DT 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
combined VBN 1 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
indomethacin NN 0 1 14 B-Drug
and CC 0 0 12 O
diflunisal NN 0 1 13 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
fatal JJ 0 1 13 O
gastrointestinal JJ 0 1 6 O
hemorrhage NN 0 1 6 O
. . 0 0 12 O

Antimycobacterial JJ 0 1 UNK B-Group
: : 0 0 2 O
rifampin NN 0 1 16 B-Drug

In IN 0 0 2 O
a DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
study NN 0 1 1 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
female NN 0 1 12 O
subjects NNS 1 1 UNK O
received VBD 1 1 12 O
ketoconazole JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
with IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
alosetron NN 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
on IN 0 0 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
day NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
magnitude NN 0 1 UNK O
of IN 0 0 12 O
interaction NN 0 1 UNK O
within IN 0 0 1 O
the DT 0 0 12 O
recommended VBN 1 1 1 O
dose NN 0 1 6 O
ranges NNS 1 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
case NN 0 1 12 O
that IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
digoxin NN 0 1 14 B-Drug
while IN 0 0 12 O
taking VBG 1 0 12 O
aminosalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
higher JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
needed VBN 1 1 12 O
. . 0 0 12 O

Anti NNP 0 0 UNK B-Group
- : 0 0 2 O
arrhythmics NNS 0 0 UNK I-Group
and CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
depressants NNS 1 0 13 I-Group
could MD 0 0 12 O
exaggerate VB 0 1 UNK O
the DT 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
observed VBD 1 1 1 O
with IN 0 0 12 O
bepridil JJ 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
. . 0 0 12 O

The DT 0 0 2 O
rate NN 0 1 1 O
and CC 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
perindopril JJ 0 1 UNK B-Drug
absorption NN 0 1 1 O
and CC 0 0 12 O
elimination NN 0 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
diuretics NNS 1 1 14 B-Group
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
imipramine JJ 0 1 0 B-Drug
hydrochloride NN 0 1 0 I-Drug
is VBZ 1 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
agents NNS 1 1 1 O
that WDT 0 0 12 O
lower JJR 1 1 1 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Cephalosporins NNP 0 1 15 B-Group
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
occasionally RB 0 1 12 O
induce VB 0 1 6 O
a DT 0 0 12 O
positive JJ 0 1 1 O
direct JJ 0 1 1 O
Coombs NNP 0 1 19 O
test NN 0 1 1 O
. . 0 0 12 O

Cerubidine NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
have VBP 0 0 12 O
previously RB 0 0 1 O
received VBN 1 1 12 O
the DT 0 0 12 O
recommended VBN 1 1 1 O
maximum NN 0 1 1 O
cumulative JJ 0 1 13 O
doses NNS 1 1 6 O
of IN 0 0 12 O
doxorubicin NN 0 1 13 B-Drug
or CC 0 0 12 O
Cerubidine NNP 0 1 UNK B-Brand
. . 0 0 12 O

Acetazolamide NN 0 1 0 B-Drug
: : 0 0 2 O
Concurrent JJ 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
acetazolamide NN 0 1 0 B-Drug
and CC 0 0 12 O
procaine JJ 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
may MD 0 0 1 O
extend VB 0 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
procaine NN 0 1 UNK B-Drug
. . 0 0 12 O

urticaria NNS 0 1 13 O

Other JJ 0 0 2 O
nephrotoxic JJ 0 1 UNK O
medications NNS 1 1 6 O
: : 0 0 2 O
agents NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
aminoglycosides NNS 0 1 13 B-Group
cyclosporine NN 0 1 14 B-Drug
and CC 0 0 12 O
pentamidine NN 0 1 14 B-Drug
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
induced JJ 0 1 6 O
renal JJ 0 1 6 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
only RB 0 1 12 O
with IN 0 0 12 O
great JJ 0 1 12 O
caution NN 0 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomes NNS 1 1 UNK O
showed VBD 1 1 12 O
that IN 0 0 12 O
terbinafine NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
tolbutamide JJ 0 1 UNK B-Drug
ethinylestradiol NN 0 1 UNK B-Drug
ethoxycoumarin NN 0 0 UNK B-Drug_n
and CC 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
treated VBN 1 1 1 O
with IN 0 0 12 O
Nalfon NNP 0 1 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
resistant JJ 0 1 3 O
to TO 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
loop NN 0 1 3 B-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

Inhibition NN 0 1 UNK O
of IN 0 0 12 O
metabolism NN 0 1 16 O
may MD 0 0 1 O
produce VB 0 0 1 O
significant JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
circulating VBG 1 1 13 O
phenytoin JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
and CC 0 0 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Systemic NNP 0 1 7 O
clonidine NN 0 1 0 B-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
production NN 0 1 1 O
of IN 0 0 12 O
catecholamines NNS 1 1 14 O
in IN 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
insulin VB 0 1 14 O
- : 0 0 2 O
induced VBN 1 1 6 O
hypoglycemia NN 0 1 6 O
and CC 0 0 12 O
mask VB 0 1 3 O
the DT 0 0 12 O
signs NNS 1 1 12 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
hypoglycemia NN 0 1 6 O
. . 0 0 12 O

- : 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
change VB 0 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
profile NN 0 1 1 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
( ( 0 0 2 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
fexofenadine VB 0 1 16 B-Drug
its PRP$ 1 0 12 O
carboxylated VBN 1 1 UNK O
metabolite NN 0 1 UNK O
and CC 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
QTc NNP 0 0 14 O
interval NN 0 1 1 O
following VBG 1 1 1 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
with IN 0 0 12 O
terfenadine JJ 0 1 UNK B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
onset NN 0 1 6 O
of IN 0 0 12 O
neuromuscular JJ 0 1 6 O
blockade NN 0 1 1 O
by IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
was VBD 1 0 12 O
unaffected VBN 0 1 UNK O
by IN 0 0 12 O
BREVIBLOC NNP 0 1 UNK B-Brand
but CC 0 0 12 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
neuromuscular JJ 0 1 6 O
blockade NN 0 1 1 O
was VBD 1 0 12 O
prolonged VBN 1 1 6 O
from IN 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
induce VBP 0 1 6 O
hepatic JJ 0 1 14 O
enzymes NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
phenobarbital JJ 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
and CC 0 0 12 O
may MD 0 0 1 O
require VB 0 0 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
corticosteroid NN 0 1 UNK B-Group
dose NN 0 1 6 O
to TO 0 0 12 O
achieve VB 0 0 1 O
the DT 0 0 12 O
desired JJ 0 1 1 O
response NN 0 1 1 O
. . 0 0 12 O

Agents NNS 0 1 2 O
with IN 0 0 12 O
Increased JJ 0 1 7 O
Levels NNS 0 1 2 O
in IN 0 0 12 O
the DT 0 0 12 O
Presence NNP 0 1 UNK O
of IN 0 0 12 O
Carbamazepine NNP 0 1 UNK B-Drug
: : 0 0 2 O
EQUETROTM NN 0 0 UNK B-Brand
increases VBZ 1 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
agents NNS 1 1 1 O
: : 0 0 2 O
Clomipramine NNP 0 1 0 B-Drug
HCl NNP 0 0 14 I-Drug
Phenytoin NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
primidone NN 0 1 13 B-Drug
Thus RB 0 0 1 O
if IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
titrated VBN 1 1 14 O
to TO 0 0 12 O
a DT 0 0 12 O
stable JJ 0 1 1 O
dosage NN 0 1 0 O
on IN 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
agents NNS 1 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
category NN 0 1 16 O
and CC 0 0 12 O
then RB 0 1 12 O
begins VBZ 1 1 12 O
a DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
EQUETROTM NNP 0 0 UNK B-Brand
it PRP 0 0 12 O
is VBZ 1 0 12 O
reasonable JJ 0 0 1 O
to TO 0 0 12 O
expect VB 0 0 12 O
that IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
decrease NN 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
agent NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Fenbufen NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
approved VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
United NNP 0 0 2 O
States NNPS 0 1 2 O
at IN 0 0 12 O
this DT 0 0 12 O
time NN 0 1 12 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
may MD 0 0 1 O
decrease VB 0 1 1 O
dasatinib VB 0 1 13 B-Drug
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
CYP9A9 NNP 0 0 UNK O
Inducers NNS 0 1 UNK O
: : 0 0 2 O
Drugs NNS 0 1 2 O
that IN 0 0 12 O
induce VBP 0 1 6 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
may MD 0 0 1 O
decrease VB 0 1 1 O
dasatinib VB 0 1 13 B-Drug
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Therefore IN 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
are VBP 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
Myfortic JJ 0 1 UNK B-Brand
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
additional JJ 0 1 1 O
birth NN 0 1 12 O
control NN 0 1 1 O
methods NNS 1 1 1 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Disulfiram NNP 0 1 UNK B-Drug
appears VBZ 1 1 12 O
to TO 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
rate NN 0 1 1 O
at IN 0 0 12 O
which WDT 0 0 12 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
and CC 0 0 12 O
therefore RB 0 0 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that IN 0 0 12 O
block NN 0 1 3 O
angiotensin NN 0 1 UNK O
II NNP 0 0 2 O
or CC 0 0 12 O
its PRP$ 1 0 12 O
effects NNS 1 1 1 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing NN 0 0 6 I-Group
diuretics NNS 1 1 14 I-Group
( ( 0 0 2 O
e.g. VB 0 0 UNK O
spironolactone NN 0 1 0 B-Drug
triamterene NN 0 1 13 B-Drug
amiloride NN 0 1 16 B-Drug
) ) 0 0 2 O
potassium NN 0 1 14 B-Drug
supplements NNS 1 1 6 O
or CC 0 0 12 O
salt NN 0 1 3 O
substitutes NNS 1 0 13 O
containing VBG 1 1 1 O
potassium NN 0 1 14 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
DIABINESE NNP 0 1 UNK B-Brand
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
hypoglycemia NN 0 1 6 O
. . 0 0 12 O

Therefore RB 0 0 1 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
clozapine NN 0 1 13 B-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
this DT 0 0 12 O
isozyme NN 0 1 UNK O
including VBG 1 1 1 O
antidepressants NNS 1 1 13 B-Group
phenothiazines NNS 1 1 UNK B-Group
carbamazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
Type NNP 0 1 2 B-Group
9C CD 0 0 UNK I-Group
antiarrhythmics NNS 1 1 UNK I-Group
( ( 0 0 2 O
e.g. VB 0 0 UNK O
propafenone NN 0 1 16 B-Drug
flecainide NN 0 1 16 B-Drug
and CC 0 0 12 O
encainide NN 0 1 UNK B-Drug
) ) 0 0 2 O
or CC 0 0 12 O
that DT 0 0 12 O
inhibit NN 0 1 13 O
this DT 0 0 12 O
enzyme NN 0 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
quinidine NN 0 1 16 B-Drug
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
approached VBN 1 1 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

ARAMINE NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
digitalized JJ 0 1 UNK O
patients NNS 1 1 6 O
since IN 0 1 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
digitalis NN 0 1 14 B-Group
and CC 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
amines NNS 1 1 13 I-Group
may MD 0 0 1 O
cause VB 0 1 12 O
ectopic NN 0 1 6 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

Downward NNP 0 1 UNK O
dosage NN 0 1 0 O
adjustments NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
Ritalin NNP 0 1 0 B-Brand
. . 0 0 12 O

As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
interaction NN 0 1 UNK O
by IN 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
mechanisms NNS 1 1 UNK O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
pharmacodynamic JJ 0 1 UNK O
pharmacokinetic JJ 0 1 UNK O
inhibition NN 0 1 13 O
or CC 0 0 12 O
enhancement JJ 0 1 1 O
etc NN 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O

this DT 0 0 12 O
phenomenon NN 0 1 1 O
was VBD 1 0 12 O
not RB 0 1 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
North JJ 0 1 2 O
American JJ 0 1 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

9HT9 CD 0 0 UNK B-Group
Antagonists NNS 0 1 UNK I-Group
: : 0 0 2 O
Based VBN 0 1 2 O
on IN 0 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
profound JJ 0 1 1 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
consciousness NN 0 1 1 O
when WRB 0 0 12 O
apomorphine NN 0 1 UNK B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
ondansetron NN 0 1 16 B-Drug
the DT 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
apomorphine NN 0 1 UNK B-Drug
with IN 0 0 12 O
drugs NNS 1 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
9HT9 CD 0 0 UNK B-Group
antagonist JJ 0 1 13 I-Group
class NN 0 1 12 I-Group
( ( 0 0 2 O
including VBG 1 1 1 O
for IN 0 0 12 O
example NN 0 1 1 O
ondansetron NN 0 1 16 B-Drug
granisetron NN 0 1 13 B-Drug
dolasetron NN 0 1 0 B-Drug
palonosetron NN 0 1 UNK B-Drug
and CC 0 0 12 O
alosetron NN 0 1 UNK B-Drug
) ) 0 0 2 O
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
BARACLUDE NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
renally RB 0 0 14 O
eliminated VBN 1 1 UNK O
or CC 0 0 12 O
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
and CC 0 0 12 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
when WRB 0 0 12 O
BARACLUDE NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
current JJ 0 1 1 O
evidence NN 0 1 1 O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
isoniazid NN 0 1 13 B-Drug
does VBZ 1 0 12 O
induce VB 0 1 6 O
P NNP 0 1 2 O
- : 0 0 2 O
9IIE9 CD 0 0 UNK O
a DT 0 0 12 O
mixed JJ 0 1 3 O
- : 0 0 2 O
function NN 0 1 1 O
oxidase NN 0 1 13 O
enzyme NN 0 1 14 O
that WDT 0 0 12 O
appears VBZ 1 1 12 O
to TO 0 0 12 O
generate VB 0 0 UNK O
the DT 0 0 12 O
toxic NN 0 1 1 O
metabolites VBZ 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
. . 0 0 12 O

Benzthiazide NNP 0 1 UNK B-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
blood NN 0 1 6 B-Group
thinners NNS 1 1 14 I-Group
decongestant VBP 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
allergy NN 0 1 6 O
cold NN 0 1 3 O
and CC 0 0 12 O
sinus NN 0 1 6 O
medicines NNS 1 1 6 O
) ) 0 0 2 O
diabetic JJ 0 1 6 O
drugs NNS 1 1 6 O
lithium VBP 0 1 16 B-Drug
norepinephrine JJ 0 1 14 B-Drug
NSAIDs NNP 0 1 UNK B-Group
like IN 0 0 12 O
Aleve NNP 0 1 UNK B-Brand
or CC 0 0 12 O
Ibuprofen NNP 0 1 0 B-Drug
and CC 0 0 12 O
high JJ 0 1 1 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
medications NNS 1 1 6 O
. . 0 0 12 O

cimetidine NN 0 1 13 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
many JJ 0 0 12 O
that WDT 0 0 12 O
are VBP 1 0 12 O
substrates VBZ 0 1 UNK O
for IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
( ( 0 0 2 O
many JJ 0 0 12 O
other JJ 0 0 12 O
antidepressants NNS 1 1 13 B-Group
phenothiazines NNS 1 1 UNK B-Group
and CC 0 0 12 O
the DT 0 0 12 O
Type NNP 0 1 2 B-Group
9C CD 0 0 UNK I-Group
antiarrhythmics NNS 1 1 UNK I-Group
propafenone NN 0 1 16 B-Drug
and CC 0 0 12 O
flecainide NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Increases NNS 0 1 UNK O
in IN 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Drug
antidepressants NNS 1 1 13 I-Drug
and CC 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
frequency NN 0 1 1 O
and CC 0 0 12 O
severity NN 0 1 6 O
of IN 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
particularly RB 0 0 1 O
anticholinergic NNS 0 1 13 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
when WRB 0 0 12 O
cimetidine NN 0 1 13 B-Drug
was VBD 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 B-Drug
regimen NNS 0 1 6 O
. . 0 0 12 O

Phenytoin NNP 0 1 0 B-Drug
phenobarbital NN 0 1 16 B-Drug
and CC 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
are VBP 1 0 12 O
ge VBN 0 1 13 O
nerally RB 0 0 UNK O
classified VBN 1 1 13 O
as IN 1 0 12 O
enzyme JJ 0 1 14 O
inducers NNS 1 1 UNK O
; : 0 0 2 O

Tetracyclines NNS 0 1 14 B-Group
: : 0 0 2 O
Since IN 0 1 2 O
both DT 0 0 12 O
acitretin NNS 0 1 13 B-Drug
and CC 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
can MD 0 0 12 O
cause VB 0 1 12 O
increased VBN 1 1 1 O
intracranial JJ 0 1 8 O
pressure NN 0 1 1 O
their PRP$ 0 0 12 O
combined VBN 1 1 1 O
use NN 0 1 1 O
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

When WRB 0 0 12 O
DIFLUCAN NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
these DT 0 0 12 O
or CC 0 0 12 O
other JJ 0 0 12 O
sulfonylurea JJ 0 1 UNK B-Group
oral JJ 0 1 6 I-Group
hypoglycemic JJ 0 1 14 I-Group
agents NNS 1 1 1 I-Group
blood VBD 0 1 6 O
glucose JJ 0 1 14 O
concentrations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
sulfonylurea NN 0 1 UNK B-Group
should MD 0 0 12 O
be VB 0 0 12 O
adjusted VBN 1 1 1 O
as IN 1 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

ranitidine NN 0 1 0 B-Drug
* NN 0 0 2 O
; : 0 0 2 O

Zidovudine NN 0 1 UNK B-Drug
: : 0 0 2 O
There EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
ZDV NNP 0 1 UNK B-Drug
and CC 0 0 12 O
zalcitabine NN 0 1 UNK B-Drug
which WDT 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
confirmed VBN 1 1 12 O
clinically RB 0 0 6 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
study NN 0 1 1 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
female NN 0 1 12 O
subjects NNS 1 1 UNK O
received VBD 1 1 12 O
fluvoxamine NN 0 1 16 B-Drug
in IN 0 0 12 O
escalating VBG 1 0 UNK O
doses NNS 1 1 6 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
per IN 0 0 1 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
with IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
alosetron NN 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
on IN 0 0 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
day NN 0 1 12 O
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
- : 0 0 2 O
adrenergic NN 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
also RB 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
sympathomimetics NNS 0 1 13 B-Group
. . 0 0 12 O

Results NNS 0 1 2 O
demonstrate VBP 0 0 1 O
that IN 0 0 12 O
oxcarbazepine NN 0 1 16 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
pharmacologically RB 0 0 UNK O
active JJ 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
monohydroxy NN 0 0 UNK O
metabolite NN 0 1 UNK O
( ( 0 0 2 O
MHD NNP 0 0 UNK B-Drug_n
) ) 0 0 2 O
have VBP 0 0 12 O
little JJ 0 1 12 O
or CC 0 0 12 O
no DT 0 0 12 O
capacity NN 0 1 1 O
to TO 0 0 12 O
function NN 0 1 1 O
as IN 1 0 12 O
inhibitors NNS 1 1 14 O
for IN 0 0 12 O
most JJS 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes RB 0 1 14 O
evaluated VBD 1 1 1 O
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
CYP9E9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
) ) 0 0 2 O
with IN 0 0 12 O
the DT 0 0 12 O
exception NN 0 1 12 O
of IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
/ NNP 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Both DT 0 0 2 O
groups NNS 1 1 1 O
of IN 0 0 12 O
agents NNS 1 1 1 O
increase VB 0 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
and CC 0 0 12 O
therefore RB 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
actions NNS 1 1 UNK O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
. . 0 0 12 O

Fluconazole NN 0 1 0 B-Drug

( ( 0 0 2 O
See VB 0 1 2 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
) ) 0 0 2 O
Coadministration NNP 0 1 UNK O
of IN 0 0 12 O
Femara NNP 0 1 UNK B-Brand
and CC 0 0 12 O
tamoxifen $ 0 1 0 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily RB 0 1 12 O
resulted VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
of IN 0 0 12 O
letrozole JJ 0 1 13 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
on IN 0 0 12 O
average NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
carcinogenic JJ 0 1 UNK O
potential NN 0 1 1 O
of IN 0 0 12 O
ribavirin NN 0 1 13 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
fully RB 0 0 1 O
determined VBN 1 1 1 O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
: : 0 0 2 O
There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
increased VBN 1 1 1 O
anticoagulant JJ 0 1 13 O
effects NNS 1 1 1 O
when WRB 0 0 12 O
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
were VBD 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

The DT 0 0 2 O
mean JJ 0 1 12 O
minimum JJ 0 1 1 O
lithium NN 0 1 16 B-Drug
concentration NN 0 1 1 O
increased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
the DT 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
was VBD 1 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Although IN 0 0 12 O
this DT 0 0 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
occurred VBN 1 1 1 O
in IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
coumarin JJ 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants NNS 1 1 13 I-Group
interactions NNS 1 1 UNK O
with IN 0 0 12 O
coumarin JJ 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants NNS 1 1 13 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
FELDENE NNP 0 1 UNK B-Brand
since IN 0 1 12 O
marketing VBG 1 1 UNK O
therefore RB 0 0 1 O
physicians NNS 1 1 6 O
should MD 0 0 12 O
closely RB 0 0 1 O
monitor VB 0 1 1 O
patients NNS 1 1 6 O
for IN 0 0 12 O
a DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
dosage NN 0 1 0 O
requirements NNS 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
FELDENE NNP 0 1 UNK B-Brand
to TO 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
coumarin JJ 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants NNS 1 1 13 I-Group
and CC 0 0 12 O
other JJ 0 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
risk NN 0 1 1 O
of IN 0 0 12 O
hypoglycemia NN 0 1 6 O
secondary JJ 0 1 1 O
to TO 0 0 12 O
this DT 0 0 12 O
mechanism NN 0 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
if IN 0 0 12 O
allopurinol NN 0 1 13 B-Drug
and CC 0 0 12 O
chlorpropamide NN 0 1 13 B-Drug
are VBP 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
renal JJ 0 1 6 O
insufficiency NN 0 1 6 O
. . 0 0 12 O

Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
. . 0 0 12 O

Drug NN 0 1 2 O
Name NN 0 1 2 O

Ingestion NN 0 1 UNK O
of IN 0 0 12 O
diclofenac NN 0 1 16 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
methotrexate NN 0 1 16 B-Drug
and CC 0 0 12 O
increase VB 0 1 1 O
cyclosporine NN 0 1 14 B-Drug
nephrotoxicity NN 0 1 UNK O
. . 0 0 12 O

Such JJ 0 0 1 O
agents NNS 1 1 1 O
must MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
at IN 0 0 12 O
least JJS 0 1 12 O
seven CD 0 1 12 O
days NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
starting VBG 1 1 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
VISTIDE NNP 0 1 UNK B-Brand
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
inhibit VBP 0 1 13 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
isozyme NN 0 1 UNK O
and CC 0 0 12 O
make VB 0 1 12 O
normal JJ 0 1 1 O
metabolizers NNS 0 0 UNK O
resemble JJ 0 0 UNK O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
. . 0 0 12 O

- : 0 0 2 O
Vitamin NN 0 1 2 B-Group
K NNP 0 1 2 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
AquaMEPHYTON NNP 0 1 UNK B-Brand
Synkayvite NNP 0 1 UNK B-Brand
) ) 0 0 2 O
Use NNP 0 1 2 O
of IN 0 0 12 O
sulfapyridine NN 0 1 UNK B-Drug
with IN 0 0 12 O
these DT 0 0 12 O
medicines NNS 1 1 6 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
chance NN 0 1 12 O
of IN 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
affecting VBG 1 1 1 O
the DT 0 0 12 O
blood NN 0 1 6 O

Streptozocin NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
doxorubicin NN 0 1 13 B-Drug
and CC 0 0 12 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
severe VB 0 1 6 O
bone NN 0 1 6 O
marrow JJ 0 1 6 O
suppression NN 0 1 1 O
; : 0 0 2 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsomes NNS 1 1 UNK O
suggest VBP 0 1 1 O
that IN 0 0 12 O
decitabine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
or CC 0 0 12 O
induce VB 0 1 6 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Lovastatin NNP 0 1 UNK B-Drug
therapy NN 0 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
bleeding NN 0 1 6 O
or CC 0 0 12 O
with IN 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
not RB 0 1 12 O
taking VBG 1 0 12 O
anticoagulants NNS 1 1 13 B-Group
. . 0 0 12 O

- : 0 0 2 O
The DT 0 0 2 O
action NN 0 1 13 O
of IN 0 0 12 O
sulphonylureas NNS 0 1 UNK B-Group
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
Bezalip NNP 0 1 UNK B-Brand
or CC 0 0 12 O
Bezalip NNP 0 1 UNK B-Brand
retard NN 0 1 13 I-Brand
. . 0 0 12 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
and CC 0 0 12 O
Mexitil NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
decrease NN 0 1 1 O
or CC 0 0 12 O
leave VB 0 0 12 O
unchanged JJ 0 1 1 O
Mexitil NNP 0 1 UNK B-Brand
plasma NN 0 1 14 O
levels NNS 1 1 1 O
; : 0 0 2 O

When WRB 0 0 12 O
indinavir NN 0 1 16 B-Drug
at IN 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
dose NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
) ) 0 0 2 O
was VBD 1 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
the DT 0 0 12 O
indinavir NN 0 1 16 B-Drug
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmin NNP 0 1 UNK O
were VBD 1 0 12 O
decreased VBN 1 1 1 O
on IN 0 0 12 O
average NN 0 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
compared VBN 1 1 1 O
to TO 0 0 12 O
when WRB 0 0 12 O
indinavir NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
) ) 0 0 2 O
was VBD 1 0 12 O
given VBN 1 1 12 O
alone RB 0 1 12 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
HIVID NNP 0 1 UNK B-Drug
with IN 0 0 12 O
didanosine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Other JJ 0 0 2 O
quinolones NNS 0 1 13 B-Group
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
moderate JJ 0 1 1 O
to TO 0 0 12 O
marked VB 1 1 1 O
interference NN 0 1 13 O
with IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
reduced JJ 0 1 1 O
clearance NN 0 1 16 O
a DT 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
plasma NN 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
and CC 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
symptoms NNS 1 1 6 O
that IN 0 0 12 O
accompany VBP 0 0 UNK O
high JJ 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Laboratory NNP 0 1 2 O
- : 0 0 2 O
Test NN 0 1 2 O
Interactions NNPS 0 1 UNK O
Interactions NNP 0 1 UNK O
between IN 0 0 12 O
Sanctura NNP 0 1 UNK B-Brand
and CC 0 0 12 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Phospholine NNP 0 1 UNK B-Drug
Iodide NNP 0 1 UNK I-Drug
potentiates VBZ 1 0 UNK O
other JJ 0 0 12 O
cholinesterase NN 0 1 UNK B-Group
inhibitors NNS 1 1 14 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
succinylcholine NN 0 1 16 B-Drug
or CC 0 0 12 O
organophosphate NN 0 1 13 B-Drug_n
and CC 0 0 12 O
carbamate NN 0 1 13 B-Drug_n
insecticide NN 0 1 UNK I-Drug_n
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Spontaneous JJ 0 1 7 O
adverse JJ 0 0 1 O
reaction NN 0 1 1 O
reports NNS 1 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
concomitant JJ 0 1 6 O
ketoconazole NN 0 1 16 B-Drug
with IN 0 0 12 O
recommended JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
demonstrate NN 0 0 1 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
prolongation NN 0 1 6 O
and CC 0 0 12 O
rare JJ 0 1 12 O
serious JJ 0 1 12 O
cardiac JJ 0 1 6 O
events NNS 1 1 12 O
e.g NN 0 0 UNK O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
no DT 0 0 12 O
formal JJ 0 1 1 O
studies NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
LEVULAN NNP 0 1 UNK B-Brand
KERASTICK NNP 0 0 UNK I-Brand
for IN 0 0 12 O
Topical NNP 0 1 7 O
Solution NNP 0 1 2 O
with IN 0 0 12 O
any DT 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
no DT 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
specific JJ 0 1 1 O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
noted VBN 1 0 1 O
during IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
controlled JJ 0 1 1 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

Corticosteroids NNS 0 1 UNK B-Group
or CC 0 0 12 O
ACTH NNP 0 1 UNK B-Drug
: : 0 0 2 O
May NNP 0 1 2 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
hypokalemia NN 0 1 14 O
and CC 0 0 12 O
increase VB 0 1 1 O
salt NN 0 1 3 O
and CC 0 0 12 O
water NN 0 1 3 O
retention NN 0 1 1 O
. . 0 0 12 O

- : 0 0 2 O
Although IN 0 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
true JJ 0 1 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
precipitate VB 0 1 13 O
seizures NNS 1 1 6 O
in IN 0 0 12 O
susceptible JJ 0 1 1 O
patients NNS 1 1 6 O
and CC 0 0 12 O
Cerebyx NNP 0 1 UNK B-Brand
dosage NN 0 1 0 O
may MD 0 0 1 O
need VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
adjusted VBN 1 1 1 O

Certain NNP 0 1 UNK O
concomitant JJ 0 1 6 O
medications NNS 1 1 6 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
rifampin NN 0 1 16 B-Drug
anticonvulsants NNS 1 1 13 B-Group
St NNP 0 1 2 O
. . 0 0 12 O

Aminophylline NNP 0 1 0 B-Drug
Etomidate NNP 0 1 0 B-Drug
antagonism NN 0 1 UNK O

In IN 0 0 2 O
uninfected JJ 0 0 14 O
volunteers NNS 1 1 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
developed VBD 1 0 1 O
rash NN 0 1 6 O
while IN 0 0 12 O
receiving VBG 1 1 1 O
SUSTIVA NNP 0 1 UNK B-Brand
and CC 0 0 12 O
clarithromycin NN 0 1 13 B-Drug
. . 0 0 12 O

Edema NNP 0 1 7 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
concomitantly RB 0 0 14 O
receiving VBG 1 1 1 O
Itraconazole NNP 0 1 UNK B-Drug
and CC 0 0 12 O
dihydropyridine VB 0 1 UNK B-Group
calcium NN 0 1 14 I-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

Pharmacokinetic NNP 0 1 UNK O
- : 0 0 2 O
related JJ 0 1 1 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Clozapine NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
many JJ 0 0 12 O
CYP NNP 0 1 UNK O
9 CD 0 0 2 O
isozymes NNS 0 1 UNK O
in IN 0 0 12 O
particular JJ 0 0 1 O
9A9 CD 0 0 UNK O
9D9 CD 0 0 UNK O
and CC 0 0 12 O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Cardiovascular JJ 0 1 7 O
: : 0 0 2 O
Hypotension NN 0 1 7 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
butorphanol NN 0 1 13 B-Drug
with IN 0 0 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
alcohol NN 0 1 1 B-Drug
barbiturates VBZ 0 1 14 B-Group
tranquilizers NNS 1 1 13 B-Group
and CC 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
) ) 0 0 2 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressant JJ 0 0 UNK I-Group
effects NNS 1 1 1 O
. . 0 0 12 O

Of IN 0 0 2 O
particular JJ 0 0 1 O
importance NN 0 1 1 O
sufficient JJ 0 1 1 O
time NN 0 1 12 O
must MD 0 0 12 O
elapse VB 0 1 UNK O
before IN 0 1 12 O
initiating VBG 1 1 1 O
TCA NNP 0 1 13 B-Group
treatment NN 0 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
being VBG 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
given VBN 1 1 12 O
the DT 0 0 12 O
long JJ 0 1 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
parent NN 0 1 13 O
and CC 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
( ( 0 0 2 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
) ) 0 0 2 O
. . 0 0 12 O

Inhibition NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
isozymes NNS 0 1 UNK O
evaluated VBN 1 1 1 O
( ( 0 0 2 O
CYPs NNP 0 1 UNK O
9A9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9D9 CD 0 0 UNK O
9A9 CD 0 0 UNK O
and CC 0 0 12 O
9E9 CD 0 0 UNK O
) ) 0 0 2 O
was VBD 1 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
bosentan $ 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
b.i.d NN 0 1 UNK O
. . 0 0 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
both DT 0 0 12 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin NN 0 1 14 I-Drug
( ( 0 0 2 O
a DT 0 0 12 O
CYP9C9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
R NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin NN 0 1 14 I-Drug
( ( 0 0 2 O
a DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
substrate NN 0 1 UNK O
) ) 0 0 2 O
by IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O

Neither DT 0 0 12 O
racemic JJ 0 1 14 O
warfarin NN 0 1 14 B-Drug
nor CC 0 0 12 O
isradipine JJ 0 1 13 B-Drug
binding NN 0 1 1 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
was VBD 1 0 12 O
altered VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
ketoconazole JJ 0 1 16 B-Drug
tablets NNS 1 1 3 O
with IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
may MD 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
one CD 0 1 12 O
or CC 0 0 12 O
both DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Concurrent NNP 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
increases VBZ 1 1 1 O
the DT 0 0 12 O
metabolic JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
ZEBETA NNP 0 1 UNK B-Brand
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
shortened JJ 0 1 1 O
elimination NN 0 1 UNK O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
ZEBETA NNP 0 1 UNK B-Brand
. . 0 0 12 O

Calcium NNP 0 1 7 B-Group
channel NN 0 1 1 I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
did VBD 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
any DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
safety NN 0 1 1 O
or CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
ibutilide NN 0 1 14 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

Antacids NNP 0 1 UNK B-Group
kaolin VBD 0 1 13 B-Drug
- : 0 0 2 O
pectin NN 0 1 13 O
sulfasalazine NN 0 1 0 B-Drug
neomycin JJ 0 1 16 B-Drug
cholestyramine NN 0 1 13 B-Drug
certain JJ 0 1 1 O
anticancer NN 0 0 UNK O
drugs NNS 1 1 6 O
and CC 0 0 12 O
metoclopramide NN 0 1 16 B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
intestinal JJ 0 1 13 O
digoxin NN 0 1 14 B-Drug
absorption NN 0 1 1 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
unexpectedly RB 0 0 UNK O
low JJ 0 1 1 O
serum NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

A DT 0 0 2 O
study NN 0 1 1 O
in IN 0 0 12 O
eight CD 0 1 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
has VBZ 1 0 12 O
shown VBN 1 1 1 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
mean JJ 0 1 12 O
peak JJ 0 1 1 O
nimodipine NN 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
mean JJ 0 1 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
curve NN 0 1 13 O
after IN 0 0 12 O
a DT 0 0 12 O
one CD 0 1 12 O
week NN 0 1 12 O
course NN 0 1 12 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
and CC 0 0 12 O
nimodipine NN 0 1 16 B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
urinary JJ 0 1 6 O
steroid JJ 0 1 6 O
determinations NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
heparin NN 0 1 14 B-Drug
is VBZ 1 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
concurrent NN 0 1 1 O
treatment NN 0 1 6 O
with IN 0 0 12 O
antithrombin JJ 0 1 14 B-Drug
III NNP 0 1 2 I-Drug
( ( 0 0 2 O
human JJ 0 1 1 O
) ) 0 0 2 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
hereditary JJ 0 1 13 O
antithrombin NN 0 1 14 O
III NNP 0 1 2 O
deficiency NN 0 1 6 O
. . 0 0 12 O

Hypokalemia NNP 0 1 7 O
may MD 0 0 1 O
develop VB 0 0 1 O
during IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
steroids NNS 1 1 6 B-Group
or CC 0 0 12 O
ACTH NNP 0 1 UNK B-Drug
. . 0 0 12 O

Vitamin NNP 0 1 2 B-Group
A NNP 0 0 2 I-Group
and CC 0 0 12 O
oral JJ 0 1 6 O
retinoids NNS 0 1 UNK B-Group
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
vitamin FW 0 1 6 B-Group
A NNP 0 0 2 I-Group
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
other JJ 0 0 12 O
oral JJ 0 1 6 O
retinoids NNS 0 1 UNK B-Group
with IN 0 0 12 O
acitretin NN 0 1 13 B-Drug
must MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
hypervitaminosis NN 0 1 13 O
A NNP 0 0 2 O
. . 0 0 12 O

Use NN 0 1 2 O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
be VB 0 0 12 O
prepared VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
hypertension NN 0 1 6 O
if IN 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
clear JJ 0 1 12 O
whether IN 0 0 12 O
this DT 0 0 12 O
was VBD 1 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
therapy NN 0 1 6 O
. . 0 0 12 O

Neuromuscular JJ 0 1 UNK B-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
suxamethonium NN 0 1 UNK B-Drug
chloride NN 0 1 14 I-Drug
) ) 0 0 2 O
: : 0 0 2 O
Concurrent JJ 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
procaine NN 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
and CC 0 0 12 O
neuromuscular JJ 0 1 6 B-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
prolongation NN 0 1 6 O
or CC 0 0 12 O
enhancement NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
neuromuscular JJ 0 1 6 O
blockade NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
following JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
studied VBN 1 0 1 O
with IN 0 0 12 O
ketoprofen JJ 0 1 UNK B-Drug
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

When WRB 0 0 12 O
concomitant JJ 0 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
agents NNS 1 1 1 B-Group
with IN 0 0 12 I-Group
b SYM 0 0 16 I-Group
- : 0 0 2 O
blocking NN 0 1 UNK I-Group
properties NNS 1 1 UNK I-Group
and CC 0 0 12 O
clonidine NN 0 1 0 B-Drug
is VBZ 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
terminated VBN 1 1 1 O
the DT 0 0 12 O
b NN 0 0 16 B-Group
- : 0 0 2 O
blocking NN 0 1 UNK I-Group
agent NN 0 1 1 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
discontinued VBN 1 1 1 O
first RB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
orally RB 0 1 14 O
ingested VBN 1 1 14 O
peginterferon NN 0 1 13 B-Drug
or CC 0 0 12 O
ribavirin NN 0 1 13 B-Drug
from IN 0 0 12 O
breast NN 0 1 6 O
milk NN 0 1 3 O
on IN 0 0 12 O
the DT 0 0 12 O
nursing NN 0 1 12 O
infant NN 0 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Nephrotoxicity NNP 0 1 UNK O
associated VBN 1 1 1 O
with IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
may MD 0 0 1 O
also RB 0 0 12 O
be VB 0 0 12 O
enhanced VBN 1 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
reasonable JJ 0 0 1 O
to TO 0 0 12 O
employ VB 0 1 UNK O
appropriate JJ 0 1 1 O
clinical JJ 0 1 6 O
monitoring NN 0 1 1 O
when WRB 0 0 12 O
potent JJ 0 1 UNK O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
enzyme VBZ 0 1 14 O
inducers NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
phenobarbital NN 0 1 16 B-Drug
or CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
are VBP 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
montelukast NN 0 1 16 B-Drug
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
GABITRIL NNP 0 1 UNK B-Brand
on IN 0 0 12 O
other JJ 0 0 12 O
Antiepilepsy NNP 0 0 UNK O
Drugs NNP 0 1 2 O
( ( 0 0 2 O
AEDs NNP 0 1 UNK B-Group
) ) 0 0 2 O
: : 0 0 2 O
Phenytoin NN 0 1 0 B-Drug
: : 0 0 2 O
Tiagabine NN 0 1 UNK B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
epilepsy NN 0 1 13 O
. . 0 0 12 O

Patients NNS 0 1 7 O
with IN 0 0 12 O
Congenital NNP 0 1 UNK O
or CC 0 0 12 O
Acquired NNP 0 1 UNK O
QT NNP 0 1 13 O
Prolongation NNP 0 1 UNK O
In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
solifenacin NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
women NNS 1 1 UNK O
the DT 0 0 12 O
QT NNP 0 1 13 O
prolonging VBG 1 0 UNK O
effect NN 0 1 1 O
appeared VBD 1 1 12 O
less RBR 0 1 12 O
with IN 0 0 12 O
solifenacin JJ 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
than IN 0 0 12 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
( ( 0 0 2 O
three CD 0 1 12 O
times NNS 1 1 12 O
the DT 0 0 12 O
maximum NN 0 1 1 O
recommended VBD 1 1 1 O
dose NN 0 1 6 O
) ) 0 0 2 O
and CC 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
solifenacin NN 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
did VBD 1 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
as RB 0 0 12 O
large JJ 0 1 3 O
as IN 1 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
positive JJ 0 1 1 O
control NN 0 1 1 O
moxifloxacin NN 0 1 16 B-Drug
at IN 0 0 12 O
its PRP$ 1 0 12 O
therapeutic JJ 0 1 6 O
dose NN 0 1 6 O
. . 0 0 12 O

Do VB 0 0 2 O
not RB 0 1 12 O
take VB 0 1 12 O
this DT 0 0 12 O
medicine NN 0 1 6 O
with IN 0 0 12 O
thioridizine NN 0 0 UNK O
or CC 0 0 12 O
within IN 0 0 1 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
of IN 0 0 12 O
taking VBG 1 0 12 O
fluoxetine NN 0 1 16 B-Drug
. . 0 0 12 O

. . 0 0 12 O

ondansetron NN 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
increase VB 0 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
dose JJ 0 1 6 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

. . 0 0 12 O

Insulin NNP 0 1 7 B-Drug
or CC 0 0 12 O
Oral JJ 0 1 2 O
Hypoglycemics NNS 0 1 UNK B-Group
: : 0 0 2 O
Initiating NNP 0 1 UNK O
thyroid JJ 0 1 6 O
replacement NN 0 1 1 O
therapy NN 0 1 6 O
may MD 0 0 1 O
cause VB 0 1 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
insulin NN 0 1 14 B-Drug
or CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
requirements NNS 1 1 1 O
. . 0 0 12 O

CYP9A9 JJ 0 0 UNK O
inducers NNS 1 1 UNK O
: : 0 0 2 O
CYP9A9 NNP 0 0 UNK O
inducers NNS 1 1 UNK O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
levels NNS 1 1 1 O
/ VBP 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Laboratory JJ 0 1 2 O
Test NNP 0 1 2 O
Interactions NNPS 0 1 UNK O
There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
known JJ 0 1 12 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
CAMPTOSAR NNP 0 1 UNK B-Brand
and CC 0 0 12 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

Ergotamine NN 0 1 UNK B-Drug
or CC 0 0 12 O
dihydroergotamine VB 0 1 UNK B-Drug
acute JJ 0 1 6 O
ergot JJ 0 1 UNK O
toxicity NN 0 1 6 O
characterized VBN 1 1 1 O
by IN 0 0 12 O
severe JJ 0 1 6 O
peripheral JJ 0 1 6 O
vasospasm NN 0 1 8 O
and CC 0 0 12 O
dysesthesia NN 0 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
treatment NN 0 1 6 O
arm NN 0 1 3 O
was VBD 1 0 12 O
discontinued VBN 1 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
trial NN 0 1 12 O
. . 0 0 12 O

Also RB 0 0 2 O
antimyasthenics NNS 0 0 UNK O
may MD 0 0 1 O
have VB 0 0 12 O
anticholinesterase NN 0 1 UNK O
activity NN 0 1 1 O
. . 0 0 12 O

Thus RB 0 0 1 O
when WRB 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
and CC 0 0 12 O
lithium NN 0 1 16 B-Drug
are VBP 1 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
subjects NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
carefully RB 0 0 12 O
for IN 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
dexmedetomidine NN 0 1 16 B-Drug
and CC 0 0 12 O
isoflurane NN 0 1 UNK B-Drug
propofol NN 0 1 14 B-Drug
alfentanil NN 0 1 UNK B-Drug
and CC 0 0 12 O
midazolam NN 0 1 16 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
A DT 0 0 2 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
on IN 0 0 12 O
Day NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
on IN 0 0 12 O
Days NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
who WP 0 0 12 O
were VBD 1 0 12 O
stabilized VBN 1 1 1 O
on IN 0 0 12 O
chronic JJ 0 1 6 O
warfarin NN 0 1 14 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

An DT 0 0 2 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
gemfibrozil NNS 0 1 16 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
rosiglitazone NN 0 1 16 B-Drug
and CC 0 0 12 O
an DT 0 0 12 O
inducer NN 0 1 UNK O
of IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
rifampin NN 0 1 16 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
rosiglitazone NN 0 1 16 B-Drug
. . 0 0 12 O

Vardenafil NN 0 1 UNK B-Drug

Mean NNP 0 1 2 O
oxybutynin MD 0 1 13 B-Drug
chloride VB 0 1 14 I-Drug
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
fold VBD 0 1 3 O
higher JJR 1 1 1 O
when WRB 0 0 12 O
DITROPAN NNP 0 1 UNK B-Brand
XL NNP 0 1 2 I-Brand
was VBD 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
a DT 0 0 12 O
potent JJ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
. . 0 0 12 O

Patients NNS 0 1 7 O
may MD 0 0 1 O
require VB 0 0 1 O
reduced JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
anesthetics NNS 1 1 13 B-Group
when WRB 0 0 12 O
on IN 0 0 12 O
methyldopa NN 0 1 13 B-Drug
. . 0 0 12 O

Beta NNP 0 1 2 B-Group
Blockers NNS 0 0 UNK I-Group

Therefore RB 0 0 1 O
if IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
agents NNS 1 1 1 O
is VBZ 1 0 12 O
indicated JJ 0 1 1 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
the DT 0 0 12 O
patients NNS 1 1 6 O
serum VBP 0 1 14 O
potassium NN 0 1 14 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
frequently RB 0 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
both DT 0 0 12 O
flurbiprofen NN 0 1 16 B-Drug
and CC 0 0 12 O
a DT 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blocker NN 0 0 3 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
to TO 0 0 12 O
ensure VB 0 1 1 O
that IN 0 0 12 O
a DT 0 0 12 O
satisfactory JJ 0 1 1 O
hypotensive JJ 0 1 14 O
effect NN 0 1 1 O
is VBZ 1 0 12 O
achieved VBN 1 0 1 O
. . 0 0 12 O

Antiacid NNP 0 0 UNK O
clarithromycin NN 0 1 13 B-Drug
Didanosine NNP 0 1 0 B-Drug
Fluconazole NNP 0 1 0 B-Drug
Fluoxetine NNP 0 1 0 B-Drug
Indanavir NNP 0 0 UNK O
Ketoconazole NNP 0 1 UNK B-Drug
Phenytoin NNP 0 1 0 B-Drug
Phenobarbitol NNP 0 1 UNK O
carbamazepine NN 0 1 16 B-Drug
Rifabutin NNP 0 1 UNK B-Drug
Rifampin NNP 0 1 0 B-Drug
Ritanovir NNP 0 0 UNK O
Saquinavir NNP 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
following VBG 1 1 1 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
Kerlone NNP 0 1 UNK B-Brand
and CC 0 0 12 O
have VBP 0 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
its PRP$ 1 0 12 O
pharmacokinetics NNS 0 1 UNK O
: : 0 0 2 O
cimetidine NN 0 1 13 B-Drug
nifedipine NN 0 1 0 B-Drug
chlorthalidone NN 0 1 13 B-Drug
and CC 0 0 12 O
hydrochlorothiazide NN 0 1 0 B-Drug
. . 0 0 12 O

THE DT 0 0 11 O
DOSAGE NNP 0 1 UNK O
OF IN 0 0 11 O
THE NNP 0 0 11 O
ANTICOAGULANTS NNP 0 1 UNK B-Group
SHOULD NNP 0 0 UNK O
BE NNP 0 0 11 O
REDUCED NNP 0 1 UNK O
TO NNP 0 0 11 O
MAINTAIN NNP 0 1 UNK O
THE NNP 0 0 11 O
PROTHROMBIN NNP 0 1 UNK O
TIME NNP 0 1 11 O
/ NNP 0 0 2 O
INR NNP 0 1 13 O
AT NNP 0 0 11 O
THE NNP 0 0 11 O
DESIRED NNP 0 1 UNK O
LEVEL NNP 0 1 11 O
TO NNP 0 0 11 O
PREVENT NNP 0 1 UNK O
BLEEDING NNP 0 1 11 O
COMPLICATIONS NNP 0 1 11 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
propofol VBP 0 1 14 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
action NN 0 1 13 O
or CC 0 0 12 O
dosing NN 0 0 14 O
requirements NNS 1 1 1 O
for IN 0 0 12 O
NIMBEX NNP 0 1 UNK B-Brand
. . 0 0 12 O

If IN 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
needed VBN 1 1 12 O
their PRP$ 0 0 12 O
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
reassessed VBN 1 0 15 O
and CC 0 0 12 O
where WRB 0 0 12 O
appropriate JJ 0 1 1 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
measured VBD 1 1 1 O
. . 0 0 12 O

Micafungin NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
and CC 0 0 12 O
therefore RB 0 0 1 O
would MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
alter VB 0 1 13 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
- : 0 0 2 O
mediated VBN 1 1 13 O
drug NN 0 1 1 O
transport NN 0 1 1 O
activity NN 0 1 1 O
. . 0 0 12 O

Refer NN 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
package NN 0 1 13 O
insert NN 0 1 13 O
for IN 0 0 12 O
lithium NN 0 1 16 B-Drug
preparations NNS 1 1 13 O
before IN 0 1 12 O
use NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
preparations NNS 1 1 13 O
with IN 0 0 12 O
Hydrochlorothiazide NNP 0 1 0 B-Drug
. . 0 0 12 O

PEGASYS NNP 0 1 UNK B-Brand
and CC 0 0 12 O
COPEGUS NNP 0 1 UNK B-Brand
are VBP 1 0 12 O
excreted VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
kidney NN 0 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
toxic JJ 0 1 1 O
reactions NNS 1 1 1 O
to TO 0 0 12 O
this DT 0 0 12 O
therapy NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
greater JJR 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
impaired JJ 0 1 6 O
renal JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

Orthostatic JJ 0 1 7 O
hypotension NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
clozapine NN 0 1 13 B-Drug
can MD 0 0 12 O
in IN 0 0 12 O
rare JJ 0 1 12 O
cases NNS 1 1 UNK O
( ( 0 0 2 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
case NN 0 1 12 O
per IN 0 0 1 O
9 CD 0 0 2 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
) ) 0 0 2 O
be VB 0 0 12 O
accompanied VBN 1 0 12 O
by IN 0 0 12 O
profound NN 0 1 1 O
collapse NN 0 1 1 O
and CC 0 0 12 O
respiratory NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
cardiac JJ 0 1 6 O
arrest NN 0 1 12 O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
spontaneous JJ 0 1 1 O
reports NNS 1 1 1 O
of IN 0 0 12 O
increase NN 0 1 1 O
or CC 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
prothrombin JJ 0 1 14 O
times NNS 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
concomitantly RB 0 0 14 O
taking VBG 1 0 12 O
oral JJ 0 1 6 O
terbinafine NN 0 1 16 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
however RB 0 0 12 O
a DT 0 0 12 O
causal NN 0 1 UNK O
relationship NN 0 1 12 O
between IN 0 0 12 O
LAMISIL NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
and CC 0 0 12 O
these DT 0 0 12 O
changes NNS 1 1 1 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
common JJ 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
broad JJ 0 1 1 B-Group
- : 0 0 2 O
spectrum NN 0 1 1 I-Group
antibiotics NNS 1 1 6 I-Group
AUGMENTIN NNP 0 1 UNK B-Brand
XR NN 0 1 0 I-Brand
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group

Ergotamine NN 0 1 UNK B-Drug
: : 0 0 2 O
Concurrent JJ 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
ergotamine NN 0 1 UNK B-Drug
or CC 0 0 12 O
dihydroergotamine NN 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
acute JJ 0 1 6 O
ergot FW 0 1 UNK O
toxicity NN 0 1 6 O
characterized VBN 1 1 1 O
by IN 0 0 12 O
severe JJ 0 1 6 O
peripheral JJ 0 1 6 O
vasospasm NN 0 1 8 O
and CC 0 0 12 O
dysesthesia NN 0 1 UNK O
. . 0 0 12 O

and CC 0 0 12 O
rarely RB 0 1 UNK O
enuresis JJ 0 1 13 O
urinary JJ 0 1 6 O
retention NN 0 1 1 O
dysuria NNS 0 1 8 O
impotence NN 0 1 6 O
inability NN 0 0 1 O
to TO 0 0 12 O
ejaculate VB 0 1 UNK O
nocturia NNS 0 1 8 O
hematuria NNS 0 1 8 O
. . 0 0 12 O

Ampicillin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
of IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
chloroquine VBP 0 1 13 B-Drug
significantly RB 0 0 1 O
reduced VBN 1 1 1 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
ampicillin NN 0 1 0 B-Drug
. . 0 0 12 O

Lamivudine NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
predominantly RB 0 0 1 O
eliminated VBN 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
by IN 0 0 12 O
active JJ 0 1 1 O
organic JJ 0 1 13 O
cationic JJ 0 1 UNK O
secretion NN 0 1 14 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
with IN 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
led VBN 1 1 12 O
to TO 0 0 12 O
elevated VBN 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
rare JJ 0 1 12 O
instances NNS 1 1 UNK O
of IN 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening JJ 0 0 12 O
cardiac JJ 0 1 6 O
dysrhythmias NN 0 1 13 O
and CC 0 0 12 O
one CD 0 1 12 O
death NN 0 1 12 O
. . 0 0 12 O

No DT 0 0 2 O
volunteer NN 0 1 13 O
showed VBD 1 1 12 O
hormonal JJ 0 1 6 O
evidence NN 0 1 1 O
of IN 0 0 12 O
ovulation NN 0 1 13 O
but CC 0 0 12 O
one CD 0 1 12 O
volunteer NN 0 1 13 O
reported VBD 1 1 1 O
intermenstrual JJ 0 0 UNK O
bleeding NN 0 1 6 O
during IN 0 0 12 O
felbamate JJ 0 1 13 B-Drug
treatment NN 0 1 6 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
can MD 0 0 12 O
cause VB 0 1 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
elevation NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
corticosteroid NN 0 1 UNK O
levels NNS 1 1 1 O
. . 0 0 12 O

Dosage NNP 0 1 UNK O
adjustment NN 0 1 1 O
of IN 0 0 12 O
STRATTERA NNP 0 1 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
e.g. VBP 0 0 UNK O
paroxetine JJ 0 1 16 B-Drug
fluoxetine NN 0 1 16 B-Drug
and CC 0 0 12 O
quinidine NN 0 1 16 B-Drug
. . 0 0 12 O

diflunisal NN 0 1 13 B-Drug
; : 0 0 2 O

Other JJ 0 0 2 O
common JJ 0 1 1 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
are VBP 1 0 12 O
dizziness JJ 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
weakness NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
fatigue NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
month NN 0 1 12 O
controlled VBD 1 1 1 O
trial NN 0 1 12 O
that WDT 0 0 12 O
included VBD 1 1 1 O
a DT 0 0 12 O
9 CD 0 0 2 O
mcg NN 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
BROVANA NNP 0 1 UNK B-Brand
dose VBD 0 1 6 O
9 CD 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
BROVANA NNP 0 1 UNK B-Brand
- : 0 0 2 O
treated JJ 0 1 1 O
subjects NNS 1 1 UNK O
received VBD 1 1 12 O
concomitant JJ 0 1 6 O
theophylline NN 0 1 16 B-Drug
at IN 0 0 12 O
study NN 0 1 1 O
entry NN 0 1 1 O
. . 0 0 12 O

. . 0 0 12 O

Potential NNP 0 1 UNK O
for IN 0 0 12 O
Other JJ 0 0 2 O
Drugs NNP 0 1 2 O
to TO 0 0 12 O
Affect NNP 0 1 UNK O
ABILIFY NNP 0 1 UNK B-Brand
Aripiprazole NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9B9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
or CC 0 0 12 O
CYP9E9 NNP 0 0 UNK O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Heparin NN 0 1 0 B-Drug
: : 0 0 2 O
Since IN 0 1 2 O
heparin NN 0 1 14 B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
heparin JJ 0 1 14 B-Drug
- : 0 0 2 O
induced VBN 1 1 6 O
thrombocytopenia IN 0 1 14 O
the DT 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
Argatroban NNP 0 1 0 B-Drug
and CC 0 0 12 O
heparin NN 0 1 14 B-Drug
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
for IN 0 0 12 O
this DT 0 0 12 O
indication NN 0 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
warranted VBN 1 0 1 O
and CC 0 0 12 O
clinical JJ 0 1 6 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Similarly RB 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
year NN 0 1 12 O
monthly RB 0 1 1 O
comparison NN 0 1 1 O
study NN 0 1 1 O
aspirin NN 0 1 14 B-Brand
and CC 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti NN 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
were VBD 1 0 12 O
taken VBN 1 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
. . 0 0 12 O

- : 0 0 2 O
Quinine NN 0 1 0 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Quinamm NNP 0 1 UNK B-Brand
) ) 0 0 2 O
or CC 0 0 12 O

Cholestyramine NNP 0 1 UNK B-Drug
- : 0 0 2 O
Concomitant JJ 0 1 UNK O
intake NN 0 1 3 O
of IN 0 0 12 O
cholestyramine NN 0 1 13 B-Drug
and CC 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
. . 0 0 12 O

Drugs NNS 0 1 2 O
Metabolized VBN 0 1 UNK O
by IN 0 0 12 O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
- : 0 0 2 O
The DT 0 0 2 O
biochemical JJ 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
metabolizing VBG 1 0 UNK O
isozyme JJ 0 1 UNK O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9D9 CD 0 0 UNK O
( ( 0 0 2 O
debrisoquin JJ 0 1 UNK O
hydroxylase NN 0 1 UNK O
) ) 0 0 2 O
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
subset NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
caucasian JJ 0 1 3 O
population NN 0 1 13 O
( ( 0 0 2 O
about IN 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
caucasians NNS 1 1 UNK O
are VBP 1 0 12 O
so RB 0 1 12 O
called JJ 0 1 12 O
poor JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
) ) 0 0 2 O
; : 0 0 2 O

Hepatotoxic NNP 0 1 UNK O
medications NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
dose JJ 0 1 6 O
methotrexate NN 0 1 16 B-Drug
may MD 0 0 1 O
impair VB 0 0 13 O
liver JJR 0 1 6 O
function NN 0 1 1 O
and CC 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
toxicity NN 0 1 6 O
. . 0 0 12 O

When WRB 0 0 12 O
these DT 0 0 12 O
products NNS 1 1 1 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
other JJ 0 0 12 O
suitable JJ 0 1 1 O
coagulation NN 0 1 14 O
test NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Nevertheless RB 0 0 1 O
the DT 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
or CC 0 0 12 O
other JJ 0 0 12 O
suitable JJ 0 1 1 O
coagulation NN 0 1 14 O
test NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
when WRB 0 0 12 O
warfarin NN 0 1 14 B-Drug
or CC 0 0 12 O
its PRP$ 1 0 12 O
derivatives NNS 1 1 13 O
and CC 0 0 12 O
enoxacin NN 0 1 UNK B-Drug
are VBP 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
glucose NN 0 1 14 O
tests NNS 1 1 1 O
based VBN 1 1 1 O
on IN 0 0 12 O
enzymatic JJ 0 1 UNK O
glucose JJ 0 1 14 O
oxidase NN 0 1 13 O
reactions NNS 1 1 1 O
be VB 0 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

Fluoxetine NNP 0 1 0 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
norfluoxe SYM 0 0 UNK O
- : 0 0 2 O
tine NN 0 1 UNK O
have VBP 0 0 12 O
long RB 0 1 12 O
half JJ 0 1 12 O
- : 0 0 2 O
lives NNS 1 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
for IN 0 0 12 O
norfluoxetine NN 0 1 UNK B-Drug_n
) ) 0 0 2 O
that WDT 0 0 12 O
may MD 0 0 1 O
affect VB 0 1 1 O
strategies NNS 1 1 UNK O
during IN 0 0 12 O
conversion NN 0 1 13 O
from IN 0 0 12 O
one CD 0 1 12 O
drug NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
. . 0 0 12 O

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
with IN 0 0 12 O
LODOSYN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
levodopa NN 0 1 UNK B-Drug
or CC 0 0 12 O
carbidopa VB 0 1 13 B-Drug
- : 0 0 2 O
levodopa NN 0 1 UNK B-Drug
combination NN 0 1 1 O
products NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
observed VBN 1 1 1 O
for IN 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
therapeutic JJ 0 1 6 O
response NN 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
clearance NN 0 1 16 O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
was VBD 1 0 12 O
slightly RB 0 1 3 O
increased VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
addition NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
to TO 0 0 12 O
Streptokinase NNP 0 1 15 B-Drug
causes VBZ 1 1 6 O
a DT 0 0 12 O
minimal JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
minor JJ 0 1 1 O
bleeding NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
vs. FW 0 1 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
but CC 0 0 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
major JJ 0 1 1 O
bleeding NN 0 1 6 O
( ( 0 0 2 O
see VB 0 1 12 O

Potential JJ 0 1 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
TAXOL NNP 0 1 UNK B-Brand
a DT 0 0 12 O
substrate NN 0 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
protease NN 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
ritonavir VB 0 1 16 B-Drug
saquinavir NN 0 1 13 B-Drug
indinavir NN 0 1 16 B-Drug
and CC 0 0 12 O
nelfinavir NN 0 1 16 B-Drug
) ) 0 0 2 O
which WDT 0 0 12 O
are VBP 1 0 12 O
substrates NNS 1 1 UNK O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

Salicylates NNS 0 1 UNK B-Group
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
may MD 0 0 1 O
predispose VB 0 0 UNK O
to TO 0 0 12 O
systemic VB 0 1 6 O
bleeding NN 0 1 6 O
. . 0 0 12 O

Nursing NN 0 1 2 O
Mothers NNS 0 1 UNK O

indinavir NN 0 1 16 B-Drug
concentration NN 0 1 1 O

isoflurane NN 0 1 UNK B-Drug
; : 0 0 2 O

Warfarin NNS 0 1 0 B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
were VBD 1 0 12 O
administered VBN 1 1 1 O
Starlix NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
three CD 0 1 12 O
times NNS 1 1 12 O
daily JJ 0 1 12 O
before IN 0 1 12 O
meals NNS 1 1 12 O
for IN 0 0 12 O
four CD 0 1 12 O
days NNS 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
warfarin $ 0 1 14 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
on IN 0 0 12 O
day NN 0 1 12 O
9 CD 0 0 2 O
there EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
agent NN 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
is VBZ 1 0 12 O
also RB 0 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
leflunomide JJ 0 1 13 B-Drug
treatment NN 0 1 6 O
is VBZ 1 0 12 O
followed VBN 1 1 12 O
by IN 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
without IN 0 0 12 O
a DT 0 0 12 O
drug NN 0 1 1 O
elimination NN 0 1 UNK O
procedure NN 0 1 1 O
. . 0 0 12 O

Bosentan NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
also RB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
reduce VB 0 0 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
other JJ 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
that WDT 0 0 12 O
are VBP 1 0 12 O
predominantly RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
or CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

However RB 0 0 1 O
LDL NNP 0 0 14 O
- : 0 0 2 O
C NNP 0 0 2 O
reduction NN 0 1 1 O
was VBD 1 0 12 O
greater JJR 1 1 1 O
when WRB 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
and CC 0 0 12 O
colestipol NN 0 1 13 B-Drug
were VBD 1 0 12 O
coadministered VBN 0 0 UNK O
than IN 0 0 12 O
when WRB 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
was VBD 1 0 12 O
given VBN 1 1 12 O
alone RB 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
: : 0 0 2 O
Vardenafil NNP 0 1 UNK B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
9A9 CD 0 0 UNK O
and CC 0 0 12 O
9E9 CD 0 0 UNK O
( ( 0 0 2 O
Ki NNP 0 0 UNK O
9uM CD 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug
: : 0 0 2 O
Ketoconazole NNP 0 1 UNK B-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
both DT 0 0 12 O
synthetic JJ 0 1 3 O
and CC 0 0 12 O
catabolic JJ 0 1 14 O
enzymes NNS 1 1 14 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
. . 0 0 12 O

If IN 0 0 12 O
midazolam VBN 0 1 16 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
parenterally RB 0 0 UNK O
special JJ 0 1 12 O
precaution NN 0 1 1 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
since IN 0 1 12 O
the DT 0 0 12 O
sedative JJ 0 1 6 O
effect NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
prolonged VBN 1 1 6 O
. . 0 0 12 O

Other JJ 0 0 2 O
beta NN 0 1 16 B-Group
adrenergic JJ 0 1 UNK I-Group
aerosol JJ 0 1 3 I-Group
bronchodilators NNS 1 1 14 I-Group
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
Alupent NNP 0 1 UNK B-Brand
( ( 0 0 2 O
metaproterenol JJ 0 1 UNK B-Drug
sulfate NN 0 1 14 I-Drug
USP NNP 0 1 UNK O
) ) 0 0 2 O
because IN 0 0 12 O
they PRP 0 0 12 O
may MD 0 0 1 O
have VB 0 0 12 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
facts NNS 1 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
when WRB 0 0 12 O
evaluating VBG 1 1 1 O
plasma RB 0 1 14 O
renin JJ 0 1 UNK O
activity NN 0 1 1 O
in IN 0 0 12 O
hypertensive JJ 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

( ( 0 0 2 O
d NN 0 1 16 O
) ) 0 0 2 O
T9 NNP 0 1 13 O
- : 0 0 2 O
uptake JJ 0 1 14 O
values NNS 1 1 1 O
may MD 0 0 1 O
decrease VB 0 1 1 O
. . 0 0 12 O

T9 NNP 0 1 13 O
resin NN 0 1 UNK O
uptake NN 0 1 14 O
is VBZ 1 0 12 O
decreased VBN 1 1 1 O
reflecting VBG 1 1 1 O
the DT 0 0 12 O
elevated JJ 0 1 1 O
TBG NNP 0 1 UNK O
. . 0 0 12 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
vasopressor NN 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
of IN 0 0 12 O
ergot JJ 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
oxytocic IN 0 1 13 I-Group
drugs NNS 1 1 6 I-Group
may MD 0 0 1 O
cause VB 0 1 12 O
severe JJ 0 1 6 O
persistent JJ 0 1 1 O
hypertension NN 0 1 6 O
or CC 0 0 12 O
cerebrovascular JJ 0 1 8 O
accidents NNS 1 1 1 O
. . 0 0 12 O

9% CD 0 0 UNK O
9% CD 0 0 UNK O
9% CD 0 0 UNK O
9% CD 0 0 UNK O

Laboratory NN 0 1 2 O
Tests NNS 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
combination NN 0 1 1 O
of IN 0 0 12 O
Amprenavir NNP 0 1 UNK B-Drug
and CC 0 0 12 O
low JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
ritonavir NN 0 1 16 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
elevations NNS 1 1 1 O
of IN 0 0 12 O
cholesterol NN 0 1 6 O
and CC 0 0 12 O
triglycerides NNS 1 1 14 O
SGOT NNP 0 0 14 O
( ( 0 0 2 O
AST NNP 0 1 13 O
) ) 0 0 2 O
and CC 0 0 12 O
SGPT NNP 0 0 14 O
( ( 0 0 2 O
ALT NNP 0 1 13 O
) ) 0 0 2 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

If IN 0 0 12 O
they PRP 0 0 12 O
do VBP 0 0 12 O
occur VB 0 1 1 O
the DT 0 0 12 O
EPA NNP 0 0 UNK B-Drug
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
lowered VBN 1 1 3 O
or CC 0 0 12 O
discontinued VBN 1 1 1 O
. . 0 0 12 O

Tricyclic JJ 0 0 UNK B-Group
antidepressants NNS 1 1 13 I-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
blunt VB 0 1 3 O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
systemic JJ 0 1 6 O
clonidine NN 0 1 0 B-Drug
. . 0 0 12 O

Use NN 0 1 2 O
With IN 0 0 2 O
Ribavirin NNP 0 1 0 B-Drug
Ribavirin NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
genotoxic JJ 0 1 UNK O
and CC 0 0 12 O
mutagenic JJ 0 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
little JJ 0 1 12 O
if IN 0 0 12 O
any DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
Acarbose NNP 0 1 UNK B-Drug
and CC 0 0 12 O
metformin NN 0 1 0 B-Drug
. . 0 0 12 O

. . 0 0 12 O

zaleplon NN 0 1 13 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
stimulate VBP 0 0 UNK O
alpha SYM 0 1 1 O
- : 0 0 2 O
adrenergic JJ 0 1 UNK O
receptors NNS 1 1 13 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
phenylephrine NN 0 1 14 B-Drug
pseudoephedrine NN 0 1 16 B-Drug
ephedrine VBP 0 1 13 B-Drug
phenylpropanolamine NN 0 1 UNK B-Drug
or CC 0 0 12 O
dihydroergotamine NN 0 1 UNK B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
enhance VB 0 1 UNK O
or CC 0 0 12 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
pressor NN 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
ProAmatine NNP 0 1 UNK B-Brand
. . 0 0 12 O
Therefore NNP 0 0 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
ProAmatine NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
agents NNS 1 1 1 O
that WDT 0 0 12 O
cause VBP 0 1 12 O
vasoconstriction NN 0 1 UNK O
. . 0 0 12 O

Sinus NNP 0 1 7 O
bradycardia NN 0 1 8 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
with IN 0 0 12 O
oral JJ 0 1 6 O
amiodarone NN 0 1 0 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
lidocaine NN 0 1 14 B-Drug
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK B-Drug
substrate NN 0 1 UNK O
) ) 0 0 2 O
given VBN 1 1 12 O
for IN 0 0 12 O
local JJ 0 1 12 O
anesthesia NN 0 1 6 B-Drug
. . 0 0 12 O

If IN 0 0 12 O
indicated VBN 1 1 1 O
dosage NN 0 1 0 O
of IN 0 0 12 O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

Acarbose NNP 0 1 UNK B-Drug
may MD 0 0 1 O
affect VB 0 1 1 O
digoxin NN 0 1 14 B-Drug
bioavailabillty NN 0 0 UNK O
and CC 0 0 12 O
may MD 0 0 1 O
require VB 0 0 1 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
confidence NN 0 1 UNK O
interval NN 0 1 1 O
: : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
decrease NN 0 1 1 O
mean JJ 0 1 12 O
C NNP 0 0 2 O
max NN 0 0 3 O
digoxin NN 0 1 14 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
confidence NN 0 1 UNK O
interval NN 0 1 1 O
: : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
decrease JJ 0 1 1 O
mean NN 0 1 12 O
trough IN 0 1 3 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
confidence NN 0 1 UNK O
limit NN 0 1 1 O
: : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Antidepressants NNS 0 1 UNK B-Group
( ( 0 0 2 O
tricyclic JJ 0 0 14 B-Group
) ) 0 0 2 O
atropine NN 0 1 14 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
or CC 0 0 12 O
digitalis NNS 0 1 14 B-Group
glycosides NNS 1 1 13 I-Group
: : 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
with IN 0 0 12 O
arbutamine NN 0 1 UNK B-Drug
may MD 0 0 1 O
produce VB 0 0 1 O
additive JJ 0 1 16 O
inotropic NN 0 0 14 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
chronotropic NN 0 1 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

Plasma NNP 0 1 UNK O
levels NNS 1 1 1 O
of IN 0 0 12 O
flecainide NN 0 1 16 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
amiodarone NN 0 1 0 B-Drug
; : 0 0 2 O

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
bromocriptine NN 0 1 16 B-Drug
mesylate NN 0 1 16 I-Drug
with IN 0 0 12 O
other JJ 0 0 12 O
ergot JJ 0 1 UNK B-Group
alkaloids NNS 1 1 13 I-Group
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Careful JJ 0 1 UNK O
supervision NN 0 1 1 O
of IN 0 0 12 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
under IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
Soriatane NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Tablets NNS 0 1 0 O
Injection NNP 0 1 7 O
and CC 0 0 12 O
Oral NNP 0 1 2 O
Solution NNP 0 1 2 O
One NNP 0 1 2 O
study NN 0 1 1 O
in IN 0 0 12 O
six CD 0 1 12 O
subjects NNS 1 1 UNK O
demonstrated VBD 1 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
and CC 0 0 12 O
acetylsalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
temporarily RB 0 0 1 O
reduced VBN 1 1 1 O
creatinine JJ 0 1 14 O
clearance NN 0 1 16 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
chronic JJ 0 1 6 O
renal JJ 0 1 6 O
insufficiency NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
butorphanol NN 0 1 13 B-Drug
administered VBN 1 1 1 O
as IN 1 0 12 O
STADOL NNP 0 1 UNK B-Brand
NS NNP 0 1 13 I-Brand
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
QID NNP 0 1 15 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
CAMPTOSAR NNP 0 1 UNK B-Brand
such JJ 0 0 1 O
as IN 1 0 12 O
myelosuppression NN 0 1 8 O
and CC 0 0 12 O
diarrhea NN 0 1 6 O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
exacerbated VBN 1 1 1 O
by IN 0 0 12 O
other JJ 0 0 12 O
antineoplastic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
having VBG 1 0 12 O
similar JJ 0 1 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
of IN 0 0 12 O
TOBI NNP 0 1 UNK B-Brand
patients NNS 1 1 6 O
taking VBG 1 0 12 O
TOBI NNP 0 1 UNK B-Brand
concomitantly RB 0 0 14 O
with IN 0 0 12 O
dornase NN 0 0 16 B-Drug
alfa NN 0 1 16 I-Drug
( ( 0 0 2 O
PULMOZYME NNP 0 1 UNK B-Brand
Genentech NNP 0 1 UNK O
) ) 0 0 2 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
agonists NNS 1 1 UNK I-Group
inhaled VBD 1 1 14 O
corticosteroids NNS 1 1 14 B-Group
other JJ 0 0 12 O
anti JJ 0 0 3 B-Group
- : 0 0 2 O
pseudomonal JJ 0 1 13 I-Group
antibiotics NNS 1 1 6 I-Group
or CC 0 0 12 O
parenteral JJ 0 1 14 O
aminoglycosides NNS 0 1 13 B-Group
demonstrated VBD 1 0 1 O
adverse JJ 0 0 1 O
experience NN 0 1 12 O
profiles NNS 1 1 UNK O
similar JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
study NN 0 1 1 O
population NN 0 1 13 O
as IN 1 0 12 O
a DT 0 0 12 O
whole NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
syndrome NN 0 1 6 O
requires VBZ 1 0 1 O
immediate JJ 0 1 1 O
medical JJ 0 1 1 O
attention NN 0 1 12 O
and CC 0 0 12 O
may MD 0 0 1 O
include VB 0 1 1 O
one CD 0 1 12 O
or CC 0 0 12 O
more JJR 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
symptoms NNS 1 1 6 O
: : 0 0 2 O
excitement NN 0 1 12 O
hypomania NN 0 1 8 O
restlessness JJ 0 1 13 O
loss NN 0 1 1 O
of IN 0 0 12 O
consciousness JJ 0 1 1 O
confusion NN 0 1 1 O
disorientation NN 0 1 6 O
anxiety NN 0 1 6 O
agitation NN 0 1 1 O
motor NN 0 1 3 O
weakness NN 0 1 6 O
myoclonus NN 0 1 13 O
tremor NN 0 1 6 O
hemiballismus NN 0 1 UNK O
hyperreflexia NN 0 1 8 O
ataxia NN 0 1 6 O
dysarthria NN 0 1 8 O
incoordination NN 0 1 UNK O
hyperthermia NN 0 1 13 O
shivering VBG 1 1 3 O
pupillary JJ 0 1 8 O
dilation NN 0 1 6 O
diaphoresis NN 0 1 8 O
emesis NN 0 1 8 O
and CC 0 0 12 O
tachycardia NN 0 1 8 O
. . 0 0 12 O

The DT 0 0 2 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
nevirapine NN 0 1 13 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
antithrombotic JJ 0 0 13 B-Group
agent NN 0 1 1 I-Group
warfarin NN 0 1 14 B-Drug
is VBZ 1 0 12 O
complex JJ 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
will MD 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
diagnosis NN 0 1 6 O
of IN 0 0 12 O
pheochromocytoma NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
elevated JJ 0 1 1 O
plasma NN 0 1 14 O
alprazolam NN 0 1 0 B-Drug
concentrations NNS 1 1 13 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
decreased JJ 0 1 1 O
psychomotor NN 0 0 13 O
performance NN 0 1 13 O
and CC 0 0 12 O
memory NN 0 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
case NN 0 1 12 O
report NN 0 1 1 O
which WDT 0 0 12 O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
sucralfate NN 0 1 0 B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
anagrelide JJ 0 1 13 B-Drug
absorption NN 0 1 1 O
. . 0 0 12 O

Salicylate NN 0 1 UNK B-Group
levels NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
falsely RB 0 0 1 O
elevated VBN 1 1 1 O
with IN 0 0 12 O
some DT 0 0 12 O
assay VBP 0 1 14 O
methods NNS 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
information NN 0 1 1 O
provided VBD 1 1 1 O

In IN 0 0 2 O
addition NN 0 1 1 O
to TO 0 0 12 O
bleeding VBG 1 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
heparin NN 0 1 14 B-Drug
and CC 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
antagonists VBZ 0 1 13 I-Group
drugs NNS 1 1 6 O
that IN 0 0 12 O
alter NN 0 1 13 O
platelet NN 0 1 14 O
function NN 0 1 1 O
( ( 0 0 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
aspirin JJ 0 1 14 B-Brand
dipyridamole NN 0 1 0 B-Drug
and CC 0 0 12 O
abciximab NN 0 1 13 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding VBG 1 1 6 O
if IN 0 0 12 O
administered VBN 1 1 1 O
prior RB 0 1 1 O
to TO 0 0 12 O
or CC 0 0 12 O
after IN 0 0 12 O
Retavase NNP 0 1 0 B-Brand
therapy NN 0 1 6 O
. . 0 0 12 O

. . 0 0 12 O

When WRB 0 0 12 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
BREVIBLOC NNP 0 1 UNK B-Brand
were VBD 1 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
intravenously RB 0 0 14 O
to TO 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
there EX 0 0 12 O
was VBD 1 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
digoxin JJ 0 1 14 B-Drug
blood NN 0 1 6 O
levels NNS 1 1 1 O
at IN 0 0 12 O
some DT 0 0 12 O
time NN 0 1 12 O
points NNS 1 1 12 O
. . 0 0 12 O

Although IN 0 0 12 O
there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
clinical JJ 0 1 6 O
evidence NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
vehicle NN 0 1 1 O
- : 0 0 2 O
controlled VBN 1 1 1 O
studies NNS 1 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
systemic JJ 0 1 6 O
antiretroviral JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
including VBG 1 1 1 O
protease NN 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
macrolide VBP 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
and CC 0 0 12 O
azole JJ 0 1 UNK B-Group
antifungals NNS 1 1 UNK I-Group
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
Panretin NNP 0 1 UNK B-Brand
gel NN 0 1 3 O
on IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

Theoretically RB 0 0 UNK O
fenoprofen NNS 0 1 UNK B-Drug
could MD 0 0 12 O
likewise RB 0 0 1 O
be VB 0 0 12 O
displaced VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
information NN 0 1 1 O
available JJ 0 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
cytochrome JJ 0 1 UNK O
P9IID9 NNP 0 0 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
quinidine NN 0 1 16 B-Drug
might MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
flecainide NN 0 1 16 B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
on IN 0 0 12 O
chronic JJ 0 1 6 O
flecainide JJ 0 1 16 B-Drug
therapy NN 0 1 6 O
; : 0 0 2 O

Calcium NNP 0 1 7 B-Group
Channel NNP 0 1 2 I-Group
Blockers NNS 0 0 UNK I-Group
: : 0 0 2 O
Isolated VBN 0 1 UNK O
cases NNS 1 1 UNK O
of IN 0 0 12 O
conduction NN 0 1 6 O
disturbance NN 0 1 13 O
( ( 0 0 2 O
rarely RB 0 1 UNK O
with IN 0 0 12 O
hemodynamic JJ 0 1 8 O
compromise NN 0 1 1 O
) ) 0 0 2 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
COREG NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
. . 0 0 12 O

MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
prolong RB 0 0 13 O
and CC 0 0 12 O
intensify VB 0 0 UNK O
the DT 0 0 12 O
anticholinergic NN 0 1 13 O
( ( 0 0 2 O
drying VBG 1 1 3 O
) ) 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihistamines NNS 1 1 UNK B-Group
. . 0 0 12 O

Tinnitus NNP 0 1 UNK O
and CC 0 0 12 O
decreased VBN 1 1 1 O
hearing NN 0 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
concomitantly RB 0 0 14 O
receiving VBG 1 1 1 O
Itraconazole NNP 0 1 UNK B-Drug
and CC 0 0 12 O
quinidine NN 0 1 16 B-Drug
. . 0 0 12 O

a DT 0 0 12 O
reduction NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
doxorubicin JJ 0 1 13 B-Drug
dosage NN 0 1 0 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
ZANOSAR NNP 0 1 UNK B-Brand
concurrently RB 0 0 1 O
. . 0 0 12 O

PEGASYS NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
for IN 0 0 12 O
use NN 0 1 1 O
in IN 0 0 12 O
women NNS 1 1 UNK O
of IN 0 0 12 O
childbearing VBG 0 0 UNK O
potential JJ 0 1 1 O
only RB 0 1 12 O
when WRB 0 0 12 O
they PRP 0 0 12 O
are VBP 1 0 12 O
using VBG 1 1 1 O
effective JJ 0 1 1 O
contraception NN 0 1 13 O
during IN 0 0 12 O
therapy NN 0 1 6 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
and CC 0 0 12 O
kaolin NN 0 1 13 B-Drug
: : 0 0 2 O
Antacids NNS 0 1 UNK B-Group
and CC 0 0 12 O
kaolin NN 0 1 13 B-Drug
can MD 0 0 12 O
reduce VB 0 0 1 O
absorption NN 0 1 1 O
of IN 0 0 12 O
chloroquine NN 0 1 13 B-Drug
; : 0 0 2 O

When WRB 0 0 12 O
other JJ 0 0 12 O
potent JJ 0 1 UNK O
parental JJ 0 1 UNK O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
diazoxide NN 0 1 16 B-Drug
are VBP 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
hydralazine JJ 0 1 14 B-Drug
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
continuously RB 0 0 UNK O
observed VBN 1 1 1 O
for IN 0 0 12 O
several JJ 0 1 12 O
hours NNS 1 1 12 O
for IN 0 0 12 O
any DT 0 0 12 O
excessive JJ 0 1 1 O
fall NN 0 1 12 O
in IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
dose JJ 0 1 6 O
increase NN 0 1 1 O
of IN 0 0 12 O
lopinavir JJ 0 1 13 B-Drug
/ NNP 0 0 2 O
ritonavir NN 0 1 16 B-Drug
to TO 0 0 12 O
9 CD 0 0 2 O
/ NNS 0 0 2 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
with IN 0 0 12 O
food NN 0 1 12 O
isrecommended VBN 0 0 UNK O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
nevirapine NN 0 1 13 B-Drug
. . 0 0 12 O

Posicor NNP 0 1 UNK B-Brand
inhibits VBZ 1 1 UNK O
some DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
's POS 0 1 12 O
ability NN 0 1 1 O
to TO 0 0 12 O
metabolize VB 0 0 UNK O
some DT 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
- : 0 0 2 O
terfenadine NN 0 1 UNK B-Drug
astemizole JJ 0 1 UNK B-Drug
cisapride NN 0 1 UNK B-Drug
cyclosporine NN 0 1 14 B-Drug
and CC 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
serum JJ 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
. . 0 0 12 O

Erythromycin NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
q9h NN 0 1 UNK O
) ) 0 0 2 O
+ VBZ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
9% CD 0 0 UNK O

There EX 0 0 12 O
is VBZ 1 0 12 O
limited JJ 0 1 1 O
experience NN 0 1 12 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
antihypertensive JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
alpha JJ 0 1 1 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
calcium VBP 0 1 14 B-Group
channel SYM 0 1 1 I-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
ACE VBP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
diuretics NNS 1 1 14 B-Group
( ( 0 0 2 O
both DT 0 0 12 O
thiazide RB 0 1 UNK B-Group
- : 0 0 2 O
like IN 0 0 12 O
and CC 0 0 12 O
loop NN 0 1 3 O
) ) 0 0 2 O
. . 0 0 12 O

If IN 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
closely RB 0 0 1 O
monitor JJ 0 1 1 O
serum NN 0 1 14 O
electrolytes NNS 1 1 14 O
and CC 0 0 12 O
cardiac JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

Acetazolamide NNP 0 1 0 B-Drug
may MD 0 0 1 O
prevent VB 0 1 1 O
the DT 0 0 12 O
urinary JJ 0 1 6 O
antiseptic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
methenamine NN 0 1 13 B-Drug
. . 0 0 12 O

Bentiromide NNP 0 1 UNK B-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Tylenol NNP 0 1 0 B-Brand
) ) 0 0 2 O
chloramphenicol NN 0 1 14 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Chloromycetin NNP 0 1 UNK B-Brand
) ) 0 0 2 O
local JJ 0 1 12 O
anesthetics NNS 1 1 13 B-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
benzocaine NN 0 1 16 B-Drug
and CC 0 0 12 O
lidocaine NN 0 1 14 B-Drug
) ) 0 0 2 O
para NN 0 1 13 B-Drug_n
- : 0 0 2 O
aminobenzoic NN 0 0 UNK I-Drug_n
acid NN 0 1 14 I-Drug_n
( ( 0 0 2 O
PABA NNP 0 1 UNK B-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
containing VBG 1 1 1 O
preparations NNS 1 1 13 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
sunscreens NNS 1 1 UNK O
and CC 0 0 12 O
some DT 0 0 12 O
multivitamins NNS 1 1 14 B-Group
) ) 0 0 2 O
procainamide NN 0 1 16 B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Pronestyl NNP 0 1 0 B-Brand
) ) 0 0 2 O
sulfonamides NNS 1 1 13 B-Group
( ( 0 0 2 O
sulfa JJ 0 1 0 O
medicines NNS 1 1 6 O
) ) 0 0 2 O
thiazide VBP 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
( ( 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
medicines NNS 1 1 6 O
during IN 0 0 12 O
the DT 0 0 12 O
test NN 0 1 1 O
period NN 0 1 1 O
will MD 0 0 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
test NN 0 1 1 O
results NNS 1 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
pancreatic JJ 0 1 6 O
supplements NNS 1 1 6 O
( ( 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
pancreatic JJ 0 1 6 O
supplements NNS 1 1 6 O
may MD 0 0 1 O
give VB 0 1 12 O
false JJ 0 1 13 O
test NN 0 1 1 O
results NNS 1 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Valdecoxib NNP 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
a DT 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
( ( 0 0 2 O
a DT 0 0 12 O
CYP NNP 0 1 UNK O
9C9 CD 0 0 UNK O
and CC 0 0 12 O
CYP NNP 0 1 UNK O
9C9 CD 0 0 UNK O
substrate NN 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
As IN 0 0 2 O
with IN 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
Ponstel NNP 0 1 UNK B-Brand
and CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
generally RB 0 0 1 O
recommended VBN 1 1 1 O
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
of IN 0 0 12 O
increased JJ 0 1 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
may MD 0 0 1 O
have VB 0 0 12 O
their PRP$ 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
altered VBN 1 1 1 O
by IN 0 0 12 O
dasatinib NN 0 1 13 B-Drug
CYP9A9 NNP 0 0 UNK O
Substrates VBZ 0 1 UNK O
: : 0 0 2 O
Dasatinib NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
time NN 0 1 12 O
- : 0 0 2 O
dependent JJ 0 1 1 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
cefdinir NN 0 1 UNK B-Drug
pharmacokinetics NNS 0 1 UNK O
if IN 0 0 12 O
the DT 0 0 12 O
antacid NN 0 1 UNK B-Group
is VBZ 1 0 12 O
administered VBN 1 1 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
cefdinir NN 0 1 UNK B-Drug
. . 0 0 12 O

Nonsteroidal NNP 0 0 UNK B-Group
Anti NNP 0 0 UNK I-Group
- : 0 0 2 O
Inflammatory NN 0 1 UNK I-Group
Drugs NNS 0 1 2 I-Group
: : 0 0 2 O
The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
diflunisal NN 0 1 13 B-Drug
to TO 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
receiving VBG 1 1 1 O
indomethacin NN 0 1 14 B-Drug
decreased VBD 1 1 1 O
the DT 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
and CC 0 0 12 O
significantly RB 0 0 1 O
increased VBD 1 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
indomethacin NN 0 1 14 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
clinical JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
Highly NNP 0 1 UNK O
Bound NNP 0 1 UNK O
To TO 0 0 2 O
Plasma NNP 0 1 UNK O
Protein NNP 0 1 2 O
Eszopiclone NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
highly RB 0 1 1 O
bound VBN 1 1 12 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
bound NN 0 1 12 O
) ) 0 0 2 O
; : 0 0 2 O

When WRB 0 0 12 O
methyldopa NN 0 1 13 B-Drug
and CC 0 0 12 O
lithium NN 0 1 16 B-Drug
are VBP 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
separate JJ 0 1 1 O
studies NNS 1 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
maintenance NN 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
warfarin JJ 0 1 14 B-Drug
hydrochlorothiazide NN 0 1 0 B-Drug
or CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
irbesartan JJ 0 1 16 B-Drug
administration NN 0 1 1 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
( ( 0 0 2 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
) ) 0 0 2 O
or CC 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

However RB 0 0 1 O
prudent JJ 0 0 1 O
evaluation NN 0 1 1 O
of IN 0 0 12 O
individual JJ 0 1 1 O
cases NNS 1 1 UNK O
is VBZ 1 0 12 O
warranted VBN 1 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
setting NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
magnitude NN 0 1 UNK O
of IN 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
multiple JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

Cimetidine NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
qid NN 0 1 15 O
) ) 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
+ JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O

This DT 0 0 2 O
may MD 0 0 1 O
be VB 0 0 12 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
relevance NN 0 1 UNK O
for IN 0 0 12 O
compounds NNS 1 1 13 O
predominantly RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
this DT 0 0 12 O
enzyme NN 0 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
- : 0 0 2 O
blockers NNS 1 0 6 O
selective VBP 0 1 13 B-Group
serotonin JJ 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
) ) 0 0 2 O
and CC 0 0 12 O
monoamine JJ 0 1 13 B-Group
oxidase NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
MAO NNP 0 1 14 I-Group
- : 0 0 2 O
Is VBZ 0 0 2 I-Group
Type NNP 0 1 2 I-Group
B NNP 0 0 2 I-Group
if IN 0 0 12 O
they PRP 0 0 12 O
have VBP 0 0 12 O
a DT 0 0 12 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
window NN 0 1 3 O
. . 0 0 12 O

CNS NNP 0 1 6 O
depression NN 0 1 6 O
producing VBG 1 0 1 O
medications NNS 1 1 6 O
- : 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
either CC 0 1 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
or CC 0 0 12 O
diphenidol NN 0 1 UNK B-Drug
; : 0 0 2 O

The DT 0 0 2 O
vasodilating VBG 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
isosorbide JJ 0 1 16 B-Drug
mononitrate NN 0 0 0 I-Drug
may MD 0 0 1 O
be VB 0 0 12 O
additive JJ 0 1 16 O
with IN 0 0 12 O
those DT 0 0 12 O
of IN 0 0 12 O
other JJ 0 0 12 O
vasodilators NNS 1 1 13 B-Group
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
antibiotics NNS 1 1 6 B-Group
and CC 0 0 12 O
sulfonamides NNS 1 1 13 B-Group
generally RB 0 0 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
ganglion NN 0 1 8 B-Group
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

Anagrelide NNP 0 1 UNK B-Drug
demonstrates VBZ 1 1 1 O
some DT 0 0 12 O
limited JJ 0 1 1 O
inhibitory NN 0 1 UNK O
activity NN 0 1 1 O
towards NNS 0 0 12 O
CYP9A9 NNP 0 0 UNK O
which WDT 0 0 12 O
may MD 0 0 1 O
present VB 0 1 1 O
a DT 0 0 12 O
theoretical JJ 0 1 UNK O
potential NN 0 1 1 O
for IN 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
coadministered VBD 0 0 UNK O
medicinal JJ 0 0 16 O
products NNS 1 1 1 O
sharing VBG 1 1 UNK O
that IN 0 0 12 O
clearance NN 0 1 16 O
mechanism NN 0 1 13 O
e.g NN 0 0 UNK O
. . 0 0 12 O
theophylline NN 0 1 16 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
some DT 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
diuretic JJ 0 1 14 O
natriuretic JJ 0 1 UNK O
and CC 0 0 12 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
loop NN 0 1 3 B-Group
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing NN 0 0 6 I-Group
and CC 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

Prior NNP 0 1 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
neuromuscular JJ 0 1 6 O
block NN 0 1 3 O
following VBG 1 1 1 O
initial JJ 0 1 1 O
or CC 0 0 12 O
maintenance NN 0 1 1 O
bolus JJ 0 1 14 O
doses NNS 1 1 6 O
of IN 0 0 12 O
NIMBEX NNP 0 1 UNK B-Brand
. . 0 0 12 O

Pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
levetiracetam NN 0 1 16 B-Drug
were VBD 1 0 12 O
also RB 0 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
. . 0 0 12 O

Phenytoin NNP 0 1 0 B-Drug
nicotine NN 0 1 6 B-Drug
and CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
may MD 0 0 1 O
decrease VB 0 1 1 O
Clozapine NNP 0 1 0 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
previously RB 0 0 1 O
effective JJ 0 1 1 O
Clozapine NNP 0 1 0 B-Drug
dose NN 0 1 6 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNPS 0 1 UNK O
The DT 0 0 2 O
following VBG 1 1 1 O
drugs NNS 1 1 6 O
or CC 0 0 12 O
moieties NNS 1 0 UNK O
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
performed VBD 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
thyroid JJ 0 1 6 B-Group
hormone NN 0 1 6 I-Group
therapy NN 0 1 6 O
: : 0 0 2 O
androgens NNS 1 1 13 B-Group
corticosteroids NNS 1 1 14 B-Group
estrogens VBZ 0 1 16 B-Group
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
containing VBG 1 1 1 O
estrogens NNS 1 1 16 B-Group
iodine JJ 0 1 14 B-Group
- : 0 0 2 O
containing NN 0 1 1 O
preparations NNS 1 1 13 O
and CC 0 0 12 O
the DT 0 0 12 O
numerous JJ 0 1 1 O
preparations NNS 1 1 13 O
containing VBG 1 1 1 O
salicylates NNS 1 1 13 B-Group
. . 0 0 12 O

Less NNP 0 1 2 O
potent JJ 0 1 UNK O
inhibitors NNS 1 1 14 O
include VBP 0 1 1 O
saquinavir JJ 0 1 13 B-Drug
nefazodone JJ 0 1 16 B-Drug
fluconazole NN 0 1 0 B-Drug
grapefruit NN 0 1 3 O
juice NN 0 1 3 O
fluoxetine NN 0 1 16 B-Drug
fluvoxamine VBP 0 1 16 B-Drug
zileuton NN 0 1 13 B-Drug
and CC 0 0 12 O
clotrimazole NN 0 1 0 B-Drug
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
known VBN 1 1 12 O
metabolic JJ 0 1 6 O
profiles NNS 1 1 UNK O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
between IN 0 0 12 O
VIRACEPT NNP 0 1 UNK B-Brand
and CC 0 0 12 O
dapsone NN 0 1 13 B-Drug
trimethoprim JJ 0 1 16 B-Drug
/ JJ 0 0 2 O
sulfamethoxazole NN 0 1 13 B-Drug
clarithromycin NN 0 1 13 B-Drug
erythromycin JJ 0 1 0 B-Drug
itraconazole NN 0 1 0 B-Drug
or CC 0 0 12 O
fluconazole NN 0 1 0 B-Drug
. . 0 0 12 O

- : 0 0 2 O
Methyldopa NN 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Aldomet NNP 0 1 0 B-Brand
) ) 0 0 2 O
Use NNP 0 1 2 O
of IN 0 0 12 O
methyldopa NN 0 1 13 B-Drug
with IN 0 0 12 O
sulfapyridine NN 0 1 UNK B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
chance NN 0 1 12 O
of IN 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
affecting VBG 1 1 1 O
the DT 0 0 12 O
liver NN 0 1 6 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
the DT 0 0 12 O
blood NN 0 1 6 O

reduced VBN 1 1 1 O
serum JJ 0 1 14 O
folate JJ 0 1 14 O
concentration NN 0 1 1 O
; : 0 0 2 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
bacteriostatic JJ 0 0 UNK B-Group
antibiotics NNS 1 1 6 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
erythromycin FW 0 1 0 B-Drug
tetracycline NN 0 1 0 B-Drug
) ) 0 0 2 O
may MD 0 0 1 O
diminish VB 0 1 UNK O
the DT 0 0 12 O
bactericidal JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
penicillins NNS 1 1 14 B-Group
by IN 0 0 12 O
slowing VBG 1 1 1 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
bacterial JJ 0 1 6 O
growth NN 0 1 1 O
. . 0 0 12 O

Alteration NN 0 1 UNK O
of IN 0 0 12 O
pH NN 0 1 14 O
may MD 0 0 1 O
affect VB 0 1 1 O
absorption NN 0 1 1 O
of IN 0 0 12 O
certain JJ 0 1 1 O
drugs NNS 1 1 6 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
ketoconazole NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Peak NNP 0 1 2 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
rimantadine NN 0 1 13 B-Drug
were VBD 1 0 12 O
reduced VBN 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
. . 0 0 12 O

Carbidopa NNP 0 1 0 B-Drug
/ NNP 0 0 2 O
Levodopa NNP 0 1 0 B-Drug
: : 0 0 2 O
Carbidopa NNP 0 1 0 B-Drug
/ NNP 0 0 2 O
Levodopa NNP 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
pramipexole NN 0 1 16 B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
( ( 0 0 2 O
N= NNP 0 1 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
aluminum NN 0 1 16 B-Drug
and CC 0 0 12 O
magnesium NN 0 1 14 B-Drug
hydroxides NNS 1 1 UNK I-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
meclofenamate NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
substances NNS 1 1 1 O
that WDT 0 0 12 O
are VBP 1 0 12 O
also RB 0 0 12 O
tubularly RB 0 0 UNK O
secreted VBN 1 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
probenecid NN 0 1 13 B-Drug
) ) 0 0 2 O
could MD 0 0 12 O
potentially RB 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
delayed JJ 0 1 1 O
clearance NN 0 1 16 O
of IN 0 0 12 O
ALIMTA NNP 0 1 UNK B-Brand
. . 0 0 12 O

. . 0 0 12 O

Antihypertensives NNS 0 1 UNK B-Group
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihypertensives NNS 1 1 14 B-Group
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
buspirone NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
displace VB 0 0 13 O
tightly RB 0 0 3 O
bound VBN 1 1 12 O
drugs NNS 1 1 6 O
like IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
propranolol NN 0 1 16 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
from IN 0 0 12 O
serum JJ 0 1 14 O
proteins NNS 1 1 14 O
. . 0 0 12 O

Prescribers NNS 0 0 UNK O
are VBP 1 0 12 O
advised VBN 1 0 12 O
to TO 0 0 12 O
consult VB 0 1 1 O
the DT 0 0 12 O
package NN 0 1 13 O
insert NN 0 1 13 O
of IN 0 0 12 O
medication NN 0 1 6 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
since IN 0 1 12 O
some DT 0 0 12 O
medications NNS 1 1 6 O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
birth NNS 0 1 12 O
control NN 0 1 1 O
products NNS 1 1 1 O
. . 0 0 12 O

Aspirin NNP 0 1 0 B-Brand
/ NNP 0 0 2 O
Acetaminophen NNP 0 1 0 B-Drug
: : 0 0 2 O
Pharmacokinetic JJ 0 1 UNK O
or CC 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
between IN 0 0 12 O
Argatroban NNP 0 1 0 B-Drug
and CC 0 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
aspirin NN 0 1 14 B-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
orally RB 0 1 14 O
given VBN 1 1 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
Argatroban NNP 0 1 0 B-Drug
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
kg NNP 0 1 18 O
/ NNP 0 0 2 O
min NN 0 1 16 O
. . 0 0 12 O
over IN 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
) ) 0 0 2 O
or CC 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
orally RB 0 1 14 O
given VBN 1 1 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
subsequent JJ 0 1 1 O
to TO 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
Argatroban NNP 0 1 0 B-Drug
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
kg NNP 0 1 18 O
/ NNP 0 0 2 O
min NN 0 1 16 O
. . 0 0 12 O
over IN 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

Oral JJ 0 1 2 O
Contraceptives NNS 0 1 UNK B-Group
: : 0 0 2 O
Valdecoxib NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
BID NNP 0 0 11 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
induce VB 0 1 6 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
oral JJ 0 1 6 O
contraceptive JJ 0 1 13 B-Group
norethindrone NN 0 1 13 B-Drug
/ NNP 0 0 2 O
ethinyl NN 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ VBD 0 0 2 O
9 CD 0 0 2 O
mcg JJ 0 1 0 O
combination NN 0 1 1 O
Ortho NNP 0 1 7 B-Brand
- : 0 0 2 O
Novum NN 0 0 UNK I-Brand
9 CD 0 0 2 O
/ $ 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Serum NNP 0 1 7 O
theophylline NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
increase NN 0 1 1 O
when WRB 0 0 12 O
grepafloxacin NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
initiated VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
maintained VBN 1 1 1 O
on IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
. . 0 0 12 O

These DT 0 0 1 O
effects NNS 1 1 1 O
are VBP 1 0 12 O
usually RB 0 1 12 O
reversible JJ 0 1 3 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
BREVIBLOC NNP 0 1 UNK B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
succinylcholine JJ 0 1 16 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
neuromuscular JJ 0 1 6 O
blockade NN 0 1 1 O
was VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
undergoing JJ 0 0 6 O
surgery NN 0 1 6 O
. . 0 0 12 O

These DT 0 0 1 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
frequent JJ 0 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

therefore RB 0 0 1 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
followed VBN 1 1 12 O
carefully RB 0 0 12 O
during IN 0 0 12 O
concurrent JJ 0 1 1 O
therapy NN 0 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
and CC 0 0 12 O
a DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
used VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
hypoxic JJ 0 1 14 O
respiratory JJ 0 1 6 O
failure NN 0 1 1 O
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
excluded VBN 1 1 1 O
based VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
available JJ 0 1 1 O
data NNS 0 1 1 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
Meclofenamate NNP 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
enhances VBZ 1 1 UNK O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

in IN 0 0 12 O
vitro NNP 0 1 UNK O
data NNS 0 1 1 O
on IN 0 0 12 O
metabolic JJ 0 1 6 O
interactions NNS 1 1 UNK O
indicate VBP 0 0 1 O
that IN 0 0 12 O
Keppra NNP 0 1 0 B-Brand
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
produce VB 0 0 1 O
or CC 0 0 12 O
be VB 0 0 12 O
subject JJ 0 1 UNK O
to TO 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
that WDT 0 0 12 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
serious JJ 0 1 12 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening JJ 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
clinical JJ 0 1 6 O
importance NN 0 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
identified VBN 1 1 1 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Diclofenac NNP 0 1 UNK B-Drug
decreases VBZ 1 1 UNK O
lithium JJ 0 1 16 B-Drug
renal JJ 0 1 6 O
clearance NN 0 1 16 O
and CC 0 0 12 O
increases VBZ 1 1 1 O
lithium NN 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
: : 0 0 2 O
Ten CD 0 1 2 O
patients NNS 1 1 6 O
who WP 0 0 12 O
were VBD 1 0 12 O
stabilized VBN 1 1 1 O
on IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
were VBD 1 0 12 O
given VBN 1 1 12 O
guanfacine JJ 0 1 13 B-Drug
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
. . 0 0 12 O

Particular JJ 0 0 UNK O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
digitalis JJ 0 1 14 B-Group
preparations NNS 1 1 13 I-Group
since IN 0 1 12 O
there EX 0 0 12 O
are VBP 1 0 12 O
conflicting VBG 1 1 UNK O
results NNS 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
colestipol NN 0 1 13 B-Drug
hydrochloride NN 0 1 0 I-Drug
on IN 0 0 12 O
the DT 0 0 12 O
availability NN 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
digitoxin NN 0 1 UNK B-Drug
. . 0 0 12 O

May NNP 0 1 2 O
interact NN 0 0 UNK O
with IN 0 0 12 O
thyroid JJ 0 1 6 O
medication NN 0 1 6 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
levothyroxine NN 0 1 0 B-Drug
) ) 0 0 2 O
iodine NN 0 1 14 B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
products NNS 1 1 1 O
antacids NNS 1 1 14 B-Group
H9 NNP 0 0 UNK B-Group
- : 0 0 2 O
antagonists NNS 1 1 13 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
famotidine NN 0 1 0 B-Drug
ranitidine NN 0 1 0 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
proton JJ 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
lansoprazole JJ 0 1 16 B-Drug
omeprazole NN 0 1 0 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

As IN 0 0 2 O
with IN 0 0 12 O
some DT 0 0 12 O
other JJ 0 0 12 O
nondepolarizing JJ 0 0 UNK B-Group
neuromuscular JJ 0 1 6 I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
the DT 0 0 12 O
time NN 0 1 12 O
of IN 0 0 12 O
onset NN 0 1 6 O
of IN 0 0 12 O
neuromuscular JJ 0 1 6 O
block NN 0 1 3 O
induced VBN 1 1 6 O
by IN 0 0 12 O
NUROMAX NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
lengthened VBN 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
block NN 0 1 3 O
is VBZ 1 0 12 O
shortened VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
carbamazepine NN 0 1 16 B-Drug
. . 0 0 12 O

Care NN 0 1 2 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
when WRB 0 0 12 O
using VBG 1 1 1 O
immunoanalytical JJ 0 0 UNK O
methods NNS 1 1 1 O
to TO 0 0 12 O
measure VB 0 1 1 O
plasma JJ 0 1 14 O
phenytoin NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
following VBG 1 1 1 O
Cerebyx NNP 0 1 UNK B-Brand
administration NN 0 1 1 O
. . 0 0 12 O

Anesthetics NNS 0 1 UNK B-Group

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
During IN 0 0 2 O
TNKase NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
results NNS 1 1 1 O
of IN 0 0 12 O
coagulation NN 0 1 14 O
tests NNS 1 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
measures NNS 1 1 1 O
of IN 0 0 12 O
fibrinolytic JJ 0 1 UNK O
activity NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
unreliable JJ 0 1 1 O
unless IN 0 0 12 O
specific JJ 0 1 1 O
precautions NNS 1 1 1 O
are VBP 1 0 12 O
taken VBN 1 1 12 O
to TO 0 0 12 O
prevent VB 0 1 1 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
artifacts NNS 1 1 UNK O
. . 0 0 12 O

Drug NN 0 1 2 O
Interaction NNP 0 1 2 O
with IN 0 0 12 O
Fluoxetine NNP 0 1 0 B-Drug
: : 0 0 2 O
A DT 0 0 2 O
multiple JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
study NN 0 1 1 O
was VBD 1 0 12 O
conducted VBN 1 1 1 O
to TO 0 0 12 O
assess VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
BID NNP 0 0 11 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
estazolam JJ 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
QHS NNP 0 1 15 O
after IN 0 0 12 O
seven CD 0 1 12 O
days NNS 1 1 12 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
oral JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
( ( 0 0 2 O
a DT 0 0 12 O
known VBN 1 1 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
and CC 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
intestinal JJ 0 1 13 O
mucosa NN 0 1 8 O
) ) 0 0 2 O
caused VBD 1 1 1 O
an DT 0 0 12 O
eight CD 0 1 12 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
to TO 0 0 12 O
oral JJ 0 1 6 O
budesonide NN 0 1 16 B-Drug
. . 0 0 12 O

Although IN 0 0 12 O
bupropion NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
this DT 0 0 12 O
isoenzyme JJ 0 1 13 O
bupropion NN 0 1 16 B-Drug
and CC 0 0 12 O
hydroxybupropion NN 0 1 UNK B-Drug_n
are VBP 1 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
CYP9D9 NNP 0 0 UNK O
isoenzyme NN 0 1 13 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

DIFLUCAN NNP 0 1 UNK B-Brand
reduces VBZ 1 0 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
tolbutamide JJ 0 1 UNK B-Drug
glyburide NN 0 1 16 B-Drug
and CC 0 0 12 O
glipizide NN 0 1 0 B-Drug
and CC 0 0 12 O
increases VBZ 1 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

Periodic JJ 0 1 13 O
measurement NN 0 1 1 O
of IN 0 0 12 O
serum NN 0 1 14 O
PSA NNP 0 1 13 O
levels NNS 1 1 1 O
may MD 0 0 1 O
also RB 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
CHEMET NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
chelation NN 0 1 UNK O
therapy NN 0 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
CaNa NNP 0 0 UNK B-Drug
9 CD 0 0 2 I-Drug
EDTA NNP 0 1 UNK I-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
medications NNS 1 1 6 O
have VBP 0 0 12 O
included VBN 1 1 1 O
heparin NN 0 1 14 B-Drug
warfarin NN 0 1 14 B-Drug
beta SYM 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
receptor NN 0 1 14 I-Group
blockers NNS 1 0 6 I-Group
calcium VBP 0 1 14 B-Group
channel NN 0 1 1 I-Group
antagonists NNS 1 1 13 I-Group
angiotensin VBP 0 1 UNK B-Group
converting VBG 1 0 UNK I-Group
enzyme NN 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
intravenous JJ 0 1 14 O
and CC 0 0 12 O
oral JJ 0 1 6 O
nitrates NNS 1 1 14 B-Group
ticlopidine VBP 0 1 16 B-Drug
and CC 0 0 12 O
aspirin VBP 0 1 14 B-Brand
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
NIZORAL NNP 0 1 UNK B-Brand
Tablets NNP 0 1 0 O
with IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
or CC 0 0 12 O
triazolam NN 0 1 13 B-Drug
has VBZ 1 0 12 O
resulted VBN 1 1 1 O
in IN 0 0 12 O
elevated JJ 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
latter JJ 0 0 UNK O
two CD 0 1 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

A DT 0 0 2 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
with IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
has VBZ 1 0 12 O
shown VBN 1 1 1 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
decrease NN 0 1 1 O
in IN 0 0 12 O
caspofungin NN 0 1 14 B-Drug
trough IN 0 1 3 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Haloperidol NN 0 1 0 B-Drug
: : 0 0 2 O
Haloperidol NN 0 1 0 B-Drug
blocks NNS 1 1 3 O
dopamine VBP 0 1 14 O
receptors NNS 1 1 13 O
thus RB 0 0 1 O
inhibiting VBG 1 1 UNK O
the DT 0 0 12 O
central JJ 0 1 1 O
stimulant JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
amphetamines NNS 1 1 14 B-Group
. . 0 0 12 O

Indinavir NNP 0 1 UNK B-Drug
and CC 0 0 12 O
didanosine JJ 0 1 16 B-Drug
formulations NNS 1 1 UNK O
containing VBG 1 1 1 O
buffer NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
at IN 0 0 12 O
least JJS 0 1 12 O
one CD 0 1 12 O
hour NN 0 1 12 O
apart NN 0 0 12 O
on IN 0 0 12 O
an DT 0 0 12 O
empty JJ 0 1 3 O
stomach NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
benzodiazepines NNS 1 1 14 B-Group
including VBG 1 1 1 O
alprazolam JJ 0 1 0 B-Drug
produce NN 0 0 1 O
additive JJ 0 1 16 O
CNS NNP 0 1 6 O
depressant NN 0 0 UNK O
effects NNS 1 1 1 O
when WRB 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
psychotropic NN 0 1 13 B-Group
medications NNS 1 1 6 I-Group
anticonvulsants NNS 1 1 13 B-Group
antihistaminics NNS 0 1 UNK B-Group
ethanol VBP 0 1 1 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
themselves PRP 0 0 UNK O
produce VBP 0 0 1 O
CNS JJ 0 1 6 O
depression NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
interactions NNS 1 1 UNK O
on IN 0 0 12 O
mean JJ 0 1 12 O
AUCs NNP 0 1 UNK O
and CC 0 0 12 O
Cmin NNP 0 1 UNK O
are VBP 1 0 12 O
summarized VBN 1 0 1 O
in IN 0 0 12 O
Table JJ 0 1 UNK O
9 CD 0 0 2 O
: : 0 0 2 O
Table JJ 0 1 UNK O
9 CD 0 0 2 O
: : 0 0 2 O
Summary NN 0 1 2 O
of IN 0 0 12 O
AED NNP 0 1 UNK O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
Trileptal NNP 0 1 UNK B-Brand

Reported VBN 0 1 2 O
examples NNS 1 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
include VBP 0 1 1 O
the DT 0 0 12 O
following JJ 0 1 1 O
: : 0 0 2 O
Immunosuppressives NNS 0 1 UNK B-Drug
: : 0 0 2 O
Cyclosporine NNP 0 1 UNK B-Drug
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK B-Drug
substrate NN 0 1 UNK O
) ) 0 0 2 O
administered VBN 1 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
oral JJ 0 1 6 O
amiodarone NN 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
produce VB 0 0 1 O
persistently RB 0 1 1 O
elevated VBN 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
elevated VBN 1 1 1 O
creatinine NN 0 1 14 O
despite IN 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
active JJ 0 1 1 O
RA NNP 0 1 13 O
were VBD 1 0 12 O
treated VBN 1 1 1 O
for IN 0 0 12 O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
with IN 0 0 12 O
concurrent JJ 0 1 1 O
ENBREL NNP 0 1 UNK B-Brand
and CC 0 0 12 O
anakinra JJ 0 1 13 B-Drug
therapy NN 0 1 6 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
rate NN 0 1 1 O
of IN 0 0 12 O
serious JJ 0 1 12 O
infections NNS 1 1 6 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
which WDT 0 0 12 O
was VBD 1 0 12 O
higher JJR 1 1 1 O
than IN 0 0 12 O
that DT 0 0 12 O
observed VBD 1 1 1 O
with IN 0 0 12 O
ENBREL NNP 0 1 UNK B-Brand
alone RB 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

Hypokalemia NNP 0 1 7 O
may MD 0 0 1 O
increase VB 0 1 1 O
susceptibility NN 0 1 6 O
to TO 0 0 12 O
cardiac VB 0 1 6 O
arrhythmias NN 1 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
digitalis NN 0 1 14 B-Group
. . 0 0 12 O

however RB 0 0 12 O
patients NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
signs NNS 1 1 12 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
increased JJ 0 1 1 O
narcotic JJ 0 1 6 O
effect NN 0 1 1 O
. . 0 0 12 O

Because IN 0 0 12 O
many JJ 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
excreted VBN 1 1 UNK O
in IN 0 0 12 O
human JJ 0 1 1 O
milk NN 0 1 3 O
and CC 0 0 12 O
because IN 0 0 12 O
there EX 0 0 12 O
exists VBZ 1 1 UNK O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
in IN 0 0 12 O
nursing VBG 1 1 12 O
infants NNS 1 1 6 O
from IN 0 0 12 O
AMEVIVE NNP 0 1 UNK B-Brand
a DT 0 0 12 O
decision NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
made VBN 1 1 12 O
whether IN 0 0 12 O
to TO 0 0 12 O
discontinue VB 0 1 1 O
nursing VBG 1 1 12 O
while IN 0 0 12 O
taking VBG 1 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
or CC 0 0 12 O
to TO 0 0 12 O
discontinue VB 0 1 1 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
taking VBG 1 0 12 O
into IN 0 0 12 O
account NN 0 1 1 O
the DT 0 0 12 O
importance NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
mother NN 0 1 12 O
. . 0 0 12 O

Examples NNS 0 1 UNK O
of IN 0 0 12 O
some DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
more RBR 0 1 12 O
potent JJ 0 1 UNK O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
include VBP 0 1 1 O
macrolide JJ 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
erythromycin NN 0 1 0 B-Drug
troleandomycin NN 0 1 UNK B-Drug
clarithromycin NN 0 1 13 B-Drug
) ) 0 0 2 O
HIV NNP 0 1 6 B-Group
protease NN 0 1 13 I-Group
or CC 0 0 12 O
reverse VB 0 1 1 B-Group
transcriptase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
ritonavir NN 0 1 16 B-Drug
indinavir NN 0 1 16 B-Drug
nelfinavir JJ 0 1 16 B-Drug
delavirdine NN 0 1 13 B-Drug
) ) 0 0 2 O
or CC 0 0 12 O
azole JJ 0 1 UNK B-Group
antifungals NNS 1 1 UNK I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
ketoconazole NN 0 1 16 B-Drug
itraconazole JJ 0 1 0 B-Drug
voriconazole NN 0 1 14 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Upon IN 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
TID NNP 0 1 15 O
indinavir VBP 0 1 16 B-Drug
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
were VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O

Higher JJR 0 1 UNK O
dosage NN 0 1 0 O
of IN 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interferences VBZ 0 1 UNK O
: : 0 0 2 O
Dicumarol NN 0 1 UNK B-Drug
and CC 0 0 12 O
indanedione NN 0 1 UNK B-Group
anticoagulants NNS 1 1 13 I-Group
including VBG 1 1 1 O
anisindione NN 0 1 UNK B-Drug
or CC 0 0 12 O
their PRP$ 0 0 12 O
metabolites NNS 1 1 UNK O
may MD 0 0 1 O
color VB 0 1 3 O
alkaline NN 0 1 14 O
urine NN 0 1 6 O
red JJ 0 1 3 O
- : 0 0 2 O
orange NN 0 1 16 O
which WDT 0 0 12 O
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
spectrophotometrically RB 0 0 UNK O
determined VBN 1 1 1 O
urinary JJ 0 1 6 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
Quinolones NNS 0 1 UNK B-Group
including VBG 1 1 1 O
enoxacin JJ 0 1 UNK B-Drug
decrease NN 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
R NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin VBD 0 1 14 I-Drug
the DT 0 0 12 O
less RBR 0 1 12 O
active JJ 0 1 1 O
isomer NN 0 1 UNK O
of IN 0 0 12 O
racemic JJ 0 1 14 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Insulin NNP 0 1 7 B-Drug
or CC 0 0 12 O
Oral JJ 0 1 2 O
Hypoglycemics NNS 0 1 UNK B-Group
: : 0 0 2 O
Agents NNS 0 1 2 B-Group
with IN 0 0 12 I-Group
b SYM 0 0 16 I-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
properties NNS 1 1 UNK I-Group
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
blood NN 0 1 6 O
- : 0 0 2 O
sugar NN 0 1 3 O
- : 0 0 2 O
reducing VBG 1 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
insulin NN 0 1 14 B-Drug
and CC 0 0 12 O
oral JJ 0 1 6 O
hypoglycemics NNS 0 1 14 B-Group
. . 0 0 12 O

Pyrazolone NN 0 1 UNK B-Group
Derivatives NNS 0 1 UNK I-Group
( ( 0 0 2 O
phenylbutazone NN 0 1 UNK B-Drug
oxyphenbutazone NN 0 1 UNK B-Drug
and CC 0 0 12 O
possibly RB 0 1 12 O
dipyrone NN 0 1 UNK B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
with IN 0 0 12 O
aspirin NN 0 1 14 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
ulceration NN 0 1 8 O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
the DT 0 0 12 O
chemical NN 0 1 13 O
resemblance NN 0 0 UNK O
of IN 0 0 12 O
itraconazole NN 0 1 0 B-Drug
and CC 0 0 12 O
ketoconazole JJ 0 1 16 B-Drug
coadministration NN 0 1 UNK O
of IN 0 0 12 O
astemizole NN 0 1 UNK B-Drug
with IN 0 0 12 O
itraconazole NN 0 1 0 B-Drug
is VBZ 1 0 12 O
contraindicated VBN 1 1 14 O
. . 0 0 12 O

Tizoxanide NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
highly RB 0 1 1 O
bound VBN 1 1 12 O
to TO 0 0 12 O
plasma VB 0 1 14 O
protein NN 0 1 14 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

clinical JJ 0 1 6 O
implications NNS 1 0 UNK O
are VBP 1 0 12 O
unclear JJ 0 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
some DT 0 0 12 O
patients NNS 1 1 6 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
steroidal JJ 0 1 UNK I-Group
antiinflammatory JJ 0 1 14 I-Group
agent NN 0 1 1 I-Group
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
diuretic JJ 0 1 14 O
natriuretic JJ 0 1 UNK O
and CC 0 0 12 O
antihypertensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
loop NN 0 1 3 B-Group
potassium NN 0 1 14 B-Group
- : 0 0 2 O
sparing NN 0 0 6 I-Group
and CC 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

Both DT 0 0 2 O
CRIXIVAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
atazanavir NNS 0 1 13 B-Drug
are VBP 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
indirect JJ 0 1 1 O
( ( 0 0 2 O
unconjugated JJ 0 1 UNK O
) ) 0 0 2 O
hyperbilirubinemia NN 0 1 8 O
. . 0 0 12 O

These DT 0 0 1 O
reactions NNS 1 1 1 O
have VBP 0 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
have VBP 0 0 12 O
discontinued VBN 1 1 1 O
that IN 0 0 12 O
drug NN 0 1 1 O
and CC 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
started VBN 1 1 12 O
on IN 0 0 12 O
a DT 0 0 12 O
MAOI NNP 0 1 UNK B-Group
. . 0 0 12 O

vii NN 0 1 13 O
. . 0 0 12 O

Administer NNP 0 1 7 O
LEVSIN NNP 0 1 UNK B-Brand
before IN 0 1 12 O
meals NNS 1 1 12 O
; : 0 0 2 O

Drugs NNS 0 1 2 O
With IN 0 0 2 O
A DT 0 0 2 O
Narrow NNP 0 1 UNK O
Therapeutic NNP 0 1 UNK O
Index NNP 0 1 2 O
Digoxin NNP 0 1 0 B-Drug
A NNP 0 0 2 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
eszopiclone NN 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
measured VBN 1 1 1 O
at IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
following VBG 1 1 1 O
dosing NN 0 0 14 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
for IN 0 0 12 O
one CD 0 1 12 O
day NN 0 1 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
daily RB 0 1 12 O
for IN 0 0 12 O
the DT 0 0 12 O
next JJ 0 1 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

General JJ 0 1 2 O
: : 0 0 2 O
Significant JJ 0 1 2 O
interactions NNS 1 1 UNK O
may MD 0 0 1 O
occur VB 0 1 1 O
when WRB 0 0 12 O
celecoxib NN 0 1 16 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
together RB 0 1 12 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
P9 JJ 0 1 UNK O
9C9 CD 0 0 UNK O
. . 0 0 12 O

Cholestyramine NN 0 1 UNK B-Drug
: : 0 0 2 O
Pretreatment NN 0 1 UNK O
for IN 0 0 12 O
four CD 0 1 12 O
days NNS 1 1 12 O
with IN 0 0 12 O
cholestyramine JJ 0 1 13 B-Drug
significantly RB 0 0 1 O
increased VBD 1 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
meloxicam NN 0 1 13 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Although IN 0 0 12 O
undercarboxylated JJ 0 0 UNK O
osteocalcin IN 0 1 UNK O
a DT 0 0 12 O
marker NN 0 1 13 O
of IN 0 0 12 O
vitamin NN 0 1 6 O
K NNP 0 1 2 O
nutritional JJ 0 1 6 O
status NN 0 1 1 O
was VBD 1 0 12 O
unaltered VBN 0 1 UNK O
with IN 0 0 12 O
XENICAL NNP 0 1 UNK B-Brand
administration NN 0 1 1 O
vitamin NN 0 1 6 O
K NNP 0 1 2 O
levels NNS 1 1 1 O
tended VBD 1 0 1 O
to TO 0 0 12 O
decline VB 0 0 1 O
in IN 0 0 12 O
subjects NNS 1 1 UNK O
taking VBG 1 0 12 O
XENICAL NN 0 1 UNK B-Brand
. . 0 0 12 O

Ritonavir NNP 0 1 0 B-Drug
and CC 0 0 12 O
indinavir NN 0 1 16 B-Drug
: : 0 0 2 O
Upon NNP 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
BID NNP 0 0 11 O
ritonavir VBZ 0 1 16 B-Drug
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
ritonavir NN 0 1 16 B-Drug
were VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Sucralfate NNP 0 1 0 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
of IN 0 0 12 O
FACTIVE NNP 0 1 UNK B-Brand
. . 0 0 12 O

Trough NNP 0 1 13 O
plasma NN 0 1 14 O
enoxacin NN 0 1 UNK B-Drug
levels NNS 1 1 1 O
were VBD 1 0 12 O
also RB 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
higher JJR 1 1 1 O
when WRB 0 0 12 O
caffeine NN 0 1 6 B-Drug
and CC 0 0 12 O
enoxacin NN 0 1 UNK B-Drug
were VBD 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

ANTACID NNP 0 1 UNK B-Group
( ( 0 0 2 O
Magnesium NNP 0 1 7 B-Drug
- : 0 0 2 O
Aluminum NNP 0 1 2 I-Drug
Hydroxide NNP 0 1 14 I-Drug
) ) 0 0 2 O
: : 0 0 2 O
Cerivastatin NNP 0 1 UNK B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
antacid NN 0 1 UNK B-Group
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
impair VBP 0 0 13 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
fat JJ 0 1 3 B-Group
- : 0 0 2 O
soluble JJ 0 1 16 I-Group
vitamins NNS 1 1 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
cholestyramine NN 0 1 13 B-Drug
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
Zemplar JJ 0 1 UNK B-Brand
Capsules NNP 0 1 0 O
. . 0 0 12 O

Carbamazepine NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
the DT 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inducer NN 0 1 UNK O
carbamazepine NN 0 1 16 B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
to TO 0 0 12 O
lapatinib VB 0 1 13 B-Drug
was VBD 1 0 12 O
decreased VBN 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Although IN 0 0 12 O
the DT 0 0 12 O
specific JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
was VBD 1 0 12 O
not RB 0 1 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
a DT 0 0 12 O
clinical JJ 0 1 6 O
trial NN 0 1 12 O
there EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
more JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
episodes NNS 1 1 12 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
antifibrinolytic JJ 0 1 UNK O
therapies NNS 1 1 6 O
( ( 0 0 2 O
i.e. JJ 0 1 1 O
tranexamic JJ 0 0 13 B-Drug
acid NN 0 1 14 I-Drug
aminocaproic IN 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
) ) 0 0 2 O
and CC 0 0 12 O
NovoSeven NNP 0 1 UNK B-Brand
. . 0 0 12 O

The DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
were VBD 1 0 12 O
performed VBN 1 1 1 O
both DT 0 0 12 O
with IN 0 0 12 O
valdecoxib NN 0 1 13 B-Drug
and CC 0 0 12 O
a DT 0 0 12 O
rapidly RB 0 1 1 O
hydrolyzed VBN 1 0 UNK O
intravenous JJ 0 1 14 O
prodrug JJ 0 1 UNK O
form NN 0 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
on IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Serious JJ 0 1 UNK O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
with IN 0 0 12 O
clonidine NN 0 1 0 B-Drug
although IN 0 0 12 O
no DT 0 0 12 O
causality NN 0 1 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressants NNS 1 0 13 I-Group
may MD 0 0 1 O
have VB 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
MIVACRON NNP 0 1 UNK B-Brand
( ( 0 0 2 O
a DT 0 0 12 O
mixture NN 0 1 3 O
of IN 0 0 12 O
three CD 0 1 12 O
stereoisomers NNS 0 1 UNK O
) ) 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
safely RB 0 0 UNK O
following VBG 1 1 1 O
succinylcholine JJ 0 1 16 O
- : 0 0 2 O
facilitated VBN 1 0 UNK O
tracheal JJ 0 1 8 O
intubation NN 0 1 8 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
MIVACRON NNP 0 1 UNK B-Brand
and CC 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
systematically RB 0 0 UNK O
studied VBN 1 0 1 O
. . 0 0 12 O

as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
atropine NN 0 1 14 B-Drug
and CC 0 0 12 O
phosphorous JJ 0 1 14 B-Drug_n
insecticides NNS 1 1 13 I-Drug_n
. . 0 0 12 O

Norepinephrine NN 0 1 UNK B-Drug

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
anticoagulants NNS 1 1 13 B-Group
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
be VB 0 0 12 O
determined VBN 1 1 1 O
before IN 0 1 12 O
starting VBG 1 1 12 O
lovastatin NN 0 1 13 B-Drug
and CC 0 0 12 O
frequently RB 0 1 1 O
enough RB 0 0 12 O
during IN 0 0 12 O
early JJ 0 1 12 O
therapy NN 0 1 6 O
to TO 0 0 12 O
insure VB 0 0 1 O
that IN 0 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
alteration NN 0 1 1 O
of IN 0 0 12 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
occurs VBZ 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
amiloride NN 0 1 16 B-Drug
HCl NNP 0 0 14 O
is VBZ 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
an DT 0 0 12 O
angiotensin NN 0 1 UNK B-Group
- : 0 0 2 O
converting VBG 1 0 UNK I-Group
enzyme JJ 0 1 14 I-Group
inhibitor NN 0 1 14 I-Group
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
hyperkalemia NN 0 1 14 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
initial JJ 0 1 1 O
treatment NN 0 1 6 O
of IN 0 0 12 O
severe JJ 0 1 6 O
malaria NNS 0 1 13 O
Mefloquine NNP 0 1 UNK B-Drug
administration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
delayed VBN 1 1 1 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
dose NN 0 1 6 O
. . 0 0 12 O

Alcohol NNP 0 1 2 B-Drug
in IN 0 0 12 O
particular NN 0 0 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
exhibit VB 0 1 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
variety NN 0 1 1 O
. . 0 0 12 O

Tetracyclines NNS 0 1 14 B-Group
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
treatment NN 0 1 6 O
with IN 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
and CC 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
because RB 0 0 12 O
Accutane NNP 0 1 UNK B-Brand
use NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
pseudotumor NN 0 1 8 O
cerebri NN 0 0 8 O
( ( 0 0 2 O
benign JJ 0 1 6 O
intracranial JJ 0 1 8 O
hypertension NN 0 1 6 O
) ) 0 0 2 O
some DT 0 0 12 O
of IN 0 0 12 O
which WDT 0 0 12 O
involved VBD 1 1 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
tetracyclines NNS 1 1 13 B-Group

Valdecoxib NNP 0 1 UNK B-Drug
caused VBD 1 1 1 O
a DT 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
exposures NNS 1 1 UNK O
of IN 0 0 12 O
R NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin NN 0 1 14 I-Drug
and CC 0 0 12 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin NN 0 1 14 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
) ) 0 0 2 O
and CC 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
effects NNS 1 1 1 O
( ( 0 0 2 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
measured VBN 1 1 1 O
as IN 1 0 12 O
INR NNP 0 1 13 O
) ) 0 0 2 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
and CC 0 0 12 O
drugs NNS 1 1 6 O
primarily RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
could MD 0 0 12 O
increase VB 0 1 1 O
or CC 0 0 12 O
prolong VB 0 0 13 O
both DT 0 0 12 O
therapeutic JJ 0 1 6 O
and CC 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Population NNP 0 1 UNK O
pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
showed VBD 1 1 12 O
higher JJR 1 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
cilostazol NN 0 1 16 B-Drug
among IN 0 0 12 O
patients NNS 1 1 6 O
concurrently RB 0 0 1 O
treated VBN 1 1 1 O
with IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
C.P.A.. NNP 0 0 UNK O

Cholestyramine NN 0 1 UNK B-Drug
: : 0 0 2 O
Cholestyramine NN 0 1 UNK B-Drug
binds VBZ 1 1 UNK O
both DT 0 0 12 O
T9 NNP 0 1 13 B-Drug
and CC 0 0 12 O
T9 NNP 0 1 13 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
intestine NN 0 1 6 O
thus RB 0 0 1 O
impairing VBG 1 1 UNK O
absorption NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
thyroid JJ 0 1 6 B-Group
hormones NNS 1 1 13 I-Group
. . 0 0 12 O

Cyclosporine NNP 0 1 UNK B-Drug
tacrolimus NN 0 1 16 B-Drug
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
concentrations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
therapy NN 0 1 6 O
and CC 0 0 12 O
frequently RB 0 1 1 O
thereafter RB 0 0 1 O
and CC 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
these DT 0 0 12 O
three CD 0 1 12 O
drug NN 0 1 1 O
products NNS 1 1 1 O
adjusted VBN 1 1 1 O
appropriately RB 0 0 1 O
. . 0 0 12 O

Preliminary JJ 0 1 2 O
clinical JJ 0 1 6 O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
nephrolithiasis NN 0 1 8 O
is VBZ 1 0 12 O
higher JJR 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
indinavir NN 0 1 16 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
ritonavir NN 0 1 16 B-Drug
than IN 0 0 12 O
those DT 0 0 12 O
receiving VBG 1 1 1 O
CRIXIVAN NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
q9h NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
and CC 0 0 12 O
cimetidine NN 0 1 13 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
physician NN 0 1 6 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
to TO 0 0 12 O
monitor VB 0 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
itraconazole NN 0 1 0 B-Drug
when WRB 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
taken VBN 1 1 12 O
concurrently RB 0 0 1 O
and CC 0 0 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
Itraconazole NNP 0 1 UNK B-Drug
if IN 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Proquin NNP 0 1 UNK B-Brand
XR NNP 0 1 0 I-Brand
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
these DT 0 0 12 O
products NNS 1 1 1 O
. . 0 0 12 O

Dose JJ 0 1 7 O
adjustments NNS 1 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
class NN 0 1 12 O
of IN 0 0 12 O
agents NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

A DT 0 0 2 O
multiple JJ 0 1 1 O
dose JJ 0 1 6 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
demonstrated VBD 1 0 1 O
that IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
approximately RB 0 1 1 O
doubled VBD 1 1 12 O
paricalcitol NN 0 1 16 B-Drug
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
. . 0 0 12 O
Since IN 0 1 2 O
paricalcitol NN 0 1 16 B-Drug
is VBZ 1 0 12 O
partially RB 0 0 1 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A NNP 0 0 UNK O
and CC 0 0 12 O
ketoconazole JJ 0 1 16 B-Drug
le NN 0 1 13 O
is VBZ 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
a DT 0 0 12 O
strong JJ 0 1 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A CD 0 1 UNK O
enzyme NN 0 1 14 O
care NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
while IN 0 0 12 O
dosing VBG 1 0 14 O
paricalcitol NN 0 1 16 B-Drug
with IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
strong JJ 0 1 12 O
P9 NNP 0 1 UNK O
9A CD 0 1 UNK O
inhibitors NNS 1 1 14 O
including VBG 1 1 1 O
atazanavir JJ 0 1 13 B-Drug
clarithromycin NN 0 1 13 B-Drug
indinavir NN 0 1 16 B-Drug
itraconazole JJ 0 1 0 B-Drug
nefazodone NN 0 1 16 B-Drug
nelfinavir NN 0 1 16 B-Drug
ritonavir NN 0 1 16 B-Drug
saquinavir NN 0 1 13 B-Drug
telithromycin NN 0 1 UNK B-Drug
or CC 0 0 12 O
voriconazole NN 0 1 14 B-Drug
. . 0 0 12 O

However RB 0 0 1 O
reports NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
may MD 0 0 1 O
diminish VB 0 1 UNK O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
ACE NNP 0 1 13 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
undesirable JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
FORADIL NNP 0 1 UNK B-Brand
. . 0 0 12 O

CRIXIVAN NNP 0 1 UNK B-Brand
may MD 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
effective JJ 0 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
decreased JJ 0 1 1 O
indinavir JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

Thus RB 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
not RB 0 1 12 O
to TO 0 0 12 O
use VB 0 1 1 O
such JJ 0 0 1 O
methods NNS 1 1 1 O
for IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
Omniscan NNP 0 1 UNK B-Brand
. . 0 0 12 O

Ketoconazole NNP 0 1 UNK B-Drug

Cimetidine NNP 0 1 0 B-Drug
treatment NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
stopped VBN 1 1 12 O
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
ELLENCE NNP 0 1 UNK B-Brand
. . 0 0 12 O

astemizole JJ 0 1 UNK B-Drug
bepridil NN 0 1 UNK B-Drug
sparfloxacin NN 0 1 UNK B-Drug
and CC 0 0 12 O
terodiline NN 0 1 UNK B-Drug
. . 0 0 12 O

Tricyclic JJ 0 0 UNK B-Group
Antidepressants NNS 0 1 UNK I-Group
: : 0 0 2 O
Use NN 0 1 2 O
of IN 0 0 12 O
thyroid NN 0 1 6 B-Group
products NNS 1 1 1 I-Group
with IN 0 0 12 O
imipramine NN 0 1 0 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
receptor NN 0 1 14 O
sensitivity NN 0 1 1 O
and CC 0 0 12 O
enhance NN 0 1 UNK O
antidepressant JJ 0 1 6 O
activity NN 0 1 1 O
transient NN 0 1 1 O
cardiac NN 0 1 6 O
arrhythmias NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Lovastatin NN 0 1 UNK B-Drug

These DT 0 0 1 O
cephalosporins NNS 1 1 14 B-Group
are VBP 1 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
vitamin NN 0 1 6 O
K NNP 0 1 2 O
epoxide IN 0 1 UNK O
reductase NN 0 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
diminution NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
sufficient JJ 0 1 1 O
to TO 0 0 12 O
preclude VB 0 0 UNK O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
pressor NN 0 1 14 O
agent NN 0 1 1 O
for IN 0 0 12 O
therapeutic JJ 0 1 6 O
use NN 0 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
DIABINESE NNP 0 1 UNK B-Brand
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
hypoglycemia NN 0 1 6 O
. . 0 0 12 O

Therefore RB 0 0 1 O
if IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
agents NNS 1 1 1 O
is VBZ 1 0 12 O
indicated JJ 0 1 1 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
's POS 0 1 12 O
serum JJ 0 1 14 O
potassium NN 0 1 14 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

( ( 0 0 2 O
May NNP 0 1 2 O
inhibit VB 0 1 13 O
gastrointestinal JJ 0 1 6 O
absorption NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
; : 0 0 2 O

INH NNP 0 1 14 B-Drug
( ( 0 0 2 O
Isoniazid NNP 0 1 UNK B-Drug
) ) 0 0 2 O
is VBZ 1 0 12 O
also RB 0 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
affect VB 0 1 1 O
ketoconazole JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
adversely RB 0 0 UNK O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
EVISTA NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
clofibrate NN 0 1 UNK B-Drug
indomethacin NN 0 1 14 B-Drug
naproxen JJ 0 1 16 B-Drug
ibuprofen NN 0 1 0 B-Drug
diazepam NN 0 1 0 B-Drug
and CC 0 0 12 O
diazoxide NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
ratios NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
AUCs NNP 0 1 UNK O
of IN 0 0 12 O
unbound JJ 0 0 UNK O
valproate NN 0 1 16 B-Drug
to TO 0 0 12 O
the DT 0 0 12 O
AUCs NNP 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
total JJ 0 1 1 O
valproate NN 0 1 16 B-Drug
were VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
with IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
of IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
respectively RB 0 0 1 O
. . 0 0 12 O

Cyclosporine NN 0 1 UNK B-Drug
: : 0 0 2 O
Administration NN 0 1 UNK O
of IN 0 0 12 O
nonsteroial JJ 0 0 UNK B-Group
anti JJ 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
concomitantly RB 0 0 14 O
with IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
cyclosporine JJ 0 1 14 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
toxicity NN 0 1 6 O
possibly RB 0 1 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
decreased JJ 0 1 1 O
synthesis NN 0 1 UNK O
of IN 0 0 12 O
renal JJ 0 1 6 O
prostacyclin NN 0 1 UNK O
. . 0 0 12 O

CELEBREX NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
introduced VBN 1 1 12 O
at IN 0 0 12 O
the DT 0 0 12 O
lowest JJS 1 1 13 O
recommended VBD 1 1 1 O
dose NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
fluconazole NN 0 1 0 B-Drug
. . 0 0 12 O

A DT 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
nisoldipine NN 0 1 13 B-Drug
was VBD 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
cimetidine JJ 0 1 13 B-Drug
9 CD 0 0 2 I-Drug
mg JJ 0 1 0 I-Drug
twice RB 0 1 12 O
daily RB 0 1 12 O
. . 0 0 12 O

These DT 0 0 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
concentration NN 0 1 1 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
increased VBN 1 1 1 O
effects NNS 1 1 1 O
( ( 0 0 2 O
lower JJR 1 1 1 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
and CC 0 0 12 O
increased JJ 0 1 1 O
heart NN 0 1 12 O
rate NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

However RB 0 0 1 O
antacids NNS 1 1 14 B-Group
can MD 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
peak JJ 0 1 1 O
concentration NN 0 1 1 O
reached VBN 1 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
but CC 0 0 12 O
have VBP 0 0 12 O
no DT 0 0 12 O
detectable JJ 0 1 UNK O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
time NN 0 1 12 O
- : 0 0 2 O
to TO 0 0 12 O
- : 0 0 2 O
peak NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
long JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
safety NN 0 1 1 O
studies NNS 1 1 1 O
guanfacine VBP 0 1 13 B-Drug
was VBD 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
many JJ 0 0 12 O
drugs NNS 1 1 6 O
without IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
any DT 0 0 12 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
nursing NN 0 1 12 O
infants NNS 1 1 6 O
a DT 0 0 12 O
decision NN 0 1 12 O
must MD 0 0 12 O
be VB 0 0 12 O
made VBN 1 1 12 O
whether IN 0 0 12 O
to TO 0 0 12 O
discontinue VB 0 1 1 O
nursing NN 0 1 12 O
or CC 0 0 12 O
discontinue NN 0 1 1 O
PEGASYS NNP 0 1 UNK B-Brand
and CC 0 0 12 O
COPEGUS NNP 0 1 UNK B-Brand
treatment NN 0 1 6 O
. . 0 0 12 O

Because IN 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
efavirenz NN 0 1 13 B-Drug
with IN 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
fully RB 0 0 1 O
characterized VBN 1 1 1 O
a DT 0 0 12 O
reliable JJ 0 1 UNK O
method NN 0 1 13 O
of IN 0 0 12 O
barrier JJR 0 1 1 O
contraception NN 0 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
addition NN 0 1 1 O
to TO 0 0 12 O
oral JJ 0 1 6 O
contraceptives NNS 1 1 13 B-Group
. . 0 0 12 O

Some DT 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
are VBP 1 0 12 O
: : 0 0 2 O
- : 0 0 2 O
birth NN 0 1 12 O
control NN 0 1 1 O
pills VBZ 0 1 6 O
- : 0 0 2 O
corticosteroids NNS 1 1 14 B-Group
- : 0 0 2 O
medicines NNS 1 1 6 O
for IN 0 0 12 O
angina NN 0 1 6 O
or CC 0 0 12 O
high JJ 0 1 1 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
- : 0 0 2 O
medicines NNS 1 1 6 O
for IN 0 0 12 O
pain NN 0 1 6 O
- : 0 0 2 O
medicines NNS 1 1 6 O
to TO 0 0 12 O
control VB 0 1 1 O
seizures NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
carbamazepine VB 0 1 16 B-Drug
- : 0 0 2 O
certain JJ 0 1 1 O
antibiotics NNS 1 1 6 B-Group
given VBN 1 1 12 O
by IN 0 0 12 O
injection NN 0 1 3 O
- : 0 0 2 O
cisplatin NN 0 1 14 B-Drug
- : 0 0 2 O
edrophonium NN 0 1 16 B-Drug
- : 0 0 2 O
neostigmine JJ 0 1 16 B-Drug
- : 0 0 2 O
polymyxin NN 0 1 16 B-Drug
B NNP 0 0 2 I-Drug
or CC 0 0 12 O
bacitracin SYM 0 1 16 B-Drug
- : 0 0 2 O
local JJ 0 1 12 O
anesthetics NNS 1 1 13 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
procaine NN 0 1 UNK B-Drug
- : 0 0 2 O
general JJ 0 1 1 O
anesthetics NNS 1 1 13 B-Group
- : 0 0 2 O
succinylcholine NN 0 1 16 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
muscle NN 0 1 6 B-Group
relaxants NNS 1 0 13 I-Group

Quinidine NN 0 1 0 B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
bid NN 0 0 12 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
nisoldipine NN 0 1 13 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
but CC 0 0 12 O
not RB 0 1 12 O
the DT 0 0 12 O
peak JJ 0 1 1 O
concentration NN 0 1 1 O
. . 0 0 12 O

INDOCIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
triamterene NN 0 1 13 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
together RB 0 1 12 O
. . 0 0 12 O

therefore RB 0 0 1 O
patients NNS 1 1 6 O
who WP 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
adversely RB 0 0 UNK O
affected VBN 1 1 1 O
by IN 0 0 12 O
such JJ 0 0 1 O
an DT 0 0 12 O
action NN 0 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
alosetron NN 0 1 UNK B-Drug
and CC 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
are VBP 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

CNS NNP 0 1 6 O
Toxicity NNP 0 1 UNK O
Brain NNP 0 1 2 O
hemorrhage NN 0 1 6 O
was VBD 1 0 12 O
seen VBN 1 1 12 O
in IN 0 0 12 O
a DT 0 0 12 O
female JJ 0 1 12 O
dog NN 0 1 12 O
treated VBD 1 1 1 O
for IN 0 0 12 O
9 CD 0 0 2 O
months NNS 1 1 12 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

Also RB 0 0 2 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
experiments NNS 1 1 UNK O
demonstrated VBD 1 0 1 O
a DT 0 0 12 O
lack NN 0 1 1 O
of IN 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
dirithromycin NN 0 1 UNK B-Drug
and CC 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
. . 0 0 12 O

Both DT 0 0 2 O
the DT 0 0 12 O
sedative NN 0 1 6 O
and CC 0 0 12 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
major JJ 0 1 1 B-Group
tranquilizers NNS 1 1 13 I-Group
are VBP 1 0 12 O
also RB 0 0 12 O
additive JJ 0 1 16 O
to TO 0 0 12 O
those DT 0 0 12 O
of IN 0 0 12 O
desipramine NN 0 1 16 B-Drug
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
are VBP 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Other JJ 0 0 2 O
than IN 0 0 12 O
with IN 0 0 12 O
probenecid JJ 0 1 13 B-Drug
no DT 0 0 12 O
specific JJ 0 1 1 O
clinical JJ 0 1 6 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O

Sulfamethoxazole NNP 0 1 0 B-Drug
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
. . 0 0 12 O

Serum NNP 0 1 7 O
potassium NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
cardiac JJ 0 1 6 O
function NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored JJ 0 1 1 O
and CC 0 0 12 O
any DT 0 0 12 O
deficit NN 0 1 1 O
promptly RB 0 0 12 O
corrected VBN 1 1 1 O
. . 0 0 12 O

Read VB 0 1 2 O
the DT 0 0 12 O
circular NN 0 1 13 O
for IN 0 0 12 O
lithium NN 0 1 16 B-Drug
preparations NNS 1 1 13 O
. . 0 0 12 O

monitor NN 0 1 1 O
cyclosporine NN 0 1 14 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

Concurrent NN 0 1 13 O
use NN 0 1 1 O
with IN 0 0 12 O
vasoconstrictor NN 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
including VBG 1 1 1 O
ergot JJ 0 1 UNK B-Group
alkaloids NNS 1 1 13 I-Group
sumatriptan NN 0 1 16 B-Drug
and CC 0 0 12 O
nicotine NN 0 1 6 B-Drug
( ( 0 0 2 O
e.g JJ 0 0 UNK O
. . 0 0 12 O
smoking VBG 1 1 12 O
) ) 0 0 2 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
enhanced JJ 0 1 1 O
vasoconstriction NN 0 1 UNK O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
The DT 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
ceftazidime NN 0 1 14 B-Drug
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
false JJ 0 1 13 O
- : 0 0 2 O
positive JJ 0 1 1 O
reaction NN 0 1 1 O
for IN 0 0 12 O
glucose NN 0 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
when WRB 0 0 12 O
using VBG 1 1 1 O
CLINITEST NNP 0 1 UNK O
tablets NNS 1 1 3 O
Benedicts NNPS 0 0 UNK O
solution NN 0 1 1 O
or CC 0 0 12 O
Fehlings NNP 0 0 UNK O
solution NN 0 1 1 O
. . 0 0 12 O

Johns NNP 0 0 UNK O
Wort NNP 0 0 UNK O
may MD 0 0 1 O
decrease VB 0 1 1 O
SUTENT NNP 0 1 0 B-Brand
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
unpredictably RB 0 0 UNK O
. . 0 0 12 O

as IN 1 0 12 O
such JJ 0 0 1 O
it PRP 0 0 12 O
may MD 0 0 1 O
impair VB 0 0 13 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
. . 0 0 12 O

it PRP 0 0 12 O
is VBZ 1 0 12 O
possible JJ 0 1 1 O
that IN 0 0 12 O
larger JJR 1 1 1 O
theophylline NN 0 1 16 B-Drug
doses NNS 1 1 6 O
could MD 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
greater JJR 1 1 1 O
effect NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
Sanctura NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
that WDT 0 0 12 O
produce VBP 0 0 1 O
dry JJ 0 1 3 O
mouth NN 0 1 3 O
constipation NN 0 1 6 O
and CC 0 0 12 O
other JJ 0 0 12 O
anticholinergic JJ 0 1 13 O
pharmacological JJ 0 1 14 O
effects NNS 1 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
frequency NN 0 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
severity NN 0 1 6 O
of IN 0 0 12 O
such JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Few JJ 0 1 2 O
systemic JJ 0 1 6 O
data NNS 0 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
collected VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
WELLBUTRIN NNP 0 1 0 B-Brand
following VBG 1 1 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
or CC 0 0 12 O
alternatively RB 0 0 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
WELLBUTRIN NNP 0 1 0 B-Brand
on IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
differences NNS 1 1 UNK O
in IN 0 0 12 O
safety NN 0 1 1 O
or CC 0 0 12 O
efficacy NN 0 1 UNK O
were VBD 1 0 12 O
observed VBN 1 1 1 O
between IN 0 0 12 O
older JJR 1 1 12 O
and CC 0 0 12 O
younger JJR 1 1 12 O
patients NNS 1 1 6 O
but CC 0 0 12 O
there EX 0 0 12 O
were VBD 1 0 12 O
not RB 0 1 12 O
sufficient JJ 0 1 1 O
data NNS 0 1 1 O
to TO 0 0 12 O
exclude VB 0 1 1 O
important JJ 0 1 1 O
differences NNS 1 1 UNK O
. . 0 0 12 O

monitor NN 0 1 1 O
and CC 0 0 12 O
adjust NN 0 0 1 O
anticoagulant JJ 0 1 13 B-Group
dosage NN 0 1 0 O
accordingly RB 0 0 1 O
. . 0 0 12 O

Additives NNS 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
incompatible JJ 0 1 13 O
. . 0 0 12 O

Potential JJ 0 1 UNK O
Terfenadine NNP 0 1 UNK B-Drug
Astemizole NNP 0 1 UNK B-Drug
and CC 0 0 12 O
Cisapride NNP 0 1 0 B-Drug
Interactions NNP 0 1 UNK O

Pharmacokinetic JJ 0 1 UNK O
properties NNS 1 1 UNK O
of IN 0 0 12 O
abacavir NNS 0 1 16 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
lamivudine NN 0 1 16 B-Drug
or CC 0 0 12 O
zidovudine NN 0 1 13 B-Drug
or CC 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
lamivudine NN 0 1 16 B-Drug
and CC 0 0 12 O
zidovudine NN 0 1 13 B-Drug
. . 0 0 12 O

Medication NN 0 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
digitalis NN 0 1 14 B-Group
may MD 0 0 1 O
also RB 0 0 12 O
influence VB 0 0 UNK O
serum NN 0 1 14 O
electrolytes NNS 1 1 14 O
. . 0 0 12 O

Symptoms NNS 0 1 7 O
resolved VBD 1 1 1 O
when WRB 0 0 12 O
clonidine NN 0 1 0 B-Drug
was VBD 1 0 12 O
withdrawn VBN 1 1 1 O
and CC 0 0 12 O
recurred VBN 1 1 6 O
when WRB 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
was VBD 1 0 12 O
rechallenged VBN 0 1 UNK O
with IN 0 0 12 O
clonidine NN 0 1 0 B-Drug
. . 0 0 12 O

Tolbutamide NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
M9 NNP 0 1 UNK O
was VBD 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
increases NNS 1 1 1 O
ranging VBG 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
the DT 0 0 12 O
free JJ 0 1 12 O
fraction NN 0 1 1 O
of IN 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
at IN 0 0 12 O
concentrations NNS 1 1 13 O
in IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
range NN 0 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
if IN 0 0 12 O
CASODEX NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
started VBN 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
already RB 0 0 12 O
receiving VBG 1 1 1 O
coumarin NN 0 1 UNK B-Group
anticoagulants NNS 1 1 13 I-Group
prothrombin VBP 0 1 14 O
times NNS 1 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored JJ 0 1 1 O
and CC 0 0 12 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
dose NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Preliminary JJ 0 1 2 O
evidence NN 0 1 1 O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
inhibits NNS 0 1 UNK O
mebendazole VBP 0 1 13 B-Drug
metabolism NN 0 1 16 O
and CC 0 0 12 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
mebendazole NN 0 1 13 B-Drug
. . 0 0 12 O

Notably RB 0 0 13 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
( ( 0 0 2 O
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
of IN 0 0 12 O
dapsone NN 0 1 13 B-Drug_n
hydroxylamine NN 0 1 UNK I-Drug_n
( ( 0 0 2 O
DHA NNP 0 1 UNK B-Drug_n
) ) 0 0 2 O
was VBD 1 0 12 O
more RBR 0 1 12 O
than IN 0 0 12 O
doubled VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
TMP NNP 0 0 UNK B-Drug
/ NNP 0 0 2 O
SMX NNP 0 1 UNK B-Drug
. . 0 0 12 O

In IN 0 0 2 O
vivo JJ 0 1 13 O
studies NNS 1 1 1 O
: : 0 0 2 O
Nitrates NNS 0 1 UNK B-Group
: : 0 0 2 O
The DT 0 0 2 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
lowering VBG 1 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
sublingual JJ 0 1 0 O
nitrates NNS 1 1 14 B-Group
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
taken VBN 1 1 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
vardenafil NN 0 1 UNK B-Drug
and CC 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
heart NN 0 1 12 O
rate NN 0 1 1 O
when WRB 0 0 12 O
taken VBN 1 1 12 O
at IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
were VBD 1 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
middle JJ 0 1 12 O
- : 0 0 2 O
aged VBN 1 1 12 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
glipizide VB 0 1 0 B-Drug
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
observed VBN 1 1 1 O
for IN 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
control NN 0 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
QTc NNP 0 0 14 O
prolongation NN 0 1 6 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
TdP NNP 0 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
amiodarone NN 0 1 0 B-Drug
when WRB 0 0 12 O
fluoroquinolones NNS 0 1 UNK B-Drug
macrolide VBP 0 1 UNK B-Drug
antibiotics NNS 1 1 6 I-Drug
or CC 0 0 12 O
azoles NNS 0 1 UNK O
were VBD 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
information NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
highly RB 0 1 1 O
plasma JJ 0 1 14 O
protein NN 0 1 14 O
bound NN 0 1 12 O
drugs NNS 1 1 6 O
on IN 0 0 12 O
doxazosin NN 0 1 13 B-Drug
binding NN 0 1 1 O
. . 0 0 12 O

9% CD 0 0 UNK O
9% CD 0 0 UNK O
9% CD 0 0 UNK O
9% CD 0 0 UNK O

- : 0 0 2 O
Medicinal NN 0 0 UNK O
or CC 0 0 12 O
dietary JJ 0 1 6 O
iodine NN 0 1 14 B-Group
interferes NNS 0 1 UNK O
with IN 0 0 12 O
all DT 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
tests NNS 1 1 1 O
of IN 0 0 12 O
radio NN 0 1 12 O
- : 0 0 2 O
iodine JJ 0 1 14 O
uptake JJ 0 1 14 O
producing VBG 1 0 1 O
low JJ 0 1 1 O
uptakes NNS 1 1 UNK O
which WDT 0 0 12 O
may MD 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
reflective JJ 0 1 3 O
of IN 0 0 12 O
a DT 0 0 12 O
true JJ 0 1 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
hormone NN 0 1 6 O
synthesis NN 0 1 UNK O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
postmarketing VBG 0 0 UNK O
reports NNS 1 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
when WRB 0 0 12 O
erythromycin NN 0 1 0 B-Drug
is VBZ 1 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
QT NNP 0 1 13 O
prolongation NN 0 1 6 O
cardiac NN 0 1 6 O
arrythmias IN 0 1 UNK O
ventricular JJ 0 1 8 O
tachycardia NN 0 1 8 O
ventricular JJ 0 1 8 O
fibrulation NN 0 0 13 O
and CC 0 0 12 O
torsades NNS 0 0 13 O
de VBP 0 1 2 O
pointes VBZ 1 0 UNK O
most JJS 0 0 12 O
like IN 0 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
by IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
. . 0 0 12 O

One CD 0 1 2 O
case NN 0 1 12 O
of IN 0 0 12 O
hypertensive JJ 0 1 6 O
crisis NN 0 1 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
taking VBG 1 0 12 O
the DT 0 0 12 O
recommended JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
selegiline NN 0 1 13 B-Drug
and CC 0 0 12 O
a DT 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
medication NN 0 1 6 I-Group
( ( 0 0 2 O
ephedrine NN 0 1 13 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Chlorotrianisene NNP 0 1 UNK B-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
antidepressants NNS 1 1 13 B-Group
aspirin VBP 0 1 14 B-Brand
barbiturates NNS 1 1 14 B-Group
bromocriptine VBP 0 1 16 B-Drug
calcium NN 0 1 14 B-Drug
supplements NNS 1 1 6 O
corticosteroids NNS 1 1 14 B-Group
corticotropin VBP 0 1 13 B-Drug
cyclosporine JJ 0 1 14 B-Drug
dantrolene NN 0 1 16 B-Drug
nicotine JJ 0 1 6 B-Drug
somatropin NN 0 1 13 B-Drug
tamoxifen NN 0 1 0 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

False NNP 0 1 UNK O
- : 0 0 2 O
positive JJ 0 1 1 O
direct JJ 0 1 1 O
Coombs NNP 0 1 19 O
tests NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
other JJ 0 0 12 O
cephalosporins NNS 1 1 14 B-Group
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
diflunisal JJ 0 1 13 B-Drug
tablets NNS 1 1 3 O
and CC 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
increased VBN 1 1 1 O
possibility NN 0 1 1 O
of IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
toxicity NN 0 1 6 O
with IN 0 0 12 O
little JJ 0 1 12 O
or CC 0 0 12 O
no DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
efficacy NN 0 1 UNK O
. . 0 0 12 O

However RB 0 0 1 O
this DT 0 0 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
investigated VBN 1 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
studies NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
citalopram NN 0 1 16 B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
observation NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
decisions NNS 1 1 1 O
to TO 0 0 12 O
prescribe VB 0 0 UNK O
VESIcare NNP 0 1 UNK B-Brand
for IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
known JJ 0 1 12 O
history NN 0 1 12 O
of IN 0 0 12 O
QT NNP 0 1 13 O
prolongation NN 0 1 6 O
or CC 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
medications NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
prolong VB 0 0 13 O
the DT 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
on IN 0 0 12 O
Vardenafil NNP 0 1 UNK B-Drug

Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
calcium NN 0 1 14 B-Drug
- : 0 0 2 O
containing NN 0 1 1 O
medicines NNS 1 1 6 O
( ( 0 0 2 O
including VBG 1 1 1 O
antacids NNS 1 1 14 B-Group
) ) 0 0 2 O
may MD 0 0 1 O
cause VB 0 1 12 O
too RB 0 0 12 O
much JJ 0 0 12 O
calcium NN 0 1 14 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
blood NN 0 1 6 O
or CC 0 0 12 O
urine NN 0 1 6 O
which WDT 0 0 12 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
chance NN 0 1 12 O
of IN 0 0 12 O
side JJ 0 1 3 O
effects NNS 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
was VBD 1 0 12 O
seen VBN 1 1 12 O
in IN 0 0 12 O
another DT 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
. . 0 0 12 O

BREVIBLOC NNP 0 1 UNK B-Brand
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
equivocally RB 0 0 UNK O
higher JJR 1 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
but CC 0 0 12 O
this DT 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
however RB 0 0 12 O
is VBZ 1 0 12 O
advised VBN 1 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
which WDT 0 0 12 O
can MD 0 0 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
uptake NN 0 1 14 O
of IN 0 0 12 O
circulating VBG 1 1 13 O
amines NNS 1 1 13 O
. . 0 0 12 O

Conversely RB 0 0 UNK O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
STADOL NNP 0 1 UNK B-Brand
NS NNP 0 1 13 I-Brand
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
butorphanol NN 0 1 13 B-Drug
QID NNP 0 1 15 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

Thus RB 0 0 1 O
cimetidine NN 0 1 13 B-Drug
appeared VBD 1 1 12 O
to TO 0 0 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
both DT 0 0 12 O
gabapentin NN 0 1 0 B-Drug
and CC 0 0 12 O
creatinine VB 0 1 14 O
an DT 0 0 12 O
endogenous JJ 0 1 14 O
marker NN 0 1 13 O
of IN 0 0 12 O
renal JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

Significant JJ 0 1 2 O
increases NNS 1 1 1 O
In IN 0 0 2 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
decreases VBZ 1 1 UNK O
in IN 0 0 12 O
tmax NN 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
of IN 0 0 12 O
propranolol NN 0 1 16 B-Drug
were VBD 1 0 12 O
noted VBN 1 0 1 O
in IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
. . 0 0 12 O

Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
Probenecid VB 0 1 UNK B-Drug
a DT 0 0 12 O
renal JJ 0 1 6 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
blocking VBG 1 1 UNK O
agent NN 0 1 1 O
administered VBN 1 1 1 O
at IN 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
four CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
change VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
levetiracetam JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
. . 0 0 12 O

Antifungals NNS 0 1 UNK B-Group

Drugs NNS 0 1 2 O
such JJ 0 0 1 O
as IN 1 0 12 O
erythromycin JJ 0 1 0 B-Drug
diltiazem NN 0 1 0 B-Drug
verapamil NN 0 1 0 B-Drug
ketoconazole JJ 0 1 16 B-Drug
fluconazole NN 0 1 0 B-Drug
and CC 0 0 12 O
itraconazole NN 0 1 0 B-Drug
were VBD 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
significantly RB 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
C NNP 0 0 2 O
max NN 0 0 3 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
orally RB 0 1 14 O
administered VBN 1 1 1 O
midazolam NN 0 1 16 B-Drug
. . 0 0 12 O

carbamazepine NN 0 1 16 B-Drug
; : 0 0 2 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
None NN 0 0 2 O
known VBN 1 1 12 O
. . 0 0 12 O

Some DT 0 0 2 O
cases NNS 1 1 UNK O
presented VBN 1 1 1 O
with IN 0 0 12 O
features NNS 1 1 1 O
resembling VBG 1 0 16 O
neuroleptic JJ 0 1 13 O
malignant JJ 0 1 6 O
syndrome NN 0 1 6 O
. . 0 0 12 O

Dosage NN 0 1 UNK O
adjustments NNS 1 1 1 O
of IN 0 0 12 O
BROVANA NNP 0 1 UNK B-Brand
are VBP 1 0 12 O
not RB 0 1 12 O
necessary JJ 0 0 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
potent JJ 0 1 UNK O
CYP9D9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
. . 0 0 12 O

Thus RB 0 0 1 O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
status NN 0 1 1 O
is VBZ 1 0 12 O
warranted VBN 1 0 1 O
when WRB 0 0 12 O
rifampin NN 0 1 16 B-Drug
is VBZ 1 0 12 O
administered VBN 1 1 1 O
or CC 0 0 12 O
discontinued VBN 1 1 1 O
in IN 0 0 12 O
haloperidol NN 0 1 16 B-Drug
- : 0 0 2 O
treated JJ 0 1 1 O
patients NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
magnitude NN 0 1 UNK O
of IN 0 0 12 O
interaction NN 0 1 UNK O
at IN 0 0 12 O
other JJ 0 0 12 O
doses NNS 1 1 6 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

DIDREX NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
other JJ 0 0 12 O
CNS NNP 0 1 6 B-Group
stimulants NNS 1 1 13 I-Group
. . 0 0 12 O

Starlix NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
a DT 0 0 12 O
potential JJ 0 1 1 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
CYP9C9 NNP 0 0 UNK O
isoenzyme NN 0 1 13 O
in IN 0 0 12 O
vivo NN 0 1 13 O
as IN 1 0 12 O
indicated VBN 1 1 1 O
by IN 0 0 12 O
its PRP$ 1 0 12 O
ability NN 0 1 1 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
metabolism NN 0 1 16 O
of IN 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that IN 0 0 12 O
inhibit NN 0 1 13 O
CYP9A9 NNP 0 0 UNK O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
and CC 0 0 12 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
. . 0 0 12 O

Volatile NNP 0 1 UNK O
Anesthetic JJ 0 1 UNK B-Drug
Agents NNS 0 1 2 O
: : 0 0 2 O
. . 0 0 12 O

Fulvestrant NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

Theophylline NN 0 1 UNK B-Drug
: : 0 0 2 O
A DT 0 0 2 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
at IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
. . 0 0 12 O

Fat NNP 0 1 UNK B-Group
- : 0 0 2 O
soluble JJ 0 1 16 I-Group
Vitamin NNP 0 1 2 I-Group
Supplements NNP 0 1 UNK I-Group
and CC 0 0 12 O
Analogues NNP 0 1 UNK O
: : 0 0 2 O
A DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
study NN 0 1 1 O
showed VBD 1 1 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
reduction NN 0 1 1 O
in IN 0 0 12 O
beta NN 0 1 16 B-Drug
- : 0 0 2 O
carotene NN 0 1 UNK I-Drug
supplement JJ 0 1 1 O
absorption NN 0 1 1 O
when WRB 0 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
with IN 0 0 12 O
XENICAL NNP 0 1 UNK B-Brand
. . 0 0 12 O

Tubocurarine NN 0 1 UNK B-Drug

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
alosetron NN 0 1 UNK B-Drug
on IN 0 0 12 O
monoamine NN 0 1 13 O
oxidases NNS 1 1 UNK O
and CC 0 0 12 O
on IN 0 0 12 O
intestinal JJ 0 1 13 O
first JJ 0 1 12 O
pass NN 1 1 12 O
secondary NN 0 1 1 O
to TO 0 0 12 O
high JJ 0 1 1 O
intraluminal JJ 0 1 8 O
concentrations NNS 1 1 13 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
examined VBN 1 1 1 O
. . 0 0 12 O

Another DT 0 0 2 O
oral JJ 0 1 6 O
azole NN 0 1 UNK B-Group
antifungal JJ 0 1 14 I-Group
ketoconazole NN 0 1 16 B-Drug
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
astemizole JJ 0 1 UNK B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
elevated VBN 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
astemizole NN 0 1 UNK B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
desmethylastermizole NN 0 0 UNK B-Drug_n
which WDT 0 0 12 O
may MD 0 0 1 O
prolong VB 0 0 13 O
QT NNP 0 1 13 O
intervals NNS 1 1 1 O
. . 0 0 12 O

Methotrexate NN 0 1 0 B-Drug
: : 0 0 2 O
Ketoprofen NNP 0 1 UNK B-Drug
like IN 0 0 12 O
other JJ 0 0 12 O
NSAIDs NNP 0 1 UNK B-Group
may MD 0 0 1 O
cause VB 0 1 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
methotrexate NN 0 1 16 B-Drug
leading VBG 1 1 1 O
to TO 0 0 12 O
elevated VBN 1 1 1 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
and CC 0 0 12 O
increased JJ 0 1 1 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Therefore RB 0 0 1 O
patients NNS 1 1 6 O
with IN 0 0 12 O
COPD NNP 0 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
normally RB 0 0 1 O
be VB 0 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
possible JJ 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
cardiovascular JJ 0 1 6 O
action NN 0 1 13 O
of IN 0 0 12 O
other JJ 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
could MD 0 0 12 O
be VB 0 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
Nimotop NNP 0 1 UNK B-Brand
. . 0 0 12 O

Plasma NNP 0 1 UNK O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
azole JJ 0 1 UNK B-Group
antifungal JJ 0 1 14 I-Group
agents NNS 1 1 1 I-Group
are VBP 1 0 12 O
reduced VBN 1 1 1 O
when WRB 0 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
isoniazid NN 0 1 13 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
an DT 0 0 12 O
uncontrolled JJ 0 1 6 O
study NN 0 1 1 O
of IN 0 0 12 O
over IN 0 1 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
congestive JJ 0 1 6 O
heart NN 0 1 12 O
failure NN 0 1 1 O
during IN 0 0 12 O
which WDT 0 0 12 O
digoxin NN 0 1 14 B-Drug
blood NN 0 1 6 O
levels NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
measured VBN 1 1 1 O
digitalis JJ 0 1 14 O
toxicity NN 0 1 6 O
was VBD 1 0 12 O
not RB 0 1 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
withdrawn VBN 1 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
receiving VBG 1 1 1 O
MICRONASE NNP 0 1 UNK B-Brand
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
control NN 0 1 1 O
. . 0 0 12 O

Bosentan NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
an DT 0 0 12 O
inducer NN 0 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9C9 NNP 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
praziquantel NN 0 1 13 B-Drug
were VBD 1 0 12 O
unchanged JJ 0 1 1 O
following VBG 1 1 1 O
coadministration NN 0 1 UNK O
with IN 0 0 12 O
albendazole NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
. . 0 0 12 O

. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
and CC 0 0 12 O
FLOMAX NNP 0 1 UNK B-Brand
capsules NNS 1 1 3 O
was VBD 1 0 12 O
investigated VBN 1 1 1 O
. . 0 0 12 O

. . 0 0 12 O

Acetaminophen NN 0 1 0 B-Drug
: : 0 0 2 O
Rimantadine NNP 0 1 UNK B-Drug
HCl NNP 0 0 14 I-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
was VBD 1 0 12 O
given VBN 1 1 12 O
twice RB 0 1 12 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Fluconazole NNP 0 1 0 B-Drug
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
P9 NNP 0 1 UNK O
9C9 CD 0 0 UNK O
decreased VBD 1 1 1 O
active JJ 0 1 1 O
metabolite JJ 0 1 UNK O
concentration NN 0 1 1 O
and CC 0 0 12 O
increased VBD 1 1 1 O
losartan JJ 0 1 0 B-Drug
concentration NN 0 1 1 O
. . 0 0 12 O

chymotrypsin NN 0 1 UNK B-Drug
; : 0 0 2 O

When WRB 0 0 12 O
administering VBG 1 1 1 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
for IN 0 0 12 O
which WDT 0 0 12 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
could MD 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
safety NN 0 1 1 O
or CC 0 0 12 O
efficacy NN 0 1 UNK O
physicians NNS 1 1 6 O
should MD 0 0 12 O
consider VB 0 1 12 O
monitoring VBG 1 1 1 O
drug NN 0 1 1 O
levels NNS 1 1 1 O
or CC 0 0 12 O
effects NNS 1 1 1 O
. . 0 0 12 O

( ( 0 0 2 O
g NN 0 1 16 O
) ) 0 0 2 O
There EX 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
small JJ 0 1 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
lipid JJ 0 1 14 O
profiles NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
inhibitors NNS 1 1 14 O
to TO 0 0 12 O
PMs NNP 0 1 UNK O
will MD 0 0 12 O
not RB 0 1 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
atomoxetine NN 0 1 13 B-Drug
. . 0 0 12 O

Indinavir NN 0 1 UNK B-Drug

In IN 0 0 2 O
patients NNS 1 1 6 O
in IN 0 0 12 O
whom WP 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inducers NNS 1 1 UNK O
( ( 0 0 2 O
eg VB 0 1 UNK O
dexamethasone NN 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
carbamazepine NN 0 1 16 B-Drug
rifampicin VBP 0 1 UNK B-Drug
phenobarbital NN 0 1 16 B-Drug
) ) 0 0 2 O
are VBP 1 0 12 O
indicated VBN 1 1 1 O
alternative JJ 0 1 1 O
agents NNS 1 1 1 O
with IN 0 0 12 O
less JJR 0 1 12 O
enzyme JJ 0 1 14 O
induction NN 0 1 1 O
potential NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

An DT 0 0 2 O
evaluation NN 0 1 1 O
of IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
and CC 0 0 12 O
an DT 0 0 12 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
dosage NN 0 1 0 O
are VBP 1 0 12 O
recommended VBN 1 1 1 O

In IN 0 0 2 O
another DT 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
orally RB 0 1 14 O
inhaled VBN 1 1 14 O
ciclesonide NN 0 1 13 B-Drug
and CC 0 0 12 O
oral JJ 0 1 6 O
ketoconazole NN 0 1 16 B-Drug
a DT 0 0 12 O
potent JJ 0 1 UNK O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
increased VBD 1 1 1 O
the DT 0 0 12 O
exposure NN 0 1 1 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
des NNS 1 0 13 B-Drug
- : 0 0 2 O
ciclesonide NN 0 1 13 I-Drug
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
at IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
while IN 0 0 12 O
levels NNS 1 1 1 O
of IN 0 0 12 O
ciclesonide NN 0 1 13 B-Drug
remained VBD 1 0 12 O
unchanged JJ 0 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
treated VBD 1 1 1 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
BREVIBLOC NNP 0 1 UNK B-Brand
( ( 0 0 2 O
esmolol JJ 0 1 13 B-Drug
HCl NNP 0 0 14 I-Drug
) ) 0 0 2 O
and CC 0 0 12 O
a DT 0 0 12 O
catecholamine NN 0 1 14 O
depletor NN 0 0 UNK O
should MD 0 0 12 O
therefore RB 0 0 1 O
be VB 0 0 12 O
closely RB 0 0 1 O
observed VBN 1 1 1 O
for IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
hypotension NN 0 1 6 O
or CC 0 0 12 O
marked VBN 1 1 1 O
bradycardia IN 0 1 8 O
which WDT 0 0 12 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
vertigo JJ 0 1 6 O
syncope NN 0 1 8 O
or CC 0 0 12 O
postural JJ 0 1 13 O
hypotension NN 0 1 6 O
. . 0 0 12 O

If IN 0 0 12 O
glucocorticoid JJ 0 1 13 B-Group
replacement NN 0 1 1 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
the DT 0 0 12 O
glucocorticoid NN 0 1 13 B-Group
dose NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
adjusted VBN 1 1 1 O
. . 0 0 12 O

however RB 0 0 12 O
during IN 0 0 12 O
the DT 0 0 12 O
period NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
physicians NNS 1 1 6 O
should MD 0 0 12 O
monitor VB 0 1 1 O
blood NN 0 1 6 O
cell NN 0 1 1 O
counts NNS 1 1 1 O
. . 0 0 12 O

Dose NNP 0 1 7 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
Sensipar NNP 0 1 UNK B-Brand
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
and CC 0 0 12 O
PTH NNP 0 0 14 O
and CC 0 0 12 O
serum JJ 0 1 14 O
calcium NN 0 1 14 O
concentrations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
closely RB 0 0 1 O
monitored VBN 1 1 1 O
if IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
initiates VBZ 1 1 UNK O
or CC 0 0 12 O
discontinues NNS 0 1 UNK O
therapy VBP 0 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
strong JJ 0 1 12 O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
ketoconazole NN 0 1 16 B-Drug
erythromycin JJ 0 1 0 B-Drug
itraconazole NN 0 1 0 B-Drug
; : 0 0 2 O

Information NN 0 1 2 O
on IN 0 0 12 O
concurrent JJ 0 1 1 O
usage NN 0 1 UNK O
of IN 0 0 12 O
atenolol NN 0 1 0 B-Drug
and CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
is VBZ 1 0 12 O
limited VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
risk NN 0 1 1 O
of IN 0 0 12 O
using VBG 1 1 1 O
bromocriptine JJ 0 1 16 B-Drug
mesylate NN 0 1 16 I-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
systematically RB 0 0 UNK O
evaluated VBN 1 1 1 O
but CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
may MD 0 0 1 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
side NN 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
bromocriptine NN 0 1 16 B-Drug
mesylate NN 0 1 16 I-Drug
. . 0 0 12 O

Loratadine NNP 0 1 UNK B-Drug
Descarboethoxyloratadine NNP 0 1 UNK B-Drug

- : 0 0 2 O
a DT 0 0 12 O
steroid JJ 0 1 6 B-Group
medicine NN 0 1 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
prednisone NN 0 1 0 B-Drug
( ( 0 0 2 O
Deltasone NNP 0 1 UNK B-Brand
Orasone NNP 0 1 UNK B-Brand
others NNS 0 1 12 O
) ) 0 0 2 O
methylprednisolone NN 0 1 16 B-Drug
( ( 0 0 2 O
Medrol NNP 0 1 0 B-Brand
others NNS 0 1 12 O
) ) 0 0 2 O
prednisolone NN 0 1 0 B-Drug
( ( 0 0 2 O
Prelone NNP 0 1 UNK B-Brand
Pediapred NNP 0 1 UNK B-Brand
others NNS 0 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
others NNS 0 1 12 O
; : 0 0 2 O

For IN 0 0 2 O
example NN 0 1 1 O
diuretics NNS 1 1 14 B-Group
( ( 0 0 2 O
e.g. VB 0 0 UNK O
thiazides NNS 1 1 UNK B-Group
) ) 0 0 2 O
may MD 0 0 1 O
activate VB 0 1 UNK O
the DT 0 0 12 O
renin NN 0 1 UNK O
- : 0 0 2 O
angiotensin NN 0 1 UNK O
- : 0 0 2 O
aldosterone NN 0 1 UNK O
system NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
where WRB 0 0 12 O
rifampin NN 0 1 16 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
CYP9A9 NNP 0 0 UNK O
inducers NNS 1 1 UNK O
are VBP 1 0 12 O
indicated JJ 0 1 1 O
alternative JJ 0 1 1 O
therapeutic JJ 0 1 6 O
agents NNS 1 1 1 O
with IN 0 0 12 O
less JJR 0 1 12 O
enzyme JJ 0 1 14 O
induction NN 0 1 1 O
potential NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Potential NNP 0 1 UNK O
for IN 0 0 12 O
serious JJ 0 1 12 O
reactions NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
myopathy JJ 0 1 8 O
including VBG 1 1 1 O
rhabdomyolysis NN 0 1 8 O
. . 0 0 12 O

Oral JJ 0 1 2 O
Hypoglycemics NNS 0 1 UNK B-Group
: : 0 0 2 O
Diclofenac NNP 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
glucose JJ 0 1 14 O
metabolism NN 0 1 16 O
in IN 0 0 12 O
normal JJ 0 1 1 O
subjects NNS 1 1 UNK O
nor CC 0 0 12 O
does VBZ 1 0 12 O
it PRP 0 0 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

The DT 0 0 2 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
. . 0 0 12 O

- : 0 0 2 O
Antidiabetic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
: : 0 0 2 O
( ( 0 0 2 O
Oral JJ 0 1 2 O
agents NNS 1 1 1 O
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
) ) 0 0 2 O
Dosage NNP 0 1 UNK O
adjustment NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
antidiabetic JJ 0 1 13 B-Group
drug NN 0 1 1 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O

Antihypertensives NNS 0 1 UNK B-Group
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
hypotensive JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihypertensives NNS 1 1 14 B-Drug
. . 0 0 12 O

Diltiazem NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
both DT 0 0 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
and CC 0 0 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
9A9 CD 0 0 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
depo JJ 0 1 UNK B-Brand
- : 0 0 2 O
subQ NN 0 0 15 I-Brand
provera NN 0 1 13 I-Brand
9 CD 0 0 2 I-Brand
. . 0 0 12 O

- : 0 0 2 O
Gold NN 0 1 UNK B-Drug
salts NNS 1 1 13 O
( ( 0 0 2 O
medicine NN 0 1 6 O
for IN 0 0 12 O
arthritis NN 0 1 6 O
) ) 0 0 2 O
or CC 0 0 12 O

free JJ 0 1 12 O
T9 NNP 0 1 13 O
concentration NN 0 1 1 O
is VBZ 1 0 12 O
unaltered JJ 0 1 UNK O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
Increased VBN 0 1 7 O
serum NN 0 1 14 O
lithium NN 0 1 16 B-Drug
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
lithium NN 0 1 16 B-Drug
toxicity NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
lithium NN 0 1 16 B-Drug
and CC 0 0 12 O
ACE NNP 0 1 13 O
inhibitor NN 0 1 14 O
therapy NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
human JJ 0 1 1 O
liver NN 0 1 6 O
microsome NN 0 1 UNK O
studies NNS 1 1 1 O
and CC 0 0 12 O
an DT 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
metabolic NN 0 1 6 O
probe NN 0 1 1 O
study NN 0 1 1 O
demonstrated VBD 1 0 1 O
that IN 0 0 12 O
alosetron NN 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
CYP NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
9D9 CD 0 0 UNK O
9A9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
or CC 0 0 12 O
9C9 CD 0 0 UNK O
. . 0 0 12 O

If IN 0 0 12 O
these DT 0 0 12 O
products NNS 1 1 1 O
are VBP 1 0 12 O
needed VBN 1 1 12 O
they PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
cimetidine JJ 0 1 13 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

Amprenavir NNP 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
CYP9D9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9E9 NNP 0 0 UNK O
or CC 0 0 12 O
uridine JJ 0 1 UNK O
glucuronosyltransferase NN 0 1 UNK O
( ( 0 0 2 O
UDPGT NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Additionally RB 0 0 1 O
paroxetine VB 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
Sonata NNP 0 1 UNK B-Brand
reflecting VBG 1 1 1 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
role NN 0 1 1 O
of IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
in IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
metabolism NN 0 1 16 O
. . 0 0 12 O

Antacids NNS 0 1 UNK B-Group
containing VBG 1 1 1 O
magnesium NN 0 1 14 B-Drug
trisilicate NN 0 0 UNK I-Drug
when WRB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
nitrofurantoin JJ 0 1 0 B-Drug
reduce VB 0 0 1 O
both DT 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
and CC 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
. . 0 0 12 O

Similar JJ 0 1 2 O
decreases NNS 1 1 UNK O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
were VBD 1 0 12 O
seen VBN 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
dose NN 0 1 6 O
. . 0 0 12 O

Because IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
may MD 0 0 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
hepatic JJ 0 1 14 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
toxic NN 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
anticonvulsant NN 0 1 14 B-Group
may MD 0 0 1 O
occur VB 0 1 1 O
when WRB 0 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
anticoagulant NN 0 1 13 B-Group
and CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
are VBP 1 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
. . 0 0 12 O

Pediatric NNP 0 1 7 O
Use NNP 0 1 2 O
The DT 0 0 2 O
safety NN 0 1 1 O
and CC 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
PEGASYS NNP 0 1 UNK B-Brand
alone RB 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
COPEGUS NNP 0 1 UNK B-Brand
in IN 0 0 12 O
patients NNS 1 1 6 O
below IN 0 0 12 O
the DT 0 0 12 O
age NN 0 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
. . 0 0 12 O

iv NN 0 1 16 O
. . 0 0 12 O

In IN 0 0 2 O
some DT 0 0 12 O
cases NNS 1 1 UNK O
where WRB 0 0 12 O
serious JJ 0 1 12 O
ventricular JJ 0 1 8 O
arrhythmias NN 1 1 6 O
QT NNP 0 1 13 O
prolongation NN 0 1 6 O
and CC 0 0 12 O
torsades NNS 0 0 13 O
de VBP 0 1 2 O
pointes NNS 0 0 UNK O
have VBP 0 0 12 O
occurred VBN 1 1 1 O
when WRB 0 0 12 O
cisapride NN 0 1 UNK B-Drug
was VBD 1 0 12 O
taken VBN 1 1 12 O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
elevated VBD 1 1 1 O
blood NN 0 1 6 O
cisapride NN 0 1 UNK B-Drug
levels NNS 1 1 1 O
were VBD 1 0 12 O
noted VBN 1 0 1 O
at IN 0 0 12 O
the DT 0 0 12 O
time NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
QT NNP 0 1 13 O
prolongation NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
involving VBG 1 1 1 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
TAMBOCOR NNP 0 1 UNK B-Brand
and CC 0 0 12 O
propranolol VB 0 1 16 B-Drug
concurrently RB 0 0 1 O
plasma JJ 0 1 14 O
flecainide NN 0 1 16 B-Drug
levels NNS 1 1 1 O
were VBD 1 0 12 O
increased VBN 1 1 1 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
propranolol NN 0 1 16 B-Drug
levels NNS 1 1 1 O
were VBD 1 0 12 O
increased VBN 1 1 1 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
compared VBN 1 1 1 O
to TO 0 0 12 O
control VB 0 1 1 O
values NNS 1 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
usually RB 0 1 12 O
complete JJ 0 1 1 O
cross NN 0 1 12 O
- : 0 0 2 O
resistance NN 0 1 1 O
between IN 0 0 12 O
PURINETHOL NNP 0 1 UNK B-Brand
( ( 0 0 2 O
mercaptopurine NN 0 1 13 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
TABLOID NNP 0 1 UNK B-Brand
brand NN 0 1 13 O
Thioguanine NNP 0 1 UNK B-Drug
. . 0 0 12 O

No DT 0 0 2 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
azithromycin NN 0 1 0 B-Drug
is VBZ 1 0 12 O
co JJ 0 1 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
above JJ 0 1 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

unreliable JJ 0 1 1 O
prothrombin NN 0 1 14 O
time NN 0 1 12 O
determinations NNS 1 1 UNK O
; : 0 0 2 O

Cyclosporine NN 0 1 UNK B-Drug
: : 0 0 2 O
Increased VBN 0 1 7 O
activity NN 0 1 1 O
of IN 0 0 12 O
both DT 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
and CC 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
may MD 0 0 1 O
occur VB 0 1 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
are VBP 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
. . 0 0 12 O

Studies NNS 0 1 2 O
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
that IN 0 0 12 O
pretreatment NN 0 1 UNK O
with IN 0 0 12 O
isoniazid JJ 0 1 13 B-Drug
potentiates NNS 0 0 UNK O
a DT 0 0 12 O
cetaminophen NN 0 0 UNK O
hepatoxicity NN 0 0 UNK O
in IN 0 0 12 O
rats NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
MIVACRON NNP 0 1 UNK B-Brand
before IN 0 1 12 O
succinylcholine NN 0 1 16 B-Drug
to TO 0 0 12 O
attenuate VB 0 1 UNK O
some DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
side NN 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Pilocarpine NN 0 1 0 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
caution NN 0 0 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
beta JJ 0 1 16 B-Group
adrenergic JJ 0 1 UNK I-Group
antagonists NNS 1 1 13 I-Group
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
conduction NN 0 1 6 O
disturbances NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
show VBP 0 1 12 O
that IN 0 0 12 O
tiludronate NN 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
displace VB 0 0 13 O
warfarin NN 0 1 14 B-Drug
from IN 0 0 12 O
its PRP$ 1 0 12 O
binding VBG 1 1 1 O
site NN 0 1 12 O
on IN 0 0 12 O
protein NN 0 1 14 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
these DT 0 0 12 O
tests NNS 1 1 1 O
be VB 0 0 12 O
performed VBN 1 1 1 O
prior RB 0 1 1 O
to TO 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
Soriatane NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
at IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
week NN 0 1 12 O
intervals NNS 1 1 1 O
until IN 0 0 12 O
stable JJ 0 1 1 O
and CC 0 0 12 O
thereafter RB 0 0 1 O
at IN 0 0 12 O
intervals NNS 1 1 1 O
as IN 1 0 12 O
clinically RB 0 0 6 O
indicated VBN 1 1 1 O
. . 0 0 12 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
dyphylline NN 0 1 UNK B-Drug
and CC 0 0 12 O
probenecid NN 0 1 13 B-Drug
which WDT 0 0 12 O
competes VBZ 1 0 UNK O
for IN 0 0 12 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
dyphylline NN 0 1 UNK B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
should MD 0 0 12 O
be VB 0 0 12 O
cautioned VBN 1 0 UNK O
against IN 0 0 12 O
engaging VBG 1 1 UNK O
in IN 0 0 12 O
hazardous JJ 0 1 13 O
activities NNS 1 1 1 O
requiring VBG 1 0 1 O
complete JJ 0 1 1 O
mental JJ 0 1 1 O
alertness NN 0 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
operating NN 0 1 1 O
machinery NN 0 1 13 O
or CC 0 0 12 O
driving VBG 1 1 12 O
a DT 0 0 12 O
motor NN 0 1 3 O
vehicle NN 0 1 1 O
. . 0 0 12 O

this DT 0 0 12 O
can MD 0 0 12 O
cause VB 0 1 12 O
headaches NNS 1 1 6 O
and CC 0 0 12 O
other JJ 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
hypertensive JJ 0 1 6 O
crisis NN 0 1 12 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
may MD 0 0 1 O
occur VB 0 1 1 O
between IN 0 0 12 O
EPA NNP 0 0 UNK B-Drug
supplements NNS 1 1 6 O
and CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
herbs NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
garlic NN 0 1 UNK O
( ( 0 0 2 O
Allium NNP 0 1 UNK O
sativum NN 0 0 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
ginkgo NN 0 1 UNK B-Drug
( ( 0 0 2 O
Ginkgo NNP 0 1 UNK B-Drug
biloba NN 0 0 UNK I-Drug
) ) 0 0 2 O
. . 0 0 12 O

indinavir NN 0 1 16 B-Drug
concentration NN 0 1 1 O

Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
with IN 0 0 12 O
celecoxib NNS 0 1 16 B-Drug
have VBP 0 0 12 O
identified VBN 1 1 1 O
potentially RB 0 0 1 O
significant JJ 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
fluconazole JJ 0 1 0 B-Drug
and CC 0 0 12 O
lithium NN 0 1 16 B-Drug
. . 0 0 12 O

Barbiturates NNS 0 1 UNK B-Group
phenytoin VBP 0 1 16 B-Drug
or CC 0 0 12 O
rifampin VBP 0 1 16 B-Drug
increased VBN 1 1 1 O
metabolic JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
fludrocortisone NN 0 1 0 B-Drug
acetate NN 0 1 14 I-Drug
because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
induction NN 0 1 1 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
enzymes NNS 1 1 14 O
. . 0 0 12 O

These DT 0 0 1 O
agents NNS 1 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
anesthetic JJ 0 1 13 O
or CC 0 0 12 O
sedative JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
DIPRIVAN NNP 0 1 UNK B-Brand
Injectable NNP 0 1 UNK O
Emulsion NNP 0 1 UNK O
and CC 0 0 12 O
may MD 0 0 1 O
also RB 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
more RBR 0 1 12 O
pronounced JJ 0 0 12 O
decreases NNS 1 1 UNK O
in IN 0 0 12 O
systolic JJ 0 1 8 O
diastolic NN 0 1 8 O
and CC 0 0 12 O
mean JJ 0 1 12 O
arterial JJ 0 1 6 O
pressures NNS 1 1 1 O
and CC 0 0 12 O
cardiac JJ 0 1 6 O
output NN 0 1 1 O
. . 0 0 12 O

Corresponding VBG 0 0 UNK O
values NNS 1 1 1 O
for IN 0 0 12 O
free JJ 0 1 12 O
valproate NN 0 1 16 B-Drug
Cmin NNP 0 1 UNK O
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
/ VBP 0 0 2 O
mL NN 0 1 14 O
for IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
Felbatol NNP 0 1 UNK B-Brand
respectively RB 0 0 1 O
. . 0 0 12 O

In IN 0 0 2 O
studies NNS 1 1 1 O
in IN 0 0 12 O
female JJ 0 1 12 O
rats NNS 1 1 UNK O
at IN 0 0 12 O
doses NNS 1 1 6 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ JJ 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
IM NNP 0 1 11 O
; : 0 0 2 O

Oral JJ 0 1 2 O
Contraceptives NNP 0 1 UNK B-Group
Rofecoxib NNP 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
any DT 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
norethindrone NN 0 1 13 B-Drug
. . 0 0 12 O

This DT 0 0 2 O
response NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
renal JJ 0 1 6 O
prostaglandin NN 0 1 13 O
synthesis NN 0 1 UNK O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
when WRB 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
are VBP 1 0 12 O
given VBN 1 1 12 O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
Atromid NNP 0 1 UNK B-Brand
- : 0 0 2 O
S NN 0 1 2 I-Brand
. . 0 0 12 O

A DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
and CC 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
during IN 0 0 12 O
studies NNS 1 1 1 O
involving VBG 1 1 1 O
renal JJ 0 1 6 O
and CC 0 0 12 O
cardiac JJ 0 1 6 O
transplant NN 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

Phosphate NNP 0 1 14 O
- : 0 0 2 O
Binding VBG 0 1 UNK O
Agents NNS 0 1 2 O
: : 0 0 2 O
Since IN 0 1 2 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
also RB 0 0 12 O
has VBZ 1 0 12 O
an DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
phosphate NN 0 1 14 O
transport NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
intestine NN 0 1 6 O
kidneys NN 1 1 6 O
and CC 0 0 12 O
bones VBZ 1 1 3 O
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
phosphate NN 0 1 14 O
- : 0 0 2 O
binding NN 0 1 1 O
agents NNS 1 1 1 O
must MD 0 0 12 O
be VB 0 0 12 O
adjusted VBN 1 1 1 O
in IN 0 0 12 O
accordance NN 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
phosphate NN 0 1 14 O
concentration NN 0 1 1 O
. . 0 0 12 O

Aminosalicylic NNP 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
may MD 0 0 1 O
also RB 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Drug
B9 NNP 0 0 UNK I-Drug
which WDT 0 0 12 O
can MD 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
a DT 0 0 12 O
deficiency NN 0 1 6 O
. . 0 0 12 O

adjust JJ 0 0 1 O
dosage NN 0 1 0 O
of IN 0 0 12 O
antidiabetic JJ 0 1 13 B-Group
drug NN 0 1 1 I-Group
accordingly RB 0 0 1 O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
inhibition NN 0 1 13 O
information NN 0 1 1 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
mifepristone NN 0 1 UNK B-Drug
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
substrates NNS 1 1 UNK O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
induce VBP 0 1 6 O
hepatic JJ 0 1 14 O
enzymes NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
phenobarbital JJ 0 1 16 B-Drug
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
and CC 0 0 12 O
may MD 0 0 1 O
require VB 0 0 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
corticosteroid NN 0 1 UNK B-Group
dose NN 0 1 6 O
to TO 0 0 12 O
achieve VB 0 0 1 O
the DT 0 0 12 O
desired JJ 0 1 1 O
response NN 0 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
concurrently RB 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
a DT 0 0 12 O
potential JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
. . 0 0 12 O

When WRB 0 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
butorphanol NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
the DT 0 0 12 O
smallest JJS 1 1 UNK O
effective JJ 0 1 1 O
dose NN 0 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
frequency NN 0 1 1 O
of IN 0 0 12 O
dosing VBG 1 0 14 O
reduced VBN 1 1 1 O
as RB 0 0 12 O
much JJ 0 0 12 O
as IN 1 0 12 O
possible JJ 0 1 1 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
potentiate VBP 0 0 UNK O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
opioids NNS 0 1 14 B-Group
. . 0 0 12 O

The DT 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
anticholinergics NNS 1 1 13 B-Group
with IN 0 0 12 O
hydrocodone NN 0 1 UNK B-Drug
may MD 0 0 1 O
produce VB 0 0 1 O
paralytic JJ 0 0 13 O
ileus NN 0 1 8 O
. . 0 0 12 O

A DT 0 0 2 O
single JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
pravastatin NN 0 1 16 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
fenofibric JJ 0 0 13 B-Drug_n
acid NN 0 1 14 I-Drug_n
. . 0 0 12 O

In IN 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
treatment NN 0 1 6 O
with IN 0 0 12 O
SPRYCEL NNP 0 1 UNK B-Brand
close JJ 0 1 12 O
monitoring NN 0 1 1 O
for IN 0 0 12 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
a DT 0 0 12 O
SPRYCEL NNP 0 1 UNK B-Brand
dose JJ 0 1 6 O
reduction NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
if IN 0 0 12 O
systemic JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
CYP9A9 NNP 0 0 UNK O
inhibitor NN 0 1 14 O
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Cholestyramine NNP 0 1 UNK B-Drug
and CC 0 0 12 O
Charcoal NNP 0 1 UNK B-Drug
Administration NNP 0 1 UNK O
of IN 0 0 12 O
cholestyramine NN 0 1 13 B-Drug
or CC 0 0 12 O
activated VBN 1 1 1 B-Drug
charcoal NN 0 1 3 I-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
volunteers NNS 1 1 UNK O
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
rapid JJ 0 1 1 O
and CC 0 0 12 O
significant JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
plasma NN 0 1 14 O
M9 NNP 0 1 UNK O
( ( 0 0 2 O
the DT 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
of IN 0 0 12 O
leflunomide NN 0 1 13 B-Drug
) ) 0 0 2 O
concentration NN 0 1 1 O
. . 0 0 12 O

vitamin NN 0 1 6 B-Drug
C NNP 0 0 2 I-Drug
; : 0 0 2 O

The DT 0 0 2 O
hypotensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
sodium NN 0 1 14 B-Drug
nitroprusside NN 0 1 14 I-Drug
is VBZ 1 0 12 O
augmented VBN 1 1 1 O
by IN 0 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
most JJS 0 0 12 O
other JJ 0 0 12 O
hypotensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
including VBG 1 1 1 O
ganglionic JJ 0 1 UNK B-Group
blocking NN 0 1 UNK I-Group
agents NNS 1 1 1 I-Group
negative JJ 0 1 1 O
inotropic NN 0 0 14 O
agents NNS 1 1 1 O
and CC 0 0 12 O
inhaled JJ 0 1 14 O
anesthetics NNS 1 1 13 B-Group
. . 0 0 12 O

Interaction NN 0 1 2 O
of IN 0 0 12 O
GABITRIL NNP 0 1 UNK B-Brand
with IN 0 0 12 O
Highly NNP 0 1 UNK O
Protein NNP 0 1 2 O
Bound NNP 0 1 UNK O
Drugs NNP 0 1 2 O
: : 0 0 2 O
In IN 0 0 2 O
vitro NN 0 1 UNK O
data NNS 0 1 1 O
showed VBD 1 1 12 O
that IN 0 0 12 O
tiagabine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
bound NN 0 1 12 O
to TO 0 0 12 O
human JJ 0 1 1 O
plasma NN 0 1 14 O
protein NN 0 1 14 O
and CC 0 0 12 O
therefore NN 0 0 1 O
has VBZ 1 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
highly RB 0 1 1 O
protein VBP 0 1 14 O
bound JJ 0 1 12 O
compounds NNS 1 1 13 O
. . 0 0 12 O

Potassium NNP 0 1 14 B-Group
- : 0 0 2 O
depleting NN 0 1 UNK I-Group
diuretics NNS 1 1 14 I-Group
are VBP 1 0 12 O
a DT 0 0 12 O
major JJ 0 1 1 O
contributing VBG 1 1 1 O
factor NN 0 1 1 O
to TO 0 0 12 O
digitalis VB 0 1 14 B-Group
toxicity NN 0 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
because IN 0 0 12 O
nafarelin JJ 0 1 UNK B-Drug
acetate NN 0 1 14 I-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
peptide NN 0 1 13 O
that WDT 0 0 12 O
is VBZ 1 0 12 O
primarily RB 0 0 1 O
degraded VBN 1 1 1 O
by IN 0 0 12 O
peptidase NN 0 1 UNK O
and CC 0 0 12 O
not RB 0 1 12 O
by IN 0 0 12 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
enzymes NNS 1 1 14 O
and CC 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
only RB 0 1 12 O
about RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
bound NN 0 1 12 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
at IN 0 0 12 O
9 CD 0 0 2 O
C NNP 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
would MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
occur VB 0 1 1 O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
gemfibrozil NN 0 1 16 B-Drug
with IN 0 0 12 O
Targretin NNP 0 1 UNK B-Brand
capsules NNS 1 1 3 O
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
week NN 0 1 12 O
dietary JJ 0 1 6 O
carcinogenicity NN 0 1 UNK O
study NN 0 1 1 O
with IN 0 0 12 O
ezetimibe NN 0 1 16 B-Drug
was VBD 1 0 12 O
also RB 0 0 12 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
mice NN 1 1 UNK O
at IN 0 0 12 O
doses VBZ 1 1 6 O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ JJ 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
> $ 0 0 2 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
exposure NN 0 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
daily RB 0 1 12 O
based VBN 1 1 1 O
on IN 0 0 12 O
AUC9 NNP 0 0 UNK O
- : 0 0 2 O
9hr CD 0 0 UNK O
for IN 0 0 12 O
total JJ 0 1 1 O
ezetimibe NN 0 1 16 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Antibiotics NNS 0 1 7 B-Group
( ( 0 0 2 O
ampicillin JJ 0 1 0 B-Drug
tetracycline NN 0 1 0 B-Drug
) ) 0 0 2 O
: : 0 0 2 O
Pregnancy NN 0 1 7 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
following VBG 1 1 1 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
however RB 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
shown VBN 1 1 1 O
consistent JJ 0 1 1 O
effects NNS 1 1 1 O
with IN 0 0 12 O
these DT 0 0 12 O
antibiotics NNS 1 1 6 B-Group
on IN 0 0 12 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
synthetic JJ 0 1 3 B-Group
steroids NNS 1 1 6 I-Group
. . 0 0 12 O

This DT 0 0 2 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
reduced JJ 0 1 1 O
clearance NN 0 1 16 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
plasma NN 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
. . 0 0 12 O

Pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
that IN 0 0 12 O
omeprazole NN 0 1 0 B-Drug
and CC 0 0 12 O
erythromycin VB 0 1 0 B-Drug
significantly RB 0 0 1 O
increased VBN 1 1 1 O
the DT 0 0 12 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
of IN 0 0 12 O
cilostazol NN 0 1 16 B-Drug
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
its PRP$ 1 0 12 O
major JJ 0 1 1 O
metabolites NNS 1 1 UNK O
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
Anticoagulants NNP 0 1 UNK B-Group
and CC 0 0 12 O
Antiplatelet NNP 0 0 UNK B-Group
Agents NNP 0 1 2 I-Group
- : 0 0 2 O
- : 0 0 2 O
Streptase NN 0 1 UNK B-Brand
Streptokinase NNP 0 1 15 B-Drug
alone RB 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
antiplatelet NN 0 0 13 B-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
anticoagulants NNS 1 1 13 B-Group
may MD 0 0 1 O
cause VB 0 1 12 O
bleeding VBG 1 1 6 O
complications NNS 1 1 6 O
. . 0 0 12 O

Imidazoles NNS 0 1 UNK B-Group
( ( 0 0 2 O
e. JJ 0 0 1 O
g. NNS 0 1 13 O
ketoconazole JJ 0 1 16 B-Drug
miconazole JJ 0 1 16 B-Drug
clotrimazole NN 0 1 0 B-Drug
fluconazole NN 0 1 0 B-Drug
etc FW 0 1 12 O
. . 0 0 12 O
) ) 0 0 2 O
: : 0 0 2 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
animal JJ 0 1 13 O
studies NNS 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
and CC 0 0 12 O
imidazoles NNS 1 1 UNK B-Group
suggest VBP 0 1 1 O
that IN 0 0 12 O
imidazoles NNS 1 1 UNK B-Group
may MD 0 0 1 O
induce VB 0 1 6 O
fungal JJ 0 1 6 O
resistance NN 0 1 1 O
to TO 0 0 12 O
amphotericin VB 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Inhibitors NNS 0 1 7 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
duloxetine NN 0 1 0 B-Drug
with IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
results NNS 1 1 1 O
in IN 0 0 12 O
approximately RB 0 1 1 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
about IN 0 1 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
duloxetine NN 0 1 0 B-Drug
. . 0 0 12 O

Skin JJ 0 1 2 O
tests NNS 1 1 1 O
: : 0 0 2 O
Corticosteroids NNS 0 1 UNK B-Group
may MD 0 0 1 O
suppress VB 0 1 1 O
reactions NNS 1 1 1 O
to TO 0 0 12 O
skin VB 0 1 3 O
tests NNS 1 1 1 O
. . 0 0 12 O

Because IN 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
depress VB 0 0 13 O
plasma JJ 0 1 14 O
prothrombin NN 0 1 14 O
activity NN 0 1 1 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
on IN 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
therapy NN 0 1 6 O
may MD 0 0 1 O
require VB 0 0 1 O
downward JJ 0 1 3 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
their PRP$ 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
dosage NN 0 1 0 O
. . 0 0 12 O

If IN 0 0 12 O
co VBN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
is VBZ 1 0 12 O
essential JJ 0 1 13 O
close JJ 0 1 12 O
monitoring NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
appropriate JJ 0 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
iron NN 0 1 3 B-Group
supplements NNS 1 1 6 I-Group
are VBP 1 0 12 O
required VBN 1 1 1 O
during IN 0 0 12 O
OMNICEF NNP 0 1 UNK B-Brand
therapy NN 0 1 6 O
OMNICEF NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
after IN 0 0 12 O
the DT 0 0 12 O
supplement NN 0 1 1 O
. . 0 0 12 O

Colestipol NN 0 1 UNK B-Drug

. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
study NN 0 1 1 O
with IN 0 0 12 O
warfarin JJ 0 1 14 B-Drug
bioavailability NN 0 1 UNK O
parameters VBZ 0 1 1 O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
protein NN 0 1 14 O
binding NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
anticoagulant JJ 0 1 13 O
effect NN 0 1 1 O
( ( 0 0 2 O
measured VBN 1 1 1 O
by IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
) ) 0 0 2 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
were VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
changed VBN 1 1 12 O
. . 0 0 12 O

Agents NNS 0 1 2 O
Causing VBG 0 1 7 O
Renin NNP 0 1 UNK O
Release NNP 0 1 2 O
Captopril NNP 0 1 0 B-Drug
's POS 0 1 12 O
effect NN 0 1 1 O
will MD 0 0 12 O
be VB 0 0 12 O
augmented VBN 1 1 1 O
by IN 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
that WDT 0 0 12 O
cause VBP 0 1 12 O
renin JJ 0 1 UNK O
release NN 0 1 12 O
. . 0 0 12 O

Doxazosin NNP 0 1 UNK B-Drug
mesylate NN 0 1 16 I-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
without IN 0 0 12 O
any DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
adverse JJ 0 0 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti NN 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

therefore RB 0 0 1 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
Aprepitant NNP 0 1 UNK B-Drug
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
increased JJ 0 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
aprepitant NN 0 1 13 B-Drug
. . 0 0 12 O

Methotrexate NN 0 1 0 B-Drug
: : 0 0 2 O
HUMIRA NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
rheumatoid JJ 0 0 6 O
arthritis NN 0 1 6 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
concomitant JJ 0 1 6 O
MTX NNP 0 1 UNK B-Drug
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
likely JJ 0 1 12 O
that IN 0 0 12 O
experience NN 0 1 12 O
significantly RB 0 0 1 O
underestimates VBZ 1 0 UNK O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
accumulation NN 0 1 1 O
that WDT 0 0 12 O
might MD 0 0 12 O
occur VB 0 1 1 O
with IN 0 0 12 O
repealed JJ 0 1 UNK O
diazepam JJ 0 1 0 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
are VBP 1 0 12 O
contraindicated VBN 1 1 14 O
specifically RB 0 0 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
expected VBN 1 1 12 O
magnitude NN 0 1 UNK O
of IN 0 0 12 O
interaction NN 0 1 UNK O
and CC 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
are VBP 1 0 12 O
listed VBN 1 1 1 O
CONTRAINDICATIONS NNP 0 1 0 O
. . 0 0 12 O

Routine JJ 0 1 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
vaccines NNS 1 1 6 B-Group
or CC 0 0 12 O
toxoids NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
deferred VBN 1 1 1 O
until IN 0 0 12 O
corticosteroid JJ 0 1 UNK B-Group
therapy NN 0 1 6 O
is VBZ 1 0 12 O
discontinued VBN 1 1 1 O
if IN 0 0 12 O
possible JJ 0 1 1 O
. . 0 0 12 O

Serum NNP 0 1 7 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
concurrently RB 0 0 1 O
receiving VBG 1 1 1 O
erythromycin NN 0 1 0 B-Drug
. . 0 0 12 O

Appropriate JJ 0 1 2 O
doses NNS 1 1 6 O
for IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
arenot RB 0 0 UNK O
established VBN 1 1 1 O
but CC 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
thedosage NN 0 0 UNK O
of IN 0 0 12 O
saquinavir NN 0 1 13 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Thalidomide NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
sedative JJ 0 1 6 O
activity NN 0 1 1 O
of IN 0 0 12 O
barbiturates NNS 1 1 14 B-Group
alcohol VBP 0 1 1 B-Drug
chlorpromazine NN 0 1 16 B-Drug
and CC 0 0 12 O
reserpine NN 0 1 UNK B-Drug
. . 0 0 12 O

Cyclosporin NN 0 1 0 B-Drug
: : 0 0 2 O
After IN 0 0 2 O
introduction NN 0 1 1 O
of IN 0 0 12 O
chloroquine NN 0 1 13 B-Drug
( ( 0 0 2 O
oral JJ 0 1 6 O
form NN 0 1 1 O
) ) 0 0 2 O
a DT 0 0 12 O
sudden JJ 0 1 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
cyclosporin NN 0 1 14 B-Drug
level NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Dofetilide NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
nor CC 0 0 12 O
of IN 0 0 12 O
other JJ 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
isoenzymes NNS 0 1 14 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
sympathomimetics NNS 0 1 13 B-Group
are VBP 1 0 12 O
increased VBN 1 1 1 O
with IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
beta NN 0 1 16 B-Group
adrenergic JJ 0 1 UNK I-Group
blockers NNS 1 0 6 I-Group
. . 0 0 12 O

However RB 0 0 1 O
if IN 0 0 12 O
the DT 0 0 12 O
patients NNS 1 1 6 O
thyroid JJ 0 1 6 O
gland NN 0 1 6 O
has VBZ 1 0 12 O
sufficient JJ 0 1 1 O
function NN 0 1 1 O
the DT 0 0 12 O
decreased JJ 0 1 1 O
free JJ 0 1 12 O
thyroxine NN 0 1 14 B-Drug
will MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
compensatory JJ 0 1 13 O
increase NN 0 1 1 O
in IN 0 0 12 O
thyroxin NN 0 1 UNK O
output NN 0 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
thyroid NN 0 1 6 O
. . 0 0 12 O

Aspirin NN 0 1 0 B-Brand
: : 0 0 2 O
Rimantadine NNP 0 1 UNK B-Drug
HCl NNP 0 0 14 I-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
was VBD 1 0 12 O
given VBN 1 1 12 O
twice RB 0 1 12 O
daily JJ 0 1 12 O
fro NNS 0 1 3 O
9 CD 0 0 2 O
days NNS 1 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

Danazol NN 0 1 UNK B-Drug
: : 0 0 2 O
The DT 0 0 2 O
risk NN 0 1 1 O
of IN 0 0 12 O
myopathy JJ 0 1 8 O
/ JJ 0 0 2 O
rhabdomyolysis NN 0 1 8 O
is VBZ 1 0 12 O
increased VBN 1 1 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
danazol NNS 0 1 13 B-Drug
particularly RB 0 0 1 O
with IN 0 0 12 O
higher JJR 1 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
lovastatin NN 0 1 13 B-Drug
( ( 0 0 2 O
see VB 0 1 12 O
WARNINGS NNP 0 1 UNK O
Myopathy NNP 0 1 UNK O
/ NNP 0 0 2 O
Rhabdomyolysis NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

This DT 0 0 2 O
medicine NN 0 1 6 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
with IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Drugs NNS 0 1 2 O
Affecting NNP 0 1 UNK O
Hepatic NNP 0 1 7 O
Metabolism NNP 0 1 UNK O
The DT 0 0 2 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
REMERON NNP 0 1 UNK B-Brand
SolTab NNP 0 0 UNK I-Brand
( ( 0 0 2 O
mirtazapine NN 0 1 0 B-Drug
) ) 0 0 2 O
Orally RB 0 1 UNK O
Disintegrating VBG 0 1 UNK O
Tablets NNS 0 1 0 O
may MD 0 0 1 O
be VB 0 0 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
induction NN 0 1 1 O
or CC 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
metab NN 0 0 13 O
- : 0 0 2 O
olizing VBG 0 0 UNK O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Monoamine NNP 0 1 UNK B-Drug
Oxidase NNP 0 1 UNK I-Drug
Inhibitors NNS 0 1 7 I-Drug
: : 0 0 2 O
Guanethidine NNP 0 1 UNK B-Drug
or CC 0 0 12 O
similarly RB 0 0 1 O
acting JJ 0 1 12 O
compounds NNS 1 1 13 O
; : 0 0 2 O

The DT 0 0 2 O
peripheral JJ 0 1 6 O
vasoconstriction NN 0 1 UNK O
caused VBN 1 1 1 O
by IN 0 0 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
dopamine NN 0 1 14 B-Drug
HCl NNP 0 0 14 I-Drug
is VBZ 1 0 12 O
antagonized VBN 1 0 UNK O
by IN 0 0 12 O
alpha JJ 0 1 1 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Prospective JJ 0 1 UNK O
studies NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
hydroxyurea NN 0 1 14 B-Drug
to TO 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Agents NNS 0 1 2 O
Affecting VBG 0 1 UNK O
Cytochrome NNP 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
Isoenzyme NNP 0 1 UNK O
System NNP 0 1 2 O
Fentanyl NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
mainly RB 0 0 1 O
via IN 0 0 1 O
the DT 0 0 12 O
human JJ 0 1 1 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
isoenzyme NN 0 1 13 O
system NN 0 1 1 O
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
) ) 0 0 2 O
therefore RB 0 0 1 O
potential JJ 0 1 1 O
interactions NNS 1 1 UNK O
may MD 0 0 1 O
occur VB 0 1 1 O
when WRB 0 0 12 O
DURAGESIC NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
agents NNS 1 1 1 O
that WDT 0 0 12 O
affect VBP 0 1 1 O
CYP9A9 NNP 0 0 UNK O
activity NN 0 1 1 O
. . 0 0 12 O

Cimetidine JJ 0 1 0 B-Drug
Ranitidine NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
( ( 0 0 2 O
n=9 NN 0 1 UNK O
) ) 0 0 2 O
pretreatment NN 0 1 UNK O
with IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
or CC 0 0 12 O
ranitidine NN 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
flurbiprofen NN 0 1 16 B-Drug
pharmacokinetics NNS 0 1 UNK O
except IN 0 0 12 O
that IN 0 0 12 O
a DT 0 0 12 O
small JJ 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
but CC 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
concentration NN 0 1 1 O
curve NN 0 1 13 O
of IN 0 0 12 O
flurbiprofen NN 0 1 16 B-Drug
resulted VBD 1 1 1 O
with IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
DOXIL NNP 0 1 UNK B-Brand
. . 0 0 12 O

multivitamins NNS 1 1 14 B-Group
containing VBG 1 1 1 O
zinc NN 0 1 14 B-Drug
; : 0 0 2 O

Consequently RB 0 0 1 O
estazolam WRB 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
ketoconazole NN 0 1 16 B-Drug
and CC 0 0 12 O
itraconazole NN 0 1 0 B-Drug
which WDT 0 0 12 O
are VBP 1 0 12 O
very RB 0 1 12 O
potent JJ 0 1 UNK O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
CYP9A NNP 0 0 UNK O
. . 0 0 12 O

While IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
minimally RB 0 0 6 O
involved VBN 1 1 12 O
in IN 0 0 12 O
paliperidone NN 0 1 16 B-Drug
metabolism NN 0 1 16 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
studies NNS 1 1 1 O
do VBP 0 0 12 O
not RB 0 1 12 O
show VB 0 1 12 O
decreased JJ 0 1 1 O
elimination NN 0 1 UNK O
by IN 0 0 12 O
these DT 0 0 12 O
isozymes NNS 0 1 UNK O
and CC 0 0 12 O
they PRP 0 0 12 O
contribute VBP 0 1 UNK O
to TO 0 0 12 O
only RB 0 1 12 O
a DT 0 0 12 O
small JJ 0 1 12 O
fraction NN 0 1 1 O
of IN 0 0 12 O
total JJ 0 1 1 O
body NN 0 1 3 O
clearance NN 0 1 16 O
. . 0 0 12 O

Additionally RB 0 0 1 O
saquinavir NN 0 1 13 B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
P NNP 0 1 2 O
- : 0 0 2 O
Glycoprotein NNP 0 1 UNK O
( ( 0 0 2 O
Pgp NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
FLOLAN NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
diuretics NNS 1 1 14 B-Group
anticoagulants NNS 1 1 13 B-Group
oral JJ 0 1 6 O
vasodilators NNS 1 1 13 B-Group
and CC 0 0 12 O
supplemental JJ 0 1 1 O
oxygen NN 0 1 3 B-Drug
. . 0 0 12 O
In IN 0 0 2 O
a DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
substudy NN 0 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
congestive JJ 0 1 6 O
heart NN 0 1 12 O
failure NN 0 1 1 O
receiving VBG 1 1 1 O
furosemide NN 0 1 0 B-Drug
or CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
in IN 0 0 12 O
whom WP 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
FLOLAN NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
initiated VBN 1 1 1 O
apparent JJ 0 1 1 O
oral JJ 0 1 6 O
clearance NN 0 1 16 O
values NNS 1 1 1 O
for IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
( ( 0 0 2 O
n JJ 0 1 12 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
( ( 0 0 2 O
n JJ 0 1 12 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
were VBD 1 0 12 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
on IN 0 0 12 O
the DT 0 0 12 O
second JJ 0 1 12 O
day NN 0 1 12 O
of IN 0 0 12 O
therapy NN 0 1 6 O
and CC 0 0 12 O
had VBD 1 0 12 O
returned VBN 1 1 12 O
to TO 0 0 12 O
baseline VB 0 1 1 O
values NNS 1 1 1 O
by IN 0 0 12 O
day NN 0 1 12 O
9 CD 0 0 2 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
primary JJ 0 1 1 O
CNS NNP 0 1 6 O
effect NN 0 1 1 O
caution NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
EQUETROTM NNP 0 0 UNK B-Brand
is VBZ 1 0 12 O
taken VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
centrally RB 0 0 UNK B-Group
acting VBG 1 1 12 I-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

Greater NNP 0 1 UNK O
sensitivity NN 0 1 1 O
of IN 0 0 12 O
some DT 0 0 12 O
older JJR 1 1 12 O
individuals NNS 1 1 1 O
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
ruled VBN 1 1 12 O
out RP 0 1 12 O
. . 0 0 12 O

Fluvoxamine NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
known VBN 1 1 12 O
strong JJ 0 1 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
also RB 0 0 12 O
inhibits VBZ 1 1 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9C9 NNP 0 0 UNK O
. . 0 0 12 O

Cyclosporine NN 0 1 UNK B-Drug
: : 0 0 2 O
Combination NNP 0 1 UNK O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
leading VBG 1 1 1 O
to TO 0 0 12 O
increased VBN 1 1 1 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
; : 0 0 2 O

Valproate NN 0 1 0 B-Drug
: : 0 0 2 O
Tiagabine NN 0 1 UNK B-Drug
causes VBZ 1 1 6 O
a DT 0 0 12 O
slight JJ 0 1 3 O
decrease NN 0 1 1 O
( ( 0 0 2 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
in IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
valproate NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

inhalation NN 0 1 16 O
anesthetics NNS 1 1 13 B-Group
; : 0 0 2 O

Though IN 0 0 12 O
individual JJ 0 1 1 O
theophylline NN 0 1 16 B-Drug
levels NNS 1 1 1 O
fluctuated VBN 1 1 13 O
there EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
drug NN 0 1 1 O
inter NN 0 1 13 O
- : 0 0 2 O
action NN 0 1 13 O
. . 0 0 12 O

This DT 0 0 2 O
could MD 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
decreased JJ 0 1 1 O
salicylate NN 0 1 13 B-Group
serum NN 0 1 14 O
levels NNS 1 1 1 O
or CC 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
salicylate JJ 0 1 13 B-Group
toxicity NN 0 1 6 O
when WRB 0 0 12 O
methylprednisolone NN 0 1 16 B-Drug
is VBZ 1 0 12 O
withdrawn VBN 1 1 1 O
. . 0 0 12 O

Ergot NNP 0 1 UNK B-Group
- : 0 0 2 O
containing VBG 1 1 1 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
prolonged JJ 0 1 6 O
vasospastic JJ 0 0 UNK O
reactions NNS 1 1 1 O
. . 0 0 12 O

Coumarin NNP 0 1 UNK B-Group
- : 0 0 2 O
Type NN 0 1 2 I-Group
Anticoagulants NNS 0 1 UNK I-Group
: : 0 0 2 O
Several JJ 0 1 2 O
short JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
controlled VBD 1 1 1 O
studies NNS 1 1 1 O
failed VBD 1 1 12 O
to TO 0 0 12 O
wshow VB 0 0 UNK O
that DT 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
significantly RB 0 0 1 O
affected VBD 1 1 1 O
prothrombin JJ 0 1 14 O
times NNS 1 1 12 O
or CC 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
clotting VBG 1 1 14 O
factors NNS 1 1 1 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
individuals NNS 1 1 1 O
on IN 0 0 12 O
coumarin NN 0 1 UNK B-Group
- : 0 0 2 O
type NN 0 1 1 I-Group
anticoagulants NNS 1 1 13 I-Group
. . 0 0 12 O

When WRB 0 0 12 O
such JJ 0 0 1 O
combined VBN 1 1 1 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
contemplated VBN 1 0 UNK O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
one CD 0 1 12 O
or CC 0 0 12 O
both DT 0 0 12 O
agents NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
significantly RB 0 0 1 O
reduced VBN 1 1 1 O
. . 0 0 12 O

All DT 0 0 2 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
are VBP 1 0 12 O
contraindicated VBN 1 1 14 O
in IN 0 0 12 O
pregnant JJ 0 1 13 O
and CC 0 0 12 O
nursing JJ 0 1 12 O
women NNS 1 1 UNK O
. . 0 0 12 O

. . 0 0 12 O

indinavir NN 0 1 16 B-Drug
concentration NN 0 1 1 O

Norepinephrine NN 0 1 UNK B-Drug
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
enhance VB 0 1 UNK O
the DT 0 0 12 O
adrenergic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
norepinephrine NN 0 1 14 B-Drug
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Use NNP 0 1 2 O
of IN 0 0 12 O
barrier NN 0 1 1 O
form NN 0 1 1 O
of IN 0 0 12 O
contraception NN 0 1 13 O
is VBZ 1 0 12 O
suggested VBN 1 1 12 O
while IN 0 0 12 O
on IN 0 0 12 O
griseofulvin NN 0 1 UNK B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Clinical JJ 0 1 7 O
Comment NN 0 1 2 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
PEGASYS NNP 0 1 UNK B-Brand
on IN 0 0 12 O
male NN 0 1 12 O
fertility NN 0 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

This DT 0 0 2 O
increase NN 0 1 1 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
test NN 0 1 1 O
point NN 0 1 12 O
which WDT 0 0 12 O
was VBD 1 0 12 O
the DT 0 0 12 O
second JJ 0 1 12 O
day NN 0 1 12 O
after IN 0 0 12 O
starting VBG 1 1 12 O
Mexitil NNP 0 1 UNK B-Brand
. . 0 0 12 O
Theophylline NNP 0 1 UNK B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
returned VBN 1 1 12 O
to TO 0 0 12 O
pre VB 0 1 1 O
- : 0 0 2 O
Mexitil NN 0 1 UNK B-Brand
values NNS 1 1 1 O
within IN 0 0 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
discontinuing VBG 1 1 6 O
Mexitil NNP 0 1 UNK B-Brand
. . 0 0 12 O
If IN 0 0 12 O
Mexitil NNP 0 1 UNK B-Brand
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
are VBP 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
theophylline JJ 0 1 16 B-Drug
blood NN 0 1 6 O
levels NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
particularly RB 0 0 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
Mexitil NNP 0 1 UNK B-Brand
dose NN 0 1 6 O
is VBZ 1 0 12 O
changed VBN 1 1 12 O
. . 0 0 12 O

Mutagenesis NNP 0 1 UNK O
PEGASYS NNP 0 1 UNK B-Brand
did VBD 1 0 12 O
not RB 0 1 12 O
cause VB 0 1 12 O
DNA NNP 0 1 1 O
damage NN 0 1 1 O
when WRB 0 0 12 O
tested VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
Ames NNP 0 1 UNK O
bacterial JJ 0 1 6 O
mutagenicity NN 0 1 UNK O
assay NN 0 1 14 O
and CC 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
chromosomal JJ 0 1 13 O
aberration NN 0 1 UNK O
assay NN 0 1 14 O
in IN 0 0 12 O
human JJ 0 1 1 O
lymphocytes NNS 1 1 14 O
either CC 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
or CC 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
metabolic JJ 0 1 6 O
activation NN 0 1 13 O
. . 0 0 12 O

Antidepressants NNS 0 1 UNK B-Group
: : 0 0 2 O
In IN 0 0 2 O
vitro NN 0 1 UNK O
data NNS 0 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
nefazodone NN 0 1 16 B-Drug
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
which WDT 0 0 12 O
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
cisapride NN 0 1 UNK B-Drug
levels NNS 1 1 1 O
and CC 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
ECG NNP 0 1 6 O
. . 0 0 12 O

Theophylline NN 0 1 UNK B-Drug
: : 0 0 2 O
Twelve NNP 0 1 UNK O
healthy JJ 0 1 12 O
male NN 0 1 12 O
volunteers NNS 1 1 UNK O
were VBD 1 0 12 O
administered VBN 1 1 1 O
one CD 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
ceftibuten JJ 0 1 UNK B-Drug
capsule NN 0 1 3 O
twice RB 0 1 12 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

Erythromycin NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
healthy JJ 0 1 12 O
individuals NNS 1 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
increased VBD 1 1 1 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
with IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug
and CC 0 0 12 O
erythromycin VB 0 1 0 B-Drug
a DT 0 0 12 O
known JJ 0 1 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
with IN 0 0 12 O
Fruit NNP 0 1 UNK O
Juices NNP 0 1 UNK O
Fruit NNP 0 1 UNK O
juices NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
grapefruit NN 0 1 3 O
orange NN 0 1 16 O
and CC 0 0 12 O
apple NN 0 1 UNK O
may MD 0 0 1 O
reduce VB 0 0 1 O
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
and CC 0 0 12 O
exposure NN 0 1 1 O
of IN 0 0 12 O
fexofenadine NN 0 1 16 B-Drug
. . 0 0 12 O

Cytokines NNS 0 1 UNK B-Group
( ( 0 0 2 O
interferon VB 0 1 14 B-Group
interleukin NN 0 1 13 B-Group
) ) 0 0 2 O
: : 0 0 2 O
Cytokines NNS 0 1 UNK B-Group
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
induce VB 0 1 6 O
both DT 0 0 12 O
hyperthyroidism NN 0 1 6 O
and CC 0 0 12 O
hypothyroidism NN 0 1 6 O
. . 0 0 12 O

Human JJ 0 1 2 O
pharmacokinetics NNS 0 1 UNK O
data NNS 0 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
oral JJ 0 1 6 O
ketoconazole FW 0 1 16 B-Drug
potently RB 0 0 UNK O
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
resulting VBG 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
eight CD 0 1 12 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
mean JJ 0 1 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
. . 0 0 12 O

Theophylline NNP 0 1 UNK B-Drug
- : 0 0 2 O
related JJ 0 1 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
have VBP 0 0 12 O
occurred VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
when WRB 0 0 12 O
theophylline NN 0 1 16 B-Drug
and CC 0 0 12 O
enoxacin NN 0 1 UNK B-Drug
were VBD 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Meclofenamate NNP 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
serum NN 0 1 14 O
salicylate NN 0 1 13 B-Group
levels NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
the DT 0 0 12 O
beneficial JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
levodopa NN 0 1 UNK B-Drug
in IN 0 0 12 O
Parkinsons NNP 0 1 7 O
disease NN 0 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
reversed VBN 1 1 1 O
by IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
papaverine NN 0 1 13 B-Drug
. . 0 0 12 O

or CC 0 0 12 O
- : 0 0 2 O
over IN 0 1 12 O
- : 0 0 2 O
the DT 0 0 12 O
- : 0 0 2 O
counter NN 0 1 3 O
cough NN 0 1 6 O
cold NN 0 1 3 O
allergy NN 0 1 6 O
or CC 0 0 12 O
weight JJ 0 1 3 O
loss NN 0 1 1 O
medications NNS 1 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
possible JJ 0 1 1 O
pharmacodynamic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
when WRB 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
PRECEDEX NNP 0 1 UNK B-Brand
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
PRECEDEX NNP 0 1 UNK B-Brand
on IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
anesthetic JJ 0 1 13 B-Group
sedative JJ 0 1 6 B-Group
hypnotic NN 0 1 13 B-Group
or CC 0 0 12 O
opioid NN 0 1 13 B-Group
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
attributed VBD 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
combined VBN 1 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
baclofen NN 0 1 0 B-Drug
injection NN 0 1 3 O
and CC 0 0 12 O
epidural JJ 0 1 6 O
morphine NN 0 1 14 B-Drug
include VBP 0 1 1 O
hypotension NN 0 1 6 O
and CC 0 0 12 O
dyspnea NN 0 1 8 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
with IN 0 0 12 O
acyclovir NN 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
mean JJ 0 1 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
and CC 0 0 12 O
the DT 0 0 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
concentration NN 0 1 1 O
- : 0 0 2 O
time NN 0 1 12 O
curve NN 0 1 13 O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
: : 0 0 2 O
Flurbiprofen NNP 0 1 UNK B-Drug
like IN 0 0 12 O
other JJ 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
affect VB 0 1 1 O
bleeding VBG 1 1 6 O
parameters NNS 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
anti JJ 0 0 3 B-Group
- : 0 0 2 O
coagulants NNS 1 1 13 I-Group
and CC 0 0 12 O
serious JJ 0 1 12 O
clinical JJ 0 1 6 O
bleeding NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
between IN 0 0 12 O
nizatidine NN 0 1 13 B-Drug
and CC 0 0 12 O
theophylline JJ 0 1 16 B-Drug
chlordiazepoxide NN 0 1 16 B-Drug
lorazepam NN 0 1 0 B-Drug
lidocaine NN 0 1 14 B-Drug
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Mutagenesis NNP 0 1 UNK O
Impairment NNP 0 1 UNK O
of IN 0 0 12 O
Fertility NNP 0 1 7 O
PEGASYS NNP 0 1 UNK B-Brand
may MD 0 0 1 O
impair VB 0 0 13 O
fertility NN 0 1 6 O
in IN 0 0 12 O
women NNS 1 1 UNK O
. . 0 0 12 O

Physicians NNS 0 1 2 O
should MD 0 0 12 O
be VB 0 0 12 O
aware JJ 0 1 12 O
that IN 0 0 12 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
medications NNS 1 1 6 O
other JJ 0 0 12 O
than IN 0 0 12 O
those DT 0 0 12 O
listed VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
< NN 0 0 16 O
a DT 0 0 12 O
href= NN 0 0 UNK O
`` `` 0 0 13 O
flucon_cp.htm JJ 0 1 UNK O
# # 0 0 2 O
CP NNP 0 1 13 O
'' '' 0 0 13 O
> NNP 0 0 2 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O
section NN 0 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
but CC 0 0 12 O
such JJ 0 0 1 O
interactions NNS 1 1 UNK O
may MD 0 0 1 O
occur VB 0 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
study NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
male NN 0 1 12 O
and CC 0 0 12 O
female JJ 0 1 12 O
volunteers NNS 1 1 UNK O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
and CC 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
ECG NNP 0 1 6 O
. . 0 0 12 O

Check NNP 0 1 2 O
serum VBD 0 1 14 O
potassium NN 0 1 14 O
levels NNS 1 1 1 O
at IN 0 0 12 O
frequent JJ 0 1 1 O
intervals NNS 1 1 1 O
; : 0 0 2 O

In IN 0 0 2 O
such JJ 0 0 1 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
combined JJ 0 1 1 O
treatment NN 0 1 6 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
one CD 0 1 12 O
or CC 0 0 12 O
both DT 0 0 12 O
agents NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
. . 0 0 12 O

Therefore IN 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
Fluvoxamine NNP 0 1 UNK B-Drug
Tablets NNP 0 1 0 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
MAOIs NNP 0 1 UNK B-Group
or CC 0 0 12 O
within IN 0 0 1 O
9 CD 0 0 2 O
days NNS 1 1 12 O
of IN 0 0 12 O
discontinuing VBG 1 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
MAOI NNP 0 1 UNK B-Group
. . 0 0 12 O

Anticholinergics NNS 0 1 UNK B-Group
: : 0 0 2 O
Concurrent NNP 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
certain JJ 0 1 1 O
anticholinergic JJ 0 1 13 B-Group
compounds NNS 1 1 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
belladonna NN 0 1 16 B-Group
alkaloids NNS 1 1 13 I-Group
and CC 0 0 12 O
dicyclomine NN 0 1 13 B-Drug
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
compromise VB 0 1 1 O
the DT 0 0 12 O
beneficial JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
oral JJ 0 1 6 O
: : 0 0 2 O
Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
and CC 0 0 12 O
warfarin NNS 0 1 14 B-Drug
usually RB 0 1 12 O
results NNS 1 1 1 O
in IN 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
warfarin VB 0 1 14 B-Drug
although IN 0 0 12 O
there RB 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
some DT 0 0 12 O
conflicting VBG 1 1 UNK O
reports NNS 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
erlotinib JJ 0 1 13 B-Drug
exposure NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
hepatic JJ 0 1 14 O
dysfunction NN 0 1 6 O
. . 0 0 12 O

Pyrantel NNP 0 1 UNK B-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Antiminth NNP 0 1 UNK B-Drug
) ) 0 0 2 O
- : 0 0 2 O
Taking VBG 0 0 UNK O
piperazine NN 0 1 UNK B-Drug
and CC 0 0 12 O
pyrantel NN 0 1 UNK B-Drug
together RB 0 1 12 O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
piperazine NN 0 1 UNK B-Drug
. . 0 0 12 O

In IN 0 0 2 O
some DT 0 0 12 O
patients NNS 1 1 6 O
combined VBN 1 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
diflunisal NN 0 1 13 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
fatal JJ 0 1 13 O
gastrointestinal JJ 0 1 6 O
hemorrhage NN 0 1 6 O
. . 0 0 12 O

Plasma NNP 0 1 UNK O
concentrations NNS 1 1 13 O
decreased VBN 1 1 1 O
by IN 0 0 12 O
SUSTIVA NNP 0 1 UNK B-Brand
; : 0 0 2 O

Although IN 0 0 12 O
specific JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
ALPHAGAN NNP 0 1 0 B-Brand
P NNP 0 1 2 I-Brand
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
or CC 0 0 12 O
potentiating VBG 1 0 UNK O
effect NN 0 1 1 O
with IN 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
( ( 0 0 2 O
alcohol NN 0 1 1 B-Drug
barbiturates VBZ 0 1 14 B-Group
opiates VBZ 0 1 6 B-Group
sedatives NNS 1 1 6 B-Group
or CC 0 0 12 O
anesthetics NNS 1 1 13 B-Group
) ) 0 0 2 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
patients NNS 1 1 6 O
have VBP 0 0 12 O
received VBN 1 1 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
INAPSINE NNP 0 1 UNK B-Brand
required VBN 1 1 1 O
will MD 0 0 12 O
be VB 0 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
usual JJ 0 1 12 O
. . 0 0 12 O

Fluoroquinolones NNS 0 1 7 B-Drug
macrolide VBP 0 1 UNK B-Drug
antibiotics NNS 1 1 6 I-Drug
and CC 0 0 12 O
azoles NNS 0 1 UNK O
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
QTc NNP 0 0 14 O
prolongation NN 0 1 6 O
. . 0 0 12 O

d LS 0 1 16 B-Drug
- : 0 0 2 O
amphetamine NN 0 1 13 I-Drug
with IN 0 0 12 O
desipramine NN 0 1 16 B-Drug
or CC 0 0 12 O
protriptyline NN 0 1 UNK B-Drug
and CC 0 0 12 O
possibly RB 0 1 12 O
other JJ 0 0 12 O
tricyclics NNS 1 1 UNK B-Group
cause VBP 0 1 12 O
striking VBG 1 1 12 O
and CC 0 0 12 O
sustained JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
d JJ 0 1 16 B-Drug
- : 0 0 2 O
amphetamine NN 0 1 13 I-Drug
in IN 0 0 12 O
the DT 0 0 12 O
brain NN 0 1 6 O
; : 0 0 2 O

Sulfacetamide JJ 0 1 UNK B-Drug
preparations NNS 1 1 13 O
are VBP 1 0 12 O
incompatible JJ 0 1 13 O
with IN 0 0 12 O
silver JJ 0 1 16 B-Drug
preparations NNS 1 1 13 O
. . 0 0 12 O

Digoxin NN 0 1 0 O
When WRB 0 0 12 O
given VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
PLENDIL NNP 0 1 UNK B-Drug
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
heart NN 0 1 12 O
failure NN 0 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
altered VBN 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
agents NNS 1 1 1 O
include VBP 0 1 1 O
medications NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
: : 0 0 2 O
anticoagulants NNS 1 1 13 B-Group
platelet VBP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
including VBG 1 1 1 O
acetylsalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
sali SYM 0 0 UNK O
- : 0 0 2 O
cylates NNS 0 1 UNK O
NSAIDs NNP 0 1 UNK B-Group
( ( 0 0 2 O
including VBG 1 1 1 O
ketorolac VB 0 1 16 B-Drug
tromethamine NN 0 1 13 I-Drug
) ) 0 0 2 O
dipyridamole NN 0 1 0 B-Drug
or CC 0 0 12 O
sulfinpyrazone NN 0 1 13 B-Drug
. . 0 0 12 O

Furosemide NN 0 1 0 B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
aliskiren NN 0 1 13 B-Drug
was VBD 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
the DT 0 0 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
of IN 0 0 12 O
furosemide NN 0 1 0 B-Drug
were VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
net JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
interactions NNS 1 1 UNK O
is VBZ 1 0 12 O
summarized VBN 1 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
table NN 0 1 3 O
: : 0 0 2 O
AED NNP 0 1 UNK B-Group
AED NNP 0 1 UNK B-Group
Felbatol NNP 0 1 UNK B-Brand

substrates NNS 1 1 UNK O
in IN 0 0 12 O
vitro NN 0 1 UNK O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
similar JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
grepafloxacin NN 0 1 UNK B-Drug
in IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
mediated VBD 1 1 13 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
theophylline JJ 0 1 16 B-Drug
metabolism NN 0 1 16 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
INDOCIN NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
probenecid IN 0 1 13 B-Drug
the DT 0 0 12 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
indomethacin NN 0 1 14 B-Drug
are VBP 1 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
could MD 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
. . 0 0 12 O

Paliperidone NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
therefore RB 0 0 1 O
not RB 0 1 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
inhibit VB 0 1 13 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
- : 0 0 2 O
mediated VBN 1 1 13 O
transport NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
manner NN 0 0 1 O
. . 0 0 12 O

quinine NN 0 1 16 B-Drug
; : 0 0 2 O

Alcohol NNP 0 1 2 B-Drug
- : 0 0 2 O
Although IN 0 0 12 O
LEXAPRO NNP 0 1 UNK B-Brand
did VBD 1 0 12 O
not RB 0 1 12 O
potentiate VB 0 0 UNK O
the DT 0 0 12 O
cognitive NN 0 1 1 O
and CC 0 0 12 O
motor NN 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
in IN 0 0 12 O
a DT 0 0 12 O
clinical JJ 0 1 6 O
trial NN 0 1 12 O
as IN 1 0 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
psychotropic NN 0 1 13 B-Group
medications NNS 1 1 6 I-Group
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
by IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
LEXAPRO NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
methotrexate NN 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
displace VB 0 0 13 O
meloxicam NN 0 1 13 B-Drug
from IN 0 0 12 O
its PRP$ 1 0 12 O
human JJ 0 1 1 O
serum NN 0 1 14 O
binding NN 0 1 1 O
sites NNS 1 1 1 O
. . 0 0 12 O

ZEBETA NNP 0 1 UNK B-Brand
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Exacerbation NN 0 0 UNK O
or CC 0 0 12 O
the DT 0 0 12 O
initial JJ 0 1 1 O
presentation NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
autoimmune NN 0 1 6 O
and CC 0 0 12 O
inflammatory NN 0 1 6 O
disorders NNS 1 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
following VBG 1 1 1 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
interferon NN 0 1 14 B-Drug
- : 0 0 2 O
alfa NN 0 1 16 I-Drug
and CC 0 0 12 O
PROLEUKIN NNP 0 1 UNK B-Brand
including VBG 1 1 1 O
crescentic JJ 0 1 UNK O
IgA NNP 0 1 14 O
glomerulonephritis NN 0 1 8 O
oculo SYM 0 0 UNK O
- : 0 0 2 O
bulbar NN 0 1 13 O
myasthenia NN 0 1 6 O
gravis NN 0 1 6 O
inflammatory NN 0 1 6 O
arthritis NN 0 1 6 O
thyroiditis NN 0 1 8 O
bullous JJ 0 1 13 O
pemphigoid NN 0 1 13 O
and CC 0 0 12 O
Stevens NNP 0 1 UNK O
- : 0 0 2 O
Johnson NNP 0 0 19 O
syndrome NN 0 1 6 O
. . 0 0 12 O

CONTRAINDICATED NNS 0 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
threatening VBG 1 0 12 O
reactions NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

SINCE NNP 0 1 11 O
THE NNP 0 0 11 O
CONCOMITANT NNP 0 1 UNK O
ADMINISTRATION NNP 0 1 11 O
OF IN 0 0 11 O
THESE NNP 0 0 11 O
TWO NNP 0 1 11 O
DRUGS NNP 0 1 UNK O
CAN NNP 0 0 11 O
LEAD NNP 0 1 UNK O
TO NNP 0 0 11 O
PHENYTOIN NNP 0 1 UNK B-Drug
INTOXICATION NNP 0 1 UNK O
PRIOR NNP 0 1 11 O
TO NNP 0 0 11 O
ADMINISTERING NNP 0 1 UNK O
DISULFIRAM NNP 0 1 UNK B-Drug
TO NNP 0 0 11 O
A NNP 0 0 2 O
PATIENT NNP 0 1 11 O
ON NNP 0 0 11 O
PHENYTOIN NNP 0 1 UNK B-Drug
THERAPY NNP 0 1 UNK O
A NNP 0 0 2 O
BASELINE NNP 0 1 UNK O
PHENYTOIN NNP 0 1 UNK B-Drug
SERUM NNP 0 1 UNK O
LEVEL NNP 0 1 11 O
SHOULD NNP 0 0 UNK O
BE NNP 0 0 11 O
OBTAINED NNP 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
many JJ 0 0 12 O
of IN 0 0 12 O
these DT 0 0 12 O
cases NNS 1 1 UNK O
buprenorphine NN 0 1 13 B-Drug
was VBD 1 0 12 O
misused VBN 1 1 UNK O
by IN 0 0 12 O
self PRP 0 1 12 O
- : 0 0 2 O
injection NN 0 1 3 O
of IN 0 0 12 O
crushed JJ 0 1 3 O
SUBUTEX NNP 0 1 UNK B-Brand
tablets NNS 1 1 3 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
the DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
concomitantly RB 0 0 14 O
should MD 0 0 12 O
be VB 0 0 12 O
carefully RB 0 0 12 O
monitored VBN 1 1 1 O
. . 0 0 12 O

MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
beta NN 0 1 16 B-Group
adrenergic NN 0 1 UNK I-Group
blockers NNS 1 0 6 I-Group
increase VBP 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
pseudoephedrine NN 0 1 16 B-Drug
. . 0 0 12 O

antibody NN 0 1 14 O

This DT 0 0 2 O
response NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
renal JJ 0 1 6 O
prostaglandin NN 0 1 13 O
synthesis NN 0 1 UNK O
. . 0 0 12 O

Potassium NN 0 1 14 B-Drug
Supplements NNS 0 1 UNK O
and CC 0 0 12 O
Potassium NNP 0 1 14 B-Group
- : 0 0 2 O
Sparing VBG 0 0 UNK I-Group
Diuretics NNS 0 1 UNK I-Group
Lotensin NNP 0 1 UNK O
can MD 0 0 12 O
attenuate VB 0 1 UNK O
potassium JJ 0 1 14 O
loss NN 0 1 1 O
caused VBN 1 1 1 O
by IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
. . 0 0 12 O

Positive JJ 0 1 2 O
direct JJ 0 1 1 O
and CC 0 0 12 O
indirect JJ 0 1 1 O
antiglobulin NN 0 1 UNK O
( ( 0 0 2 O
Coombs NNP 0 1 19 O
) ) 0 0 2 O
tests NNS 1 1 1 O
have VBP 0 0 12 O
occurred VBN 1 1 1 O
; : 0 0 2 O

No DT 0 0 2 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
at IN 0 0 12 O
intermediate JJ 0 1 13 O
doses NNS 1 1 6 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
zaleplon NN 0 1 13 B-Drug
and CC 0 0 12 O
diphenhydramine NN 0 1 16 B-Drug
following VBG 1 1 1 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
respectively RB 0 0 1 O
) ) 0 0 2 O
of IN 0 0 12 O
each DT 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Amitriptyline NN 0 1 0 B-Drug
: : 0 0 2 O
Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
cinacalcet NN 0 1 16 B-Drug
with IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
amitriptyline NN 0 1 16 B-Drug
increased VBD 1 1 1 O
amitriptyline JJ 0 1 16 B-Drug
exposure NN 0 1 1 O
and CC 0 0 12 O
nortriptyline NN 0 1 16 B-Drug_n
( ( 0 0 2 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
) ) 0 0 2 O
exposure NN 0 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
CYP9D9 NNP 0 0 UNK O
extensive JJ 0 1 1 O
metabolizers NNS 0 0 UNK O
. . 0 0 12 O

Depending VBG 0 1 1 O
on IN 0 0 12 O
clinical JJ 0 1 6 O
circumstances NNS 1 0 1 O
consideration NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
increasing VBG 1 1 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
DIFLUCAN NNP 0 1 UNK B-Brand
when WRB 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
. . 0 0 12 O

Theoretically RB 0 0 UNK O
the DT 0 0 12 O
naproxen NN 0 1 16 B-Drug
anion NN 0 1 14 O
itself PRP 0 0 UNK O
could MD 0 0 12 O
likewise RB 0 0 1 O
be VB 0 0 12 O
displaced VBN 1 1 1 O
. . 0 0 12 O

MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
narcotic JJ 0 1 6 B-Group
analgesics NNS 1 1 14 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
meperidine NN 0 1 16 B-Drug
) ) 0 0 2 O
nitrates NNS 1 1 14 B-Group
and CC 0 0 12 O
nitrites NNS 1 1 UNK B-Group
sympathomimetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
tricyclic JJ 0 0 14 B-Group
antidepressants NNS 1 1 13 I-Group
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
having VBG 1 0 12 O
anticholinergic JJ 0 1 13 O
activity NN 0 1 1 O
. . 0 0 12 O

Maalox NNP 0 1 0 B-Brand
* NNP 0 0 2 O
Coadministration NNP 0 1 UNK O
of IN 0 0 12 O
Maalox NNP 0 1 0 B-Brand
TC NNP 0 1 13 I-Brand
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
nicardipine NN 0 1 16 B-Drug
HCl NNP 0 0 14 I-Drug
absorption NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
absorption NN 0 1 1 O
of IN 0 0 12 O
lymecycline NN 0 1 UNK B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
simultaneous JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
indigestion NN 0 1 6 O
remedies NNS 1 0 6 O
iron VBP 0 1 3 B-Drug
or CC 0 0 12 O
zinc JJ 0 1 14 B-Drug
supplements NNS 1 1 6 O
. . 0 0 12 O

A DT 0 0 2 O
few JJ 0 1 12 O
spontaneous JJ 0 1 1 O
accounts NNS 1 1 UNK O
of IN 0 0 12 O
QT NNP 0 1 13 O
interval JJ 0 1 1 O
prolongation NN 0 1 6 O
with IN 0 0 12 O
ventricular JJ 0 1 8 O
arrhythmia NN 0 1 6 O
including VBG 1 1 1 O
torsades NNS 0 0 13 O
de IN 0 1 2 O
pointes NNS 0 0 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
erythromycin NN 0 1 0 B-Drug
or CC 0 0 12 O
troleandomycin NN 0 1 UNK B-Drug
. . 0 0 12 O

In IN 0 0 2 O
situations NNS 1 0 UNK O
when WRB 0 0 12 O
concurrent NN 0 1 1 O
therapy NN 0 1 6 O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
careful JJ 0 1 12 O
patient NN 0 1 6 O
monitoring NN 0 1 1 O
is VBZ 1 0 12 O
essential JJ 0 1 13 O
. . 0 0 12 O

Insulin NN 0 1 7 B-Drug
requirements NNS 1 1 1 O
in IN 0 0 12 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
increased VBN 1 1 1 O
decreased JJ 0 1 1 O
or CC 0 0 12 O
unchanged JJ 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
first JJ 0 1 12 O
study NN 0 1 1 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
cerivastatin NN 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
and CC 0 0 12 O
9 CD 0 0 2 O
g NNS 0 1 16 O
cholestyramine NN 0 1 13 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
decreases NNS 1 1 UNK O
of IN 0 0 12 O
more JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
for IN 0 0 12 O
AUC NNP 0 1 UNK O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
for IN 0 0 12 O
Cmax NNP 0 1 UNK O
when WRB 0 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
dosing VBG 1 0 14 O
cerivastatin JJ 0 1 UNK B-Drug
sodium NN 0 1 14 I-Drug
alone RB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
absorption NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
gemifloxacin NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
significantly RB 0 0 1 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
antacid NN 0 1 UNK B-Group
containing VBG 1 1 1 O
aluminum NN 0 1 16 B-Drug
and CC 0 0 12 O
magnesium NN 0 1 14 B-Drug
. . 0 0 12 O

If IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
coadministered VBN 0 0 UNK O
the DT 0 0 12 O
beta NN 0 1 16 B-Group
blocker NN 0 0 3 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
withdrawn VBN 1 1 1 O
several JJ 0 1 12 O
days NNS 1 1 12 O
before IN 0 1 12 O
the DT 0 0 12 O
gradual JJ 0 1 1 O
withdrawal NN 0 1 1 O
of IN 0 0 12 O
clonidine NN 0 1 0 B-Drug
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
Eszopiclone CD 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NNS 0 1 0 O
administered VBN 1 1 1 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
R NNP 0 1 2 B-Drug
- : 0 0 2 O
or CC 0 0 12 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
warfarin NN 0 1 14 I-Drug
nor CC 0 0 12 O
were VBD 1 0 12 O
there EX 0 0 12 O
any DT 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
profile NN 0 1 1 O
( ( 0 0 2 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
) ) 0 0 2 O
following VBG 1 1 1 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug

The DT 0 0 2 O
clinical JJ 0 1 6 O
significance NN 0 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
interactions NNS 1 1 UNK O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
; : 0 0 2 O

Dose NNP 0 1 7 O
reduction NN 0 1 1 O
of IN 0 0 12 O
rifabutin NN 0 1 13 B-Drug
to TO 0 0 12 O
half PDT 0 1 12 O
the DT 0 0 12 O
standard NN 0 1 1 O
dose NN 0 1 6 O
and CC 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
increase NN 0 1 1 O
of IN 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand
to TO 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
( ( 0 0 2 O
three CD 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
capsules NNS 1 1 3 O
) ) 0 0 2 O
every DT 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
are VBP 1 0 12 O
recommended VBN 1 1 1 O
when WRB 0 0 12 O
rifabutin NN 0 1 13 B-Drug
and CC 0 0 12 O
CRIXIVAN NNP 0 1 UNK B-Brand
are VBP 1 0 12 O
coadministered VBN 0 0 UNK O
. . 0 0 12 O

Warfarin NNS 0 1 0 B-Drug
: : 0 0 2 O
When WRB 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
maleate NN 0 1 16 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
tid NN 0 1 13 O
) ) 0 0 2 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
warfarin NNS 0 1 14 B-Drug
for IN 0 0 12 O
two CD 0 1 12 O
weeks NNS 1 1 12 O
warfarin VBP 0 1 14 B-Drug
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
increased VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
prothrombin NN 0 1 14 O
times NNS 1 1 12 O
were VBD 1 0 12 O
prolonged VBN 1 1 6 O
. . 0 0 12 O

Dose NNP 0 1 7 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
lapatinib NN 0 1 13 B-Drug
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
for IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
must MD 0 0 12 O
receive VB 0 1 1 O
concomitant NN 0 1 6 O
strong JJ 0 1 12 O
inhibitors NNS 1 1 14 O
or CC 0 0 12 O
concomitant NN 0 1 6 O
strong JJ 0 1 12 O
inducers NNS 1 1 UNK O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
enzymes NNS 1 1 14 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
None NNP 0 0 2 O
known VBN 1 1 12 O
. . 0 0 12 O

Food NN 0 1 2 O
: : 0 0 2 O
Isoniazid NNP 0 1 UNK B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
food NN 0 1 12 O
. . 0 0 12 O

However RB 0 0 1 O
it PRP 0 0 12 O
should MD 0 0 12 O
be VB 0 0 12 O
noted VBN 1 0 1 O
that IN 0 0 12 O
both DT 0 0 12 O
products NNS 1 1 1 O
are VBP 1 0 12 O
capable JJ 0 1 UNK O
of IN 0 0 12 O
producing VBG 1 0 1 O
transient NN 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
taking VBG 1 0 12 O
Acamprosate NNP 0 1 UNK B-Drug
concomitantly RB 0 0 14 O
with IN 0 0 12 O
antidepressants NNS 1 1 13 B-Group
more RBR 0 1 12 O
commonly RB 0 0 UNK O
reported VBD 1 1 1 O
both DT 0 0 12 O
weight JJ 0 1 3 O
gain NN 0 1 1 O
and CC 0 0 12 O
weight JJ 0 1 3 O
loss NN 0 1 1 O
compared VBN 1 1 1 O
with IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
either DT 0 1 12 O
medication NN 0 1 6 O
alone RB 0 1 12 O
. . 0 0 12 O

These DT 0 0 1 O
six CD 0 1 12 O
volunteers NNS 1 1 UNK O
received VBD 1 1 12 O
terfenadine JJ 0 1 UNK B-Drug
alone RB 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
followed VBN 1 1 12 O
by IN 0 0 12 O
terfenadine NN 0 1 UNK B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
dirithromycin NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

Catecholamine NNP 0 1 UNK O
- : 0 0 2 O
depleting NN 0 1 UNK O
drugs NNS 1 1 6 O
( ( 0 0 2 O
e.g. FW 0 0 UNK O
reserpine NN 0 1 UNK B-Drug
) ) 0 0 2 O
: : 0 0 2 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
; : 0 0 2 O

9 CD 0 0 2 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
of IN 0 0 12 O
PEGASYS NNP 0 1 UNK B-Brand
alone RB 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
COPEGUS NNP 0 1 UNK B-Brand
did VBD 1 0 12 O
not RB 0 1 12 O
include VB 0 1 1 O
sufficient JJ 0 1 1 O
numbers NNS 1 1 1 O
of IN 0 0 12 O
subjects NNS 1 1 UNK O
aged VBN 1 1 12 O
9 CD 0 0 2 O
or CC 0 0 12 O
over IN 0 1 12 O
to TO 0 0 12 O
determine VB 0 0 1 O
whether IN 0 0 12 O
they PRP 0 0 12 O
respond VBP 0 0 1 O
differently RB 0 0 UNK O
from IN 0 0 12 O
younger JJR 1 1 12 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
or CC 0 0 12 O
other JJ 0 0 12 O
central JJ 0 1 1 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
depressants NNS 1 0 13 I-Group
may MD 0 0 1 O
have VB 0 0 12 O
an DT 0 0 12 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
. . 0 0 12 O

Antigout IN 0 0 UNK B-Group
medications NNS 1 1 6 I-Group

Amiodarone NN 0 1 0 B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
to TO 0 0 12 O
desethylamiodarone VB 0 1 UNK B-Drug
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
( ( 0 0 2 O
CYP9 NNP 0 0 UNK O
) ) 0 0 2 O
enzyme NN 0 1 14 O
group NN 0 1 12 O
specifically RB 0 0 1 O
cytochromes VBZ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
CYP9C9 NNP 0 0 UNK O
. . 0 0 12 O

MOBIC NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
substitute NN 0 0 16 O
for IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
for IN 0 0 12 O
cardiovascular JJ 0 1 6 O
prophylaxis NN 0 1 6 O
. . 0 0 12 O

Concurrent JJ 0 1 13 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
TNF NNP 0 1 UNK B-Group
antagonist NN 0 1 13 I-Group
with IN 0 0 12 O
ORENCIA NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
serious JJ 0 1 12 O
infections NNS 1 1 6 O
and CC 0 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
additional JJ 0 1 1 O
efficacy NN 0 1 UNK O
over IN 0 1 12 O
use NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
TNF NNP 0 1 UNK B-Group
antagonists VBZ 0 1 13 I-Group
alone RB 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
separate JJ 0 1 1 O
single JJ 0 1 12 O
or CC 0 0 12 O
multiple JJ 0 1 1 O
dose JJ 0 1 6 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
chlorthalidone NN 0 1 13 B-Drug
nifedipine NN 0 1 0 B-Drug
propanolol NN 0 1 13 B-Drug
hydrochlorothiazide NN 0 1 0 B-Drug
cimetidine NN 0 1 13 B-Drug
metoclopramide NN 0 1 16 B-Drug
propantheline NN 0 1 13 B-Drug
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
warfarin VB 0 1 14 B-Drug
the DT 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
fosinoprilat NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
by IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
fosinopril NN 0 1 13 B-Drug
with IN 0 0 12 O
any DT 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

increased VBN 1 1 1 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
concentrations NNS 1 1 13 O
may MD 0 0 1 O
result VB 0 1 1 O
. . 0 0 12 O

Non NNP 0 1 2 B-Group
- : 0 0 2 O
selective JJ 0 1 13 I-Group
MAO NNP 0 1 14 I-Group
inhibitors NNS 1 1 14 I-Group
including VBG 1 1 1 O
tranylcypromine JJ 0 1 13 B-Drug
sulfate NN 0 1 14 I-Drug
phenelzine NN 0 1 16 B-Drug
sulfate NN 0 1 14 I-Drug
and CC 0 0 12 O
pargyline NN 0 1 UNK B-Drug
HC9 NNP 0 1 UNK O
: : 0 0 2 O
Concomitant NNP 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
L NNP 0 1 2 B-Drug
- : 0 0 2 O
tyrosine NN 0 1 13 I-Drug
and CC 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
selective JJ 0 1 13 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
may MD 0 0 1 O
cause VB 0 1 12 O
hypertension NN 0 1 6 O
. . 0 0 12 O

Lithium NN 0 1 UNK B-Drug
: : 0 0 2 O
generally RB 0 0 1 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
diuretics NNS 1 1 14 B-Group
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
ketoconazole NN 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
increased VBN 1 1 1 O
retapamulin NN 0 1 UNK B-Drug
geometric JJ 0 1 UNK O
mean NN 0 1 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
after IN 0 0 12 O
topical JJ 0 1 6 O
application NN 0 1 1 O
of IN 0 0 12 O
retapamulin NN 0 1 UNK B-Drug
ointment JJ 0 1 0 O
9 CD 0 0 2 O
% NN 0 0 18 O
on IN 0 0 12 O
the DT 0 0 12 O
abraded JJ 0 1 UNK O
skin NN 0 1 3 O
of IN 0 0 12 O
healthy JJ 0 1 12 O
adult NN 0 1 12 O
males NNS 1 1 UNK O
. . 0 0 12 O

Cholestyramine NN 0 1 UNK B-Drug
increases NNS 1 1 1 O
enterohepatic JJ 0 0 UNK O
elimination NN 0 1 UNK O
of IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
and CC 0 0 12 O
may MD 0 0 1 O
reduce VB 0 0 1 O
its PRP$ 1 0 12 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
t9 NN 0 1 13 B-Drug
/ VBP 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
Inhibitors NNP 0 1 7 O
( ( 0 0 2 O
e.g NN 0 0 UNK O
. . 0 0 12 O
Macrolide NNP 0 1 UNK B-Group
Antibiotics NNPS 0 1 7 I-Group
and CC 0 0 12 O
Protease NNP 0 1 UNK B-Group
Inhibitors NNP 0 1 7 I-Group
) ) 0 0 2 O
There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
rare JJ 0 1 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
serious JJ 0 1 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
in IN 0 0 12 O
connection NN 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
certain JJ 0 1 1 O
ergot JJ 0 1 UNK B-Group
alkaloid NN 0 1 UNK I-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
e.g NN 0 0 UNK O
. . 0 0 12 O
dihydroergotamine NN 0 1 UNK B-Drug
and CC 0 0 12 O
ergotamine NN 0 1 UNK B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
potent JJ 0 1 UNK O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
vasospasm NN 0 1 8 O
leading VBG 1 1 1 O
to TO 0 0 12 O
cerebral JJ 0 0 6 O
ischemia NN 0 1 8 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
ischemia NN 0 1 8 O
of IN 0 0 12 O
the DT 0 0 12 O
extremities NNS 1 1 6 O
. . 0 0 12 O

Blunting NN 0 1 15 O
of IN 0 0 12 O
the DT 0 0 12 O
antihypertensive JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
beta NN 0 1 16 B-Group
- : 0 0 2 O
adrenoceptor NN 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
by IN 0 0 12 O
nonsteroidal JJ 0 0 14 B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Itraconazole JJ 0 1 UNK B-Drug
decreases NNS 1 1 UNK O
busulfan JJ 0 1 13 B-Drug
clearance NN 0 1 16 O
by IN 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
may MD 0 0 1 O
produce VB 0 0 1 O
AUCs NNP 0 1 UNK O
9 CD 0 0 2 O
M NNP 0 1 2 O
min NN 0 1 16 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Studies NNS 0 1 2 O
with IN 0 0 12 O
famotidine NN 0 1 0 B-Drug
in IN 0 0 12 O
man NN 0 1 12 O
in IN 0 0 12 O
animal JJ 0 1 13 O
models NNS 1 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
vitro NNS 0 1 UNK O
have VBP 0 0 12 O
shown VBN 1 1 1 O
no DT 0 0 12 O
significant JJ 0 1 1 O
interference NN 0 1 13 O
with IN 0 0 12 O
the DT 0 0 12 O
disposition NN 0 1 1 O
of IN 0 0 12 O
compounds NNS 1 1 13 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
hepatic JJ 0 1 14 O
microsomal NN 0 1 UNK O
enzymes NNS 1 1 14 O
e.g. VBP 0 0 UNK O
cytochrome VBN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
. . 0 0 12 O

Salicylic JJ 0 1 UNK B-Drug
acid NN 0 1 14 I-Drug
: : 0 0 2 O
Combination NNP 0 1 UNK O
hormonal JJ 0 1 6 B-Group
contraceptives NNS 1 1 13 I-Group
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
clearance NN 0 1 16 O
of IN 0 0 12 O
salicylic JJ 0 1 UNK B-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O

Since IN 0 1 2 O
FOSCAVIR NNP 0 1 UNK B-Brand
decreases VBZ 1 1 UNK O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
ionized JJ 0 1 14 O
calcium NN 0 1 14 O
concurrent NN 0 1 1 O
treatment NN 0 1 6 O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
known VBN 1 1 12 O
to TO 0 0 12 O
influence VB 0 0 UNK O
serum JJ 0 1 14 O
calcium NN 0 1 14 O
concentrations NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
particular JJ 0 0 1 O
caution NN 0 0 1 O
. . 0 0 12 O

Antidepressants NNS 0 1 UNK B-Group
tricyclic JJ 0 0 14 B-Group
: : 0 0 2 O
Amphetamines NNS 0 1 UNK B-Group
may MD 0 0 1 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
tricyclic NN 0 0 14 B-Group
or CC 0 0 12 O
sympathomimetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
; : 0 0 2 O

Glyburide NN 0 1 0 B-Drug
: : 0 0 2 O
In IN 0 0 2 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
- : 0 0 2 O
weight NN 0 1 3 O
subjects NNS 1 1 UNK O
receiving VBG 1 1 1 O
orlistat RB 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NNS 0 1 0 O
three CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
orlistat RB 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
or CC 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
( ( 0 0 2 O
blood NN 0 1 6 O
glucose VB 0 1 14 O
- : 0 0 2 O
lowering VBG 1 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
glyburide NN 0 1 16 B-Drug
. . 0 0 12 O

Diclofenac NN 0 1 UNK B-Drug
: : 0 0 2 O
Administration NN 0 1 UNK O
of IN 0 0 12 O
morning NN 0 1 12 O
and CC 0 0 12 O
lunch NN 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
Starlix NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
mg NN 0 1 0 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
diclofenac NN 0 1 16 B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
resulted VBD 1 1 1 O
in IN 0 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
changes NNS 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
either DT 0 1 12 O
agent NN 0 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
when WRB 0 0 12 O
chlorothiazide NN 0 1 16 B-Drug
and CC 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
steroidal NN 0 1 UNK I-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
agents NNS 1 1 1 I-Group
are VBP 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
the DT 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
observed VBN 1 1 1 O
closely RB 0 0 1 O
to TO 0 0 12 O
determine VB 0 0 1 O
if IN 0 0 12 O
the DT 0 0 12 O
desired JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
diuretic JJ 0 1 14 B-Group
is VBZ 1 0 12 O
obtained VBN 1 1 1 O

Paroxetine NN 0 1 0 B-Drug
: : 0 0 2 O
Coadministration NN 0 1 UNK O
of IN 0 0 12 O
once RB 0 0 12 O
daily JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
aprepitant NN 0 1 13 B-Drug
as IN 1 0 12 O
a DT 0 0 12 O
tablet NN 0 1 16 O
formulation NN 0 1 13 O
comparable JJ 0 0 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
the DT 0 0 12 O
capsule NN 0 1 3 O
formulation NN 0 1 13 O
with IN 0 0 12 O
paroxetine JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily RB 0 1 12 O
resulted VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
Cmax NNP 0 1 UNK O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
both DT 0 0 12 O
aprepitant JJ 0 1 13 B-Drug
and CC 0 0 12 O
paroxetine NN 0 1 16 B-Drug
. . 0 0 12 O

Because IN 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
may MD 0 0 1 O
increase VB 0 1 1 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
buprenorphine JJ 0 1 13 B-Drug
patients NNS 1 1 6 O
already RB 0 0 12 O
on IN 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
such JJ 0 0 1 O
as IN 1 0 12 O
azole JJ 0 1 UNK B-Group
antifungals NNS 1 1 UNK I-Group
( ( 0 0 2 O
e.g NN 0 0 UNK O
. . 0 0 12 O

When WRB 0 0 12 O
administered VBN 1 1 1 O
concurrently RB 0 0 1 O
the DT 0 0 12 O
following JJ 0 1 1 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
adrenal JJ 0 0 6 B-Group
corticosteroids NNS 1 1 14 I-Group
. . 0 0 12 O

However RB 0 0 1 O
appropriate JJ 0 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
should MD 0 0 12 O
be VB 0 0 12 O
performed VBN 1 1 1 O
when WRB 0 0 12 O
initiating VBG 1 1 1 O
EXTRANEAL NNP 0 1 UNK B-Brand
in IN 0 0 12 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
and CC 0 0 12 O
insulin JJ 0 1 14 B-Drug
dosage NN 0 1 0 O
should MD 0 0 12 O
be VB 0 0 12 O
adjusted VBN 1 1 1 O
if IN 0 0 12 O
needed VBN 1 1 12 O
. . 0 0 12 O

thyroid JJ 0 1 6 B-Drug
medication NN 0 1 6 O
; : 0 0 2 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
anastrozole JJ 0 1 16 B-Drug
and CC 0 0 12 O
tamoxifen JJ 0 1 0 B-Drug
resulted VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
of IN 0 0 12 O
anastrozole JJ 0 1 16 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
compared VBN 1 1 1 O
with IN 0 0 12 O
those DT 0 0 12 O
achieved VBN 1 0 1 O
with IN 0 0 12 O
anastrozole JJ 0 1 16 B-Drug
alone RB 0 1 12 O
. . 0 0 12 O

Doxazosin NNP 0 1 UNK B-Drug
mesylate NN 0 1 16 I-Drug
tablets NNS 1 1 3 O
have VBP 0 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
the DT 0 0 12 O
following VBG 1 1 1 O
drugs NNS 1 1 6 O
or CC 0 0 12 O
drug NN 0 1 1 O
classes NNS 1 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
difference NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
administered VBN 1 1 1 O
alone RB 0 1 12 O
and CC 0 0 12 O
warfarin VB 0 1 14 B-Drug
administered VBN 1 1 1 O
with IN 0 0 12 O
Lodine NNP 0 1 UNK B-Brand
as IN 1 0 12 O
measured VBN 1 1 1 O
by IN 0 0 12 O
prothrombin JJ 0 1 14 O
time NN 0 1 12 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
additive JJ 0 1 16 O
or CC 0 0 12 O
synergistic JJ 0 1 UNK O
depressant JJ 0 0 UNK O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
SA NNP 0 1 UNK O
and CC 0 0 12 O
AV NNP 0 0 13 O
nodes NNS 1 1 1 O
however RB 0 0 12 O
Adenocard NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

On IN 0 0 2 O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
bexarotene NN 0 1 UNK B-Drug
by IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
ketoconazole JJ 0 1 16 B-Drug
itraconazole JJ 0 1 0 B-Drug
erythromycin NN 0 1 0 B-Drug
gemfibrozil NN 0 1 16 B-Drug
grapefruit NN 0 1 3 O
juice NN 0 1 3 O
and CC 0 0 12 O
other JJ 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
lead VB 0 1 12 O
to TO 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
bexarotene NN 0 1 UNK B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Therefore RB 0 0 1 O
simultaneous JJ 0 1 13 O
use NN 0 1 1 O
of IN 0 0 12 O
creams JJ 0 1 3 O
ointments NNS 1 1 6 O
or CC 0 0 12 O
oils NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

No DT 0 0 2 O
separate JJ 0 1 1 O
information NN 0 1 1 O
available JJ 0 1 1 O

In IN 0 0 2 O
order NN 0 1 1 O
to TO 0 0 12 O
monitor VB 0 1 1 O
the DT 0 0 12 O
occurrence NN 0 1 1 O
of IN 0 0 12 O
myelotoxicity NN 0 0 UNK O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
frequent JJ 0 1 1 O
peripheral JJ 0 1 6 O
blood NN 0 1 6 O
cell NN 0 1 1 O
counts VBZ 1 1 1 O
be VB 0 0 12 O
performed VBN 1 1 1 O
on IN 0 0 12 O
all DT 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
TAXOL NNP 0 1 UNK B-Brand
. . 0 0 12 O

Propantheline NNP 0 1 UNK B-Drug
and CC 0 0 12 O
diphenoxylate NN 0 1 16 B-Drug
by IN 0 0 12 O
decreasing VBG 1 1 1 O
gut JJ 0 1 3 O
motility NN 0 1 6 O
may MD 0 0 1 O
increase VB 0 1 1 O
digoxin NN 0 1 14 B-Drug
absorption NN 0 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
dose JJ 0 1 6 O
adjustment NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
fenofibric JJ 0 0 13 B-Drug_n
acid NNS 0 1 14 I-Drug_n
were VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affected VBN 1 1 1 O
by IN 0 0 12 O
atorvastatin NN 0 1 0 B-Drug

certain JJ 0 1 1 O
antibiotics NNS 1 1 6 B-Group
especially RB 0 0 12 O
the DT 0 0 12 O
aminoglycosides NNS 0 1 13 B-Group
and CC 0 0 12 O
polymyxins NNS 1 1 UNK B-Group
; : 0 0 2 O

In IN 0 0 2 O
a DT 0 0 12 O
placebo NN 0 1 13 O
- : 0 0 2 O
controlled VBN 1 1 1 O
trial NN 0 1 12 O
in IN 0 0 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
doxazosin NN 0 1 13 B-Drug
on IN 0 0 12 O
day NN 0 1 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
a DT 0 0 12 O
four CD 0 1 12 O
- : 0 0 2 O
day NN 0 1 12 O
regimen NNS 0 1 6 O
of IN 0 0 12 O
oral JJ 0 1 6 O
cimetidine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
mean JJ 0 1 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
doxazosin NN 0 1 13 B-Drug
( ( 0 0 2 O
p=9 NN 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
a DT 0 0 12 O
slight NN 0 1 3 O
but CC 0 0 12 O
not RB 0 1 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
mean JJ 0 1 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
mean JJ 0 1 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
doxazosin NN 0 1 13 B-Drug
. . 0 0 12 O

Other JJ 0 0 2 O
Agents NNS 0 1 2 O
: : 0 0 2 O
No DT 0 0 2 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
occurred VBD 1 1 1 O
when WRB 0 0 12 O
UNIVASC NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
hydrochlorothiazide JJ 0 1 0 B-Drug
digoxin NN 0 1 14 B-Drug
or CC 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
to TO 0 0 12 O
avoid VB 0 0 12 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
ethambutol NN 0 1 16 B-Drug
with IN 0 0 12 O
aluminum NN 0 1 16 B-Drug
hydroxide NN 0 1 14 I-Drug
containing VBG 1 1 1 O
antacids NNS 1 1 14 B-Group
for IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
following VBG 1 1 1 O
ethambutol JJ 0 1 16 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

During IN 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
multiple JJ 0 1 1 O
oral JJ 0 1 6 O
doses NNS 1 1 6 O
of IN 0 0 12 O
TAMBOCOR NNP 0 1 UNK B-Brand
to TO 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
stabilized VBN 1 1 1 O
on IN 0 0 12 O
a DT 0 0 12 O
maintenance NN 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
plasma JJ 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
occurred VBD 1 1 1 O
at IN 0 0 12 O
six CD 0 1 12 O
hours NNS 1 1 12 O
postdose RB 0 1 UNK O
. . 0 0 12 O

Patients NNS 0 1 7 O
should MD 0 0 12 O
take VB 0 1 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
at IN 0 0 12 O
least JJS 0 1 12 O
one CD 0 1 12 O
hour NN 0 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
four CD 0 1 12 O
hours NNS 1 1 12 O
after IN 0 0 12 O
COLESTID NNP 0 1 UNK B-Brand
Tablets NNPS 0 1 0 O
to TO 0 0 12 O
avoid VB 0 0 12 O
impeding VBG 1 0 UNK O
their PRP$ 0 0 12 O
absorption NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
the DT 0 0 12 O
metabolic JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
androgens NNS 1 1 13 B-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
and CC 0 0 12 O
therefore RB 0 0 1 O
insulin NN 0 1 14 B-Drug
requirements NNS 1 1 1 O
. . 0 0 12 O

Similarly RB 0 0 1 O
nateglinide RB 0 1 13 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
influence NN 0 0 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
protein NN 0 1 14 O
binding NN 0 1 1 O
of IN 0 0 12 O
propranolol JJ 0 1 16 B-Drug
glyburide JJ 0 1 16 B-Drug
nicardipine NN 0 1 16 B-Drug
warfarin NN 0 1 14 B-Drug
phenytoin NN 0 1 16 B-Drug
acetylsalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

Monoamine NNP 0 1 UNK B-Group
Oxidase NNP 0 1 UNK I-Group
Inhibitors NNP 0 1 7 I-Group
( ( 0 0 2 O
MAOIs NNP 0 1 UNK B-Group
) ) 0 0 2 O

TAMBOCOR NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
digitalis JJ 0 1 14 B-Group
preparations NNS 1 1 13 I-Group
or CC 0 0 12 O
beta SYM 0 1 16 B-Group
- : 0 0 2 O
adrenergic JJ 0 1 UNK I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
without IN 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
lovastatin JJ 0 1 13 B-Drug
atenolol JJ 0 1 0 B-Drug
warfarin NN 0 1 14 B-Drug
furosemide NN 0 1 0 B-Drug
digoxin NN 0 1 14 B-Drug
celecoxib NN 0 1 16 B-Drug
hydrochlorothiazide NN 0 1 0 B-Drug
ramipril NN 0 1 16 B-Drug
valsartan NN 0 1 0 B-Drug
metformin NN 0 1 0 B-Drug
and CC 0 0 12 O
amlodipine NN 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
increases NNS 1 1 1 O
in IN 0 0 12 O
aliskiren JJ 0 1 13 B-Drug
exposure NN 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
neuromuscular JJ 0 1 6 O
paralysis NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
or CC 0 0 12 O
overlapping VBG 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
different JJ 0 1 1 O
botulinum NN 0 1 13 B-Group
toxin NN 0 1 14 I-Group
serotypes NNS 0 1 UNK O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
substrates NNS 1 1 UNK O
of IN 0 0 12 O
C.P.A NNP 0 0 UNK O
. . 0 0 12 O
were VBD 1 0 12 O
not RB 0 1 12 O
excluded VBN 1 1 1 O
from IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
of IN 0 0 12 O
grepafloxacin NN 0 1 UNK B-Drug
. . 0 0 12 O

Diazepam NN 0 1 UNK B-Drug
: : 0 0 2 O
Diazepam NNP 0 1 UNK B-Drug
( ( 0 0 2 O
Valium NNP 0 1 0 B-Brand
) ) 0 0 2 O
is VBZ 1 0 12 O
a DT 0 0 12 O
CYP NNP 0 1 UNK O
9A9 CD 0 0 UNK O
and CC 0 0 12 O
CYP NNP 0 1 UNK O
9C9 CD 0 0 UNK O
substrate NN 0 1 UNK O
. . 0 0 12 O

Single NNP 0 1 2 O
doses NNS 1 1 6 O
of IN 0 0 12 O
either DT 0 1 12 O
cholestyramine NN 0 1 13 B-Drug
or CC 0 0 12 O
colestipol NN 0 1 13 B-Drug
resins NNS 1 1 UNK B-Group
bind IN 0 1 UNK O
the DT 0 0 12 O
hydrochlorothiazide NN 0 1 0 B-Drug
and CC 0 0 12 O
reduce VB 0 0 1 O
its PRP$ 1 0 12 O
absorption NN 0 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
gastrointestinal JJ 0 1 6 O
tract NN 0 1 6 O
by IN 0 0 12 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
percent NN 0 1 1 O
respectively RB 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
physician NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
notified VBN 1 1 1 O
immediately RB 0 1 12 O
if IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
situations NNS 1 0 UNK O
occur VBP 0 1 1 O
which WDT 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
a DT 0 0 12 O
sign NN 0 1 12 O
of IN 0 0 12 O
seriously RB 0 0 UNK O
worsening VBG 1 1 6 O
asthma NN 0 1 6 O
: : 0 0 2 O
Decreased JJ 0 1 7 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
short JJ 0 1 12 B-Group
- : 0 0 2 O
acting VBG 1 1 12 I-Group
inhaled VBN 1 1 14 I-Group
beta9 SYM 0 0 UNK I-Group
- : 0 0 2 O
agonists NNS 1 1 UNK I-Group
; : 0 0 2 O

These DT 0 0 1 O
drugs NNS 1 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
caution NN 0 0 1 O
and CC 0 0 12 O
frequent JJ 0 1 1 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
serum JJ 0 1 14 O
lithium NN 0 1 16 B-Drug
levels NNS 1 1 1 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Probenecid NNP 0 1 UNK B-Drug
competes VBZ 1 0 UNK O
with IN 0 0 12 O
meropenem NN 0 1 14 B-Drug
for IN 0 0 12 O
active JJ 0 1 1 O
tubular JJ 0 1 3 O
secretion NN 0 1 14 O
and CC 0 0 12 O
thus RB 0 0 1 O
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
meropenem NN 0 1 14 B-Drug
. . 0 0 12 O

Vasopressors NNS 0 1 UNK B-Group
particularly RB 0 0 1 O
metaraminol VBP 0 1 UNK B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
serious JJ 0 1 12 O
cardiac JJ 0 1 6 O
arrhythmias NN 1 1 6 O
during IN 0 0 12 O
halothane NN 0 1 13 B-Drug
anesthesia NN 0 1 6 O
and CC 0 0 12 O
therefore NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
only RB 0 1 12 O
with IN 0 0 12 O
great JJ 0 1 12 O
caution NN 0 0 1 O
or CC 0 0 12 O
not RB 0 1 12 O
at IN 0 0 12 O
all DT 0 0 12 O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
SULAR NNP 0 1 UNK B-Brand
with IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
any DT 0 0 12 O
known JJ 0 1 12 O
CYP9A9 NNP 0 0 UNK O
inducer NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
and CC 0 0 12 O
alternative JJ 0 1 1 O
antihypertensive JJ 0 1 14 B-Group
therapy NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

for IN 0 0 12 O
adult NN 0 1 12 O
- : 0 0 2 O
onset NN 0 1 6 O
diabetics NNS 1 1 UNK O
dosage VBP 0 1 0 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
hypoglycemic JJ 0 1 14 B-Group
medications NNS 1 1 6 I-Group
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
during IN 0 0 12 O
and CC 0 0 12 O
after IN 0 0 12 O
thiazide JJ 0 1 UNK B-Group
diuretic JJ 0 1 14 I-Group
therapy NN 0 1 6 O
; : 0 0 2 O

Propoxyphene NN 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
propoxyphene JJ 0 1 16 B-Drug
overdosage NN 0 0 UNK O
amphetamine NN 0 1 13 B-Drug
CNS NNP 0 1 6 O
stimulation NN 0 1 6 O
is VBZ 1 0 12 O
potentiated VBN 1 0 UNK O
and CC 0 0 12 O
fatal JJ 0 1 13 O
convulsions NNS 1 1 13 O
can MD 0 0 12 O
occur VB 0 1 1 O
. . 0 0 12 O

clofibrate NN 0 1 UNK B-Drug
; : 0 0 2 O

lithium NN 0 1 16 B-Drug
; : 0 0 2 O

However RB 0 0 1 O
the DT 0 0 12 O
impairment NN 0 1 16 O
of IN 0 0 12 O
motor NN 0 1 3 O
skills NNS 1 1 UNK O
produced VBN 1 0 1 O
by IN 0 0 12 O
REMERON NNP 0 1 UNK B-Brand
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
additive JJ 0 1 16 O
with IN 0 0 12 O
those DT 0 0 12 O
caused VBN 1 1 1 O
by IN 0 0 12 O
diazepam NN 0 1 0 B-Drug
. . 0 0 12 O

Specific JJ 0 1 UNK O
Effects NNS 0 1 UNK O
of IN 0 0 12 O
Felbatol NNP 0 1 UNK B-Brand
on IN 0 0 12 O
Other JJ 0 0 2 O
Antiepileptic NNP 0 1 UNK B-Group
Drugs NNP 0 1 2 I-Group
Phenytoin NNP 0 1 0 B-Drug
: : 0 0 2 O
Felbatol NNP 0 1 UNK B-Brand
causes VBZ 1 1 6 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
phenytoin NN 0 1 16 B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

This DT 0 0 2 O
is VBZ 1 0 12 O
based VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
results NNS 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
using VBG 1 1 1 O
histamine NN 0 1 UNK B-Drug
induced VBN 1 1 6 O
skin JJ 0 1 3 O
wheals NNS 1 1 UNK O
and CC 0 0 12 O
flares NNS 1 1 3 O
coupled VBN 1 1 UNK O
with IN 0 0 12 O
population NN 0 1 13 O
pharmacokinetic JJ 0 1 UNK O
analysis NN 0 1 1 O
. . 0 0 12 O

no DT 0 0 12 O
other JJ 0 0 12 O
specific JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
receiving VBG 1 1 1 O
sirolimus NN 0 1 16 B-Drug
or CC 0 0 12 O
nifedipine NN 0 1 0 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
MYCAMINE NNP 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
for IN 0 0 12 O
sirolimus NN 0 1 16 B-Drug
or CC 0 0 12 O
nifedipine JJ 0 1 0 B-Drug
toxicity NN 0 1 6 O
and CC 0 0 12 O
sirolimus NN 0 1 16 B-Drug
or CC 0 0 12 O
nifedipine JJ 0 1 0 B-Drug
dosage NN 0 1 0 O
should MD 0 0 12 O
be VB 0 0 12 O
reduced VBN 1 1 1 O
if IN 0 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Alternate NNP 0 1 UNK O
treatments NNS 1 1 6 O
lacking VBG 1 1 13 O
CYP9A9 NNP 0 0 UNK O
inducing VBG 1 1 6 O
activity NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

